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Cecilia Salom, Sa úl Álvarez-Teijeiro, M. Pilar Fernández, Reginald O. Morgan, Eva Allonca, 
Aitana Vallina, Corina Lorz, Lucas de Villalaı́n, M. Soledad Fernández-Garcı́a, 
Juan P. Rodrigo and Juana M. Garcı́a-Pedrero
Frequent Alteration of Annexin A9 and A10 in HPV-Negative Head and Neck Squamous Cell 
Carcinomas: Correlation with the Histopathological Differentiation Grade
Reprinted from: J. Clin. Med. 2019, 8, 229, doi:10.3390/jcm8020229 . . . . . . . . . . . . . . . . . . 3
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Abstract: While oncogenic mutations of head and neck squamous cell carcinomas (HNSCC) in head
and neck malignancies are uncommon, analysis using next-generation sequencing (NGS) technologies
is growing. Further, single-cell analysis is being developed to overcome cancer cell heterogeneity and
improve the poor survival of patients. However, it is important for researchers to know how to use
this information to improve patients’ survival.
Keywords: head and neck cancer; NGS; squamous cell carcinoma
Among head and neck malignancies, head and neck squamous cell carcinomas (HNSCC) comprise
a heterogeneous group of malignant neoplasms arising from the squamous cell epithelium of the
upper aerodigestive tract. The sites of the HNSCC development include the oral cavity, nasopharynx,
oropharynx, hypopharynx, and larynx. Squamous cell carcinomas arising from these sites account
for the sixth most common malignancy worldwide [1]. The 5-year survival rates for HNSCCs have
remained at approximately 50% for the past 40 years [2].
The understanding of the molecular and genetic alterations leading to oncogenesis in head
and neck cancers, including HNSCC, has dramatically increased in the past decade. Initial steps
taken to grasp the genetic pathogenesis of head and neck cancer paid attention to cytogenetic
studies. The development of microarray technology has made it possible to classify HNSCCs into
distinct types based on various gene expression patterns. Recently, next-generation sequencing (NGS)
technologies have enabled many researchers to sequence a large number of cancers to identify novel
gene abnormalities (i.e., mutations, translocations, and fusions). An underlying motivation for genomic
profiling studies by these researchers was to gain a more radical understanding of the molecular
alterations in head and neck cancer for the establishment of novel targeting therapeutics.
Conventional methods that have been used to study gene expression and chemotherapeutic
responses in cancer molecular assays are performed on whole cell populations in tumor tissue.
Therefore, the results from these methods average the differences between individual cells in tumor
tissue [3]. This approach oversimplifies the complexity of the various genetic profiles existing in the
tumor microenvironment (TME) and distorts results relating to the proportion and identity of cancer
stem cells.
On the contrary, single-cell genomic profiling by single-cell sequencing is performed independent
of pooled samples or cell populations, permitting a higher fidelity representation of intra- and
intertumoral cell heterogeneity in the TME [4,5]. Using single-cell sequencing means that each
unique head and neck cancer cell type can be identified and elucidated. Further, a more profound
discrimination of intra- and intertumoral differences is critical in developing novel therapeutic strategies
targeted at increasing tumor-specific antigen responses [3].
Oncogenic mutations in HNSCC are uncommon. Targeting these alterations may require
investigating comprehensive fatal approaches against cancer cells [5]. Moreover, oncogenic signaling
J. Clin. Med. 2019, 8, 1905; doi:10.3390/jcm8111905 www.mdpi.com/journal/jcm1
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pathways can be activated by various non-genetic mechanisms that are not detected by genomic efforts.
It is necessary to challenge how we use the information obtained from NGS to develop and improve
diagnostic and therapeutic modalities.
Conflicts of Interest: The authors declare no competing financial interests.
References
1. Fitzmaurice, C.; Allen, C.; Barber, R.M.; Barregard, L.; Bhutta, Z.A.; Brenner, H.; Dicker, D.J.; Chimed-Orchir, O.;
Dandona, R.; Dandona, L.; et al. Global, Regional, and National Cancer Incidence, Mortality, Years of Life
Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015:
A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol. 2017, 3, 524–548. [PubMed]
2. Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer Statistics, 2017. CA Cancer J. Clin. 2017, 67, 7–30. [CrossRef]
[PubMed]
3. Pai, S.I.; Westra, W.H. Molecular pathology of head and neck cancer: implications for diagnosis, prognosis,
and treatment. Annu. Rev. Pathol. 2009, 4, 49–70. [CrossRef] [PubMed]
4. Agrawal, N.; Frederick, M.J.; Pickering, C.R.; Bettegowda, C.; Chang, K.; Li, R.J.; Fakhry, C.; Xie, T.X.;
Zhang, J.; Wang, J.; et al. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating
mutations in NOTCH1. Science 2011, 333, 1154–1157. [CrossRef]
5. Stransky, N.; Egloff, A.M.; Tward, A.D.; Kostic, A.D.; Cibulskis, K.; Sivachenko, A.; Kryukov, G.V.;
Lawrence, M.S.; Sougnez, C.; McKenna, A.; et al. The mutational landscape of head and neck squamous cell
carcinoma. Science 2011, 333, 1157–1160. [CrossRef] [PubMed]
© 2019 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution





Frequent Alteration of Annexin A9 and A10 in
HPV-Negative Head and Neck Squamous Cell
Carcinomas: Correlation with the Histopathological
Differentiation Grade
Cecilia Salom 1,†, Saúl Álvarez-Teijeiro 1,2,†, M. Pilar Fernández 3, Reginald O. Morgan 3,
Eva Allonca 1,2, Aitana Vallina 4, Corina Lorz 2,5, Lucas de Villalaín 6,
M. Soledad Fernández-García 4, Juan P. Rodrigo 1,2,* and Juana M. García-Pedrero 1,2,*
1 Department of Otolaryngology, Hospital Universitario Central de Asturias and Instituto de Investigación
Sanitaria del Principado de Asturias, Instituto Universitario de Oncología del Principado de Asturias,
University of Oviedo, Avda. Roma, 33011 Oviedo, Spain; mariaceciliasalom@gmail.com (C.S.);
saul.teijeiro@gmail.com (S.Á.-T.); ynkc1@hotmail.com (E.A.)
2 CIBERONC, Av. Monforte de Lemos 3-5, 28029 Madrid, Spain; clorz@ciemat.es
3 Department of Biochemistry and Molecular Biology and Institute of Biotechnology of Asturias, University
of Oviedo, Julian Clavería, 33006 Oviedo, Spain; pfernandez@uniovi.es (M.P.F.);
morganreginald@uniovi.es (R.O.M.)
4 Department of Pathology, Hospital Universitario Central de Asturias and Instituto Universitario de
Oncología del Principado de Asturias, University of Oviedo, Avda. Roma, 33011 Oviedo, Spain;
alaicla@hotmail.es (A.V.); solefghdr@hotmail.com (M.S.F.-G.)
5 Molecular Oncology Unit, CIEMAT (ed 70A), Av. Complutense 40, 28040 Madrid, Spain
6 Department of Oral Surgery, Hospital Universitario Central de Asturias and Instituto de Investigación
Sanitaria del Principado de Asturias, Instituto Universitario de Oncología del Principado de Asturias,
University of Oviedo, Avda. Roma, 33011 Oviedo, Spain; lvillalain@hotmail.com
* Correspondence: jprodrigo@uniovi.es (J.P.R.); juanagp.finba@gmail.com (J.M.G.-P.);
Tel.: +34-985-108-000 (J.P.R.); +34-985-107-937 (J.M.G.-P.)
† These authors contributed equally to this work.
Received: 3 December 2018; Accepted: 4 February 2019; Published: 10 February 2019
Abstract: The annexin protein superfamily has been implicated in multiple physiological and
pathological processes, including carcinogenesis. Altered expression of various annexins has
frequently been observed and linked to the development and progression of various human
malignancies. However, information is lacking on the expression and clinical significance of annexin
A9 (ANXA9) and A10 (ANXA10) in head and neck squamous cell carcinomas (HNSCC). ANXA9
and ANXA10 expression was evaluated in a large cohort of 372 surgically treated HPV-negative
HNSCC patients and correlated with the clinicopathologic parameters and disease outcomes.
Down-regulation of ANXA9 expression was found in 42% of HNSCC tissue samples, compared to
normal epithelia. ANXA9 expression in tumors was significantly associated with oropharyngeal
location and histological differentiation grade (p < 0.001). In marked contrast, ANXA10 expression
was absent in normal epithelium, but variably detected in the cytoplasm of cancer cells. Positive
ANXA10 expression was found in 64% of tumors, and was significantly associated with differentiation
grade (p < 0.001), being also more frequent in oropharyngeal tumors (p = 0.019). These results reveal
that the expression of both ANXA9 and ANXA10 is frequently altered in HNSCC and associated
to the tumor differentiation grade, suggesting that they could be implicated in the pathogenesis of
these cancers.
J. Clin. Med. 2019, 8, 229; doi:10.3390/jcm8020229 www.mdpi.com/journal/jcm3
J. Clin. Med. 2019, 8, 229
Keywords: annexin A9; annexin A10; head and neck squamous cell carcinoma; differentiation
grade; immunohistochemistry
1. Introduction
Twelve annexins comprise a ubiquitous, multigene family in vertebrates with properties
that enable binding interactions with calcium and cell membrane components, including anionic
phospholipids, cytoskeletal proteins and extracellular matrix glycoproteins. Annexin-knockdown
or annexin-knockout models have provided limited insight into the biological functions of different
annexin proteins [1] and there are only indirect links based on statistical association with genetic
diseases. They have been implicated in a variety of biological processes, including membrane
organization, vesicle trafficking, calcium metabolism, cell adhesion, subcellular transport, growth and
differentiation, and wound healing [2,3], many of which are relevant to cancer progression.
Annexins are characterized structurally by a conserved C-terminal core that consists of a tetrad
of homologous annexin (ANX) domains, each 68–69 amino acids long, harboring ligands that can
coordinate calcium ions in conjunction with membrane phospholipids, or bind to other proteins and
carbohydrate-containing biomolecules. The binding properties and targets of each annexin are distinct,
exemplified by the apparent calcium-independence of annexins A9 and A10 [4]. The N-terminal region
of each annexin is unique, with a variable length and amino acid sequence that contributes to annexin
conformation, protein interactions and non-overlapping functional specificity in the biological activity
of different annexins [5,6].
More than 4000 annexins have been reported in different species, widely distributed among
eukaryotes and prevalent in different forms of prokaryotes and unicellular eukaryotes [1,4]. The twelve
annexins common to vertebrates are referred to as annexins A1–A13 (ANXA1–ANXA13) with ANXA12
remaining unassigned. There are 13 human annexin genes, including a unique duplication of ANXA8,
ranging in size from 15 kb (ANXA9) to 96 kb (ANXA10) and spread throughout the genome on
chromosomes 1, 2, 4, 5, 8, 9, 10 and 15 [1,7].
The expression pattern and tissue distribution of annexins vary widely. While annexins A1, A2,
A4, A5, A6, A7 and A11 are ubiquitously expressed, others exhibit very restrictive expression such as
ANXA3 in neutrophils, ANXA8 in placenta and skin, ANXA9 in the tongue, ANXA10 in the stomach
and ANXA13 in the small intestine [7]. The promoter regulation of annexin A9 has been partially
characterized [8], but distal DNA elements, regulatory RNAs and epigenetic changes are under current
study in high-throughput experiments, so the molecular basis of its expression remains incomplete.
The term annexinopathy has been used to define those human diseases in which abnormal
levels and pleiotropic effects of annexins contribute to the pathogenesis [9,10]. Although direct
involvement of these proteins in the etiology of any genetic disease has not been demonstrated, they
have been implicated in various pathologies such as diabetes, cardiovascular and autoimmune diseases,
infection and cancer [10,11]. Mounting evidence shows that several annexins are frequently altered in
cancers, suggesting a possible role in the process of tumorigenesis. Some annexins have been found
overexpressed in specific types of tumors, while others consistently show loss of expression [9–11].
Emerging mechanistic studies are helping to relate annexin expression changes to tumor cell function,
particularly tumor growth, invasion and metastasis, angiogenesis and drug resistance. The expression
of individual annexins is associated with particular cancer types hence annexins could also be useful
biomarkers in the clinic [10,11]. More precise localization of these proteins in different tissues could
deepen our understanding of their pathophysiological functions, which continues to be a key area
of investigation.
The overall goal of this study was to investigate the expression pattern and clinical significance of
ANXA9 and ANXA10, specifically in head and neck squamous cell carcinomas (HNSCC). ANXA9
shows generally restricted tissue expression but is known to exhibit altered expression in breast
4
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cancer [12], colorectal cancer [13] and cutaneous melanoma [14]. It was also shown to be overexpressed
in differentiating keratinocytes in pemphigus [15] and binds to other cytoskeletal proteins [16].
Several studies have been published to date on the expression ANXA10 in gastrointestinal cancers,
and its overexpression in oral cancer is correlated with cell proliferation [17]. We focused our
study on the expression and clinical significance of ANXA9 and ANXA10 specifically in HNSCC
using immunohistochemistry techniques in a large homogeneous cohort of 372 surgically treated,
HPV-negative, HNSCC patients.
2. Materials and Method
2.1. Patients and Tissue Specimens
Surgical tissue specimens from 372 patients with HPV-negative HNSCC who underwent
resection of their tumors at the Hospital Universitario Central de Asturias between 1990 and 2009
were retrospectively collected, in accordance to approved institutional review board guidelines.
All experimental protocols were approved by the Institutional Ethics Committee of the Hospital
Universitario Central de Asturias and by the Regional CEIC (Comité Ético de Investigación
Clínica) from Principado de Asturias (approval number: 81/2013 for the project PI13/00259).
Informed consent was obtained from all patients. Representative tissue sections were obtained from
archival, paraffin-embedded blocks and the histological diagnosis was confirmed by an experienced
pathologist (M.S.F.-G).
All patients had a single primary tumor, microscopically clear surgical margins and received no
treatment prior to surgery. Only fourteen patients were women, and the mean age was 58.6 years (range
30 to 86 years). All but twelve patients were habitual tobacco smokers, 198 moderate (1–50 pack-year)
and 153 heavy (>50 pack-year), and 335 were alcohol drinkers. The stage of the tumors was determined
according to the TNM system of the International Union Against Cancer (7th Edition). Two hundred
and thirty (62%) of 372 patients received postoperative radiotherapy. Patients were followed-up
for a minimum of 36 months. The mean follow-up for the whole series was 34.6 months (median,
21.5 months); for the patients without recurrence, 71 months (median, 67 months); and for the
patients dead by the tumor, 18 months (median, 13.5 months). Recurrence was defined as relapse
of the tumor in the five first years after treatment at any site: local recurrence, nodal metastasis,
or distant metastasis. Information on HPV status was available for all the patients. HPV status was
analyzed using p16-immunohistochemistry, high-risk HPV DNA detection by in situ hybridization
and genotyping by GP5+/6+-PCR, as previously reported [18,19]. The characteristics of the studied
cases are shown in Table 1.
2.2. Tissue Microarray (TMA) Construction
Three morphologically representative areas were selected from each individual tumor paraffin
block. Subsequently, three 1 mm cylinders were taken to construct TMA blocks, as described
previously [20,21], containing a total of 372 HNSCC (134 tonsillar, 107 base of tongue, 64
hypopharyngeal and 67 laryngeal carcinomas). In addition, each TMA included three cores of
normal epithelium as an internal negative control. The normal epithelium was obtained from adult
male, non-smokers and non-drinkers, patients that were operated from tonsillectomy due to chronic
tonsillitis, and patients operated from benign vocal cord lesions (e.g., polyps, cysts).
5
J. Clin. Med. 2019, 8, 229
Table 1. Clinicopathologic characteristics of the tumors studied.
Characteristic No. Cases (%)


























The formalin-fixed, paraffin-embedded tissue samples were cut into 3-μm sections and dried
on Flex IHC microscope slides (Dako, Glostrup, Denmark). The sections were deparaffinized with
standard xylene and hydrated through graded alcohols into water. Antigen retrieval was performed
with proteinase K and the samples were placed for 15 min in hydrogen peroxide at 3%. Staining
was done at room temperature on an automatic staining workstation (Dako Autostainer Plus) using
the following primary antibodies (developed by Dr. MP Fernández, Department of Biochemistry,
University of Oviedo [4]) and conditions: Anti-ANXA9 at a concentration of 1:100 for 30 min and
anti-ANXA10 at a concentration of 1:100 for 45 min. Immunodetection was carried out with the Dako
EnVision Flex + Visualization System (Dako Autostainer), using diaminobenzidine as a chromogen.
Counterstaining with hematoxylin for 7 min was the final step.
After staining, the sections were dehydrated and set up in a slide in a standard medium. Negative
controls were carried out without the primary antibody. The vascular endothelium, in which the
expression of both annexins had previously been shown, was used as a positive control.
Since staining showed a homogeneous distribution, a semiquantitative scoring system based
on staining intensity was applied. Immunostaining was scored blinded to clinical data by two
independent observers as negative (0), weak to moderately (1+), and strongly positive (2+) based on
staining intensity. Scores ≥ 1 were considered as positive expression.
3. Results
3.1. Expression of ANXA9 and ANX10 in Normal Epithelia
Non-keratinized stratified squamous epithelium showed different expression patterns for the
two annexins studied. ANXA9 expression was absent in basal and parabasal cells, while expression
6
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increased towards the most differentiated layers of the epithelium (Figure 1A). Contrasting this,
negative ANXA10 expression was detected in all cell layers of normal epithelium (Figure 1D).
Figure 1. Immunohistochemical analysis of annexins A9 (ANXA9) and A10 (ANXA10) expression
in head and neck squamous cell carcinomas (HNSCC) tissue specimens. Representative examples of
ANXA9 (A) and ANXA10 (D) expression in normal epithelium, positive ANXA9 (B) and ANXA10
(E) expression in carcinomas, and negative ANXA9 (C) and ANXA10 (F) expression in carcinomas.
Original magnification ×40.
3.2. Expression of ANXA9 in HNSCC Tissue Specimens
Immunohistochemical analysis of ANXA9 expression was successfully evaluated in 346 of
372 tumor samples. Two-hundred of them (58%) showed positive ANXA9 expression predominantly
with a membranous pattern, although cytoplasmic expression was also observed in some cases
(Figure 1B,C). The relationship between the expression of ANXA9 and clinicopathologic characteristics
is shown in Table 2. Positive ANXA9 expression was strongly and significantly associated with
the degree of differentiation of the tumors (p < 0.001). Thus, ANXA9 expression was mainly
found in well-differentiated tumors whereas expression was reduced in moderately and poorly
differentiated tumors (Figure 2A,C). We also observed differences in ANXA9 expression between
the different HNSCC subsites, with ANXA9 expression being significantly higher in oropharyngeal
tumors (p < 0.001).
7
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Oropharynx 234 166 (71) 231 160 (69)
Hypopharynx 58 17 (29) 0.000 # 55 28 (51) 0.019 #
Larynx 54 17 (31) 54 31 (57)
pT Classification
T1-T2 100 52 (52) 95 58 (61)
T3 120 73 (61) 0.377 # 119 75 (63) 0.591 #
T4 126 73 (59) 123 83 (67)
pN Classification
N0 87 48 (55)
0.616 †
87 53 (61)
0.439 †N1-3 259 152 (59) 253 166 (66)
Stage
I-II 33 14 (42) 32 19 (59)
III 61 39 (64) 0.124 # 60 39 (65) 0.822 #
IV 252 147 (58) 248 161 (65)
Degree of differentiation
Well-differentiated 136 98 (72) 134 103 (77)
Moderately-differentiated 137 73 (53) 0.000 # 137 85 (62) 0.000 #
Poorly-differentiated 73 29 (40) 69 31 (45)
Recurrence
No 132 77 (58)
0.91 †
132 80 (61)
0.248 †Yes 214 123 (57) 208 139 (67)
Total 346 200 (58) 340 219 (64)
# Chi-square and † Fisher’s exact tests.
No associations were found between ANXA9 expression and T and N classifications or tumor
recurrence (p = 0.91). In addition, ANXA9 expression was not associated with disease-specific survival
(log rank p = 0.497) nor overall survival (log rank p = 0.406) (data not shown).
3.3. Expression of ANXA10 in HNSCC Specimens
Immunohistochemical ANXA10 expression was successfully evaluated in 340 of 372 tumor
samples. Positive ANXA10 expression was observed in a total of 219 (64%) cases, mainly detected
in the cytoplasm of cancer cells (Figure 1E,F). Furthermore, ANXA9 and ANXA10 expression were
significantly correlated (Spearman correlation coefficient 0.459, p < 0.001).
Similar to ANXA9, ANXA10 expression was significantly higher in oropharyngeal tumors
(p = 0.019). Also, ANXA10 expression was significantly associated with the degree of differentiation
of the tumors (decreased expression with dedifferentiation, p < 0.001, Figure 2B,D). No associations
were observed with T and N classifications, disease stage, or tumor recurrence (Table 2). In addition,
ANXA10 expression was not associated with either disease-specific (log rank p = 0.077) or overall
survival (log rank p = 0.167).
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Figure 2. ANXA9 and ANXA10 protein expression in HNSCC specimens according to the degree of
differentiation. Representative examples of well-differentiated tumors showing positive expression
of ANXA9 (A) and ANXA10 (B), and poorly differentiated tumors showing negative expression of
ANXA9 (C) and ANXA10 (D) expression in carcinomas. Original magnification ×40.
3.4. In Silico Analysis of ANXA9 and ANXA10 mRNA Expression Using The Cancer Genome Atlas (TCGA)
HNSCC Data
In order to extend and confirm our results, we also performed analysis of the transcriptome
data from the TCGA HNSCC cohort accessed via the original publication [22], or using the
platform cBioPortal for Cancer Genomics (http://cbioportal.org/) [23] and the UALCAN web tools
(http://ualcan.path.uab.edu/) [24]. Thus, ANXA9 mRNA levels were found to be significantly
decreased in primary tumors compared to normal tissue samples (p < 0.001; Figure 3A), whilst ANXA10
mRNA levels increased in tumors versus normal tissue (p < 0.001; Figure 3B). These results are in
good agreement with our observations at the protein level. In addition, possible correlations between
ANXA9 and ANXA10 mRNA expression and the tumor grade were assessed using a homogeneous
cohort of 243 HPV-negative HNSCC patients. We found that ANXA9 mRNA levels inversely and
significantly correlated with the degree of histological differentiation (Spearman correlation coefficient
−0.244, p < 0.001; Figure 3C). Consistent with our IHC protein data, ANXA9 mRNA levels were higher
in well-differentiated tumors than in moderately and poorly differentiated tumors. However, ANXA10
mRNA levels did not significantly correlate with the tumor grade (p = 0.605; Figure 3D).
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Figure 3. Analysis of ANXA9 and ANXA10 mRNA expression using RNAseq data from the TCGA
HNSCC cohorts. Box plots comparing the mRNA expression levels of ANXA9 (A) and ANXA10
(B) in primary tumors (in red) versus normal tissue (in blue) using UALCAN online resources
(http://ualcan.path.uab.edu/). The median, quartiles and range of values are shown. ANXA9 (C)
and ANXA10 (D) expression (RNA seq V2 RSEM, z-score threshold ±2) was analyzed in relation to
the tumor grade, categorized as well-differentiated (G1), moderately differentiated (G2) and poorly
differentiated (G3) using the TCGA HPV-negative HNSCC cohort (n = 243). Horizontal lines (in red)
represent the median values, with interquartile range. Sigma (two-tailed) p-values.
4. Discussion
Annexins are commonly altered in cancers [9,25]. ANXA9 is a unique member of the annexin
family whose intracellular activity does not appear to be regulated by calcium [10,26]. Its closest
evolutionary relatives are ANXA1 and ANXA2 [1,4] and members of this clade are thought to function
in the organization and regulation of membrane/cytoskeleton linkages [4,27]. As both ANXA1 and
ANXA2 have been found down-regulated in head and neck squamous cell carcinoma [28–30], it was
of special interest to determine whether ANXA9 showed a similar pattern of expression as this might
relate to common features in the evolution, structure and function of these clade members.
We observed a weak membranous ANXA9 expression in the most differentiated cells in normal
epithelium. In tumor cells, the expression is mainly membranous, similar to that observed for
ANXA2 [28] and the expression of ANXA9 is mainly associated with the degree of differentiation of
the tumor, with higher expression in well differentiated cases. This is consistent with elevated ANXA9
observed in differentiating keratinocytes [15]. However, ANXA9 expression was not associated with
any other clinical and pathological parameter or with the prognosis in head and neck carcinomas.
Analogous findings were obtained by analyzing RNAseq data from the available TCGA HNSCC
cohorts. Accordingly, ANXA9 down-regulation was frequently detected in HNSCC at both mRNA
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and protein levels. Moreover, ANXA9 mRNA expression in tumors was inversely correlated with
the histological differentiation grade, thus confirming our IHC protein data. Hence, together these
results reflect that transcriptional regulatory mechanisms contribute to the loss of ANXA9 expression
in HNSCC, as we previously demonstrated for the functionally and evolutionary-related members
ANXA1 and ANXA2 [29,30].
Few studies have analyzed the expression of ANXA9 in cancers. One study showed that ANXA9
gene expression is associated with bone metastasis in breast cancer [31]. In colorectal cancer, patients
with high ANXA9 gene expression also had lower overall survival [32]. ANXA9 protein expression
in colorectal cancer was higher than in normal mucosa, and associated with invasion and lymphatic
metastasis and, consequently, a worse prognosis [13]. These studies suggest a role for ANXA9 in
invasion and metastasis, but this role could not be confirmed in head and neck cancers.
Several studies have identified ANXA10 as a tumor suppressor, diagnostic marker, potential
therapeutic target, or prognostic factor in various malignancies, including bladder cancer,
hepatocellular carcinoma, acute myeloid leukemia, gastric carcinoma, oral squamous cell carcinoma,
pancreatobiliary adenocarcinoma, and urothelial carcinoma [33–37]. Studies have shown that ANXA10
was down-regulated in hepatocellular carcinoma and was associated with a poor prognosis [34,35].
ANXA10 has recently been identified as a marker with high specificity for the serrated histology of
colorectal cancer [33,38]. The physiological importance of abundant ANXA10 expression specific to
the stomach mucosa and intestinal M-cells is currently unknown.
Only one previous study has analyzed ANXA10 in head and neck cancer; Shimizu et al. [17]
showed that ANXA10 is overexpressed frequently in oral squamous cell carcinomas and that this
overexpression is associated with tumor size. They suggested that ANXA10 expression may be
associated with tumor progression by promoting cell-cycle progression in the G1 phase through
activation of the ERK/MAPK signaling pathway, leading to decreased expression of cyclin-dependent
kinase inhibitors (CDKIs). While further studies are needed to study the interaction of ANXA10 and
the ERK/MAPK signaling pathway, these data suggested that ANXA10 plays an important role in
cellular proliferation.
We also observed that ANXA10 was not visibly expressed in normal epithelium, while it was
variably expressed in the cytoplasm of cancer cells. Consistent with this, analysis of the transcriptome
data from the TCGA HNSCC also demonstrated the up-regulation of ANXA10 mRNA expression
in tumors compared to the corresponding normal tissue. In addition, we found that ANXA10
expression, as ANXA9, was lower in poorly differentiated tumors, but it was not related to other
clinicopathologic parameters or prognosis. However, we were unable to confirm the correlation of
ANXA10 protein expression with the histological grade using RNAseq data. Nevertheless, these
apparently contradictory results may reflect the contribution of additional regulatory mechanisms
(e.g., translational or post-translational) leading to the frequent up-regulation of ANXA10 protein in
over 60% of tumor samples.
5. Conclusions
These original results indicate that the expression of annexins A9 and A10 is frequently altered in
HNSCC at both mRNA and protein level, suggesting that they could be implicated in the pathogenesis
or compensatory mechanisms of these cancers. Additional studies are ongoing to establish the
pathogenic roles of these proteins in the progression of squamous cell carcinomas of the head and
neck and especially, to determine whether their altered expression is a cause or consequence of
the cancerous state. The association of ANXA9 with pathogenic prognosis in colorectal cancer [13]
contrasts with a proposed tumor suppressor role for ANXA10 in gastric cancer [36]. The unique,
calcium-independent actions of these two annexins may also contribute to a better understanding
of their underlying mechanisms. Since these particular annexins are poorly expressed in general
but exhibit highly tissue-specific expression, it will undoubtedly be important to explore the role of
epigenetic regulatory changes responsible for their selective expression in normal versus cancer tissues.
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Abstract: Human papilloma virus (HPV) infection has been well-established as a risk factor in
head and neck squamous cell carcinoma (HNSCC). The carcinogenic effect of HPV is mainly
due to the E6 and E7 oncoproteins, which inhibit the functions of p53 and pRB, respectively.
These oncoproteins could also play a role in the Warburg effect, thus favoring tumor immune
escape. Here, we demonstrated that the pro-inflammatory cytokine macrophage migration inhibitory
factor (MIF) is expressed at higher levels in HPV-negative patients than in HPV-positive patients.
However, the secretion of MIF is higher in HPV-positive human HNSCC cell lines, than in
HPV-negative cell lines. In-HPV positive cells, the half inhibitory concentration (IC50) of MIF
inhibitor (4-iodo-6-phenylpyrimidine (4-IPP)) is higher than that in HPV-negative cells. This result
was confirmed in vitro and in vivo by the use of murine SCCVII cell lines expressing either E6 or E7,
or both E6 and E7. Finally, to examine the mechanism of MIF secretion, we conducted proton nuclear
magnetic resonance (1H-NMR) experiments, and observed that lactate production is increased in both
the intracellular and conditioned media of HPV-positive cells. In conclusion, our data suggest that the
stimulation of enzymes participating in the Warburg effect by E6 and E7 oncoproteins increases lactate
production and hypoxia inducible factor 1α (HIF-1α) expression, and finally induces MIF secretion.
Keywords: HNSCC; HPV; MIF; 4-IPP; metabolism
1. Introduction
Head and neck squamous cell carcinomas (HNSCC) are frequent in both men and women
worldwide, with approximately 550,000 new cases annually [1]. It has long been recognized that
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tobacco and alcohol are the two main risk factors for these cancers, but a few years ago, human
papilloma virus (HPV) was identified as an additional contributor leading to the development of a
new subgroup of HNSCC, mainly associated with HPV-16 and HPV-18 types [2,3]. The impact of HPV
infection remains controversial concerning the prognostic values of HNSCC, but recent studies put
to light a new blood test that contributes to the detection of circulating tumor HPV DNA (notably
HPV-16) and that can predict cancer recurrence [4,5]. It should be noted that differences throughout
the world; for example, the prevalence of HPV-16 infection in oropharyngeal cancer, is nearly 60% in
North America, whereas it is approximately 30% in Europe (Samples from Germany, United Kingdom
and Italy) [6]. However, in the county of Stockholm, researchers have observed an increase of HPV
prevalence in tonsil carcinoma by over 90% of cases until 2006 and 2007 [7]. Moreover, a large amount
of evidence supports the idea that two HPV-positive cancer subpopulations may be distinguished.
The first population is mainly composed of younger adults, primarily Caucasians and nonsmokers,
with a favorable prognosis; while the second group includes patients who smoke and use alcohol,
and these patients have a poorer prognosis [6,8–10].
Macrophage migration inhibitory factor (MIF) is an ubiquitous pro-inflammatory cytokine
discovered in 1966 by Bloom and Bennett [11]. This cytokine has been investigated in many clinical
and experimental studies in both inflammatory diseases and cancer. Indeed, MIF is involved in cancer
progression through different pathways leading to cell proliferation, cell invasion, angiogenesis and
tumor immune escape [12]. Implications for MIF in HNSCC have already been reported in several
studies, which have established that MIF leads to cancer progression and poorer prognosis, notably
in laryngeal carcinoma [13]. Indeed, our previous study has shown that mice that receive a murine
squamous carcinoma cells underexpressing MIF and are treated with cisplatin or 5-fluouracil have a
better prognosis than mice receiving control cells [13].
The objective of our research is to assess MIF production in HNSCC regarding HPV infection.
Indeed, MIF regulation has been studied in several virus-induced cancers, but it has never been
examined in HPV-infected carcinomas. Thus, we have evaluated MIF expression in a series of 156
clinical samples including oral cavity and oropharyngeal carcinomas. Moreover, MIF secretion was
investigated in vitro and in vivo by using three HPV-negative and three HPV-positive HNSCC human
cell lines, as well as murine SCCVII cell lines expressing the E6 and/or E7 HPV oncoproteins. Finally,
proton nuclear magnetic resonance (1H-NMR) experiments were conducted to examine the mechanism
involved in HPV-dependent MIF secretion in HNSCC.
2. Materials and Methods
2.1. Clinical Characteristics
Formalin-fixed paraffin-embedded oral cavity and oropharyngeal cancer specimens were obtained
from 156 patients who underwent curative surgery at Saint-Pierre Hospital (Brussels, Belgium),
EpiCURA Baudour Hospital (Baudour, Belgium) and Erasme hospital (Brussels, Belgium) during the
years from 1996–2008. The clinical characteristics of the patients are outlined in Tables 1 and 2, which
presents information concerning the patients’ age, gender, tumor localization, tumor histopathological
grade, Tumor Node Metastasis (TNM) stage, risk factors, tumor recurrence, and clinical follow-up.
This retrospective study was approved by the Institutional Review Board of Jules Bordet Institute
(CE2319). All patients included in this study have received information regarding the use of residual
human corporal materials for clinical research, and written informed consent was obtained from
the patients.
2.2. DNA Extraction
The formalin-fixed, paraffin-embedded tissue samples were sectioned, deparaffinized,
and digested with proteinase K by overnight incubation at 56 ◦C. DNA was purified using a QIAamp
DNA Mini Kit (Qiagen, Benelux, Belgium), as previously described [14].
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2.3. Detection of HPV by Polymerase Chain Reaction (PCR) Amplification
HPV DNA detection was performed using PCR with GP5+/GP6+ primers (synthesized by
Eurogentec, Liege, Belgium) that amplified a consensus region located within the L1 region of the HPV
genome, as previously described [14].
2.4. Real-time PCR Amplification of HPV Type-Specific DNA
All DNA extracts were tested for the presence of 18 different HPV genotypes using TaqMan-based
real-time quantitative PCR that targeted type-specific sequences of the viral genes, as previously
described [14].
2.5. RNA Extraction
After five days of cell culture, total RNA was collected in RLT buffer supplemented with
β-mercaptoethanol (RNeasy Mini Kit, Qiagen, Venlo, The Netherlands) at 4 ◦C, and the sample
were then centrifuged in RNeasy spin columns. After the wash steps, RNA was collected in RNase-free
water, and subjected to DNase treatment as described by the manufacturer. The RNA concentration
was evaluated using a NanoDropTM 1000 spectrophotometer (Thermo Scientific, Wilmington, DE,
USA). RNA quality was assessed, based on the RNA profile generated by a Bioanalyzer 2100 (Agilent
Technologies, Santa Clara, CA, USA).
2.6. Real-Time PCR for MIF mRNA Quantification
MIF mRNA expression was quantified by real-time PCR. Complementary DNA (cDNA) was
synthesized using a standard reverse transcription method (qScript cDNA SuperMix, Quanta
Biosciences, Gaithersburg, MD, USA). Real-time PCR reactions were performed using the SYBR
Green PCR Master Mix (Applied Biosystems, Foster City, CA, USA) and sequence-specific primer
sets designed with PrimerBank [15] for MIF (forward: 5′-GCAGAACCGCTCCTACAGCA-3′, reverse:
5′-GGCTCTTAGGCGAAGGTGGA-3) and for 18S (forward: 5′-GCGGCGGAAAATAGCCTTTG-3′,
reverse: 5′-GATCACACGTTCCACCTCATC-3′) (Life Technologies, Ghent, Belgium). The amplification
was performed on a LightCycler 480 System (Roche Diagnostics GmbH, Mannheim, Germany) using
an initial activation step (95 ◦C for 10 min) followed by 40 cycles of amplification (95 ◦C for 15 s
and 60 ◦C for 60 s). Melting curves from 60 ◦C to 99 ◦C were assessed to evaluate PCR specificity.
A preliminary analysis demonstrated linear and similar amplification efficacies. Relative quantification
was determined by normalizing the cycle threshold (CT) of MIF with the CT of β-actin (loading control)
using the 2−ΔCT method.
2.7. Immunohistochemistry of p16
Each HPV-positive case was further immunohistochemically evaluated for p16 expression,
using the recommended mouse monoclonal antibody (CINtec p16, Ventana, Tucson, USA) [16],
and an automated immunostaining protocol (Bond-Max, Leica Microsystems, Wetzlar, Germany).
Immunohistochemistry was performed as previously described [9].
2.8. Immunohistochemistry for MIF Protein Detection
MIF expression was detected by immunohistochemistry in tumor samples, and was performed
on paraffin-embedded sections, as previously detailed [17].
2.9. Computer-Assisted Morphometry
A morphological examination of immunostained tissue sections was carried out on a Zeiss
Axioplan microscope equipped with a color change-couple device (CCD) camera (ProgRes C10plus,
Jenoptik, Jena, Germany). Morphometric analysis was performed using KS 400 imaging software
(Carl Zeiss Vision, Hallbergmoos, Germany), as described previously [13].
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2.10. LC MS/MS Analysis and Data Processing
Protein identification and quantification were performed using a label-free strategy on an
UHPLC-HRMS platform (Eksigent 2D Ultra and AB SCIEX TripleTOF 5600). The peptides (2 μg) were
separated on a 25 cm C18 column (Acclaim PepMap100, 3 μm, Dionex, Thermo Scientific, Wilmington,
DE, USA) using a linear gradient (5–35% over 120 min) of acetonitrile (ACN) in water containing 0.1%
formic acid at a flow rate of 300 nL min−1. To obtain the highest possible retention time stability, which
is required for label-free quantification, the column was equilibrated with a 10× volume of 5% ACN
before each injection. Mass spectra (MS) were acquired across a 400–1500 m/z range in high-resolution
mode with a 500 ms accumulation time. The precursor selection parameters were as follows: 200 cps
intensity threshold, 50 precursor maximum per cycle, 50 ms accumulation time, and 15 s exclusion
after one spectrum. These parameters led to a duty cycle of 3 s per cycle, ensuring that high-quality
extracted ion chromatograms (XICs) were obtained for peptide quantification.
ProteinPilot Software (v4.1) was used to conduct a database search against the UniProt Trembl
database (09/30/2011 version), which was restricted to Homo sapiens entries. The search parameters
included differential amino acid mass shifts for carbamidomethyl cysteine, all biological modifications,
amino acid substitutions, and missed trypsin cleavage.
For peptide quantification, PeakView was used to construct XICs for the top five peptides of each
protein identified with a false discovery rate (FDR) of lower than 1%. Only unmodified and unshared
peptides were used for quantification. Peptides were also excluded if their identification confidence as
determined by ProteinPilot was below 0.99. A retention time window of 2 min, and a mass tolerance
of 0.015 m/z were used. The calculated XICs were exported into MarkerView, and signals were
normalized based on the summed area of the entire run. Only proteins presenting a fold-change of
greater than/less than 1.5/0.6 with a p-value lower than 0.05 across the three biological replicates
analyzed were accounted for in the metabolic characterization. Fold-changes were assessed by using a
Student’s t-test. Finally, proteins identified by one peptide were validated manually.
2.11. Cell Culture
UPCI-SCC-131, Detroit 562, UPCI-SCC-90, and UPCI-SCC-154 (DSMZ, Braunschweig, Germany)
cell lines were grown in minimum essential medium (MEM, Gibco Life Technologies, Paisley, UK)
supplemented with 10% fetal bovine serum, 2 mM L-glutamine, 1% penicillin/streptomycin, and 1%
nonessential amino acids (Gibco Life Technologies, Paisley, UK). The FaDU and 93VU-147T cell lines
were grown in Dulbecco’s modified Eagle medium (DMEM, Lonza, Verviers, Belgium) supplemented
with 10% fetal bovine serum (FBS), 2% L-glutamine, and 1% penicillin/streptomycin. The 93VU-174T
cell line was obtained from Dr. de Winter (University Medical Center of Amsterdam, Amsterdam,
The Netherlands).
Mouse SCCVII cells were transfected with three different vectors, to express either the HPV
oncoproteins E6 or E7, or both E6 and E7 in the Radiation Oncology Department at the Université
Catholique de Louvain (Prof. Vincent Grégoire), as previously described [18]. Cells were cultured in
T-flasks containing minimum essential medium (MEM) supplemented with 10% FBS, 2 mM L-glutamine,
1% antibiotic/antimycotic mix, and 1% nonessential amino acids (Gibco Life Technologies, Paisley, UK).
A MIF knockdown (MIF-KD) cell line derived from SCCVII, as well as a matched control with
normal MIF expression, was generated in the Department of Pediatrics at the Medical College of
Wisconsin (Dr. Bryon Johnson). Knock-down of MIF expression in the SCCVII cell line was achieved by
using the BLOCK-iT Lentiviral RNAi from Invitrogen (Thermo Scientific, Carlsbad, CA, USA), following
a procedure detailed in a previous publication [19]. Cells were cultured as described previously [13].
Routine cell culture was carried out at 37 ◦C in a humidified cell incubator at 5% CO2.
For the hypoxic condition, human HPV-negative and HPV-positive cell lines were maintained in a
hypoxia chamber (InvivO2 400 Hypoxia Workstation, Ruskinn) in a humidified atmosphere containing
5% CO2 and 0.1% O2 at 37 ◦C for 48 h.
18
J. Clin. Med. 2019, 8, 75
2.12. MIF Inhibitor
The MIF inhibitor 4-iodo-6-phenylpyrimidine (4-IPP) was purchased from Tocris Bioscience
(Bristol, UK). Stock solutions of the compound were prepared in ethanol, stored at −20 ◦C, and used
within one month.
2.13. Determination of MIF Concentrations
Concentrations of MIF in serum and conditioned medium were assayed by a sandwich
enzyme-linked immunosorbent assay (ELISA) using a commercial kit (DuoSet ELISA Development kit,
R&D Systems, Minneapolis, MN, USA). The assays were carried out according to the instructions
provided by the supplier. MIF concentrations in samples of serum and conditioned medium were
determined by interpolation from a reference curve established from increasing concentrations of
recombinant human or mouse MIF.
2.14. IC50 Determination for the MIF Inhibitor by a Crystal Violet Stain Assay
Cells were seeded in 96-well plates. The following day, cells were fed fresh medium (DMEM or
MEM, 10% FBS) with or without 4-IPP. After a 3-day exposure, the culture medium was discarded,
and cells were fixed with 1% glutaraldehyde. Following fixation, cells were stained with 1% crystal
violet. Destaining was performed under gently running tap water, and cell monolayers were lysed
in 0.2% Triton X-100. The absorbance of cell lysates was measured at 570 nm using a LabSystems
Multiskan MS microplate reader (ThermoScientific, Pittsburgh, PA, USA).
2.15. Western Blotting for the Evaluation of HIF-1α and MIF Expression
Human HPV-positive and HPV-negative cell lines and SCCVII CT, E6, E7, and E6/E7
murine cell lines were plated in Petri dishes, cultured for five days, and lysed using detergent
solution (RIPA buffer) supplemented with protease and phosphatase inhibitors (All reagents from
Pierce, Thermo Scientific, Pierce, Washington, USA). Protein concentrations were determined by
a BCA protein assay (Pierce) using bovine serum albumin as the standard. Extracted proteins
(40 μg) were loaded on 4–20% Mini-PROTEAN TGX gels (SDS) (Bio-Rad Laboratories, München,
Germany) and were electrotransferred onto nitrocellulose membranes (iBlot®Dry Blotting System,
Life Technologies-Invitrogen, Ghent, Belgium). Immunodetection was performed using an anti-HIF-1α
antibody (1/600), an anti-MIF antibody (1/500), and an anti-actin antibody (1/500) (Pierce).
A peroxidase-labeled anti-rabbit IgG antibody (1/5000) (Amersham Pharmacia Biotech, Roosendaal,
The Netherlands) was used as the secondary antibody. Bound peroxidase activity was detected
using the SuperSignal®West Pico Chemiluminescent Substrate (Pierce) following the manufacturer’s
instructions. The bands were visualized by exposing the membranes to photosensitive film (Hyperfilm
ECL, Amersham Pharmacia Biotech). Bands intensities were quantified using ImageJTM software
(a public domain image software developed by W. Rasband at the Research Services Branch of the
National Institute of Mental Health, NIH, Bethesda, MD, USA).
2.16. Animal Study
Experiments were conducted on 40 female C3H/HeN mice (Charles River Laboratory, L’Arbresle,
France). The animals were maintained and handled in compliance with the guidelines issued by the
Belgian Ministry of Trade and Agriculture. SCCVII cells transfected with vectors expressing E6/E7 or
with control vector (CT) were inoculated in the mylohyoid muscle following a procedure detailed in a
previous publication [18]. Animals were checked for tumor onset, and were euthanized when they
exhibited either a tumor diameter exceeding 15 mm, or a weight loss of more than 20%. Postmortem,
blood samples were collected and processed for serum.
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2.17. Cell Sample Preparation for NMR Analysis
Cells of each human cell line were seeded in six 150 mm cell culture dishes, and were maintained
in complete MEM. After four days, the medium was replaced by MEM without FBS. After 48 h,
the medium was harvested, centrifuged for 10 min at 1200 rpm and stored at −80 ◦C until NMR
analysis. Then, the cells were washed twice with ice-cold Dubelcco’s Phosphate Buffer Saline (DPBS).
Then the cells were quenched using 3 mL of cold methanol, detached using a cell scraper and pipetted
into a 15 mL centrifuge tube to which 702 μL of ice-cold distilled water was added. All cell extracts
were vortexed and suspended in a solution of chloroform/methanol/water in a ratio of 4:3:2. After
centrifugation for 30 min at 15000 g, the upper aqueous layer was extracted and used for further
analysis; the organic phase was discarded. The aqueous phases from the samples were dried at 25 ◦C
using a centrifugal vacuum concentrator (Eppendorf) and stored at −80 ◦C until NMR analysis.
2.18. H-NMR Sample Preparation and Spectroscopy
A total of 700 μL and 250 μL of phosphate buffer (0.04M NaH2PO4 and 0.2M Na2HPO4, pH 7.4)
was added to dried samples and to 500 μL of media, respectively. Samples were then centrifuged
for 10 min at 13,000 g, and 650 μL of each sample was transferred to a 5 mm NMR tube, to which
50 μL of 3.5 mM 3-(trimethylsilyl)-propionic-2,2,3,3-d4 acid (TSP) prepared in 100% D2O, was added.
The samples were analyzed on a Bruker Avance 500 spectrometer (11.8 T) operating at 500 MHz for
proton observation with a 5 mm BBI 1H/D-probe. A one-dimensional spectrum was acquired at
297 ◦K, using a 1D-NOESY PRESAT pulse sequence. For each samples, 256 free induction decays (FID)
were collected using a spectral width of 10,330.578 Hz, an acquisition time of 2.65 s, and a pulse recycle
delay of 3 s. After 1H-NMR acquisition, the FID signal was imported into MestReNova 10.0 software
(Mestrelab Research, Santiago de Compostela, Spain) for Fourier transformation. Then, the spectra
were automatically phased and baseline-corrected, and calibrated against TSP. The resonance of the
methyl groups in TSP was arbitrarily set to 0.00 ppm. The spectral region from 0.08–10.00 ppm
was automatically reduced to 496 integrated regions (bins) of 0.02 ppm width each. The regions
from 4.50–5.20 ppm containing the residual water signal were removed. Each integrated region was
normalized to the total spectral area.
The integrated reduced data were imported into SIMCA-P+12 (Umetrics, Umea, Sweden) for
PLS-DA. For the quantification of lactate, the resonance with the higher resolution was selected
and fitted. An area under the curve (AUC) in arbitrary units was obtained (MestReNova software).
This method allowed for statistical comparison between the cell lines.
2.19. Statistical Analyses
SigmaPlot® 11 software was used for statistical analyses. Parametric analyses were conducted
with the Student’s t-test or with analysis of variance for comparison among more than two groups,
and pairwise comparisons were performed using the Holm–Sidak method. Nonparametric analyses
were performed with the Mann-Whitney U test (two groups). A p ≤ 0.05 was considered to indicate a
statistically significant difference.
3. Results
3.1. Tissue MIF Expression is Decreased in the Oral Cavity and in Oropharyngeal Carcinomas Infected with HPV
The immunohistochemical staining of MIF was examined in two series of 117 cases of oral cavity,
and 39 cases of oropharyngeal carcinomas. We did not find statistical correlations between MIF
expression and age, gender, tumor localization, histological grade, tumor stage or alcohol and tobacco
consumption in these series (Tables 1 and 2). However, a staining intensity analysis demonstrated that
oropharyngeal and oral cavity cancer tissues infected with transcriptionally active HPV (p16+) showed
a decrease in MIF expression compared to oropharyngeal and oral cavity cancer tissues not infected by
HPV (n = 21 and n = 65 respectively) (Figure 1, p = 0.001 and p = 0.004 respectively, Kruskal-Wallis test).
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This result was confirmed by a previous proteomic analysis comparing HPV+ve versus HPV−ve
tumors, which indicated that the MIF expression was two-fold lower in an HPV+ve oral cavity cancer
tissue as compared to a HPV−ve oral cavity cancer tissue (p = 0.016, Student’s t-test, data not shown).
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Figure 1. Intracellular migration inhibitory factor (MIF) expression in head and neck cancer
patients. (A) Quantitative analysis of MIF expression in a series of 39 oropharyngeal cancer patients,
including 21 Human Papilloma Virus negative (HPV-ve) cases and 18 HPV+ve cases (p = 0.001,
Kruskal–Wallis test) and (B) 117 oral cavity cancer patients, including 65 HPV-ve cases and 52 HPV+ve
cases (p = 0.004, Kruskal–Wallis test). (C,D) Immunohistochemistry of MIF in HPV-ve (C) and HPV+ve
(D) oropharyngeal cancer cases and (E,F) in HPV-ve (E) and HPV+ve (F) oral cavity cancer cases.
3.2. MIF mRNA Synthesis and Protein Secretion is Increased in HPV-Infected Human Head and Neck Cancer
Cell Lines
To evaluate the differential expression of MIF in HNSCC cells with regard to HPV status,
we compared the MIF messenger RNA (mRNA) expression in three human HPV-negative (FaDu,
UPCI-SCC-131 and Detroit 562) and three HPV-positive (UPCI-SCC090, UPCI-SCC154 and 93VU147T)
cell lines. The quantitative analysis of the MIF mRNA expression by real-time PCR demonstrated that
the MIF mRNA expression was three times greater in HPV-positive cell lines than in HPV-negative
ones (Figure 2A, p <0.001, Student’s t-test), while the MIF protein expression was equally the same
among all of the cell lines (Figure 2B).
Moreover, the concentration of MIF was examined in the culture supernatants of the HNSCC
cell lines and the SCCVII MIF Knockdown (KD) and Scramble (sc). The conditioned medium from
HPV-positive cell lines showed a significantly higher MIF level than the medium originating from
HPV-negative cell lines (Figure 2C, p = 0.04, Student’s t-test). As expected, the conditioned medium
from SCCVII MIFKD exhibited a significantly lesser MIF level than the medium from SCCVII MIFsc
cells (Figure 2E, p = 0.045, Student’s t-test).
Finally, the use of 4-IPP, an inhibitor of MIF, in HPV-negative and HPV-positive HNSCC cell
lines revealed that the concentrations required to achieve a 50% inhibition of cell proliferation were
significantly higher in HPV-positive cell lines than in HPV-negative cell lines (Figure 2D, p = 0.018,
Student’s t-test). This result agrees with the observations that MIF was more highly secreted by
HPV-positive cell lines and that higher concentrations of 4-IPP were required to block this higher level
of MIF, and consequently to inhibit cell proliferation.
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Figure 2. Relative MIF messenger RNA (mRNA), protein expression and macrophage migration
inhibitory factor (MIF) concentration in culture medium from mouse and human culture cell lines
and the response to MIF inhibitor. (A) Upregulation of MIF mRNA in human papilloma virus
(HPV)-positive cell lines compared to the MIF expression in HPV-negative cell lines (p <0.001,
Student’s t-test). (B) Western blot analysis showing the MIF expression in HPV-ve and +ve cell
lines. (C) Increased MIF level in the culture medium of HPV+ve cells (n = 3) compared to the MIF
level in the culture medium of HPV-ve cells (n = 3) (p = 0.04, Student’s t-test). (D) Concentration of
4-iodo-6-phenylpyrimidine (4-IPP) required to achieve 50% inhibition of cell proliferation in human
HPV-ve and HPV+ve cell lines (p = 0.018, Student’s t-test). (E) Increased MIF levels in the culture
medium of SCCVII MIFKD cells (n = 4) compared to the SCCVII MIFsc cells (n = 3) (p = 0.045,
Student’s t-test).
3.3. MIF Secretion is Increased in Murine Head and Neck Cancer Cell Lines Transfected with E6/E7
Oncoproteins In Vitro and In Vivo
To investigate the role of HPV oncoproteins in MIF secretion, we analyzed the concentrations
of MIF in the cell culture medium of SCCVII CT, E6, E7, and E6/E7. This analysis showed that
cells expressing HPV oncoproteins released more MIF than the control cells (Figure 3A, p <0.001,
one-way-analysis of variance (ANOVA) test). Furthermore, the murine SCCVII cell lines expressing
the HPV oncoproteins E6 and/or E7 were exposed to 4-IPP for three days, to examine the resistance
to 4-IPP, as measured by cell proliferation. The results showed that SCCVII E6, E7, and E6/E7 cells
were all more resistant to the MIF inhibitor compared to the SCCVII CT cells, further demonstrating
that E6 and E7 were involved in MIF secretion (Figure 3B, p <0.001, one-way-ANOVA test). Finally,
the in vitro data were validated using an orthotopic animal model to confirm that MIF was more highly
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secreted by cells expressing HPV oncoproteins. SCCVII E6/E7 or SCCVII CT cells were injected into
the floor of the mouth of C3/Hen mice. As expected from in vitro data, mice receiving SCCVII E6/E7
cells presented higher serum MIF levels than mice receiving SCCVII CT cells (Figure 3C, p = 0.013,
Mann-Whitney test).
Figure 3. Macrophage migration inhibitory factor (MIF) secretion by murine cells in vitro and in vivo,
and 4-IPP IC50 in murine cell lines. (A) Increase in the MIF concentration in the culture medium
of SCCVII cells expressing HPV oncoproteins (p <0.001, one-way ANOVA). (B) Percentage of cell
proliferation after exposure to 50 μM 4-iodo-6-phenylpyrimidine (4-IPP) in SCCVII CT, E6, E7 and
E6/E7 cell lines (p <0.001, one-way ANOVA test). (C) Increase in the serum MIF levels of mice receiving
SCCVII E6/E7 cells (n = 18), compared to the serum MIF levels of mice in the control group (CT)
(n = 16) (p = 0.013, Mann–Whitney test).
3.4. Lactate Production and HIF-1α Expression are Increased in HPV-Positive Cell Lines
We hypothesized that MIF secretion may be affected by a Warburg effect involving E6 and E7
oncoproteins, as observed in lung cancer [20]. To assess this hypothesis, a nuclear magnetic resonance
analysis was performed; the partial least-squares discriminant analysis (PLS-DA) allowed us to divide
the HPV-positive cells from the HPV-negative ones (Figure 4A, CV-ANOVA, p <0.001). The loading
plot showed that only lactate comes through the analysis (data not shown). Thus, we examined
the lactate production in both the intracellular and extracellular compartments of HPV-negative
and HPV-positive cells. The results displayed a significant increase in lactate production in the
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culture medium (Figure 4B, p <0.001, Mann–Whitney test) as well as in the intracellular compartment
(Figure 4C, p = 0.024, Mann-Whitney test) of the HPV-positive cells compared to the lactate production
in the culture medium and the intracellular compartment of the HPV-negative cells.
Figure 4. Lactate production in human cell lines. (A) Partial least-squares discriminant analysis
(PLS-DA) for human papilloma virus (HPV)-positive and HPV-negative cell lines. Increase in
lactate production in (B) the extracellular compartment (p <0.001, Mann-Whitney test) and in (C)
the intracellular compartment (p = 0.024, Mann-Whitney test) of HPV-positive and HPV-negative cells.
Besides, it was reported that the induction of the Warburg effect by the HPV oncoproteins through
the mTOR signaling pathway leads to the accumulation of HIF-1α [21]. To verify whether HPV
oncoproteins play a role in the increase in HIF-1α in HNSCC, we analyzed HIF-1α expression by
Western blotting in HPV-positive and HPV-negative human cell lines, as well as in SCCVII CT, E6, E7,
and E6/E7 murine cell lines. The data in Figure 5A demonstrate that globally HPV-positive human
cell lines and the SCCVII E6/E7 murine cell line expressed more HIF-1α than the HPV-negative
human cell lines and the SCCVII CT murine cell line, respectively, under normoxic culture conditions.
Additionally, under hypoxic conditions, which stimulate HIF-1α expression and activity, HPV-negative
cell lines (FaDu, Detroit 562 and UPCI-SCC131) released more MIF in the culture medium (Figure 5B,
p <0.001, Student’s t-test) than did the HPV-positive ones, thus demonstrating that the increase in
HIF-1α led to the rise in MIF secretion. However, the data in Figure 5C show that, under hypoxia,
HPV-positive cell lines (UPCI-SCC154, UPCI-SCC090 and 93VU147T) did not secrete significantly
more MIF than they did under normoxia; this effect was potentially due to a high baseline level of
HIF-1α expression and MIF secretion in these cells (Figure 5C, p = N.S., Student’s t-test).
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Figure 5. Hypoxia inducible factor 1α (HIF-1α) expression in human and murine cell lines. (A) Western
blot analysis demonstrating the upregulation of HIF-1α in two human papilloma virus (HPV)-positive
cell lines (UPCI-SCC-090 and 93VU147T) and in the murine SCCVII E6/E7 cell line. Concentration
of macrophage migration inhibitory factor (MIF) in the culture medium of (B) human HPV-negative
cell lines (p <0.001, Student’s t-test), and (C) in human positive cell lines (N.S., Student’s t-test) under
normoxic and hypoxic conditions.
4. Discussion
As we have previously seen in oral carcinoma, there is no correlation between MIF expression
and age, gender, tumor localization, histological grade, tumor stage, or alcohol and tobacco
consumption [22]. So, MIF expression does not seem to correlate with these clinical characteristics.
However, our data reports an important relationship between MIF secretion and HPV infection,
an additional HNSCC risk factor.
HPV infection occurs more often in the oropharyngeal region of the head and neck, and a high
proportion of infection are caused by HPV-16 type [6]. The oncoproteins E6 and E7 play a crucial role
in the neoplastic transformation of host cells by inactivating p53 and pRb, respectively [23]. In this
study, we have demonstrated that, under normoxic conditions, the E6/E7 oncoproteins enhance
expression of HIF-1α in HNSCC cells, as it was also reported for human cervical carcinoma cells [24].
Our investigation also showed that HPV infection is conducive to an acidic environment, as evidenced
by the increase in lactate production, both in the intracellular compartment and in the culture medium.
In addition, we have observed, for the first time, that MIF expression decreased in the tumor cells
of HNSCC patients with HPV infection, and that MIF secretion was increased in HPV-positive cell
lines, an observation that we confirmed by demonstrating resistance to an inhibitor of MIF (4-IPP)
in human cell lines that were infected with HPV, as well as in murine cell lines expressing the E6
and/or E7 oncoproteins. These data were further supported by the increase in the serum MIF in
mice receiving the SCCVII E6/E7 cells. In view of these findings, we hypothesized that the acidic
environment induced by HPV explains the increase in MIF secretion through the activation of HIF-1α.
Consequently, the MIF mRNA level increases, as we have reported in human HPV-positive cell lines,
thus leading to elevated protein synthesis and the secretion of MIF.
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Other researchers have demonstrated that the E6 and E7 oncoproteins also take part in a
perturbation of cellular metabolism termed the Warburg effect, which is a hallmark of cancer cells.
Indeed, it was demonstrated that E6 interacts with the transcription factor HIF-1α to induce glycolysis
under hypoxia [25]. Moreover, previous studies have shown that the E6 oncoprotein promotes
the activity of the mammalian target of rapamycin (mTOR) signaling pathway, thus leading to the
accumulation of HIF-1α, pyruvate kinase, lactate dehydrogenase, and pyruvate dehydrogenase kinase
1 [21]. The accumulation of these enzymes induces the Warburg effect by increasing the rate of
glycolysis and the production of lactate. It was also reported that the E7 oncoprotein induces the
acetylation of the pyruvate kinase M2 isoform (PKM2), thus promoting the dimeric form of PKM2,
which leads to the conversion of pyruvate to lactate through lactate dehydrogenase (LDHA) [26].
Furthermore, the high-risk HPV E2 protein, which facilitates the integration of the HPV genome
into the host cell genome, could also interact with mitochondrial membranes, thus leading to the
production of reactive oxygen species (ROS). This ROS generation correlates with HIF-1α upregulation
and lactate production [27]. In contrast, keratinocytes infected with HPV-16 exhibit an increase in
monocarboxylate transporter 4 (MCT-4) [28], which is known to participate in lactate export from
stromal cells, releasing lactate into the microenvironment and favoring a reverse-Warburg effect for
cancer cells. All of these observations established that HPV infection leads to an acidification of
the microenvironment. These phenomena may be illustrated by the observations that MIF secretion
increased after ROS production, as was demonstrated in clear cell renal cell carcinoma, breast cancer,
and lung cancer [29]. Additionally, it is well-known that HIF-1α increases the expression of MIF.
Conversely, MIF protects HIF-1α from proteasomal degradation in cancer cells [30–32]. However,
the mechanism of MIF secretion remains unknown, and it needs further investigation.
The production of lactate and MIF by cancer cells infected with HPV could partly explain why
such cells are poorly immunogenic. Indeed, some studies have demonstrated that HPV-positive tumors
contain a low number of tumor-associated immune cells, such as Langerhans cells and cytotoxic T cells,
while they recruit high levels of regulatory T lymphocytes [18,33–35]. In addition, lactate production
induces the recruitment of immunosuppressive cells such as tumor-associated macrophages (TAMs)
and myeloid-derived suppressor cells (MDSCs) [36]. Moreover, it was demonstrated that lactate
inhibits the migration of CD4+ T lymphocytes [37]. Concerning MIF, it was observed that the increase
in MIF expression induced a reduction in the number of CD3+ T cells in the stromal compartment
of laryngeal carcinoma tissues [13]. Furthermore, Dumitru et al. demonstrated that MIF promotes
tumor-associated neutrophil recruitment in a CXCR2-dependent manner in vitro; this recruitment
enhances the migratory properties of HNSCC tumor cells [38]. Finally, MIF contributes to tumor
immune escape by inhibiting CD8+ T lymphocyte and natural killer cell responses through the
downregulation of the NKG2D receptor in ovarian cancer cells [39].
In conclusion, we have reported that MIF is more highly secreted in HPV-positive cells than in
HPV-negative cell lines, probably by a specific still-unknown mechanism of MIF secretion, and that
the E6 and E7 oncoproteins are implicated in this effect. Based on our data and literature, we explain
this relationship by the fact that HPV oncoproteins interact with several pathways and metabolic
processes, notably, the Warburg effect, thus generating MIF production. Figure 6 summarizes these
pathways and our hypothesis. First, E6 activates mTOR, which leads to the accumulation of HIF-1α
that induces the expression of several glycolytic enzymes such as PKM2, LDHA, and the lactate
transporter MCT4; in addition, HIF-1α induces MIF expression [21,32,40]. Second, the E7 oncoprotein
not only promotes the PKM2-mediated generation of lactate, but also induces HIF-1α expression,
thus leading to MIF expression [24,26]. Therefore, the increase in MIF secretion as an immune system
repressor, and the production of lactate through the Warburg effect, both by HPV oncoproteins, may
lead to the development of a pro-tumoral microenvironment.
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Figure 6. Schematic illustration of the role of human papilloma virus (HPV) oncoproteins in the
production of macrophage migration inhibitory factor (MIF). The oncoprotein E6 promotes the
activation of the mTOR signaling pathway, thus leading to the upregulation of hypoxia inducible
factor 1α (HIF-1α), which enhances the production of MIF and increases the production of lactate.
The oncoprotein E7 drives the accumulation of the dimeric form of pyruvate kinase M2 (PKM2),
thus leading to the conversion of pyruvate to lactate through lactate dehydrogenase (LDHA). Moreover,
PKM2 interacts with HIF-1α to amplify the expression of HIF-1α target genes, including MIF and LDHA.
Additionally, the HPV E2 protein localizes to the mitochondrial membrane, leading to the increased
production of reactive oxygen species (ROS), which increases the stability of HIF-1α. The enrichment
of MIF in the extracellular environment could promote the tumor immune escape by the accumulation
of pro-tumoral immune cells such as tumor-associated macrophages (TAM), and by the decrease in
antitumoral cells such as cytotoxic T cells, Langerhans/dendritic cells (DC), and natural killer (NK) cells.
Complete arrows indicate data from the literature, and the red dotted arrow indicates a hypothesis.
5. Conclusions
To conclude, we hypothesized that lactate production and HIF-1α expression induces MIF
secretion via the HPV E6 and E7 oncoproteins, by the stimulation of enzymes participating in the
Warburg effect. This production could lead to development of a pro-tumoral microenvironment.
Author Contributions: Study concept and design: N.K., S.S., F.J. Acquisition of data: N.K., J.R.L., G.D. Analysis
and interpretation of data: N.K., F.J., R.W., J.-M.C, M.R. and S.S. Drafting and reviewing of the manuscript: N.K.,
F.J., J.-M.C., R.W., G.B. and S.S.
Funding: Nadège Kindt is supported by a PhD grant from the Télévie (grant number 7484615) (Belgian National
Fund for Scientific Research, FNRS).
Acknowledgments: We thank Grégoire for providing us SCCVII E6, E7, E6/E7 and CT cell lines.
Conflicts of Interest: The authors declare no conflict of interests.
29
J. Clin. Med. 2019, 8, 75
References
1. Global Burden of Disease Cancer Collaboration; Fitzmaurice, C.; Allen, C.; Barber, R.M.; Barregard, L.;
Bhutta, Z.A.; Brenner, H.; Dicker, D.J.; Chimed-Orchir, O.; Dandona, R.; et al. Global, Regional, and National
Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted
Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study.
JAMA Oncol. 2017, 3, 524–548.
2. Elrefaey, S.; Massaro, M.A.; Chiocca, S.; Chiesa, F.; Ansarin, M. HPV in oropharyngeal cancer: The basics to
know in clinical practice. Acta Otorhinolaryngol. Ital. 2014, 34, 299–309. [PubMed]
3. Saraiya, M.; Unger, E.R.; Thompson, T.D.; Lynch, C.F.; Hernandez, B.Y.; Lyu, C.W.; Steinau, M.; Watson, M.;
Wilkinson, E.J.; Hopenhayn, C.; et al. US assessment of HPV types in cancers: Implications for current and
9-valent HPV vaccines. J. Natl. Cancer Inst. 2015, 107, djv086. [CrossRef]
4. Chera, B.S.; Kumar, S.; Shen, C.; Amdur, R.J.; Dagan, R.; Weiss, J.; Grilley-Olson, J.; Zanation, A.; Hackman, T.;
Blumberg, J.; et al. Plasma Circulating Tumor HPV DNA for the Surveillance of Cancer Recurrence in
HPV-associated Oropharyngeal Cancer. Int. J. Radiat. Oncol. 2018, 102, 1605–1606. [CrossRef]
5. Gupta, G.P.; Kumar, S.; Marron, D.; Amdur, R.J.; Hayes, D.N.; Weiss, J.; Grilley-Olson, J.; Zanation, A.;
Hackman, T.; Zevallos, J.P.; et al. Circulating Tumor HPV16 DNA as a Biomarker of Tumor Genomics and
Disease Control in HPV-associated Oropharyngeal Squamous Cell Carcinoma. Int. J. Radiat. Oncol. 2018,
100, 1310–1311. [CrossRef]
6. Anantharaman, D.; Abedi-Ardekani, B.; Beachler, D.C.; Gheit, T.; Olshan, A.F.; Wisniewski, K.;
Wunsch-Filho, V.; Toporcov, T.N.; Tajara, E.H.; Levi, J.E.; et al. Geographic heterogeneity in the prevalence of
human papillomavirus in head and neck cancer. Int. J. Cancer 2017, 140, 1968–1975. [CrossRef] [PubMed]
7. Näsman, A.; Attner, P.; Hammarstedt, L.; Du, J.; Eriksson, M.; Giraud, G.; Ahrlund-Richter, S.; Marklund, L.;
Romanitan, M.; Lindquist, D.; et al. Incidence of human papillomavirus (HPV) positive tonsillar carcinoma
in Stockholm, Sweden: An epidemic of viral-induced carcinoma? Int. J. Cancer 2009, 125, 362–366. [CrossRef]
8. Vlantis, A.C. Human Papilloma Virus and Oropharyngeal Carcinoma-Lessons from History. Chin. J. Dent.
Res. Off. J. Sci. Sect. Chin. Stomatol. Assoc. CSA 2016, 19, 9–16.
9. Descamps, G.; Karaca, Y.; Lechien, J.R.; Kindt, N.; Decaestecker, C.; Remmelink, M.; Larsimont, D.;
Andry, G.; Hassid, S.; Rodriguez, A.; et al. Classical risk factors, but not HPV status, predict survival
after chemoradiotherapy in advanced head and neck cancer patients. J. Cancer Res. Clin. Oncol. 2016, 142,
2185–2196. [CrossRef] [PubMed]
10. Filleul, O.; Preillon, J.; Crompot, E.; Lechien, J.; Saussez, S. Incidence of head and neck cancers in Belgium:
Comparison with world wide and French data. Bull. Cancer (Paris) 2011, 98, 1173–1183.
11. Bloom, B.R.; Bennett, B. Mechanism of a reaction in vitro associated with delayed-type hypersensitivity.
Science 1966, 153, 80–82. [CrossRef] [PubMed]
12. Kindt, N.; Journe, F.; Laurent, G.; Saussez, S. Involvement of macrophage migration inhibitory factor in
cancer and novel therapeutic targets. Oncol. Lett. 2016, 12, 2247–2253. [CrossRef]
13. Kindt, N.; Preillon, J.; Kaltner, H.; Gabius, H.-J.; Chevalier, D.; Rodriguez, A.; Johnson, B.D.; Megalizzi, V.;
Decaestecker, C.; Laurent, G.; et al. Macrophage migration inhibitory factor in head and neck squamous
cell carcinoma: Clinical and experimental studies. J. Cancer Res. Clin. Oncol. 2013, 139, 727–737. [CrossRef]
[PubMed]
14. Duray, A.; Descamps, G.; Decaestecker, C.; Sirtaine, N.; Gilles, A.; Khalifé, M.; Chantrain, G.;
Depuydt, C.E.; Delvenne, P.; Saussez, S. Human papillomavirus predicts the outcome following concomitant
chemoradiotherapy in patients with head and neck squamous cell carcinomas. Oncol. Rep. 2013, 30, 371–376.
[CrossRef] [PubMed]
15. PrimerBank. Available online: https://pga.mgh.harvard.edu/primerbank/ (accessed on 4 October 2018).
16. Sawicka, M.; Pawlikowski, J.; Wilson, S.; Ferdinando, D.; Wu, H.; Adams, P.D.; Gunn, D.A.; Parish, W.
The specificity and patterns of staining in human cells and tissues of p16INK4a antibodies demonstrate
variant antigen binding. PLoS ONE 2013, 8, e53313. [CrossRef] [PubMed]
17. Cludts, S.; Decaestecker, C.; Johnson, B.; Lechien, J.; Leroy, X.; Kindt, N.; Kaltner, H.; André, S.;
Gabius, H.-J.; Saussez, S. Increased expression of macrophage migration inhibitory factor during progression
to hypopharyngeal squamous cell carcinoma. Anticancer Res. 2010, 30, 3313–3319. [PubMed]
30
J. Clin. Med. 2019, 8, 75
18. Kindt, N.; Descamps, G.; Seminerio, I.; Bellier, J.; Lechien, J.R.; Mat, Q.; Pottier, C.; Delvenne, P.; Journé, F.;
Saussez, S. High stromal Foxp3-positive T cell number combined to tumor stage improved prognosis in
head and neck squamous cell carcinoma. Oral Oncol. 2017, 67, 183–191. [CrossRef]
19. Zhou, Q.; Yan, X.; Gershan, J.; Orentas, R.J.; Johnson, B.D. Expression of macrophage migration inhibitory
factor by neuroblastoma leads to the inhibition of antitumor T cell reactivity in vivo. J. Immunol. 2008, 181,
1877–1886. [CrossRef] [PubMed]
20. Fan, R.; Hou, W.-J.; Zhao, Y.-J.; Liu, S.-L.; Qiu, X.-S.; Wang, E.-H.; Wu, G.-P. Overexpression of HPV16 E6/E7
mediated HIF-1α upregulation of GLUT1 expression in lung cancer cells. Tumour Biol. J. Int. Soc. Oncodev.
Biol. Med. 2016, 37, 4655–4663. [CrossRef] [PubMed]
21. Coppock, J.D.; Lee, J.H. mTOR, metabolism, and the immune response in HPV-positive head and neck
squamous cell cancer. World J. Otorhinolaryngol. Head Neck Surg. 2016, 2, 76–83. [CrossRef]
22. Kindt, N.; Lechien, J.; Decaestecker, C.; Rodriguez, A.; Chantrain, G.; Remmelink, M.; Laurent, G.;
Gabius, H.-J.; Saussez, S. Expression of macrophage migration-inhibitory factor is correlated with progression
in oral cavity carcinomas. Anticancer Res. 2012, 32, 4499–4505. [PubMed]
23. Howard, J.D.; Chung, C.H. Biology of Human Papillomavirus–Related Oropharyngeal Cancer.
Semin. Radiat. Oncol. 2012, 22, 187–193. [CrossRef]
24. Tang, X.; Zhang, Q.; Nishitani, J.; Brown, J.; Shi, S.; Le, A.D. Overexpression of human papillomavirus type
16 oncoproteins enhances hypoxia-inducible factor 1 alpha protein accumulation and vascular endothelial
growth factor expression in human cervical carcinoma cells. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res.
2007, 13, 2568–2576. [CrossRef] [PubMed]
25. Guo, Y.; Meng, X.; Ma, J.; Zheng, Y.; Wang, Q.; Wang, Y.; Shang, H. Human papillomavirus 16 E6 contributes
HIF-1α induced Warburg effect by attenuating the VHL-HIF-1α interaction. Int. J. Mol. Sci. 2014, 15,
7974–7986. [CrossRef] [PubMed]
26. Wong, N.; Ojo, D.; Yan, J.; Tang, D. PKM2 contributes to cancer metabolism. Cancer Lett. 2015, 356, 184–191.
[CrossRef] [PubMed]
27. Lai, D.; Tan, C.L.; Gunaratne, J.; Quek, L.S.; Nei, W.; Thierry, F.; Bellanger, S. Localization of HPV-18 E2
at mitochondrial membranes induces ROS release and modulates host cell metabolism. PLoS ONE 2013,
8, e75625. [CrossRef]
28. Pinheiro, C.; Garcia, E.A.; Morais-Santos, F.; Scapulatempo-Neto, C.; Mafra, A.; Steenbergen, R.D.M.;
Boccardo, E.; Villa, L.L.; Baltazar, F.; Longatto-Filho, A. Lactate transporters and vascular factors in
HPV-induced squamous cell carcinoma of the uterine cervix. BMC Cancer 2014, 14, 751. [CrossRef]
29. Gupta, Y.; Pasupuleti, V.; Du, W.; Welford, S.M. Macrophage Migration Inhibitory Factor Secretion Is Induced
by Ionizing Radiation and Oxidative Stress in Cancer Cells. PLoS ONE 2016, 11, e0146482. [CrossRef]
[PubMed]
30. Fu, H.; Luo, F.; Yang, L.; Wu, W.; Liu, X. Hypoxia stimulates the expression of macrophage migration
inhibitory factor in human vascular smooth muscle cells via HIF-1alpha dependent pathway. BMC Cell Biol.
2010, 11, 66. [CrossRef] [PubMed]
31. Oda, S.; Oda, T.; Nishi, K.; Takabuchi, S.; Wakamatsu, T.; Tanaka, T.; Adachi, T.; Fukuda, K.; Semenza, G.L.;
Hirota, K. Macrophage migration inhibitory factor activates hypoxia-inducible factor in a p53-dependent
manner. PLoS ONE 2008, 3, e2215. [CrossRef]
32. No, Y.R.; Lee, S.-J.; Kumar, A.; Yun, C.C. HIF1α-Induced by Lysophosphatidic Acid Is Stabilized via
Interaction with MIF and CSN5. PLoS ONE 2015, 10, e0137513. [CrossRef] [PubMed]
33. Lechner, A.; Schlößer, H.; Rothschild, S.I.; Thelen, M.; Reuter, S.; Zentis, P.; Shimabukuro-Vornhagen, A.;
Theurich, S.; Wennhold, K.; Garcia-Marquez, M.; et al. Characterization of tumor-associated T-lymphocyte
subsets and immune checkpoint molecules in head and neck squamous cell carcinoma. Oncotarget 2017, 8,
44418–44433. [CrossRef] [PubMed]
34. Kindt, N.; Descamps, G.; Seminerio, I.; Bellier, J.; Lechien, J.R.; Pottier, C.; Larsimont, D.; Journé, F.;
Delvenne, P.; Saussez, S. Langerhans cell number is a strong and independent prognostic factor for head and
neck squamous cell carcinomas. Oral Oncol. 2016, 62, 1–10. [CrossRef] [PubMed]
35. Nguyen, N.; Bellile, E.; Thomas, D.; McHugh, J.; Rozek, L.; Virani, S.; Peterson, L.; Carey, T.E.; Walline, H.;
Moyer, J.; et al. Tumor infiltrating lymphocytes and survival in patients with head and neck squamous cell
carcinoma. Head Neck 2016, 38, 1074–1084. [CrossRef] [PubMed]
31
J. Clin. Med. 2019, 8, 75
36. Ding, J.; Karp, J.E.; Emadi, A. Elevated lactate dehydrogenase (LDH) can be a marker of immune suppression
in cancer: Interplay between hematologic and solid neoplastic clones and their microenvironments.
Cancer Biomark. Sect. Dis. Markers 2017, 19, 353–363. [CrossRef] [PubMed]
37. Haas, R.; Smith, J.; Rocher-Ros, V.; Nadkarni, S.; Montero-Melendez, T.; D’Acquisto, F.; Bland, E.J.;
Bombardieri, M.; Pitzalis, C.; Perretti, M.; et al. Lactate Regulates Metabolic and Pro-inflammatory Circuits
in Control of T Cell Migration and Effector Functions. PLoS Biol. 2015, 13, e1002202. [CrossRef] [PubMed]
38. Dumitru, C.A.; Gholaman, H.; Trellakis, S.; Bruderek, K.; Dominas, N.; Gu, X.; Bankfalvi, A.; Whiteside, T.L.;
Lang, S.; Brandau, S. Tumor-derived macrophage migration inhibitory factor modulates the biology of head
and neck cancer cells via neutrophil activation. Int. J. Cancer 2011, 129, 859–869. [CrossRef]
39. Krockenberger, M.; Dombrowski, Y.; Weidler, C.; Ossadnik, M.; Hönig, A.; Häusler, S.; Voigt, H.; Becker, J.C.;
Leng, L.; Steinle, A.; et al. Macrophage migration inhibitory factor contributes to the immune escape of
ovarian cancer by down-regulating NKG2D. J. Immunol. 2008, 180, 7338–7348. [CrossRef]
40. Ullah, M.S.; Davies, A.J.; Halestrap, A.P. The plasma membrane lactate transporter MCT4, but not MCT1, is
up-regulated by hypoxia through a HIF-1alpha-dependent mechanism. J. Biol. Chem. 2006, 281, 9030–9037.
[CrossRef]
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution





Polymorphisms in ERCC5 rs17655 and ERCC1
rs735482 Genes Associated with the Survival of
Male Patients with Postoperative Oral Squamous
Cell Carcinoma Treated with Adjuvant
Concurrent Chemoradiotherapy
Thomas Senghore 1,2, Huei-Tzu Chien 3,4, Wen-Chang Wang 5, You-Xin Chen 1,
Chi-Kuang Young 6, Shiang-Fu Huang 3,7,* and Chih-Ching Yeh 1,8,*
1 School of Public Health, College of Public Health, Taipei Medical University, Taipei 11031, Taiwan;
tsenghore@gmail.com (T.S.); youxin810@gmail.com (Y.-X.C.)
2 Department of Nursing, School of Medicine and Allied Health Sciences, University of The Gambia,
Independence Drive, Banjul, P.O. Box 1646, The Gambia
3 Department of Public Health, Chang Gung University, Tao-Yuan 33305, Taiwan; kathy.htchien@gmail.com
4 Department of Nutrition and Health Sciences, Chang Gung University of Science and Technology,
Taoyuan 33302, Taiwan
5 Ph.D. Program for Translational Medicine, College of Medical Science and Technology,
Taipei Medical University, Taipei 11031, Taiwan; wangwc@tmu.edu.tw
6 Department of Otolaryngology, Chang Gung Memorial Hospital, Keelung 20401, Taiwan;
rioriorioman@gmail.com
7 Department of Otolaryngology, Head and Neck Surgery, Chang Gung Memorial Hospital, Linkou,
Taoyuan 33305, Taiwan
8 Department of Public Health, College of Public Health, China Medical University, Taichung 40402, Taiwan
* Correspondence: shiangfu.huang@gmail.com (S.-F.H.); ccyeh@tmu.edu.tw (C.-C.Y.);
Tel.: +886-3-3281200 (S.-F.H.); +886-2-7361661 (ext. 6534) (C.-C.Y.)
Received: 26 November 2018; Accepted: 25 December 2018; Published: 1 January 2019
Abstract: The nucleotide excision repair (NER) pathway plays a major role in the repair of DNA
damaged by exogenous agents, such as chemotherapeutic and radiotherapeutic agents. Thus,
we investigated the association between key potentially functional single nucleotide polymorphisms
(SNPs) in the NER pathway and clinical outcomes in oral squamous cell carcinoma (OSCC) patients
treated with concurrent chemoradiotherapy (CCRT). Thirteen SNPs in five key NER genes were
genotyped in 319 male OSCC patients using iPLEX MassARRAY. Cox proportional hazards models
and Kaplan–Meier survival curves were used to estimate the risk of death or recurrence. Carriers
of the XPC rs2228000 TT genotype showed a borderline significant increased risk of poor overall
survival under the recessive model (hazard ratio (HR) = 1.81, 95% confidence interval (CI) = 0.99–3.29).
The CC genotypes of ERCC5 rs17655 (HR = 1.54, 95% CI = 1.03–2.29) and ERCC1 rs735482 (HR = 1.65,
95% CI = 1.06–2.58) were associated with an increased risk of worse disease-free survival under the
recessive model. In addition, participants carrying both the CC genotypes of ERCC5 rs17655 and
ERCC1 rs735482 exhibited an enhanced susceptibility for recurrence (HR = 2.60, 95% CI = 1.11–6.09).
However, no statistically significant interaction was observed between them. Our findings reveal that
the ERCC5 rs17655 CC and ERCC1 rs735482 CC genotypes were associated with an increased risk of
recurrence in male patients with OSCC treated with CCRT. Therefore, CCRT may not be beneficial,
and alternative treatments are required for such patients.
Keywords: nucleotide excision repair; genetic polymorphism; oral squamous cell carcinoma; concurrent
chemoradiotherapy; prognosis
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1. Introduction
Oral squamous cell carcinoma (OSCC) is the leading cause of cancer morbidity and mortality,
especially among men in Taiwan [1]. Despite new advances in the diagnosis and therapeutic
approaches, the 5-year survival remains low [1,2]. While relapse of OSCC remains a major clinical
challenge, the incidence of relapse among patients varies, even for those with a similar stage of disease
at diagnosis or those who undergo the same treatment [3]. This implies that other factors, such as
genetic variations, may play an important role in disease prognosis.
Most patients with OSCC are diagnosed at an advanced stage of the disease [4]. For these patients,
the treatment options are limited to mainly systemic therapy, often as concurrent chemoradiotherapy
(CCRT) with platinum-based DNA damaging agents as either primary treatment or adjuvant
postoperative therapy [5–7]. However, the overall survival (OS) for these patients remains poor
because most of them experience recurrence or distance metastases [8–10]. Genetic variations in DNA
repair genes affect susceptibility to the efficacy and survival outcome of a certain treatment [11,12].
Increased DNA repair capacity may affect the sensitivity of the tumor cells to chemotherapy and
radiotherapy (RT) by allowing cancer cells to repair DNA that has been damaged by these agents.
Single nucleotide polymorphism (SNP) in genes involved in the nucleotide excision repair (NER)
pathway may modulate DNA repair capacity by influencing gene expression or activity, thereby
affecting the anticancer effects of therapeutic agents and treatment response [13,14].
The excision repair cross-complementation genes, including groups 1 (ERCC1), 2 (ERCC2), and 5
(ERCC5) and xeroderma pigmentosium complementation group A (XPA) and C (XPC) encode proteins
that are involved in the NER pathway; and together with other proteins, operate to recognize and
repair damaged DNA [15]. The XPC together with XPF initially recognize the DNA lesion that is
unwound and remodeled by helicase proteins ERCC3 and ERCC2 that binds to XPA and replication
protein A (RPA). The ERCC1 and ERCC5 proteins are involved in the incision of the identified DNA
lesion. The difference in treatment response and clinical outcome have been attributed to SNPs in genes
that code of the above proteins [13,14]. Therefore, identifying genetic markers in the NER pathway
may help develop personalized management strategies, thereby maximizing treatment success and
improving survival.
Thus, we conducted a retrospective cohort study to test whether SNPs in genes involved in the
NER pathway are associated with prognosis in male patients with OSCC treated with adjuvant CCRT.
A total of 13 SNPs in ERCC5, ERCC2, ERCC1, XPC, and XPA genes, which have been found to affect
the risk and/or survival of cancers, were selected in the present study [13,14,16–20]. Their associations
with clinical outcomes were evaluated using alternative genetic models, including additive, dominant,
and recessive models.
2. Material and Methods
2.1. Study Population
In total, 360 male participants newly diagnosed with histopathological confirmed advanced
OSCC who received surgery plus adjuvant CCRT were recruited from the Head and Neck Surgery
Department’s Cancer Registry at Chang Gung Memorial Hospital, LinKou, Taiwan, from 1999 to
2016. A total of 41 participants were excluded, including 13 of aboriginal ethnicity, 23 with early-stage
oral cancer (TNM stages I and II), and 5 with missing information on clinicopathologic variables
(TNM stage, vascular invasion, and extracapsular spread). A final sample of 319 was included for
analysis. Information on demographic characteristics (age, education, occupation, and ethnicity),
lifestyle habit (cigarette smoking, alcohol drinking, and betel nut chewing), and family cancer history
were collected through an interviewer-administered questionnaire. Lifestyle habits were categorized as
either never (if the person never engaged in the habit continuously for more than a year) or ever (if the
person ever engaged in the habit for more than a year). From the weight and height measurements,
body mass index (BMI) was calculated as weight/height2 (kg/m2). Clinical information was also
34
J. Clin. Med. 2019, 8, 33
collected before treatment through a detailed medical history, physical examination, completed blood
count, routine blood chemistry, computed tomography (CT) or magnetic resonance imaging (MRI) of
the head and neck, abdominal ultrasound, and whole body bone scan or positron emission tomography
scan. This study was approved by the Chang Gung Memorial Hospital (IRB No. 201800213B0) and
Taipei Medical University ethics review committees (IRB No. N201802083). All participants provided
written informed consent after a detailed explanation of study objectives.
2.2. Sample Preparation and DNA Extraction
For each participant, a pair of tumor and normal adjacent nontumor tissue samples were
surgically removed, dissected into small pieces, and immediately stored in liquid nitrogen at −80 ◦C.
The surgically removed samples were then sent for pathological examination and staging as per the
seventh edition of the American Joint Committee on Cancer—TNM staging system [21]. Histology
diagnosis was defined as squamous cell carcinoma, verrucous carcinoma, cylindric cell carcinoma,
adenoid cystic carcinoma, mucoepidermoid carcinoma, and adenocarcinoma. For this study, only those
with a diagnosis of squamous cell carcinoma were included. Venous blood samples were also collected
and stored in heparinized tubes. Germline DNA was extracted from buffer-coated cells using the
standard phenol-chloroform method and prepared for genotyping.
2.3. SNP Selection and Genotyping
SNPs in the NER pathway were selected from studies that indicated that SNPs were associated
with the risk or prognosis of malignancies in ethnic Chinese [16,18–20]. A total of 13 potentially
functional SNPs in ERCC5 (rs2094258, rs1047768, rs17655, and rs873601), ERCC2 (rs13181 and
rs1799793), ERCC1 (rs735482, rs3212986, and rs11615), XPC (rs2228001 and rs2228000), and XPA
(rs1800975 and rs10817938) genes were genotyped using the Sequenom iPLEX MassARRAY system
(Sequenom, Inc., San Diego, CA, USA). A 10% random sample was reanalyzed, and it showed 100%
concordance for all the polymorphisms.
2.4. Patient Treatment and Follow-Up
All patients underwent radical tumor excision with clinical stage-based neck dissection
after preoperative tumor survey. The primary tumors were resected above 1-cm safety margins
(both peripheral and deep margins). Neck dissections were performed according to examination status.
If the lesion invaded deeply and crossed the midline, as observed in tongue cancer, bilateral neck
dissection was performed. Pathologic parameters included tumor stage, nodal status, extranodal
extension (ENE), tumor cell differentiation, perineural invasion, skin invasion, bone invasion,
and tumor depth. Postoperative RT was administered to patients with pT4 stage tumor, pathologically
close margins (≤4 mm), or pathologically positive lymph nodes. The radiation dose lay between
6000 and 6600 cGy. CCRT with cisplatin-based agents was administered to patients with ENE or
pathological multiple lymph node metastases 4 to 8 weeks after the surgical procedure. During the
course of RT, 5-fluorouracil was administered orally.
Following commencement of treatment, the participants were monitored during their treatment
and after treatment through regular clinical and radiological examinations. Follow-up involved
monthly checkups for the first 6 months. This was followed by checkups every 2 months in the
second 6 months, then checkups every 3 months within the second year, and checkups every 6 months
thereafter. The follow-up included an analysis of medical history, physical examination (including
complete oral examination), laboratory examination, X-rays, and CT or MRI. To confirm recurrence,
histology of biopsy or imaging studies were conducted. Data for all deaths resulting from OSCC were
based on death certificates.
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2.5. Statistical Analysis
Statistical analysis was performed using SAS (version 9.4 for Windows; SAS institute, Cary, NC,
USA). Demographic and clinical characteristics were summarized as mean and standard deviation
for continuous variables and frequency and proportions for categorical variables. The distribution
of genotypes by clinical characteristics was assessed using Chi-square test. Major clinical outcomes
were disease-free survival (DFS) and OS. DFS was measured from the first day of treatment to the
time of recurrence, metastasis, or death due to any cause. OS was calculated as the time elapsed
(in months) from the date of commencing RT to the date of death. Patients without an event at the
date of the last contact were considered as being censured or subject to administrative censoring by
the end of the follow-up period. Survival analysis was conducted using the Kaplan–Meier method,
and survival curve differences among the genotypes were compared using the log-rank test. Univariate
and multivariate Cox proportional hazards models were used to evaluate the effects of demographic,
clinical characteristics, and SNPs on survival. Hazard ratios (HRs) and their 95% confidence intervals
(CIs) were used to estimate the relative risk of death or recurrence. We evaluated the individual
variants in different genetic models, including additive, dominant, and recessive models, on OSCC
survival. Sociodemographic and clinical factors significant in the univariate analysis were adjusted in
multivariate Cox regression models. Furthermore, multiplicative interactions were evaluated using
the likelihood ratio test. Due to the location of multiple SNPs within the same chromosome or gene,
linkage disequilibrium (LD) analysis was performed using Haploview (version 4.2). For those SNPs
within the same block that were found to be in high LD with each other, further haplotypes analysis
was performed using PHASE software (version 2.1) [22]. Statistical significance was set at p < 0.05 and
was two-sided.
3. Results
3.1. Demographic and Clinical Characteristics of Study Participants
The demographic and clinical characteristics of the study patients are summarized in Table 1.
The mean age was 49.72 ± 9.8. Most participants were under 50 years (51.41%) old, of Taiwanese
descent (paternal 72.10% and maternal 74.92%), had normal BMI (49.22%), had smoked cigarettes
(according to the “ever” criterion; 85.25%), drank alcohol (69.28%), and chewed betel nut (86.21%).
A considerable number of patients exhibited poor clinical characteristics. In total, 55 (17.24%) had
poorly differentiated tumors, 197 (61.76%) had primary tumor size in the T3 to T4 range, 217 (67.92%)
had N2 to N3 nodal involvement, 177 (55.49%) had perineural invasion, 19 (5.96%) had vascular
invasion, 40 (12.54%) had lymphatic invasion, 205 (64.24%) had ENE, and 277 (86.83%) had pathologic
TNM stage IV. The genotype frequency distribution analysis showed a statistically significant difference
in genotypes of ERCC1 rs11615 in terms of tumor differentiation (p = 0.039), XPC rs2228000 in terms of
vascular invasion (p = 0.045), ERCC1 rs3212986 and XPA rs10817938 in terms of lymphatic invasion
(p = 0.046 and 0.033, respectively), XPC rs2228001 in terms of pathologic TNM stage (p = 0.039),
and ERCC5 rs17655 in terms of DFS (p = 0.049) (Table S1).
3.2. Survival Analysis
The median (range) follow-up duration was 15 months (1–199 months) and 12 months
(1–199 months) for OS and DFS, respectively. In the univariate analysis, N2–N3 nodal involvement
(HR = 2.41, 95% CI = 1.42–4.10), lymphatic invasion (HR = 2.18, 95% CI = 1.30–3.67), and ENE
(HR = 3.91, 95% CI = 2.13–7.19) were significantly associated with OS, whereas primary tumor size
in the range of T3 to T4 (HR = 1.72, 95% CI = 1.17–2.53), N2–N3 nodal involvement (HR = 1.63,
95% CI = 1.09–2.44), and ENE (HR = 1.79, 95% CI = 1.20–2.69) were significantly associated with DFS.
However, no significant association was observed between demographic and lifestyle factors and
survival (Table 2).
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Table 1. Demographic and clinical characteristics of patients with oral squamous cell carcinoma (OSCC)
treated with concurrent chemoradiotherapy (CCRT).
Variable n (%)
Total 319 (100)

























































OSCC, oral squamous cell carcinoma; SD, standard deviation; BMI, body mass index.
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Table 2. Univariate association of demographic and clinical factors with survival in patients with
OSCC treated with CCRT.
Variable
Overall Survival Disease-Free Survival
HR (95% CI) p Value HR (95% CI) p Value
Age
<50 1.00 1.00
≥50 0.67 (0.44–1.03) 0.068 0.81 (0.57–1.15) 0.239
Ethnicity of father
Taiwanese 1.00 1.00
Hakka 0.88 (0.51–1.50) 0.633 0.66 (0.40–1.08) 0.101
Mainland Chinese 1.27 (0.55–2.93) 0.577 1.72 (0.94–3.14) 0.079
Ethnicity of mother
Taiwanese 1.00 1.00
Hakka 0.75 (0.43–1.29) 0.295 0.67 (0.42–1.08) 0.100
Mainland Chinese 1.80 (0.57–5.72) 0.320 1.60 (0.59–4.37) 0.355
BMI, kg/m2
18.5–23.9 1.00 1.00
<18.5 0.85 (0.36–1.98) 0.705 1.49 (0.79–2.84) 0.223
≥24 0.66 (0.42–1.03) 0.068 0.84 (0.58–1.23) 0.372
Cigarette smoking
Never 1.00 1.00
Ever 0.89 (0.51–1.57) 0.675 1.02 (0.62–1.68) 0.938
Alcohol drinking
Never 1.00 1.00
Ever 0.99 (0.64–1.54) 0.971 1.10 (0.75–1.61) 0.636
Betel nut chewing
Never 1.00 1.00
Ever 1.09 (0.58–2.05) 0.794 1.40 (0.80–2.45) 0.240
Tea drinking
Never 1.00 1.00
Ever 0.93 (0.61–1.41) 0.727 1.07 (0.75–1.53) 0.701
Coffee drinking
Never 1.00 1.00
Ever 0.65 (0.37–1.13) 0.123 1.27 (0.85–1.89) 0.251
Tumor differentiation
Well differentiated 1.00 1.00
Moderate 0.94 (0.55–1.60) 0.819 0.89 (0.56–1.44) 0.645
Poor 0.84 (0.40–1.74) 0.629 1.22 (0.68–2.18) 0.500
Unclear 2.80 (0.37–1.19) 0.319 1.66 (0.22–2.39) 0.621
Primary tumor size
T1–T2 1.00 1.00
T3–T4 1.29 (0.83–2.01) 0.258 1.72 (1.17–2.53) 0.006 *
Nodal involvement
N0–N1 1.00 1.00
N2–N3 2.41 (1.42–4.10) 0.001 * 1.63 (1.09–2.44) 0.018 *
Perineural invasion
No 1.00 1.00
Yes 1.29 (0.85–1.98) 0.238 1.27 (0.89–1.83) 0.189
Vascular invasion
No 1.00 1.00
Yes 1.43 (0.66–3.10) 0.366 0.43 (0.43–2.00) 0.856
Lymphatic invasion
No 1.00 1.00
Yes 2.18 (1.30–3.67) 0.003 * 1.37 (0.82–2.28) 0.233
Extranodal extension
No 1.00 1.00
Yes 3.91 (2.13–7.19) <0.001 * 1.79 (1.20–2.69) 0.005 *
Pathologic TNM stage
III 1.00 1.00
IV 1.64 (0.81–3.29) 0.168 1.66 (0.93–2.96) 0.087
BMI, body mass index; OSCC, oral squamous cell carcinoma; HR, hazard ratio; CI, confidence interval. * p < 0.05.
In the univariate Cox proportional hazards models, the ERCC1 rs735482 CC genotype was
marginally significantly associated with poor DFS (HR = 1.53, 95% CI = 0.99–2.38; p = 0.058). The XPA
rs10817938 CC genotype was significantly associated with an increased risk of worse OS (HR = 2.97,
95% CI = 1.20–7.35; p = 0.019), and DFS (HR = 2.61, 95% CI = 1.06–6.41; p = 0.037), respectively
(Table S2).
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The results for the multivariate Cox proportional hazards models with covariates adjusted
for all selected SPNs are shown in Table 3. Only the XPC rs2228000 TT genotype (HR = 1.81,
95% CI = 0.99–3.29, p = 0.053) showed an increased risk of poor OS at borderline significance compared
with the CC+CT genotypes. The ERCC5 rs17655 CC (HR = 1.50, 95% CI = 1.01–2.24; p = 0.045)
and ERCC1 rs735482 CC (HR = 1.61, 95% CI = 1.04–2.51; p = 0.034) genotypes were significantly
associated with an increased risk of DFS compared with their counterparts with the GG+GC and
AA+AC genotypes, respectively, in the recessive models. The test of LD show that SNPs in ERCC5
block 1 (rs2094258 and rs1047768; D’ = 0.97, R2 = 0.19) and block 2 (rs17655 and rs873601; D’ = 0.98,
R2 = 0.89), ERCC1 block (rs3212986 and rs11615; D’ = 1.00, R2 = 0.18), XPC block (rs2228001 and
rs2228000; D’ = 1.00, R2 = 0.28), and XPA block (rs1800975 and rs10817938; D’ = 1.00, R2 = 0.24) were
in LD with each other (Figure S1). Of the haplotype constructed from these blocks, only XPA GT
haplotype (HR = 0.68, 95% CI = 0.47–0.99; p = 0.042) showed statistically significant association with
OS (Table S3).
Table 3. Multivariate association between nucleotide excision repair (NER) candidate single nucleotide
polymorphisms (SNPs) and OSCC survival in patients treated with CCRT.
SNPs
Overall Survival Disease-Free Survival




GA 1.14 (0.72–1.79) 0.574 1.07 (0.73–1.57) 0.726
AA 0.66 (0.30–1.44) 0.294 1.02 (0.57–1.83) 0.946
Additive model 0.91 (0.66–1.25) 0.559 1.03 (0.79–1.34) 0.839
Dominant model 1.03 (0.66–1.59) 0.910 1.06 (0.74–1.52) 0.754
Recessive model 0.61 (0.29–1.28) 0.193 0.99 (0.57–1.70) 0.958
rs1047768
TT 1.00 1.00
TC 1.11 (0.72–1.72) 0.635 0.93 (0.64–1.36) 0.715
CC 0.63 (0.25–1.62) 0.339 0.76 (0.39–1.51) 0.438
Additive model 0.94 (0.67–1.31) 0.699 0.90 (0.68–1.19) 0.453
Dominant model 1.03 (0.67–1.58) 0.891 0.90 (0.63–1.29) 0.574
Recessive model 0.60 (0.24–1.49) 0.272 0.79 (0.41–1.53) 0.482
rs17655
GG 1.00 1.00
GC 0.95 (0.58–1.54) 0.829 0.86 (0.56–1.31) 0.482
CC 0.93 (0.51–1.69) 0.811 1.38 (0.86–2.19) 0.180
Additive model 0.96 (0.72–1.30) 0.803 1.16 (0.91–1.49) 0.238
Dominant model 0.94 (0.60–1.49) 0.799 1.01 (0.69–1.49) 0.954
Recessive model 0.96 (0.58–1.61) 0.881 1.50 (1.01–2.24) 0.045 *
rs873601
AA 1.00 1.00
AG 0.77 (0.47–1.26) 0.298 0.84 (0.55–1.31) 0.448
GG 0.84 (0.47–1.51) 0.556 1.29 (0.80–2.09) 0.301
Additive model 0.91 (0.67–1.23) 0.530 1.14 (0.88–1.48) 0.311
Dominant model 0.79 (0.50–1.26) 0.304 0.97 (0.65–1.46) 0.900




TG 1.03 (0.59–1.81) 0.909 1.00 (0.61–1.64) 0.997
GG - 0.989 - 0.984
Additive model 1.03 (0.59–1.80) 0.921 1.00 (0.61–1.63) 0.993
Dominant model 1.03 (0.59–1.81) 0.915 1.00 (0.61–1.64) 0.998
Recessive model - 0.989 - 0.984
rs1799793
GG 1.00 1.00
GA 1.10 (0.58–2.07) 0.769 1.01 (0.58–1.73) 0.983
AA - 0.99 - -
Additive model 1.10 (0.58–2.06) 0.778 1.01 (0.58–1.73) 0.983
Dominant model 1.10 (0.58–2.07) 0.773 1.01 (0.58–1.73) 0.983
Recessive model - 0.99 - -
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Table 3. Cont.
SNPs
Overall Survival Disease-Free Survival




AC 0.72 (0.46–1.14) 0.163 0.86 (0.57–1.29) 0.466
CC 0.83 (0.44–1.59) 0.580 1.47 (0.89–2.44) 0.134
Additive model 0.86 (0.62–1.19) 0.352 1.16 (0.89–1.52) 0.283
Dominant model 0.75 (0.48–1.15) 0.183 0.98 (0.67–1.44) 0.934
Recessive model 1.01 (0.56–1.83) 0.975 1.61 (1.04–2.51) 0.034 *
rs3212986
GG 1.00 1.00
GT 1.20 (0.76–1.89) 0.436 0.95 (0.66–1.39) 0.806
TT 1.04 (0.48–2.28) 0.922 0.96 (0.50–1.85) 0.912
Additive model 1.08 (0.78–1.51) 0.642 0.97 (0.73–1.29) 0.833
Recessive model 1.17 (0.75–1.82) 0.481 0.96 (0.67–1.37) 0.805
Dominant model 0.94 (0.45–1.97) 0.870 0.99 (0.53–1.85) 0.967
rs11615
CC 1.00 1.00
CT 1.23 (0.79–1.91) 0.351 0.85 (0.59–1.23) 0.388
TT 0.90 (0.35–2.28) 0.817 0.72 (0.33–1.59) 0.416
Additive model 1.08 (0.77–1.51) 0.661 0.85 (0.63–1.14) 0.282
Dominant model 1.18 (0.77–1.81) 0.438 0.83 (0.58–1.19) 0.316




AC 1.07 (0.68–1.69) 0.766 1.21 (0.83–1.78) 0.329
CC 0.72 (0.30–1.73) 0.457 0.75 (0.37–1.54) 0.432
Additive model 0.94 (0.67–1.32) 0.716 0.99 (0.75–1.31) 0.941
Dominant model 1.01 (0.65–1.58) 0.955 1.12 (0.77–1.63) 0.539
Recessive model 0.69 (0.30–1.60) 0.384 0.68 (0.34–1.34) 0.260
rs2228000
CC 1.00 1.00
TC 1.06 (0.66–1.68) 0.822 0.81 (0.55–1.18) 0.267
TT 1.86 (0.97–3.56) 0.062 1.11 (0.59–2.08) 0.758
Additive model 1.28 (0.92–1.77) 0.144 0.94 (0.70–1.25) 0.652
Dominant model 1.18 (0.76–1.83) 0.457 0.85 (0.59–1.22) 0.373




AG 0.83 (0.50–1.36) 0.461 0.83 (0.51–1.36) 0.462
GG 0.65 (0.35–1.21) 0.175 0.65 (0.35–1.21) 0.174
Additive model 0.81 (0.60–1.10) 0.174 0.90 (0.70–1.16) 0.426
Dominant model 0.77 (0.48–1.24) 0.282 0.77 (0.48–1.24) 0.283
Recessive model 0.74 (0.44–1.25) 0.260 0.73 (0.44–1.25) 0.258
rs10817938
TT 1.00 1.00
TC 1.08 (0.68–1.72) 0.731 1.28 (0.87–1.86) 0.209
CC 1.68 (0.65–4.33) 0.286 1.88 (0.75–4.74) 0.180
Additive model 1.18 (0.82–1.69) 0.386 1.31 (0.95–1.80) 0.095
Dominant model 1.15 (0.74–1.77) 0.543 1.32 (0.91–1.90) 0.139
Recessive model 1.64 (0.64–4.17) 0.304 1.73 (0.69–4.32) 0.239
OSCC, oral squamous cell carcinoma; SNPs, single nucleotide polymorphisms; HR, hazard ratio; CI, confidence
interval. a Adjusted for age, BMI, N stage, lymphatic invasion, and extranodal extension. b Adjusted for age, T stage,
N stage, and extranodal extension. * p <0.05.
We further conducted a combination analysis for the ERCC5 rs17655 and ERCC1 rs735482
polymorphisms and DSF in patients with OSCC. The Kaplan–Meier curves showed borderline
significant differences in DFS among the four genotypes (log-rank test p = 0.078) (Figure 1).
The multivariate Cox proportional models indicated that patients with the combination of ERCC5
rs17655 CC and ERCC1 rs735482 CC genotypes exhibited a higher risk of disease recurrence than
those with the combination of ERCC5 rs17655 GG+GC and ERCC1 rs735482 AA+AC genotypes
(HR = 2.60, 95% CI = 1.11–6.09; p = 0.027) (Table 4). However, this gene-gene interaction was not
statistically significant.
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Figure 1. Kaplan–Meier survival curve for the combined ERCC5 rs17655 and ERCC1 rs735482
polymorphisms and disease-free survival in patients with oral squamous cell carcinoma treated with
concurrent chemoradiotherapy. The figure illustrates a borderline significant difference in recurrence
among the four groups (log-rank test p = 0.078).
Table 4. Interaction between the ERCC5 rs17655 and ERCC1 rs735482 polymorphisms on the
disease-free survival of patients with OSCC treated with CCRT.
ERCC5 rs17655 ERCC1 rs735482 No. Event HR (95% CI) a p Value
GG+GC AA+AC 206 71 1.00
GG+GC CC 45 19 1.63 (0.98–2.72) 0.060
CC GG+GC 59 29 1.52 (0.98–2.37) 0.062
CC CC 9 6 2.60 (1.11–6.09) 0.027 *
p for interaction 0.929
OSCC, oral squamous cell carcinoma; HR, hazard ratio; CI, confidence interval. a Adjusted for age, T stage, N stage,
and extranodal extension. * p < 0.05.
Table 5 shows the subgroup analysis for the association between significant SNPs and DFS
stratified by demographic and clinopathological factors. Results show a significant interaction between
ERCC5 rs17655 polymorphism and perineural invasion on the risk for DFS (interaction p = 0.008).
The ERCC5 rs17655 CC genotype individuals with perineural invasion (HR = 2.46, 95% CI = 1.46–4.15;
p < 0.001) had an increased risk for DFS compared to their counterparts with no perineural invasion.
Although a significant interaction between ERCC1 rs735482 polymorphism and vascular invasion was
also observed (interaction p < 0.001), the harmful effect of CC genotype on recurrence was not present
in any subgroup of vascular invasion.
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Table 5. Association between the ERCC5 rs17655 and ERCC1 rs735482 polymorphisms and
the disease-free survival in OSCC patients treated with CCRT stratified by demographic and
clinopathological factors.
ERCC5 rs17655 ERCC1 rs735482
Variable HR (95% CI) a p Value p Interaction HR (95% CI) a p Value p Interaction
Age 0.486 0.078
<50 1.74 (1.00–3.03) 0.051 1.04 (0.53–2.06) 0.911
≥50 1.24 (0.69–2.23) 0.473 2.76 (1.47–5.19) 0.002 *
BMI, kg/m2 0.160 0.597
18.5–23.9 1.64 (0.95–2.82) 0.075 1.89 (1.04–3.44) 0.037 *
<18.5 3.06 (0.65–14.49) 0.159 1.30 (0.05–31.65) 0.871
≥24 0.81 (0.37–1.77) 0.601 1.30 (0.62–2.72) 0.495
Cigarette smoking 0.664 0.975
Never 1.03 (0.35–2.98) 0.962 1.99 (0.52–7.58) 0.316
Ever 1.54 (0.99–2.41) 0.056 1.61 (1.00–2.59) 0.051
Alcohol drinking 0.993 0.676
Never 1.59 (0.74–3.42) 0.240 1.43 (0.64–3.22) 0.387
Ever 1.52 (0.94–2.46) 0.091 1.72 (1.00–2.96) 0.050
Betel nut chewing 0.445 0.968
Never 2.06 (0.53–8.11) 0.299 1.64 (0.34–7.86) 0.536
Ever 1.41 (0.92–2.14) 0.112 1.63 (1.02–2.62) 0.043 *
Tea drinking 0.331 0.986
Never 1.88 (1.05–3.35) 0.033 * 1.60 (0.87–2.94) 0.134
Ever 1.27 (0.73–2.24) 0.400 1.57 (0.81–3.04) 0.183
Coffee drinking 0.073 0.077
Never 1.30 (0.82–2.08) 0.066 2.09 (1.28–3.41) 0.003 *
Ever 2.83 (1.27–6.33) 0.011 * 0.72 (0.22–2.42) 0.601
Tumor differentiation 0.492 0.949
Well differentiated 1.08 (0.43–2.68) 0.875 3.74 (1.26–11.09) 0.018 *
Moderate 1.43 (0.84–2.42) 0.184 1.06 (0.57–1.98) 0.858
Poor 2.15 (0.88–5.22) 0.093 3.48 (1.23–9.88) 0.019 *
Primary tumor size 0.146 0.394
T1–T2 0.96 (0.45–2.03) 0.905 1.12 (0.49–2.56) 0.788
T3–T4 1.83 (1.14–2.93) 0.013 * 1.76 (1.04–3.00) 0.036 *
Nodal involvement 0.328 0.125
N0–N1 2.25 (1.06–4.81) 0.036 * 3.16 (1.47–6.80) 0.003 *
N2–N3 1.32 (0.82–2.13) 0.252 1.23 (0.69–2.19) 0.479
Perineural invasion 0.008 * 0.416
No 0.77 (0.40–1.49) 0.429 2.07 (1.06–4.03) 0.032 *
Yes 2.46 (1.46–4.15) <0.001 * 1.32 (0.72–2.44) 0.370
Vascular invasion 0.410 <0.001 *
No 1.45 (0.96–2.19) 0.078 1.51 (0.96–2.37) 0.076
Yes 1.27 (0.16–10.34) 0.826 -
Lymphatic invasion 0.553 0.449
No 1.43 (0.92–2.23) 0.111 1.71 (1.07–2.73) 0.025 *
Yes 1.84 (0.64–5.31) 0.260 0.90 (0.20–4.16) 0.892
Extranodal extension 0.253 0.720
No 2.35 (1.12–4.94) 0.024 * 2.17 (0.87–5.40) 0.097
Yes 1.31 (0.81–2.13) 0.277 1.52 (0.90–2.57) 0.118
Pathologic TNM stage 0.850 0.585
III 1.70 (0.48–6.09) 0.414 4.82 (0.98–23.58) 0.053
IV 1.51 (0.99–2.31) 0.055 1.54 (0.96–2.47) 0.075
OSCC, oral squamous cell carcinoma; HR, hazard ratio; CI, confidence interval; Int, interaction. a Adjusted for age,
T stage, N stage, and extranodal extension. * p < 0.05.
4. Discussion
In this study, we investigated the association between potentially functional SNPs in the NER
pathway genes and clinical outcomes in male patients with OSCC treated with CCRT. Our findings
suggest that the XPC rs2228000 TT genotype was marginally significantly associated with increased
risk of death, whereas the ERCC5 rs17655 CC and ERCC1 rs735482 CC genotypes were significantly
associated with the increased risk of relapse.
The NER pathway plays a major role in DNA repair through the removal of bulky DNA
lesions formed by ultraviolet (UV) radiation, environmental mutagens, and other chemotherapeutic
agents [23,24]. Studies have revealed that variations in DNA-repair capacity are related to cancer risk
and prognosis [25,26]. In addition, SNPs in the NER genes modulate susceptibility to efficacy and
survival outcome of the treatment in certain types of cancers [11,12]. Therefore, the same phenomena
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may be exhibited in patients with OSCC, particularly those undergoing CCRT. Such information
may be useful in identifying patients who may benefit from alternative therapies to achieve superior
survival and improve quality of life.
The XPC gene is a key component of the XPC complex, which plays an important role in the early
part of the global genome NER. The corresponding protein plays an important function in damage
sensing and DNA binding [27]. SNPs in this gene have been found to affect clinical outcomes in
various cancer types [18,28,29]. Li and colleagues observed that the XPC rs2228000 TT genotypes
were associated with shorter OS than the CC+CT genotype individuals in a study of Japanese gastric
cancer patients [30]. Another Chinese study demonstrated that patients with the CC genotype of
XPC rs2228000 have a borderline significant decreased risk of developing gastric cancer compared
with those with the CT+TT genotype [31]. This evidence suggests that the T-allele may have a high
susceptibility for poor prognosis. Similarly, in our study, the XPC rs2228000 TT genotype shows an
increased risk of death compared with the CC+CT genotype. Given the importance of the XPC gene
in the NER pathway, it is possible that variants of XPC alter the DNA repair capacity and thereby
affect sensitivity to therapeutic agents. However, the association observed in our study was borderline
significant and must be interpreted with caution. Furthermore, large studies may be required to
confirm these findings.
We also observed that those with the ERCC5 rs17655 CC and ERCC1 rs735482 CC genotypes have
an increased risk of relapse compared with individuals with the GG+GC and AA+AC genotypes,
respectively. Considered a central component in NER, ERCC5 encodes a specific DNA endonuclease
responsible for excision and repair of UV-induced DNA damage [23]. Evidence has linked ERCC5
polymorphism to chemotherapeutic response and prognosis of tumors [19,20]. The ERCC5 mRNA
expression levels were correlated with cytotoxicity of chemotherapy regiments [32]. Additionally,
the rs17655 leads to an amino-acid substitution from histidine to aspartic acid, which may lead to
differential interacting abilities, thus, influencing the DNA repair efficacy. Song et al. also observed
that ERCC5 rs17655 polymorphism has a moderately increased risk of recurrence in squamous cell
carcinoma of the oropharynx [33]. ERCC1 is also a crucial member of the NER pathway that forms a
complex with ERCC4, and together with ERCC5, is responsible for DNA incision [34]. Other studies
have reported that ERCC1 affects the clinical outcome and may serve as a potential biomarker for
response to cisplatin-based therapy [35,36]. On the basis of these study results, we speculate that the
CC genotypes of ERCC5 rs17655 and ERCC1 rs735482 may increase the DNA-repair capacity of cancer
cells, leading to increased susceptibility to recurrence. Therefore, if these findings are confirmed by
other studies, these SNPs may serve as therapeutic biomarkers for clinical outcome in patients with
OSCC who undergo CCRT.
Our study has several limitations. First, the hospital-based nature of the patients may have led to
selection bias. Secondly, not all SNPs in the entire NER pathway were used. Some rare functional SNPs
may have an influence on survival. Finally, the human papilloma virus (HPV) status and inflammatory
cytokines expression of patients was not included in the analysis and may limit the interpretation of
our findings; hence, HPV and cytokines may affect survival [37,38]. However, a major strength of our
study is that all the patients had a similar tumor stage and received the same treatment. This meant
that the effect of different treatments was excluded, which might lead to different levels of DNA
damage and repair.
5. Conclusions
We investigated the association between key potentially functional SNPs in the NER pathway
and susceptibility for death or relapse in male patients with advanced OSCC who were treated with
adjuvant CCRT. Our findings showed that the CC genotypes of ERCC5 rs17655 and ERCC1 rs735482
were associated with an increased risk of recurrence. CCRT may not be beneficial for these patients;
therefore, alternative treatments are required. To our knowledge, this is the largest study to investigate
the association between NER polymorphisms and survival in patients with OSCC treated with CCRT
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in ethnic Chinese. Our findings may require further confirmation in studies with a larger sample size
or other ethnic populations.
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Abstract: Zinc finger AN1-type containing 4 (ZFAND4) has emerged as a promising prognostic
marker and predictor of metastasis for patients with oral squamous cell carcinoma (OSCC).
However, further validation is fundamental before clinical implementation. Hence, this study
evaluated the expression pattern of ZFAND4 protein expression by immunohistochemistry using an
independent cohort of 125 patients with OSCC, and correlations with the clinicopathologic parameters
and disease outcome. Remarkably, ZFAND4 expression, while negligible in normal epithelium,
exhibited two distinct expression patterns in tumors that did not overlap. A gross granular staining
was characteristic of the undifferentiated cells at the invasive front of tumors, whereas the most
differentiated cells located at the center of the tumor nests showed diffuse non-granular staining.
ZFAND4 staining was higher in undifferentiated than in differentiated areas of tumors. High ZFAND4
expression in differentiated cells was significantly associated to well-differentiated (p = 0.04) and
non-recurrent tumors (p = 0.04), whereas ZFAND4 expression in undifferentiated cells correlated with
tumor location (p = 0.005). No correlations between the ZFAND4 expression and patient survival were
found. These data question the clinical relevance of ZFAND4 expression as a prognostic biomarker in
OSCC, and also reveal distinct ZFAND4 expression patterns depending on the differentiation areas
of tumors that should be evaluated separately.
Keywords: ZFAND4; ANUBL1; oral squamous cell carcinoma; immunohistochemistry; prognosis
1. Introduction
Head and neck squamous cell carcinoma that includes, among others, oral squamous cell
carcinoma (OSCC) is the sixth most common cancer in the world, with an annual prevalence of
J. Clin. Med. 2018, 7, 534; doi:10.3390/jcm7120534 www.mdpi.com/journal/jcm47
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nearly 600,000 new cases worldwide [1,2]. It is generally accepted that OSCC initiates and progresses
through a series of multiple genetic alterations caused by chronic exposure to carcinogens, such as
alcohol, smoking, and human papilloma virus [3]. Multiple genetic and molecular studies have
improved our understanding of the molecular basis of this disease. Indeed, several cellular signaling
pathways have been found dysregulated in these tumors through genetic and epigenetic alterations.
However, despite major advances in diagnosis and treatment, the survival rate of patients with OSCC
has modestly improved over the past 40 years, and it remains at approximately 50% [4].
Sasahira et al. [5] investigated the transcriptional profiles of primary and recurrent OSCC, and
found that one of the most upregulated genes identified in recurrent OSCC was zinc finger AN1-type
containing 4 (ZFAND4), also known as AN1 and ubiquitin-like homolog (ANUBL1). Although the
functional role of ZFAND4 in cancer is still unknown, Kurihara-Shimomura et al. [6] evaluated its
prognostic utility in OSCC. They concluded that ZFAND4 could be a useful marker for predicting
metastasis and poor prognosis in patients with OSCC. In addition, Tang et al. [7] demonstrated that
ZFAND4 expression is upregulated in gastric cancer and positively associated with the grading of
this disease.
In the light of these data, ZFAND4 emerges as a promising prognostic biomarker;
however, further validation in independent study cohorts is fundamental for implementation to
the clinic. Therefore, the objective of this study was to investigate the expression pattern and clinical
relevance of ZFAND4 protein expression using an independent cohort of 125 patients with OSCC,
and to establish correlations with the clinicopathologic parameters and disease outcome.
2. Experimental Section
2.1. Patients and Tissue Specimens
A retrospective study was designed. Surgical tissue specimens from 125 patients with OSCC who
underwent surgical treatment with curative purposes at the Hospital Universitario Central de Asturias
between 1996 and 2007 were retrospectively collected, in accordance to approved institutional review
board guidelines. All experimental procedures were conducted in accordance to the Declaration of
Helsinki and approved by the Institutional Ethics Committee of the Hospital Universitario Central
de Asturias and by the Regional CEIC from Principado de Asturias. Informed consent was obtained
from all patients. Clinicopathologic data were collected from medical records. Tissue specimens
were obtained from the Biobanco del Principado de Asturias, and representative tissue sections from
archival, formalin-fixed paraffin-embedded blocks.
2.2. Tissue Microarray Construction
The original archived hematoxylin- and eosin-stained slides were reviewed by an experienced
pathologist (FDI) to confirm histological diagnosis. Three representative tissue cores (1 mm diameter)
were selected from each tumor block, and transferred to a recipient ‘Master’ block in a grid-like manner
using a manual tissue microarray instrument. In addition, each tissue microarray also contained three
cores of normal epithelium as an internal control. A section from each microarray was stained with
hematoxylin and eosin, and examined by light microscopy to check the adequacy of tissue sampling.
2.3. Immunohistochemistry (IHC)
TMA sections (4 μm) were cut and dried and dried on Flex IHC microscope slides (Dako).
The sections were deparaffinized with standard xylene, hydrated through graded alcohols into water,
and pretreated by hydrogen peroxide to quench the endogenous peroxidase activity. Antigen retrieval
was performed using Envision Flex Target Retrieval solution (Dako), at room temperature on an
automatic staining workstation (DakoAutostainer Plus, Dako, Glostrup, Denmark). Staining was
carried out at room temperature on an automatic staining workstation (Dako Autostainer Plus) with
anti-ZFAND4 antibody (Atlas Antibodies, Stockholm, Sweden) diluted to 0.5 Nμg/mL using the
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Dako EnVision detection system (Dako, Glostrup, Denmark). Sections were counterstained with
hematoxylin, dehydrated with ethanol, and permanently coverslipped. For negative control purposes,
DakoCytomation mouse serum diluted at the same concentration as the primary antibody was used.
Staining was scored blinded to clinical data by two independent observers. ZFAND4 expression
was evaluated according to the percentage of stained tumor cells and the staining intensity using the
Allred score, as previously described [8]. The proportion of ZFAND4-positive cells was evaluated in
both undifferentiated and differentiated areas of the tumors. In all these groups, proportional scores
were categorized as: 0, no cells were stained; 1, 1/100 cells were stained; 2, 1/10 cells were stained;
4, 2/3 cells were stained; 5, all cells were stained. Staining intensity was scored as: 0, negative; 1, weak;
2, intermediate; and 3, strong. The total score was calculated by the sum of the proportional and
intensity scores, ranging from 0 to 8. Similar to Kurihara-Shimomura et al. [6], the optimal cut-off
score for ZFAND4 expression was selected using the receiver operating characteristic (ROC) curve
according to the survival status. ZFAND4 staining was independently evaluated in undifferentiated
areas of tumors mainly located at the invasive front, and in differentiated areas at the center of the
tumor islands.
2.4. Statistical Analysis
χ2 and the Fisher’s exact test were used for comparison between categorical variables.
Disease-specific survival (DSS) was determined for the date of treatment completion to death for
the tumor. For time-to-event analysis, survival curves were plotted using the Kaplan-Meier method.
Differences between survival times were analyzed by the log-rank test. Hazard ratios (HR) with their
95% confidence intervals (CI) for clinicopathologic variables were calculated using the univariate
Cox proportional hazards model analysis. All tests were two-sided and p values less than 0.05
were considered statistically significant. All statistical analyses were performed using SPSS version
21 (IBM Co., Armonk, NY, USA).
3. Results
3.1. Patient Characteristics
The cohort of 125 OSCC patients was composed of 82 men and 43 women, ranging from 28 to
91 years, with a median age of 57 years. Forty-one patients (33%) were never-smokers and 56 (45%)
never-drinkers. The main clinicopathologic characteristics are summarized in Table 1. Forty-nine
cases (39%) showed neck lymph node metastasis, more than 50% were well-differentiated tumors
and advanced clinical stages (III or IV), and the most common site was the tongue (41%) followed
by the floor of the mouth (30%). Adjuvant radiotherapy was administered to 75 patients (60%),
and adjuvant chemotherapy to 14 patients (11.2%). Fifty-four cases (43%) showed loco-regional
recurrence, and 19 (15%) suffered from a second primary carcinoma. Over a median follow-up of
61 months (range, 1 to 230 months) 53 deaths occurred.
Table 1. Clinical and pathological characteristics of 123 patients with oral squamous cell carcinoma
and where zinc finger AN1-type containing 4 (ZFAND4) was valuable.
Variable Number (%)














Location of oral squamous oral cell carcinoma
Tongue 51 (41)
Floor of the mouth 35 (28)











Stage I 20 (16)
Stage II 31 (25)
Stage III 25 (20)











Clinical status at the end of the follow-up
Live and without recurrence 51 (41)
Dead of index cancer 53 (43)
Lost or died of other causes (censored) 19 (16)
3.2. Immunohistochemical Analysis of ZFAND4 Expression in OSCC Tissue Specimens
ZFAND4 staining was not valuable in two (1.6%) of 125 OSCC specimens. While ZFAND4
expression was negligible in normal epithelium, two distinct expression patterns were noted in
the tumors that did not overlap in any of the samples (Figure 1). A gross granular staining
was characteristic of the undifferentiated cells at the invasive front of tumors, whereas the most
differentiated cells located at the center of the tumor nests showed diffuse non-granular staining.
The mean percentages of positive ZFAND4 staining were 44.98 (standard deviation –SD-35.38) in
undifferentiated cells and 17.18 (SD, 20.61) in differentiated cells. ZFAND4 staining intensity was
also evaluated in both undifferentiated and differentiated areas. In undifferentiated cells, there were
13 (11%) negative cases, 37 (30%) weak, 43 (35%) intermediate, and 30 (24%) cases with strong staining.
In differentiated cells, 47 (38%) cases were scored negative, 11 (9%) weak, 47 (38%) intermediate,
and 18 (15%) had strong staining. Since each tumor was represented by three different tissue
cores in the OSCC TMAs, the percentages of stained cells frequently varied in the three tumor
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areas assessed. Taking this into consideration, the Allred score was determined in two different
ways: Either considering the maximum value of ZFAND4 positivity or the mean value of the
three tumor cores. Regarding the intensity of immunostaining, the maximum value was always
used for all calculations. Finally, the total score was calculated by the sum of the percentages of
staining and intensity scores. The resulting indexes ranged between 0 and 8. The receiver operating
characteristics (ROC) curve was used to determine the best cut-off score to predict patients’ survival,
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(C) 
Figure 1. Immunoexpression of ZFAND4 in oral squamous cell carcinoma. (A) Staining in undifferentiated
areas (arrow) and differentiated areas (*). (B) Staining in undifferentiated cells, mainly located in the
invasive front of tumor tissue. (C) Staining in differentiated cells located at the center of the tumor islands.
3.3. Associations of ZFAND4 with Clinicopathologic Characteristics
We next assessed the correlations of high ZFAND4 expression with the clinical data. Table 2
shows the associations of high ZFAND4 expression determined by using the maximum value of
the percentage of stained cells to calculate the Allred score. In differentiated areas, high ZFAND4
expression was significantly associated with well-differentiated (p = 0.04) and non-recurrent tumors
(p = 0.04), whereas ZFAND4 expression in undifferentiated cells was significantly correlated with
tumor location in the tongue (p = 0.005).
On the other hand, when the Allred score was calculated using the mean value of percentage
of stained cells (Table 3), ZFAND4 expression in differentiated cells was found to be significantly
associated with N status (p = 0.02), being more frequently detected in pN0 and pN1 cases compared to
pN2. However, no significant relationship was found between ZFAND4 expression in undifferentiated
cells and any clinicopathologic variable.
Table 2. Relationships between clinical and pathological variables and high ZFAND4 expression




High ZFAND4 Expression in
Undifferentiated Cells (%)
p High ZFAND4 Expression in
Differentiated Cells (%)
Gender
0.98Men 81 50 (62) 38 (47)
Women 42 26 (62) 17 (40)
Tobacco use
0.77Smoker 83 52 (63) 34 (41)
Non-smoker 40 24 (60) 21 (52)
Alcohol use
0.99Drinker 68 42 (62) 31 (46)
Non-drinker 55 34 (62) 24 (44)
52





High ZFAND4 Expression in
Undifferentiated Cells (%)




pT1 27 19 (70) 16 (59)
pT2 53 33 (62) 25 (47)
pT3 15 10 (67) 4 (27)
pT4 28 14 (50) 10 (36)
pN
0.75
pN0 74 45 (61) 34 (46)
pN1 25 17 (68) 13 (52)
pN2 24 14 (58) 8 (33)
Clinical stage
0.69
Stage I 20 13 (65) 9 (45)
Stage II 31 20 (64) 16 (52)
Stage III 25 17 (68) 11 (44)
Stage IV 47 26 (55) 19 (40)
G status
0.14G1 (Well) 78 52 (67) 40 (51)
G2 + G3 (Moderate + poor) 45 24 (53) 15 (33)
Tumor location
0.005Tongue 51 39 (76) 23 (45)
Rest 72 37 (51) 32 (44)
Tumor location
0.5Floor of the mouth 35 20 (57) 16 (46)
Rest 88 56 (64) 39 (44)
Tumor recurrence
0.61No 69 44 (64) 36 (52)
Yes 54 32 (59) 19 (35)
Second primary carcinoma
0.89No 104 64 (61) 48 (46)
Yes 19 12 (63) 7 (37)
Clinical status at the end of
the follow-up
0.73Live and without recurrence 51 32 (63) 26 (51)
Dead of index cancer 53 31 (58) 20 (38)
Lost or died of other causes 19 13 (68) 9 (47)
Table 3. Relationships between clinical and pathological variables and high ZFAND4 expression















0.95 0.33Men 81 42 (52) 26 (32)
Women 42 22 (52) 10 (24)
Tobacco use
0.75 0.58Smoker 83 44 (53) 23 (28)
Non-smoker 40 20 (50) 13 (32)
Alcohol use
0.89 0.21Drinker 68 35 (51) 23 (34)
Non-drinker 55 29 (53) 13 (24)
53

















pT1 27 16 (59) 11 (41)
pT2 53 27 (51) 15 (28)
pT3 15 10 (67) 2 (13)
pT4 28 11 (39) 8 (29)
pN
0.85 0.02
pN0 74 37 (50) 24 (32)
pN1 25 14 (56) 10 (40)
pN2 24 13 (54) 2 (8)
Clinical stage
0.46 0.81
Stage I 20 10 (50) 6 (30)
Stage II 31 17 (55) 11 (35)
Stage III 25 16 (64) 9 (36)
Stage IV 47 21 (45) 10 (21)
G status
0.36 0.08G1 (Well) 78 43 (55) 27 (35)
G2 + G3 (Moderate + poor) 45 21 (47) 9 (20)
Tumor location
0.1 0.43Tongue 51 31 (61) 13 (25)
Rest 72 33 (46) 23 (32)
Tumor location
0.75 0.44Floor of the mouth 35 19 (54) 12 (34)
Rest 88 45 (51) 24 (27)
Tumor recurrence
0.97 0.47No 69 36 (52) 22 (32)
Yes 54 28 (52) 14 (26)
Second primary carcinoma
0.29 0.75No 104 52 (50) 31 (30)
Yes 19 12 (63) 5 (26)
Clinical status at the end of
the follow-up
0.85 0.59Live and without recurrence 51 26 (51) 17 (33)
Dead of index cancer 53 27 (51) 15 (28)
Lost or died of other causes 19 11 (58) 4 (21)
3.4. ZFAND4 Expression and Patients’ Survival
Over a median follow-up period of 61 months, 27 patients (42.1%) harboring high ZFAND4
expression in undifferentiated cells calculated by using the mean Allred score died due to the index
cancer, and 15 patients (41.6%) with high ZFAND4 expression in the differentiated cells. When
the maximum Allred score was used, 31 patients (40.7%) with high ZFAND4 expression in the
undifferentiated cells, and 20 patients (36.3%) with high ZFAND4 expression in the differentiated
cells died due to the index cancer. Kaplan-Meier analysis showed that there were no statistically
significant differences in disease-specific survival (DSS) between patients with high versus low
ZFAND4 expression in either differentiated or undifferentiated cells (Table 4).
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4. Discussion
This study aimed to investigate the clinical relevance and prognostic significance of ZFAND4 in
OSCC. The prevalence of OSCC is estimated at 264,000 cases and 128,000 deaths annually worldwide [3].
Since the completion of the Human Genome Project in 2003, the subsequent progress in understanding
the biology of cancer has led to the development of personalized therapies based on the patient’s
unique molecular and genetic profile to target defective signaling pathways of tumor cells. It is
generally accepted that OSCC arises from multiple genetic alterations, although the molecular basis
of carcinogenesis is not fully understood. DNA sequencing technologies coupled with advances in
algorithms have enormously contributed to the molecular and functional characterization of mutations,
genes, and pathways altered in multiple cancers, including OSCC [9–12]. Furthermore, the majority of
tumors showed alterations in multiple targetable genes that are candidates for combination therapy [11].
It is of paramount importance to identify molecular alterations involved in the development of
recurrent and metastatic disease, which remains the main cause of morbidity and mortality in
OSCC patients.
In a recent paper, Sasahira et al. [5] conducted a cDNA microarray analysis in order to compare
the gene expression profile of primary and recurrent OSCC. Ten genes were found to be upregulated in
recurrent OSCC compared with the primary tumors. Among these genes, ZFAND4 showed a 100-fold
recurrent/primary, thus suggesting a possible role for this gene in tumorigenesis. Tang et al. [7]
reported that ZFAND4 expression was consistently highly expressed in gastric cancer compared to
normal tissue, and positively associated with increased stage. Functionally, ZFAND4 was found
to downregulate the expression of the anti-proliferative miRNAs, miR-148b, miR-375, and miR-182,
in SGC-7901 cells, thereby promoting cell proliferation by activation of cyclin-dependent kinase and
downregulation of p21 and p53 [7], which supports the notion that ZFAND4 may act as an oncogene
in gastric cancer.
In this study, we assumed the same methodology used by Kurihara-Shimomura et al. [6] in
order to validate their results in an independent cohort of OSCC patients, and more importantly,
the utility of ZFAND4 as a predictor of metastasis and poor prognostic marker. Interestingly, ZFAND4
staining consistently showed distinct expression patterns and distribution in our cohort of 125 OSCC,
i.e., granular staining in undifferentiated areas and diffuse staining in differentiated areas of the tumors.
These two expression patterns were analyzed separately to evaluate possible correlations with the
clinical and follow-up data. Moreover, Allred scores were calculated using both maximum value and
mean value of ZFAND4-positive cells for the three tissue cores selected from each tumor.
We found that ZFAND4 staining was higher in undifferentiated than in differentiated areas of
tumors. However, ZFAND4 expression in differentiated cells showed the most relevant and significant
associations with well-differentiated (p = 0.04) and non-recurrent tumors (p = 0.04). Nevertheless,
ZFAND4 expression did not show a major impact on patient survival. Only a trend was observed
between low ZFAND4 expression in differentiated cells and tumor-associated deaths (Table 4).
Therefore, the prognostic relevance of ZFAND4 described by Kurihara-Shimomura et al. [6] has
not been replicated in our series. Furthermore, Kurihara-Shimomura et al. [6] reported that ZFAND4 is
essential for distant metastasis in OSCC, and hypothesized that ZFAND4 could facilitate metastasis to
the lymph nodes and distant organs by promoting angiogenesis and/or lymphangiogenesis. In marked
contrast, our results only proved a marginal (if any) relationship between ZFAND4 expression and
the presence of lymph node metastasis. The limitations of our study are the retrospective design
and the use of tissue microarrays to evaluate ZFAND4 immunostaining. Several factors could
contribute to the discrepant results between these two studies. On one hand, etiological, clinical,
and epidemiological differences in the patient cohorts as well as molecular/biological differences
among tumors depending on the geographic areas. Moreover, ZFAND4 expression exhibited a highly
heterogeneous pattern within the tumors depending on the differentiation status, which could certainly
have a major contribution on the varying results. Particularly since we evaluated separately the clinical
significance and correlations of the two distinct ZFAND4 expression patterns in undifferentiated and
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differentiated areas of tumors, while Kurihara-Shimomura et al. [6] did not distinguish expression
patterns within the different tumor areas. Thus, positive ZFAND4 immunostaining was scored in
the whole tumor as the diffuse staining in tumor islands, cords, or sheets, irrespective of the cell
differentiation status and the grade of keratinization. Since ZFAND4 expression showed two distinct
non-overlapping expression patterns depending on the differentiation areas of tumors, each with
a clearly distinct clinical significance, evaluation of ZFAND4 expression in the whole tumor could
therefore be misleading.
5. Conclusions
The herein presented data question the clinical relevance of ZFAND4 expression as a prognostic
biomarker in OSCC, and also revealed distinct ZFAND4 expression patterns depending on the
differentiation areas of tumors that should be evaluated separately. Further studies are necessary to
fully elucidate the pathobiological role of ZFAND4 in OSCC and the potential clinical implications.
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Abstract: Background: To investigate the prognostic value of pre-treatment neutrophil/lymphocyte
ratio (NLR) in patients treated with definitive radiotherapy (RT) for head and neck cancer.
Methods: We retrospectively analyzed 621 patients who received definitive RT for nasopharyngeal,
oropharyngeal, hypopharyngeal, and laryngeal cancer. An NLR cut-off value of 2.7 was identified
using a receiver operating characteristic curve analysis, with overall survival (OS) as an endpoint.
Results: The 5-year progression-free survival (PFS) and OS for all patients were 62.3% and 72.1%,
respectively. The patients with a high NLR (68%) had a significantly lower 5-year PFS and OS than
their counterparts with a low NLR (32%) (PFS: 39.2% vs. 75.8%, p < 0.001; OS: 50.9% vs. 83.8%,
p < 0.001). In a subgroup analysis according to primary site, a high NLR also correlated with a lower
PFS and OS, except in oropharyngeal cancer, where a high NLR only exhibited a trend towards lower
survival. In a multivariate analysis, a high NLR remained an independent prognostic factor for PFS
and OS. Conclusion: Head and neck cancer tends to be more aggressive in patients with a high NLR,
leading to a poorer outcome after RT. The optimal therapeutic approaches for these patients should
be reevaluated, given the unfavorable prognosis.
Keywords: head and neck cancer; radiotherapy; neutrophil/lymphocyte ratio; survival
1. Introduction
Currently, definitive radiotherapy (RT) is one of the main modalities used to treat locally advanced
head and neck cancer. However, patients exhibit varying degrees of RT response and may develop
recurrences even after a complete response. Although various clinical and molecular predictors of
treatment outcomes after definitive RT for head and neck cancer have been investigated, no clear
consensus regarding reliable predictive biomarkers has been reached.
Treatment outcomes are known to be affected by both tumor characteristics and host-related
factors, including age, sex, and performance status. Recent reports have also described close
associations of systemic inflammation with tumorigenesis and treatment outcomes [1,2], and several
laboratory markers associated with systemic inflammatory processes, including albumin, hemoglobin,
absolute white blood cell (WBC) count or WBC components, and platelet count, have been investigated
as prognostic and predictive markers in various types of cancer [3,4]. Inflammation plays a key role in
cancer physiology by promoting carcinogenesis, dedifferentiation, and primary tumor growth, and by
stimulating tumor cell proliferation by inhibiting apoptosis and increasing mitotic rates [5].
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Tumor–host interactions can induce systemic inflammatory responses that affect the numbers of
circulating WBCs and the neutrophil/lymphocyte ratio (NLR) in certain types of cancers [6]. Normal
NLR values are in the range of 0.78–3.53 in the general population [7]; high NLR values are associated
with poor outcomes not only in cancer patients but also in patients with cardiovascular disease [8–10].
To date, some studies of head and neck cancer have suggested an association of high NLR with a poor
prognosis. However, data regarding the prognostic significance of a high NLR are limited, especially
among patients undergoing definitive RT [11–13]. The antitumor immune response is thought to be
part of the ionizing radiation-induced tumor cell death process. Therefore, tumor shrinkage caused
by the host immune response may be a direct effect of radiation [14,15]. Accordingly, we postulated
that the host immune status, as reflected by the NLR, may predict recurrence after RT in head and
neck cancer patients. This study aimed to evaluate the relationships of pretreatment NLR and other
hematologic markers with tumor recurrence and survival in patients undergoing definitive RT for
head and neck cancer.
2. Materials and Methods
2.1. Patient Selection and Treatment Protocols
This study was approved by the institutional review board of the Gangnam Severance Hospital
(Protocol number: 3-2017-0387). We retrospectively reviewed the medical records of patients who
underwent definitive RT with or without concurrent chemotherapy for cancers of the head and
neck (including nasopharyngeal, oropharyngeal, hypopharyngeal, and laryngeal cancers) at our
institution between 2006 and 2015. Patients who underwent surgery before or after RT, received RT of
<30 Gy, had a distant metastasis at the initial diagnosis or previous history of other primary cancer,
and whose pre-RT common blood test results were unavailable were excluded. The remaining 621
patients included in the analysis were staged according to the 7th edition of the TNM classification
of the American Joint Committee on Cancer (AJCC). Human Papilloma Virus (HPV) infection status
was evaluated in oropharyngeal cancer patients. To assess HPV status of each tumor, we used
formalin-fixed, paraffin-embedded biopsy tissue to examine p16 expression, which is recognized as
a surrogate marker for HPV infection in the oropharynx. Details of this process are described in a
previous report of our institution [16].
Patients were treated with definitive RT alone, concurrent chemoradiotherapy (CCRT), or
induction chemotherapy followed by CCRT. The choice of treatment was determined by the primary
tumor and stage, risk factors, and/or the physicians’ discretion. External beam RT comprised either
3D-conformal RT or intensity-modulated RT (IMRT) and was administered 5 days per week in daily
fractions of 1.8–2.5 Gy to yield total doses to the primary tumor of 66–75 Gy.
Concurrent chemotherapy regimens included weekly cisplatin (DDP; 40 mg/m2); weekly
5-fluorouracil (5-FU) and cisplatin (FP; 750 mg/m2 and 20 mg/m2, respectively); and 5-FU, taxotere, and
cisplatin (TPF; 750 mg/m2, 70 mg/m2, and 75 mg/m2, respectively) every 3 weeks. The anti-epidermal
growth factor receptor mAb, cetuximab (Erbitux), was also used. The induction chemotherapy regimen
consisted of FP every 3 weeks for 3 cycles or TPF every 3 weeks for 2 cycles.
2.2. Hematologic Markers
The patients’ blood counts were evaluated prior to performing diagnostic procedures or
administering treatments. The WBC count, hemoglobin (Hb) level, absolute neutrophil count (ANC),
absolute lymphocyte count (ALC), platelet count, and albumin level were recorded. A diagnosis
of anemia was based on a hemoglobin level of <13 g/dL in men and <12 g/dL in women, and
hypoalbuminemia was defined as a serum albumin level <3.5 g/dL. Onodera’s prognostic nutritional
index (PNI) was calculated as 10 × Albumin + 0.005 × ALC.
The NLR was calculated as the neutrophil count divided by the lymphocyte count, and the
platelet/lymphocyte ratio (PLR) was calculated as the platelet count divided by the lymphocyte
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count. The optimum NLR cut-off values were identified via a receiver operating characteristic (ROC)
curve analysis, using overall survival (OS) as an end point (Supplement Figure S1), and patients were
categorized into high NLR (NLR ≥ 2.7) and low (NLR < 2.7) NLR groups.
2.3. Outcome Assessment
All patients were followed up for 4–6 weeks after RT, and subsequently at 3-month intervals
for the first and second years, 6-month intervals for the third year, and annually for the fourth and
fifth years. Progression was defined as regrowth of the primary tumor or the involvement of cervical
lymph node(s) (LN) or detection of any new lesion(s) in follow-up imaging studies. Progression-free
survival (PFS) was defined as the interval between the date of initial treatment to the detection of first
recurrence, death from any cause, or the last follow-up. OS was defined as the interval between the
date of initial treatment and death from any cause or the last follow-up.
2.4. Statistical Analysis
Categorical data were analyzed using Fisher’s exact test or the χ2 test. Continuous data were
compared between groups using the Mann–Whitney U test. The Kaplan–Meier method and log-rank
test were used to estimate and compare the PFS and OS rates. Hazard ratios (HRs) were obtained
using the cumulative survivor function and are reported with corresponding 95% confidence intervals
(CIs). Univariate and multivariate analyses of factors related to OS and PFS were conducted using the
Cox proportional hazards model, and multivariate analysis included all variables with p values < 0.05
in the univariate analysis. A p value < 0.05 was considered statistically significant. All analyses were
performed using IBM SPSS, version 20.0 (SPSS, Chicago, IL, USA).
3. Results
3.1. Patient and Treatment Characteristics
Table 1 presents the demographic and treatment characteristics of the 621 included patients, of
whom 425 (68.4%) and 196 (31.6%) were stratified into the low and high NLR groups, respectively.
Laryngeal cancer was the most frequent type of primary cancer in the low NLR group, whereas
nasopharyngeal cancer cases comprised the majority in the high NLR group. Patients with a high NLR
tended to have a more advanced clinical T classification and higher frequency of LN metastasis and a
significantly higher frequency of systemic chemotherapy (75.2% vs. 48.5%, p < 0.001) than those in the
low NLR group.
The groups did not differ significantly in terms of the use of IMRT. Of the 16 patients who did
not complete the planned course of RT, four (2.0%) and 12 (2.8%) belonged to the high and low NLR
groups, respectively (p = 0.787). However, more patients in the high NLR group received radiation
doses of ≥70 Gy (equivalent dose in 2 Gy fractions, α/β = 10), and the overall duration of RT tended
to be longer in this group.
Table 1. Patient characteristics.
Total Low NLR Group High NLR Group
Characteristics N = 621 (%) N = 425 (%) N = 196 (%) p Value
Age Median 60 60 60 0.166
(Range) (18–94) (18–89) (18–94)
Sex Male 514 (82.8) 365 (85.9) 149 (76.0) 0.002
Female 107 (17.2 60 (14.1) 47 (24.0)
Primary site Nasopharynx 192 (30.9) 119 (28.0) 73 (37.2) <0.001
Oropharynx 94 (15.1) 56 (13.2) 38 (19.4)
Hypopharynx 76 (12.2) 42 (9.9) 34 (17.3)
Larynx 259 (41.7) 208 (48.9) 51 (26.0)
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Table 1. Cont.
Total Low NLR Group High NLR Group
Characteristics N = 621 (%) N = 425 (%) N = 196 (%) p Value
T classification T1 259 (41.7) 206 (48.5) 53 (27.0) <0.001
T2 145 (23.3) 97 (22.8) 48 (24.5)
T3 94 (15.1) 52 (12.2) 42 (21.4)
T4 123 (19.8) 70 (16.5) 53 (27.0)
N classification N0 294 (47.3) 236 (55.5) 58 (29.6) <0.001
N1 87 (14.0) 56 (13.2) 31 (15.8)
N2 219 (35.3) 124 (29.2) 95 (48.5)
N3 21 (3.4) 9 (2.1) 12 (6.1)
Overall stage I 188 (30.3) 165 (38.8) 23 (11.7) <0.001
II 89 (14.3) 58 (13.6) 31 (15.8)
III 118 (19.0) 76 (17.9) 42 (21.4)
IVA 204 (32.9) 116 (27.3) 88 (44.9)
IVB 22 (3.5) 10 (2.4) 12 (6.1)
p16 UE b 56 (59.6) 31 (55.4) 25 (65.8) 0.529
(in oropharynx) negative 12 (1.9) 6 (10.7) 6 (15.8)
positive 26 (4.2) 19 (33.9) 7 (18.4)
Treatment RT alone 270 (43.5) 221 (52.0) 49 (25.0) <0.001
CCRT c 234 (37.7) 130 (30.6) 104 (53.1)
Induction + CCRT 117 (18.8) 74 (17.4) 43 (21.9)
RT modality 3D-CRT d 220 (35.4) 156 (36.7) 64 (32.7) 0.326
IMRT e 401 (64.6) 269 (63.3) 132 (67.3)
RT duration Median 46 45 47 <0.001
(days) (Range) (23–99) (23–99) (31–97)
Total dose <70 385 (61.0) 277 (64.6) 108 (53.5) 0.016
(EQD2Gy a, α/β = 10) ≥70 236 (37.4) 148 (34.5) 88 (43.6)
Abbreviations: a Equivalent dose in 2 Gy fractions, b unevaluable, c concurrent chemoradiotherapy, d 3-dimensional
conformal radiotherapy, e intensity modulated radiotherapy.
3.2. Hematologic Markers
Table 2 presents the values of the measured hematologic markers in all patients. The median
baseline WBC count, ANC, and ALC were 6800/μL, 3900/μL, and 1810/μL, respectively, and the WBC
and ANC values were significantly higher in the high NLR group. A higher proportion of patients
with leukocytosis (WBC count ≥9000/μL) was also observed in the high NLR group (31.7% vs. 7.8%
for low NLR, p < 0.001). The high NLR group also had higher platelet counts, which expectedly
yielded a higher PLR, and was more likely to present with anemia and hypoalbuminemia at the time
of diagnosis. Patients with a high NLR also had a significantly lower Onodera’s PNI (49.7 vs. 55 for
low NLR, p < 0.001).
Table 2. Hematologic markers.
Total low NLR Group High NLR Group
Characteristic N = 621 (%) N = 425 (%) N = 196 (%) p Value
WBC Median 6800 6300 7700 <0.001
(cells/μL) (range) (2000–21,100) (2000–10,700) (3700–21,100)
ANC a Median 3900 3460 5520 <0.001
(cells/μL) (range) (560–18,310) (940–6720) (560–18,300)
ALC b Median 1810 2040 1320 <0.001
(cells/ μL) (range) (160–3700) (700–3700) (160–2970)
Platelet Median 237 232 250 <0.001
(×103 cells/μL) (range) (14–600) (14–517) (40–600)
PLR c Median 131 116 194 <0.001
(range) (20–1733) 20–269 (26–1733)
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Table 2. Cont.
Total low NLR Group High NLR Group
Characteristic N = 621 (%) N = 425 (%) N = 196 (%) p Value
Hemoglobin Median 14 14.1 13.5 0.01
(mg/dL) (range) (51–15.1) (5.1–17.4) (8.3–51.1)
Anemia No 497 (80.0) 359 (84.5) 138 (70.4) <0.001
Yes 124 (20.0) 66 (15.5) 58 (29.6)
Albumin Median 4.4 4.4 4.3 <0.001
(g/dL) (range) (2.5–5.2) (2.7–5.2) (2.5–5.1)
Hypoalbuminemia UE e 69 (11.1) 49 (11.5) 20 (10.2) 0.02
(<3.3 g/dL) No 539 (86.8) 371 (87.3) 168 (85.7)
Yes 13 (2.1) 5 (1.2) 8 (4.1)
Onodera’s PNI d Median 53.1 55 49.7 <0.001
(range) (27.8–67.6) (32.8–67.6) (27.8–61.7)
Abbreviations: a Absolute neutrophil count, b absolute lymphocyte count, c platelet/ lymphocyte ratio, d prognostic
nutritional index, e unevaluable.
3.3. Survival Analysis
The patients were followed up for a median of 39 (range, 2–130) months. During the follow-up
period, 148 patients died and 156 experienced a recurrence. The 5-year PFS and OS rates for all patients
were 63.8% and 72.9%, respectively, and both rates were significantly lower in the high NLR group
than in the low NLR group (PFS: 39.2% vs. 75.8%, p < 0.001; OS: 50.9% vs. 83.8%, p < 0.001) (Figure 1).
In survival analyses stratified by early- (stage I–II) or advanced-stage disease (stage III–IV), a high
NLR remained significantly associated with a poor PFS and OS (Figure 2).
An additional subgroup analysis was performed after stratifying cases by the primary site
(nasopharynx, oropharynx, hypopharynx, and larynx). As shown in Figures 3 and 4, patients with
nasopharyngeal, hypopharyngeal, and laryngeal cancer and the high NLR group had poorer PFS
and OS rates. Among patients with oropharyngeal cancer, however, a high NLR status exhibited
only borderline significance in terms of 5-year PFS (42.0% vs. 54.0%, p = 0.059) (Figure 3B) and only
exhibited a trend with reduced OS (51.5% vs. 65.3%, p = 0.215) (Figure 4B).
We also conducted additional analysis according to the treatment scheme. Both PFS and OS were
significantly worse in high NLR patients receiving any type of treatment: Patients receiving RT alone,
5-year PFS 84.8% vs. 56.1%, p < 0.001 and OS 90.6% vs. 68.6%, p < 0.001; patients receiving CCRT,
5-year PFS 66.2% vs. 31.5%, p < 0.001 and OS 74.3% vs. 41.7%, p < 0.001; patients receiving induction
chemotherapy + CCRT, 5-year PFS 68.1% vs. 40.7%, p < 0.001 and OS 78.9% vs. 55.2%, p < 0.001.
Figure 1. (A) Progression-free survival and (B) overall survival of patients according to
neutrophil/lymphocyte ratio (NLR) status.
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Figure 2. Progression-free survival and overall survival of patients with head and neck cancer at (A,B)
stage I–II, and (C,D) stage III–IV.
Figure 3. Subgroup analysis of progression-free survival according to primary tumor site: Nasopharynx
(A), oropharynx (B), hypopharynx (C) and larynx (D).
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Figure 4. Subgroup analysis of overall survival according to primary tumor site: nasopharynx (A),
oropharynx (B), hypopharynx (C) and larynx (D).
3.4. Analysis of Prognostic Factors
The results of univariate and multivariate analyses performed to identify prognostic factors for
PFS and OS are shown in Table 3. The multivariate analysis revealed significant associations of a high
NLR with poor PFS, an older age, and an advanced T classification. An elevated PLR was also found to
be associated with a poor PFS. An older age, advanced T classification, and high NLR were also found
to associate significantly with OS, and an elevated PLR exhibited a borderline significant association
with a poor OS. Primary hypopharyngeal cancer was associated with both a poor PFS and a poor OS.
A low albumin level (<3.3 g/dL) exhibited a negative trend with PFS, but not with OS. LN metastasis,
overall stage, leukocytosis (WBC count ≥9000/μL), anemia, and Onodera’s PNI were not identified as
prognostic factors for PFS or OS.
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3.5. p16 Status and Hematologic Markers
We also evaluated the relationship of the p16 status with the levels of various hematologic
markers. This status was available for 38 of 94 patients with oropharyngeal cancer (40.4%). In total,
26 patients had p16-positive oropharyngeal cancer and 12 patients had p16-negative oropharyngeal
cancer. Patients with a positive p16 status tended to have a lower NLR than those with a negative
status (median NLR: 2.1 vs. 2.8, p = 0.103). In addition, the WBC count and ANC were lower in
p16-positive patients than in their p16-negative counterparts, although these differences were not
statistically significant (median WBC: 7100 vs. 8300/μL, p = 0.073; median ANC: 4000 vs. 5200/μL,
p = 0.119) (Supplement Figure S2).
Among the 26 patients with p16-positive oropharyngeal cancer, PFS and OS were not different
between the low and high NLR groups (5-year PFS 56.1% vs. 57.1%, p = 0.781 and 5-year OS 86.5% vs.
80.0%, p = 0.646). In patients with p16-negative oropharyngeal cancer (n = 12), PFS was significantly
lower in the high NLR group than in the low NLR group (5-year PFS 0% vs. 100%, p = 0.009), while OS
showed no difference, which may be due to the limited number of cases.
4. Discussion
During the past decade, various markers of systemic inflammation have been evaluated with the
aims of refining patient stratification to treatment and predictions of survival. Of these markers, the
NLR, which is derived from the ANC and ALC of a full blood count, is routinely available. Accordingly,
in this study, we evaluated the significance of the pre-treatment NLR in patients who received RT for
head and neck cancer and observed significant associations of a high NLR with disease recurrence and
OS in the patient sample.
As noted above, we stratified the patients into two groups according to NLR status and found
that those with a high NLR had a more advanced clinical stage and therefore more frequently received
concurrent chemotherapy with a higher total radiation dose and longer total duration of RT. Despite
this more aggressive treatment, however, patients with a high NLR were more likely to experience
unfavorable outcomes, and these results remained consistent regardless of disease stage. We further
found that adverse hematologic features, such as an elevated WBC, ANC, and platelet count as well as
anemia, hypoalbuminemia, and a low Onodera’s PNI, were more frequently observed in the high NLR
group. These findings suggest that certain types of tumors elicit an enhanced systemic inflammatory
response, which may reflect the aggressive nature of the tumor.
We also performed a subgroup analysis according to the primary site of head and neck carcinoma
and determined that a high NLR was significantly associated with a poorer PFS and OS among
patients with nasopharyngeal, hypopharyngeal, and laryngeal cancers. However, among patients
with oropharyngeal cancer, a high NLR was only borderline significant as a prognosticator of PFS and
exhibited a trend with OS. Other studies of oropharyngeal cancer have identified NLR as a significant
prognostic factor for disease control, and most have used a relatively higher NLR cut-off value
(≥5) [17,18] than those used for other primary sites in the head and neck [19,20]. Additionally, some
studies of oropharyngeal cancer have identified the prognostic significance of circulating neutrophil
and lymphocyte counts only for recurrence-free survival (RFS), but not for OS [21].
Our above findings may be attributable to the limited number of oropharyngeal cancer patients
in our study (n = 94) or to the effects of HPV infection. Previous studies suggested that HPV infection
might affect the distribution of WBC components and alter inflammatory responses in patients with
oropharyngeal cancer [11]. Huang et al. reported that HPV-positive patients had lower levels of
circulating neutrophil and monocyte counts when compared to their HPV-negative counterparts,
despite similar levels of lymphocyte counts [21]. In the HPV-positive cohort, a high neutrophil or
monocyte count was found to correlate with reductions in OS and RFS, whereas in the HPV-negative
cohort, the neutrophil and lymphocyte counts were not predictive of either survival parameter.
Another study also reported a significantly lower NLR among HPV-positive patients than among their
HPV-negative counterparts. Given these findings, we suggest that oropharyngeal cancer may exhibit
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behaviors or inflammatory responses that are distinct from those of head and neck cancers at other
primary sites. Although our study did not reveal significant differences in inflammatory markers
among oropharyngeal cancer patients according to p16 status, HPV infection might have altered the
WBC distribution and affected disease control and OS.
Some scientists have recommended that more accurate diagnostic tools are needed for risk
stratification according to HPV infection. Previous reports have suggested that HPV specific tests such
as DNA in situ hybridization and polymerase chain reaction should be used to confirm HPV status,
although p16 protein over-expression is very sensitive to the presence of transcriptionally-active HPV,
correlates strongly with patient outcomes, is widely available, and is easy to interpret [22]. Gupta et al.
also suggested that circulating HPV16 DNA in the plasma may be a clinically useful biomarker [23].
These biomarkers can be measured using a simple blood test, and the level of ctDNA is predictive of
an early treatment response. If used in combination with inflammatory markers, this technique will be
helpful in predicting a patient′s prognosis and determining an appropriate treatment plan.
As noted, NLR is an easily and routinely determined biomarker of systemic inflammation, and
in our study population a high NLR correlated strongly and independently with a poorer PFS and
OS. Previous studies have also identified a high NLR as an independent prognostic factor for many
other types of cancers, including colorectal cancer, renal cell cancer, pancreatic cancer, and head
and neck squamous cell carcinoma [2,24–28]. Although the tumorigenic mechanism underlying this
relationship with the NLR has not been clearly elucidated, it appears likely that increased levels of
several inflammatory cytokines contribute to a microenvironment that promotes carcinogenesis and
tumor progression [29]. Several growth factors, including epidermal growth factor, vascular endothelial
growth factor, and transforming growth factor-α, also contribute to the creation of microenvironments
supportive of angiogenesis and tumor proliferation [30]. Our results are therefore consistent with the
concept that a high NLR contributes to poor disease control by suppressing the cytolytic activities
of activated effector T cells and the peritumoral infiltration of immuno-suppressive cells such as
macrophages [31,32].
We further demonstrated that a higher PLR was associated with PFS in our multivariate analysis.
Again, the significance of interactions between platelets and the tumor microenvironment remains
somewhat unclear. The platelet count provides an additional index of systemic inflammation
elicited by the tumor and degranulation. This inflammation, together with the consequent release of
platelet-derived proangiogenic mediators within the tumor microvasculature, may also serve as an
important determinant of tumor growth [33–35].
This study had a few limitations. First, the study had a retrospective design and included various
primary sites of head and neck cancer. Additionally, patients in the high NLR group tended to have
more advanced-stage disease. However, the NLR remained a significant prognostic factor for survival
in the multivariate analysis, as well as in an additional analysis according to disease stage. Second, the
selection of treatment modalities and regimens was heterogeneous and was determined in accordance
with the primary site and physicians’ discretion. Third, we did not explore the association of LN
metastasis with patient outcomes because of the use of clinical stage and likelihood of upstaging for
LNs. Therefore, our findings should be interpreted cautiously. Nevertheless, this is one of the largest
studies to evaluate the prognostic significance of systemic inflammation in patients who underwent
RT for head and neck cancer, and we have revealed potential differences in the patients’ characteristics
and outcomes according to their NLR status. In addition, we observed different associations of the
NLR status among patients with oropharyngeal cancer versus those with other head and neck cancers,
which underscores the need for further studies of the relationship between HPV infection and the NLR.
In conclusion, the results of our large population study validate the suggested association of a high
NLR with poorer outcomes after adjusting for potential confounding factors. Although further studies
of the biological mechanisms underlying the relationship between inflammation and aggressiveness
are needed, our results suggest that a classification system based on pretreatment hematologic markers
could identify patients with a high risk of recurrence and poor survival.
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Abstract: Clear differences have been established between head and neck squamous cell carcinomas
(HNSCC) depending on human papillomavirus (HPV) infection status. This study specifically
investigated the status of the CTTN, CCND1 and ANO1 genes mapping at the 11q13 amplicon
in relation to the HPV status in HNSCC patients. CTTN, CCND1 and ANO1 protein expression
and gene amplification were respectively analyzed by immunohistochemistry and real-time PCR
in a homogeneous cohort of 392 surgically treated HNSCC patients. The results were further
confirmed using an independent cohort of 279 HNSCC patients from The Cancer Genome Atlas
(TCGA). The impact on patient survival was also evaluated. CTTN, CCND1 and ANO1 gene
amplification and protein expression were frequent in HPV-negative tumors, while absent or
rare in HPV-positive tumors. Using an independent validation cohort of 279 HNSCC patients,
we consistently found that these three genes were frequently co-amplified (28%) and overexpressed
(39–46%) in HPV-negative tumors, whereas almost absent in HPV-positive tumors. Remarkably,
these alterations (in particular CTTN and ANO1 overexpression) were associated with poor
prognosis. Taken together, the distinctive expression and amplification of these genes could
cooperatively contribute to the differences in prognosis and clinical outcome between HPV-positive
and HPV-negative tumors. These findings could serve as the basis to design more personalized
therapeutic strategies for HNSCC patients.
J. Clin. Med. 2018, 7, 501; doi:10.3390/jcm7120501 www.mdpi.com/journal/jcm73
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Keywords: head and neck squamous cell carcinoma; HPV; 11q13; gene amplification;
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1. Introduction
Head and neck cancer represents a heterogeneous group of tumors that accounts for about 5%
of the total annual worldwide cases of cancer, usually associated with poor prognosis [1,2]; however,
its incidence and other main features can significantly vary from one region to another. The most
prevalent histological type in head and neck cancers is the squamous cell carcinoma (HNSCC), and it
is widely accepted that the most important risk factors are tobacco and alcohol consumption [1,3,4].
Interestingly, the incidence of HNSCCs is currently declining in some specific regions, due to a
decrease of tobacco and alcohol consumption [4,5]. Nevertheless, there is an increasing incidence
of oropharyngeal tumors that are associated with human papillomavirus (HPV) infection in certain
developed countries [4,5].
The proportion of HPV-related oropharyngeal tumors can vary considerably among regions;
the observed prevalence in Europe varies from an estimated 17% in southern countries to as high
as 93% in northern countries like Sweden [5]. More than 90% of HPV-related HNSCC tumors are
caused by one specific virus type, the HPV-16, which also leads to HPV-related anogenital tumors [4,5].
On this basis, epidemiological studies have correlated HPV-positive tumors with sexual behaviors,
suggesting that the risk increases with the number of sexual partners and is particularly more frequent
in men [4,5].
Recent studies have consistently showed that HPV-related (HPV+) and unrelated (HPV−)
tumors represent two different entities in terms of clinical, biological, and molecular characteristics.
Thus, HPV-positive tumors generally arise in the oropharynx, have a more favorable prognosis,
a better response to chemotherapy and radiotherapy, and less genetic alterations when compared to
HPV-negative tumors [2,4–6].
One of the most frequent genetic alterations found in HNSCCs is the amplification of the
chromosomal region 11q13, which has been associated with tumor aggressive behavior, increased
lymph node metastases, and poor outcome [7]. Moreover, the comprehensive molecular analysis of
the 11q13 region led to the identification of genes evidenced to be directly related to an improved
ability for tumor growth, migration and invasion. Some of the genes mapping to the 11q13 region,
are CTTN (Cortactin), CCND1 (Cyclin D1), and the more recently discovered ANO1 (Anoctamin-1).
CTTN and CCND1 are well-established oncogenes, associated with advanced disease stage and poor
prognosis [8,9]. On the other hand, the newly characterized ANO1 encodes a calcium-activated
transmembrane chloride channel whose overexpression and amplification have been correlated with
increased cell migration and propensity to develop metastases [10,11]. However, data revealing the
role and importance of ANO1 in HNSCC have only recently emerged and, hence, are still limited.
Recent studies have evidenced important differences in the molecular alterations and the impact
of the 11q13 chromosomal region in HNSCC, depending on the anatomic site of the tumor and the HPV
infection status. These studies suggest that the amplification of 11q13 in HNSCCs is more frequent
in HPV-negative than in HPV-positive tumors [12], and this presumably contributes to the better
prognosis of the latter. On the basis of the increasing incidence of HPV-related tumors, the current
information regarding the clinical differences between HPV-related and unrelated tumors, and the
discovery of promising molecular prognosis factors like ANO1, we believe it is crucial to study in
depth the molecular alterations involved in HNSCC and their relationship with HPV infection, in order
to have a better understanding of the pathogenesis of the disease with the ultimate goal of establishing
the path for the development of new and more effective treatment strategies. This consideration
prompted us to study the status of various genes (CTTN, CCND1 and ANO1) mapping at the 11q13
amplicon in relation to HPV infection in two large independent cohorts of HNSCC patients.
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2. Materials and Methods
2.1. Patients and Tissue Specimens
Surgical tissue specimens from 392 patients with HNSCC who underwent resection of their
tumors at the Hospital Universitario Central de Asturias and Hospital Sant Pau between 1990 and
2010 were retrospectively collected, in accordance to approved institutional review board guidelines.
All experimental protocols were conducted in accordance to the Declaration of Helsinki and approved
by the Institutional Ethics Committees of the Hospital Universitario Central de Asturias and Hospital
Sant Pau and by the Regional CEIC from Principado de Asturias (approval number: 81/2013 for the
project PI13/00259). Informed consent was obtained from all patients. Representative tissue sections
were obtained from archival, paraffin-embedded blocks, and the histological diagnoses were confirmed
by an experienced pathologist (Aurora Astudillo).
Clinical, sociodemographic, follow-up, and risk factors information was collected from the
medical records. The stage of the tumors was determined according to the TNM system of the
International Union Against Cancer (7th Edition).
2.2. Tissue Microarray (TMA) Construction and DNA Extraction
The original archived hematoxylin- and eosin-stained slides were reviewed by an experienced
pathologist (Aurora Astudillo) to confirm the histological diagnoses. Five morphologically
representative areas were selected from each individual tumor paraffin block: two for DNA isolation
and three for the construction of a TMA. To avoid cross-contamination, two punches of 2 mm diameter
were taken first, using a new, sterile punch (Kai Europe GmbH, Solingen, Germany) for every tissue
block, and stored in eppendorf tubes (Sigma Aldrich, Saint Louis, MO, USA) at room temperature.
Subsequently, three representative tissue cores (1 mm diameter punches) were selected from each
tumor block and transferred to a recipient ‘Master’ block in a grid-like manner using a manual tissue
microarray instrument to construct TMA blocks, as described previously [13,14]. In addition, each TMA
included three cores of normal epithelium (tonsil) as an internal negative control and three cores of a
HPV-positive cervix carcinoma as a positive control. A section from each microarray was stained with
hematoxylin and eosin and examined by light microscopy (Leica Microsystems, Wetzlar, Germany) to
check the adequacy of tissue sampling.
The protocol for DNA extraction from paraffin-embedded tissue sections has been described
elsewhere [13]. Briefly, Formalin-fixed paraffin-embedded (FFPE) tissue samples were subjected to
thorough deparaffinization with xylene (Sigma Aldrich, Saint Louis, MO, USA), methanol (Merck,
Darmstadt, Germany) washings to remove all traces of the xylene, and a 24 h incubation in 1 mol/L
sodium thiocyanate (Sigma Aldrich Inc.) to reduce cross-links. Subsequently, the tissue pellet was
digested for 2–3 days in lysis buffer with high doses of proteinase K (final concentration, 2 μg/μL,
freshly added twice daily). Finally, DNA extraction was done using the QIAamp DNA Mini Kit
(Qiagen GmbH, Hilden, Germany).
2.3. HPV Detection
The algorithm used to detect the presence of HPV in these patients has been previously described
in detail [13,15]. Briefly, the presence of HPV was assessed by p16-immunohistochemistry in all
cases, and those cases showing p16-positive immunostaining (any nuclear and or cytoplasmic
staining) were subjected to high-risk HPV DNA detection and genotyping by GP5+/6+-PCR with an
enzyme-immuno-assay (EIA) read-out for detection of 14 high-risk HPV types. Subsequent genotyping
of EIA-positive cases was performed by bead-based array on the Luminex platform. In addition, in situ
hybridization (ISH) with biotinylated HPV DNA probes considered to react with HPV types 16, 18, 31,
33, 35, 39, 45, 51, 52, 56, 58, 59, and 68 (Y1443, DakoCytomation, Glostrup, Denmark) was performed on
all carcinomas, using 3 μm tissue sections of the TMAs, according to the manufacturer’s instructions.
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2.4. Gene Amplification Analysis
Gene amplification was evaluated by real-time PCR (Q-PCR) in an ABI PRISM 7500 Sequence
detector (Applied Biosystems, Foster City, CA) using Power SYBR Green PCR Master Mix
and oligonucleotides designed according to Primer Express software v2.0 (Applied Biosystems,
Lincoln Centre Drive Foster City, CA, USA) with the following sequences: for CCND1 gene, Fw,
5′-GGAAGATCGTCGCCACCTG-3′ and Rv, 5′- GAAACGTGGGTCTGGGCAAC-3′; for ANO1 gene,
Fw, 5′-CAAAGGCAGGTGCTTTGCA-3′ and Rv, 5′-TCTACGGGCCTCTGCTCACT-3′; for CTTN gene,
Fw, 5′-GATCTCATTTGACCCTGATGACATC-3′ and Rv, 5′-CGTACCGGCCCTTGCA-3′; and for the
reference gene TH (Tyrosine Hydroxylase, located at 11p15), Fw, 5′-TGAGATTCGGGCCTTCGA-3′ and
Rv, 5′-GACACGAAGTAGACTGACTGGTACGT-3′. Dissociation curve analysis of all PCR products
showed a single sharp peak, and the correct size of each amplified product was confirmed by agarose
gel electrophoresis. The relative gene copy number was calculated using the 2-ΔΔCT method, as we
previously described [16,17]. The ΔΔCT represents the difference between the paired tissue samples
(ΔCT of tumor − ΔCT of normal mucosa), with ΔCT being the average CT for each target gene minus
the average CT for the reference gene (TH). Relative copy numbers ≥2-fold were considered gene gain,
and relative copy numbers ≥4-fold were considered positive for gene amplification.
2.5. Immunohistochemistry
The formalin-fixed, paraffin-embedded tissues were cut into 3-μm sections and dried on Flex IHC
microscope slides (Dako, Glostrup, Denmark). The sections were deparaffinized with standard xylene
and hydrated through graded alcohols into water. Antigen retrieval was performed using Envision
Flex Target Retrieval solution, high pH (Dako, Glostrup, Denmark). Staining was done at room
temperature on an automatic staining workstation (Dako Autostainer Plus) with mouse anti-Cyclin
D1 monoclonal antibody DCS-6 (Santa Cruz Biotechnology, Inc. sc-20044) at 1:100 dilution, rabbit
polyclonal Anti-TMEM16A antibody (Abcam # ab53212) at 1:500 dilution, or mouse anti-cortactin
monoclonal antibody Clone 30 (BD Biosciences Pharmingen, San Jose, CA, USA) at 1:200 dilution,
using the Dako EnVision Flex + Visualization System (Dako Autostainer). Counterstaining with
hematoxylin was the final step.
The slides were viewed randomly without clinical data by two of the authors, according to the
scoring systems previously described [17,18] with a high level of inter-observer concordance (>95%).
CCND1 staining was evaluated as the percentage of cells with nuclear staining, scored as 0–2 according
to the semiquantitative scale (0–10, 10–50, or >50% positive tumor cells). CCND1 staining scores were
classified as negative or positive staining on the basis of values below or above the median value of
10%. Since CTTN and ANO1 staining showed a homogeneous distribution, a semiquantitative scoring
system based on staining intensity was applied. Thus, CTTN immunostaining was scored as negative
(0), weak (1), moderate (2), and strong protein expression (3). The staining data were dichotomized
as negative (scores 0 and 1) versus positive (scores 2 and 3). ANO1 immunostaining was scored as
negative (0), weak to moderate (1), and strong protein expression (2). Scores ≥1 were considered
positive ANO1 expression.
2.6. Statistical Analysis
Fisher’s exact test was used for comparison between categorical variables, and t Student test
for parametric continuous variables. Correlations between protein expression, gene amplification,
and HPV status were estimated by Kendall‘s tau correlation test. All tests were two-sided;
p values ≤0.05 were considered to be statistically significant.
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3. Results
3.1. Patient Characteristics
A large cohort of 392 homogeneous surgically treated HNSCC patients was selected for study.
A flow diagram of the experimental setup is shown in Supplementary Figure S1. All patients had
a single primary tumor, microscopically clear surgical margins, and received no treatment prior
to surgery. Only 19 patients were women, and the mean age was 60 years (range 30 to 89 years).
All but 22 patients were habitual tobacco smokers—202 moderate (1–50 pack-year) and 159 heavy
(>50 pack-year)—and 353 were alcohol drinkers. Nineteen tumors were stage I, 25 stage II, 69 stage
III, and 279 stage IV. The series included 152 tonsillar, 116 base of tongue, 62 hypopharyngeal,
and 62 laryngeal carcinomas. A total of 147 tumors were classified as well-differentiated, 151 as
moderately differentiated, and 94 as poorly differentiated. In total, 232 (59%) patients received
postoperative radiotherapy.
3.2. Distinctive Associations of CCND1, ANO1, and CTTN Protein Expression with HPV Status in
HNSCC Patients
We found that 67 cases (17%) showed nuclear and cytoplasmic p16 expression, a surrogate marker
for HPV infection (2) (Table 1). HPV DNA was assessed by GP5+/6+-PCR and by in situ hybridization
in the 67 p16-positive cases, which resulted in a total of 30 HPV-positive cases (28 oropharyngeal,
1 laryngeal, and 1 hypopharyngeal carcinoma) in our series (all were HPV type 16). Representative
images of HPV-positive and HPV-negative cases and also examples of p16 immunostaining are
shown in Figure 1. We found a total of 267 (68%) positive cases for CCND1 protein expression,
78 (21%) positive cases for ANO1 expression, and 190 (49%) positive cases for CTTN expression
(Table 1). Representative examples of protein staining are shown in Figure 2, and raw data in
Supplementary Information. We next investigated the relationship between CCND1, ANO1, and CTTN
expression and HPV infection status. The expression of these three proteins was strongly and inversely
correlated with HPV infection. Notably, all the HPV-positive cases showed negative ANO1 expression,
and 28 HPV-positive cases had also negative CTTN expression (Table 1).
Table 1. Analysis of CCND1 (Cyclin D1), ANO1 (Anoctamin-1), and CTTN (Cortactin) protein
expression in relation to human papillomavirus (HPV) status and p16 expression in 392 head and neck
squamous cell carcinomas (HNSCC) patients.
Molecular Feature Number HPV-Positive p #
CCND1 protein expression
Negative 123 21 (−0.239)
Positive (scores 1-2) 267 9 <0.001
ANO1 protein expression
Negative 299 29 (−0.147)
Positive (scores 1-2) 78 0 <0.001
CTTN protein expression
Negative 199 28 (−0.239)
Positive (scores 2-3) 190 2 <0.001
p16 protein expression
Negative 325 0 (0.634)
Positive 67 30 <0.001
# Kendall’s tau correlation coefficient with the associated p value.
3.3. Analysis of CCND1, ANO1, and CTTN Gene Amplification in Relation to HPV Status in
HNSCC Patients
CCND1, ANO1, and CTTN gene gain and amplification was assessed by real-time PCR in 88
cases selected from the same HNSCC tissue blocks, including 26 HPV-positive cases. We found gene
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gains and amplifications of CCND1 in 32 (36%) tumors, ANO1 in 42 (48%) tumors, and CTTN in 26
(30%) tumors (Table 2), with relative gene copy numbers ranging from 2- to 24-fold. Co-amplifications
of these three genes were also frequently observed (26 cases, 30%). We also found that tumors
harboring gene amplification significantly correlated with higher expression levels of each protein
(Figure 3). When analyzing the correlations with HPV infection status, we consistently found that
CCND1, ANO1, and CTTN gene amplification inversely correlated with HPV status (Table 2). Thus,
amplifications of CTTN, CCND1, and ANO1 were frequent in HPV-negative tumors (ranging from 42
to 61%), while absent in HPV-positive tumors.
Table 2. Analysis of CCND1, ANO1, and CTTN gene gain and amplification in relation to HPV status
in 88 HNSCC patients.
Copy Number Alteration No. HPV-Positive p #
CCND1 gene
Negative 55 24 (−0.430)
Gain (≥2 copies) 6 2 <0.001
Amplification (≥4 copies) 27 0
ANO1 gene
Negative 45 22 (−0.472)
Gain (≥2 copies) 16 4 <0.001
Amplification (≥4 copies) 27 0
CTTN gene
Negative 61 26 (−0.422)
Gain (≥2 copies) 3 0 <0.001
Amplification (≥4 copies) 24 0
Total Cases 88 26
# Kendall’s tau correlation coefficient with the associated p value.
p16                            HPV 
Figure 1. Representative images of p16-positive (A) and negative (C) immunostaining in the HNSCC
tissue microarrays (TMAs) and HPV-positive (B) and HPV-negative (D) cases detected by in situ
hybridization. Original magnification ×10.
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Figure 2. Representative examples of negative and strong positive staining for CCND1 (A,B), ANO1
(C,D), and CTTN (E,F). Original magnification ×20.
3.4. Analysis of CCND1, ANO1, and CTTN mRNA Expression in Relation to HPV Status in 279 HNSCC
Patients from the TGCA
In order to confirm our results, we performed an analysis of the publicly available TCGA data
from 279 HNSCC patients [19] using the platform cBioPortal for Cancer Genomics (http://cbioportal.
org/) [20]. The clinicopathologic characteristics of this cohort are summarized in Supplementary
Table S1 and Figure S2. A total of 36 (13%) patients were positive for HPV infection, most prevalent
in the oropharynx (22 cases, 61%), and associated to lower tobacco consumption, lower mutations,
improved survival, and a younger age in both men and women. The results also evidenced differential
changes in mRNA expression levels of CTTN, CCND1 and ANO1 depending on HPV infection status.
Thus, increased mRNA expression levels of these genes were frequently and significantly observed
in HPV-negative tumors (Figure 4A–D), while very rare in HPV-positive patients (Table 3). Similarly,
the analysis of copy number alterations of CTTN, CCND1, and ANO1 genes also revealed that both
amplifications and gains of these three genes were also highly frequent in HPV-negative tumors,
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whereas almost absent in HPV-positive tumors (Figure 4A,E). Furthermore, the results consistently
showed that these three genes were frequently co-amplified (28%) and overexpressed at a higher
frequency (39–46%), and, more importantly, these molecular alterations (in particular CTTN and ANO1
overexpression) were associated with a worse clinical outcome in the TCGA cohort of 279 HNSCC
patients and also in an extended TCGA cohort which added 251 new HNSCC patients (n = 530)
(Figure 5).
CCND1 
Gene Copy Number 
Total 




0 34 1 1 36 
1 16 2 7 25 
2 5 3 19 27 
Total 55 6 27 88 
Spearman Coefficient 0.653, p < 0.001. 
ANO1 
Gene Copy Number 
Total 
No Gain Gain Amplification 
Protein 
Score 
0 40 14 18 72 
1 4 2 6 12 
2 1 0 3 4 
Total 45 16 27 88 
Spearman Coefficient 0.237, p = 0.027. 
CTTN 
Gene Copy Number 
Total 
No Gain Gain Amplification 
Protein 
Score 
0 22 1 0 23 
1 32 1 0 33 
2 4 1 9 14 
3 3 0 15 18 
Total 61 3 24 88 
Spearman Coefficient 0.711, p < 0.001. 
Figure 3. Crosstab to evaluate the correlations between gene gains and amplification and protein
staining scores for CCND1, ANO1, and CTTN.
80
J. Clin. Med. 2018, 7, 501
Figure 4. Analysis of mRNA expression and copy number alterations of CTTN, CCND1 and ANO1 in
relation to HPV status related to the available HNSCC TCGA data (n = 279) obtained from cBioPortal.
(A) Schematic representation and heat map showing the percentage of cases with CTTN, CCND1, and
ANO1 gene amplification and mRNA expression in relation to the HPV status. (B) CTTN, (C) CCND1,
and (D) ANO1 mRNA expression distributed according to the HPV status. mRNA expression (RNA
seq V2 RSEM) values were Log2 transformed (y-axis). Whiskers plot (min. to max.) with median
values; p < 0.001, two-tailed Student t-test. (E) Copy number alterations of CTTN, CCND1 and ANO1
according to the HPV status using the GISTIC method.
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Figure 5. Analysis of CTTN, CCND1 and ANO1 gene amplification and mRNA expression in the TCGA
cohort of 530 HNSCC patients using cBioPortal. Schematic representation showing the percentage
of cases with amplification or mRNA upregulation of each gene. Kaplan–Meier survival curves
categorized by CTTN, CCND1 and ANO1 gene amplification dichotomized as positive versus negative;
CTTN, CCND1 and ANO1 mRNA expression (RNA seq V2 RSEM, z-score threshold ±2) dichotomized
as normal versus upregulation (UP); p values estimated using the Log-rank test.
Table 3. Analysis of CCND1, ANO1, and CTTN mRNA expression in relation to HPV status in 279
HNSCC TGCA patients.
Molecular Feature No. HPV-Positive p #
CCND1 expression
Normal 206 35 <0.001
UP 73 1
ANO1 expression
Normal 207 34 0.002
UP 72 2
CTTN expression
Normal 177 34 <0.001
UP 102 2
Total Cases 279 36
# Fisher’s exact test.
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4. Discussion
The incidence of HPV-related HNSCC is currently increasing and gaining importance,
while tumors associated to tobacco and alcohol consumption are declining [4,5]. Recent studies
have established important differences between HNSCC depending on HPV infection status, including
clinical, biological, and molecular features, emphasizing the presence of less genetic alterations,
a better response to chemotherapy and radiotherapy, and a more favorable prognosis for HPV-related
HNSCC [2,4,5]. These differences could change the way we diagnose, treat, and manage HNSCC.
One of the most frequent genetic alterations found in HNSCC is the amplification of the 11q13 locus,
which has been associated with increased tumor growth, proliferation, and dissemination [8,9].
Given the importance of the 11q13 locus in HNSCC and to contribute to the molecular
characterization of these tumors, we conducted a study on a large unbiased cohort of 392 homogeneous
surgically treated HNSCC patients to investigate the role of 11q13 amplification in relation to HPV
status. This was accomplished by assessing the specific relationship of the protein expression and
amplification of the CTTN, CCND1, and ANO1 genes mapping within this locus. Immunohistochemical
analysis of CCND1, CTTN, and ANO1 revealed that the expression of these three proteins was strongly
and inversely correlated with HPV infection. Noteworthy, all the HPV-positive cases showed negative
ANO1 expression, and 28 out of 30 HPV-positive cases had also negative CTTN expression. Likewise,
the analysis of gene copy amplification by real-time PCR consistently showed that amplifications of
CTTN, CCND1 and ANO1 were frequently detected in HPV-negative tumors (ranging from 42 to 61%),
while absent or rare in HPV-positive tumors (0–15%). Mechanistically, we found that the contribution of
gene amplification to protein expression varied widely depending on each gene. Even though tumors
harboring amplification also concomitantly expressed high protein levels, positive CCND1 and CTTN
expression occurred at a higher frequency than gene amplification, while ANO1 protein expression was
less frequent than ANO1 gene amplification. Additional regulatory mechanisms (transcriptional and
post-translational) should contribute to protein expression, as previously reported [18]. A limitation
of our study is the use of tissue microarrays to evaluate protein expression, which may constitute a
drawback to assess the possible influence of tumor heterogeneity. To minimize this, three different
representative tumor areas were selected from each tissue block and analyzed in the TMAs. Of note,
the results showed that these proteins presented homogeneous and highly concordant expression
patterns in the three tissue punches from each tumor.
These results were further and significantly validated using an independent cohort of 279 TCGA
HNSCC patients, thus confirming that the mRNA expression levels of CCND1, CTTN, and ANO1
were significantly increased in a high proportion of HPV-negative tumors, whereas most HPV-positive
patients exhibited normal mRNA levels of all these genes. Similar observations were obtained by
analyzing the frequencies of copy number alterations. These findings are also consistent with some
studies that reported that 11q13 amplifications and gains were less frequent in HPV-related tumors [2,4].
This is also in agreement with the assumption made by Kostareli et al. [6] that, in HPV-positive tumors,
a lower amount of genetic alterations is required to achieve the malignant phenotype, because of the
inactivation of p53 and pRb proteins by the viral E6 and E7 oncoproteins. To our knowledge, this is
the first study to assess specifically the protein expression and copy number alterations of various
genes mapping at the 11q13 amplicon in relation to HPV infection status using two large independent
cohorts of HNSCC patients. Our study unveils important differences regarding the expression and
amplification of the CCND1, CTTN and ANO1 genes between HPV-related and unrelated tumors.
It is worth mentioning that the two HNSCC cohorts selected for study are representative, sharing
multiple of the unique characteristics reported for HPV-positive tumors [13], such as a clear prevalence
in the oropharynx, low tobacco and alcohol consumption by the patients, lower tumor stage, basaloid
histological pattern, a younger patients’ age at diagnosis, lower mutations and CNA, and above all,
a better prognosis. A recent study by Dixit et al. [21] provided the first evidence of a link between
ANO1 expression and gene amplification and HPV status using a series of 64 pharyngeal tumors and
tissue microarrays for IHC evaluation. Therefore, our results further and significantly strength and
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validate these preliminary findings on ANO1 protein expression using a large independent cohort of
392 HNSCC patients, as well as on ANO1 mRNA levels in the TCGA cohort of 530 HNSCC patients.
Together, these findings suggest that the CCND1, CTTN and ANO1 genes within the 11q13
amplicon could play a significant role in HPV-negative tumors but not in HPV-positive tumors.
Given that 11q13 amplification has been associated with poor prognosis in HNSCC patients,
and, in particular, these three genes have been involved in tumor progression and resistance to
radio-, chemotherapy [11,22–26], and EGFR-targeted therapies [27], the herein found distinctive
molecular alterations presumably could contribute to the clinical and biological differences between
these two different HNSCC subtypes and explain the better prognosis and response to radiotherapy and
chemotherapy associated to HPV-positive tumors. In fact, we proved the impact of these molecular
alterations on patient survival. In particular, CTTN and ANO1 overexpression, rather than gene
amplification, was more frequent and found to associate with a worse clinical outcome in two TCGA
cohorts of 279 and 530 HNSCC patients. Nevertheless, given the size of the 11q13 amplicon, it cannot
be ruled out that the overexpression of these genes may be secondary and that other genes within the
11q13 amplicon could act as true drivers of HNSCC progression. A recent study has also identified
four genes (ORAOV1, CPT1A, SHANK2 and PPFIA1) as important drivers of 11q13 amplification
that showed an impact on prognosis [28]. Therefore, various genes within the 11q13 amplicon could
cooperatively contribute to the differences in prognosis and clinical outcome between HPV-positive
and HPV-negative tumors. In summary, various studies including ours have provided strong evidence
demonstrating that HPV-related and unrelated tumors are two different entities; hence, we consider
that the management of HNSCC patients should move toward a more personalized approach.
5. Conclusions
CTTN, CCND1 and ANO1 amplification and overexpression were frequent in HPV-negative
tumors and correlated with reduced patient survival, while absent or very rare in HPV-positive
tumors. Therefore, these molecular alterations could contribute to the distinct clinical outcomes of
these two HNSCC entities and serve as the basis to design more personalized therapeutic strategies for
HNSCC patients.
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Figure S1. Schematic representation of the experimental setup designed to analyze CCND1, ANO1 and CTTN
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representation showing the HPV incidence by HNSCC subsites, mutation frequencies, and Kaplan–Meier survival
curves (p = 0.024, Log-rank test). Raw data of CTTN, CCND1 and ANO1 protein scores in relation to the HPV
status for the total cohort of 392 HNSCC patients, Table S1: Clinicopathologic features of the validation cohort of
279 HNSCC patients from the TCGA.
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Abstract: Background: Nox4 has been reported to promote tumor progression of various types of
cancer through many different pathways. The current study was designed to evaluate the prognostic
significance of Nox4 in patients with oral tongue squamous cell carcinoma (OTSCC) receiving surgical
resection. Methods: We retrospectively analyzed the 161 patients with OTSCC treated with surgical
resection, including 81 patients with high expression of Nox4 and 80 patients with low expression
of Nox4. Two OTSCC cell lines, SAS and SCC4, were used to investigate the proliferation activity.
Results: The univariate and multivariable analyses showed that negative nodal metastasis and
low expression of Nox4 were significantly associated with superior disease-free survival (DFS) and
overall survival (OS). Western blotting analysis indicated that Nox4 was highly expressed in these
two OTSCC cell lines and knockdown of Nox4 was successful by transfecting with Nox4 shRNA.
In addition, these cell lines were also treated with a Nox4 inhibitor (GKT-137831) and the results
showed GKT-137831 could inhibit the proliferation of OTSCC tumor cells in a dose-dependent
manner. Conclusion: Our study suggests that Nox4 plays an important role in disease progression of
OTSCC and Nox4 overexpression is a poor prognostic factor for patients with OTSCC who received
surgical resection.
Keywords: Nox4; oral tongue cancer; squamous cell carcinoma; surgery
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1. Introduction
Head and neck squamous cell carcinoma (HNSCC) is one of the leading cancers worldwide and
there are an estimated 500,000 new cases being diagnosed annually [1]. In Taiwan, HNSCC is the
sixth most common cancer and fifth leading cause of cancer-related deaths in men [2]. The tongue
is the most frequent tumor location for intraoral cancers and tumors most often develop after a long
history of tobacco use, alcohol or betel nut consumption and its incidence has increased in recent
years. Treatment of oral tongue squamous cell carcinoma (OTSCC) includes a single surgical resection,
radiotherapy, chemotherapy, targeted therapy or a combination of these modalities. Despite significant
improvements in surgical techniques, chemotherapy, radiotherapy and targeted therapy in the last
three decades, the outcome of patients with OTSCC still remains poor [3,4]. Recurrence is the most
important prognostic factor and is primarily caused by aggressive local invasion and metastasis,
leading to a poor prognosis and a negative quality of life. Thus, OTSCC remains a challenging disease
to manage in the field of HNSCC. Therefore, identification of a reliable biomarker to correctly predict
the likelihood of a recurrence to potentially reduce mortality in patients with OTSCC is an important
research priority.
Nox4 is one of the nicotinamide adenine dinucleotide phosphate (NADPH) oxidases (NOXs)
family and is the most frequently expressed isoform in these tumor cells [5]. It generates superoxide
or hydrogen peroxide, produces reactive oxygen species (ROS) and been recognized as an important
signal molecule in several cancers. Increased generation of ROS has been implicated in the pathogenesis
of a variety of tumors [6,7], such as pancreatic cancer, breast cancer, non-small cell lung cancer and
colon cancer [8–11]. Some previous studies have identified the biochemical links between Nox4
and cancer through several mechanisms, including angiogenesis, inflammatory cytokines, apoptosis
resistance, histone modification, transforming growth factor-β and epidermal growth factor receptor
pathway and so forth. [12–17]. Growing evidence confirms that there is a close correlation of Nox4
with cancer development and progression and the inhibition of Nox4 suppresses tumor growth and
leads to cancer cell death [18].
However, the role of Nox4 in OTSCC remains unclear thus far. We postulate that Nox4
overexpression accounts for a novel mechanism that contributes to tumor progression and poor
clinical outcome in patients with OTSCC. The aim of the present study was to elucidate the prognostic
significance of Nox4 on survival in the progression of patients with OTSCC receiving surgical resection.
Furthermore, in order to explore the function of Nox4 in cancer ell metabolism of OTSCC, we examined




We retrospectively reviewed 1256 patients with OTSCC who were treated at Kaohsiung Chang
Gung Memorial Hospital between January 2006 and December 2015. Among these 1256 patients
with OTSCC, we first excluded those patients with a history of any second primary malignancy,
distant metastasis, or who underwent preoperative chemotherapy or radiotherapy. After that,
only those patients with OTSCC who received surgical resection as a curative treatment were included.
Finally, a total of 161 patients with OTSCC with available paraffin blocks and medical records were
identified. The tumor stage of each patient was determined according to the 7th American Joint
Committee on Cancer (AJCC) staging system [19].
2.2. Immunohistochemistry
Immunohistochemistry staining was achieved using an immunoperoxidase technique and performed
on slides (4 μm) of formalin-fixed paraffin-embedded tissue sections using primary antibodies against
Nox4 (ab109225, 1:200, Abcam, Cambridge, MA, USA). Briefly, after deparaffinization and rehydration,
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slides were subjected to a heat-induced epitope retrieval in 10 mM citrate buffer (pH 6.0) in a hot water bath
(95 ◦C) for 20 min. Immunodetection was performed using the LSAB2 kit (Dako, Carpinteria, CA, USA)
followed by 3-3′-diaminobenzidine for color development and hematoxylin for counterstaining. For Nox4,
incubation without the primary antibody was used as a negative control, while a slide of normal
kidney tissue was used as a positive control. The staining assessment was independently carried out
by two pathologists (S.L.W. and W.T.H.) without any information about clinicopathologic features
or prognosis. Slides were examined at 200× and in each case, at least four sections were examined.
We followed the previously published method to score the expression of Nox4 [18]. The percentage of
Nox4 positive tumor cells for all neoplastic cells in the section was recorded. Nox4 overexpression was
defined as the presence of staining in ≥50% of tumor cells.
2.3. Western Blot Analysis
For cell protein extraction, samples were homogenized in RIPA lysis buffer (50 mM Tris-HCl, pH 7.5,
150 mM NaCl, 1% NP-40, 0.5% Na-deoxycholate and 0.1% SDS). The protein concentration in each
sample was estimated using a Bio-Rad Protein Assay (Bio-Rad, Hercules, CA, USA). Immunoblotting
was performed according to standard procedures. Antibodies used in this study included polyclonal
antibodies against Nox4 (ab109225, 1:200, Abcam, Cambridge, MA, USA) and β-actin (Sigma Aldrich,
St Louis, MO, USA). The first antibodies were detected by incubation while secondary antibodies were
conjugated to horseradish peroxidase (Bio/Can Scientific, Mississauga, ON, Canada) and developed
using Western Lighting Reagent. The proteins were explored by X-ray films.
2.4. Cell Culture and Transfection
OTSCC cell lines SAS and SCC4 were established and purchased from Bioresource Collection
and Research Center in Taiwan. These cell lines were cultured under standard conditions using
Dulbecco′s modified Eagle′s medium (DMEM) with 10% fetal bovine serum, 1X MEM non-essential
amino acids, 100 U/mL penicillin, 100 μg/mL streptomycin, 0.25 μg/mL Amphotericin B and
2.0 mmol/L L-glutamine.
To examine the cell proliferative activity of Nox4 in OTSCC, a 3-(4,5-dimethylthiazole-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) assay was performed on these cell lines. The procedure
was performed as follows: each cell line (7000 cells) was incubated along with a control in
a 96-well flat-bottomed plate in triplicate. After incubation for 96 h at 37 ◦C, 100 μL of MTT
(3-(4,5-dimenthylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, 0.5 mg/mL, Sigma, St. Louis,
MO, USA) was added to each well and incubation was carried out for another four hours.
Then, the supernatant was discarded and the crystal products were eluted with dimethyl sulfoxide
(100 μL/well, Sigma). The colorimetric evaluation was tested using a spectrophotometer at 570 nm.
The proliferation of each cell line harboring Nox4 overexpression was shown as a percentage of cell
growth compared to the control cells.
To confirm the role of Nox4 in the malignant properties of OTSCC cells we transfected Nox4
shRNA into OTSCC cells to generate Nox4 knockdown cells. The above-mentioned OTSCC cell lines
were used here. These cells were seeded in a 6 cm dish and allowed to grow to 50%–60% confluence
for 24 h. Nox4 shRNA (40 nM) was purchased from RNAi Core of Academia Sinica (Taiwan) and
then transfected into OTSCC cells using Hiperfect reagent according to the manufacturer′s protocol
(Qiagen). To disrupt aggregates formed during lyophilization, shRNA was incubated at 90 ◦C for one
minute and then at 37 ◦C for 60 min prior to the transfection procedure. The silencing efficiency was
evaluated by western blotting 24 to 72 h after shRNA transfection. To examine the cell proliferative
activity of Nox4 knockdown in OTSCC, an MTT assay was performed in these cell lines.
To test the role of Nox4 in the progression of OTSCC cells, we treated OTSCC cell lines, with or
without a Nox4 inhibitor, with GKT-137831 (Selleck Chemicals, Houston, TX, USA), which is a novel
and specific dual Nox1/Nox4 inhibitor. Each cell line (2500 cells) was incubated in 200 μL with
GKT-137831 (0, 1, 5, 10, 20, 40, 80 and 100 μM) and control in a 96-well flat-bottomed plate in triplicate.
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To examine the cell proliferative activity of Nox4 inhibitor in OTSCC, an MTT assay was performed in
these cell lines according to the above-mentioned procedures.
2.5. Statistical Analysis
For patient data, the statistical analyses were performed using the SPSS 19 software package
(IBM, Armonk, NY, USA). Comparisons between the groups were performed using the chi-square test
for categorical variable data. Disease-free survival (DFS) was computed from the time of surgery to
the recurrence of cancer or death from any cause without evidence of recurrence. Overall survival
(OS) was calculated from the date of diagnosis of the OTSCC to the date of death or last contact.
The Kaplan–Meier method was used to estimate DFS and OS and the log-rank test was performed to
evaluate the differences between the groups for univariate analysis. In a stepwise forward fashion,
significant parameters at the univariate level were entered into a Cox regression model to analyze their
relative prognostic importance. For cell line experiments, a t-test was used for the statistical analysis.
Each experiment was carried out independently at least twice, with three repeats each. For all analyses,
a p-value < 0.05 was considered statistically significant.
2.6. Ethics Statement
Study approval was obtained from the Chang Gung Medical Foundation Institutional Review
Board (201700414B0) and all the patients provided the written informed consent. All the methods were
carried out in accordance with the approved guidelines and the ethical standards of the World Medical
Association Declaration of Helsinki.
3. Results
3.1. Patient Population
A total of 161 patients with OTSCC who received surgical resection were retrospectively examined
at Kaohsiung Chang Gung Memorial Hospital. All of the 161 patients with OTSCC had an Eastern
Cooperative Oncology Group performance status ≤1. The study group consisted of 148 male patients
and 13 female patients with a median age of 53 years (range: 26 to 86 years). A total of 132 patients
(82%) had a history of tobacco smoking and alcohol consumption was mentioned in 129 patients (80%).
The tumor T status was found to be T1 in 46 patients (29%), T2 in 53 patients (33%), T3 in 13 patients
(8%) and T4 in 49 patients (30%). Meanwhile, 93 patients (58%) were diagnosed as having N0 status,
22 patients (14%) as having N1 status, 44 patients (27%) as having N2 status and two patients (1%)
as having N3 status. The tumor stage indicated that 36 patients (22%) had stage I, 34 patients (21%)
had stage II, 23 patients (14%) had stage III, 62 patients (39%) had stage IVA and six patients (4%) had
stage IVB. At the time of analysis, the median period of follow-up was 87.8 months for the 76 living
survivors and 62.8 months (range: 2.3–117.6 months) for all 161 patients. The five-year DFS and OS
rates were 68.9% and 47.2%, respectively. The clinicopathological parameters of these patients are
shown in Table 1.
Table 1. Clinicopathological parameters in 161 patients with oral tongue squamous cell carcinoma
receiving surgical resection.
Characteristics

































3.2. Silencing Nox4 Expression Reduces Tumor Cell Proliferation in Vitro
In the present study, we performed western blotting analyses to determine Nox4 expression
phenotype in OTSCC cell lines, SAS and SCC4. After that, these cell lines were stably transfected with
Nox4 shRNA and knockdown of Nox4 was shown by western blotting (Figure 1). Furthermore, these
cell lines were also treated with GKT-137831, a Nox4 inhibitor. These results showed GKT-137831
could inhibit the proliferation of tumor cells in a dose-dependent manner in SAS and SCC4 cell lines at
24th, 48th and 72nd hour after GKT-137831 treatment (Figure 2).
Figure 1. Western blotting analysis of Nox4 expression and knockdown of Nox4 in two oral tongue
squamous cell carcinoma cell lines, SAS and SCC4.
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Figure 2. Nox4 inhibitor (GKT-137831) displays a growth inhibitory effect in a dose-dependent manner
in the two oral tongue squamous cell carcinoma cell lines, SAS and SCC4. Columns, mean; bars,
standard deviation. Significant difference in growth inhibition: * p < 0.05, ** p < 0.01 and *** p < 0.001.
3.3. Expression of Nox4 and Clinical Outcome
The expression of Nox4 in the immunohistochemical staining is shown in Figure 3. Among the
161 patients, 80 patients (49%) were classified as having a high expression of Nox4 and 81 patients
(51%) had a low expression of Nox4. The baseline characteristics did not differ significantly between
these two groups, including age, sex, cigarette smoking, alcohol consumption, tumor T status, tumor
N status and tumor stage (Table 2).
Figure 3. Immunohistochemical analysis of Nox4 expression in patients with oral tongue squamous
cell carcinoma.
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Table 2. Comparison of clinicopathological parameters in 161 patients with oral tongue squamous cell
carcinoma receiving surgical resection.
Characteristics
High expression of Nox4
(N = 80)
Low expression of Nox4
(N = 81) p-Value
Age 53 years old (32–86) 51 years old (26–70)
Sex
Male 75 (94%) 73 (90%) 0.40
Female 5 (6%) 8 (10%)
Cigarette smoking
Absent 14 (17%) 15 (18%) 0.87
Present 66 (83%) 66 (82%)
Alcohol consumption
Absent 16 (20%) 16 (20%) 0.97
Present 64 (80%) 65 (80%)
T status
1–2 47 (59%) 52 (64%) 0.48
3–4 33 (41%) 29 (36%)
N status
0 46 (58%) 47 (58%) 0.95
1–3 34 (42%) 34 (42%)
Tumor stage
I–III 35 (44%) 35 (43%) 0.95
IVA–IVB 45 (56%) 46 (57%)
With respect to DFS, a univariate analysis found that sex and alcohol consumption were not
statistically significant predictors of DFS. The 127 patients who were diagnosed at an age younger
than 60 years were found to have superior DFS in comparison with the 34 patients diagnosed at an
age older than 60 years (77.5 months versus 10.7 months, p < 0.001); meanwhile, 29 patients who
never used cigarettes had superior DFS compared to the 132 smokers (not reach versus 40.2 months,
p = 0.047). Significantly improved DFS was found in the 99 patients who had T1-2 status compared
to the 62 patients who had T3-4 status (77.5 months versus 12.1 months, p = 0.004) and superior
DFS was also found in the 93 patients without nodal metastasis compared to the other 68 patients
with positive lymph node metastasis (not reach versus 13.4 months, p < 0.001). The 93 patients with
stage I–III were found to have superior DFS in comparison with the 68 patients with stage IVA–IVB
(p = 0.025). The 81 patients with a low expression of Nox4 had better DFS than the other 80 patients with
a high expression of Nox4 (77.5 months versus 21.9 months, p = 0.047, Figure 4A). In a multivariable
analysis, N0 status (p = 0.009, hazard ratio (HR): 0.47, 95% confidence interval (CI): 0.27–0.83) and
a low expression of Nox4 (p = 0.0192, HR: 0.50, 95% CI: 0.28–0.89) were the independent prognostic
parameters of better DFS.
With respect to OS, there were no statistically significant differences in parameters of sex and
alcohol consumption in a univariate analysis. Significantly better OS was found in the 127 patients aged
younger than 60 years than in the 34 patients aged older than 60 years (not reach versus 13.4 months,
p = 0.001) and superior OS was also found in the 29 patients who never smoked in comparison to
the 132 smokers (not reach versus 52.1 months, p = 0.026). The 99 patients with T1-2 were found
to have better OS compared to the 62 patients with T3-4 (not reach versus 15.5 months, p = 0.001);
meanwhile, 93 patients without nodal metastasis had superior OS than other 68 patients with positive
nodal metastasis (not reach versus 15.5 months, p < 0.001). Better OS was found in the 93 patients who
were classified as stage I–III compared to the 68 patients classified as having stage IVA–IVB (not reach
versus 28.6 months, p < 0.001). The 81 patients with a low expression of Nox4 had better OS than the
other 80 patients with a high expression of Nox4 (87.9 months versus 33.0 months, p = 0.032, Figure 4B).
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A multivariable analysis showed that T1-2 status (p = 0.019, HR: 0.59, 95% CI: 0.38–0.92), N0 (p = 0.001,
HR: 0.47, 95% CI: 0.30–0.73) and a low expression of Nox4 (p = 0.011, HR: 0.57, 95% CI: 0.37–0.88) were
the independent prognostic parameters of superior OS. These univariate and multivariable survival




Figure 4. Comparison of survival curves for patients with oral tongue squamous cell carcinoma with
high and low expression of Nox4. (A) Disease-free survival (B) Overall survival.
Table 3. Univariate and multivariable analysis of disease-free survival and overall survival in in




















<60 years 127 (79%) 77.5 <0.001 * NR 0.001 *
≥60 years 34 (21%) 10.7 13.4
Sex
Male 393 (97%) 46.0 0.24 57.7 0.14
Female 11 (3%) NR NR
Cigarette smoking
Absent 29 (18%) NR 0.047 * NR 0.026 *
Present 132 (82%) 40.2 52.1
Alcohol consumption
Absent 32 (20%) 57.4 0.55 NR 0.42
Present 129 (80%) 41.2 64.5
T status
1 + 2 99 (62%) 77.5 0.004 * NR 0.001 * 0.59(0.38–0.92) 0.019 *
3 + 4 62 (38%) 12.1 15.5
N status
0 93 (58%) NR <0.001 * 0.47(0.27–0.83) 0.009 * NR <0.001 *
0.47
(0.30–0.73) 0.001 *
1 + 2 + 3 68 (42%) 13.4 15.5
Tumor stage
I–III 93 (58%) NR 0.025 * NR <0.001 *
IVA–IVB 68 (42%) NR 28.6
Nox4 expression
High 80 (49%) 21.9 0.030 * 33.0 0.032 *
Low 81 (51%) 77.5 0.50(0.28–0.89) 0.018 * 87.9
0.57
(0.37–0.88) 0.011 *
DFS: disease-free survival; OS: overall survival; NR: not reached; HR: hazard ratio; CI: confidence interval *
Statistically significant.
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4. Discussion
Nox4 has been found to promote tumor progression of many types of cancer through various
pathways. Nox4 may induce cancer cell progression through promoting tumor angiogenesis. In Nox4
knockout mice with fibrosarcoma, vessel density analysis showed a significant reduction in tumor
vascularization, leading to the attenuation of hypoxia-inducible factor 1-alpha, vascular endothelial
growth factor, glucose transporter 1 and adrenomedullin [15]. Inflammatory cytokines are one of
the critical mediators in inflammation-associated cancer, especially interleukin-6 (IL-6). In non-small
cell lung cancer, Nox4 expression is positively correlated with IL-6 expression and exogenous IL-6
treatment significantly enhances Nox4 signaling [16]. The same result was also described in renal cell
carcinoma cells [13]. Another possible mechanism for Nox4 inducing cancer progression includes
histone modification, transforming growth factor-β and epidermal growth factor receptor (EGFR)
pathway and so forth. [12,14,17].
The current study found that Nox4 and lymph node metastasis were both prognostic factors
for patients with OTSCC in the univariate and multivariable analyses. Several studies have confirmed
that the presence of neck lymph node metastasis is the most reliable prognostic factor of regional or
distant treatment failure in patients with OTSCC [20–23]. Recently, growing evidence confirmed the
role of Nox4 in the disease progression of various cancer types. Zhang et al. showed that Nox4 was
upregulated and promoted tumor cell proliferation in vitro and in vivo and overexpression of Nox4
was closely correlated to tumor stage and contributed to the poor prognosis of patients with non-small
cell lung cancer [18]. Lin et al. also demonstrated that Nox4 promoted tumor cell proliferation and
apoptosis, migration and invasion and Nox4 overexpression was highly correlated with tumor invasion
depth, positive lymph node numbers, distant metastasis and poor prognosis of patients with colorectal
cancer [24]. Nox4 also plays a crucial role in regulating gastric cancer cell growth. In a Chinese
study, Nox4 expression was correlated with tumor size and poor prognosis in 90 patients with gastric
cancer and knockdown of NOX4 expression blocked cell proliferation and the expression of Cyclin
D1, BAX and so on in vitro. Nox4 promoted cell proliferation via activation of the GLI1 pathway
and overexpression of GLI1 reversed the suppression of tumor cell growth induced by silencing
NOX4. Furthermore, overexpression of Nox4 enhanced expression of GLI1 and knockdown of GLI1
expression reduced the effects induced by Nox4 overexpression [25]. A Japanese study, reported by
Ito et al., also demonstrated that Nox4 was highly expressed in several oral squamous cell carcinoma
cell lines and NOXs knockdown markedly suppressed cell viability and induced apoptosis; in addition,
NOXs suppression significantly enhanced the cisplatin-induced cytotoxic effect [26].
In head and neck cancer, an EGFR inhibitor is one of the major therapeutic modalities for HNSCC
and is routinely used in clinical practice. Autophagy has been reported to be one of the possible
mechanisms of resistance to chemotherapy or EGFR inhibitors and Nox4 plays a critical role in
mediating this effect [27]. Chronic inflammation has been confirmed to be strongly associated with
tumor invasion, migration and metastasis through increased secretion of pro-inflammatory cytokines,
such as IL-2, IL-6, tumor necrosis factor-α and so forth. The antitumor activity of EGFR inhibitors is
suppressed by activation of Nox4-mediated pro-inflammatory pathways and knockdown of Nox4
reduced EGFR inhibitor-induced pro-inflammatory cytokine expression [14]. Several studies have
highlighted the contribution of the microenvironment to tumor progression and cancer-associated
fibroblasts (CAFs) are related to poor prognosis in various cancer types, including head and neck
cancer [28–30]. Upregulation of Nox4 expression was strongly correlated with myofibroblastic-CAFs,
contributing to decreased cancer-specific survival rates. Suppression of Nox4 was found to revert
the myofibroblastic-CAF phenotype, prevent myofibroblastic-CAF accumulation and slower tumor
proliferation [31].
The 8th edition of the AJCC staging manual has been introduced into clinical practice in 2018 [32].
There are most significant changes to oral cavity cancer staging, including changes to the T and N
staging categories, depth of invasion and extranodal extension (ENE). Several studies have been
designed to investigate the importance of the 8th edition of the AJCC staging system. Mascitti et al.
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showed that the 8th edition of the AJCC criteria is more suitable for better stratification of patients
with OTSCC and the implementation of ENE and lymph node ratio to pathological N classification
are indicated to identify patients with poor prognosis [33]. Another study reported by Pollaers et al.
revealed that the 8th edition of the AJCC staging system supports better DFS discrimination between
overall stages and between T categories in patients with oral cavity squamous cell carcinoma [34].
In our study, although the tumor stage of each OTSCC patient who underwent surgical resection was
determined according to the 7th AJCC staging system, the results showed negative nodal metastasis
and low expression of Nox4 were significantly associated with superior DFS and OS and the N0 status
was not changed whether in the 7th or 8th AJCC staging system.
This study had several limitations. First, it was a retrospective analysis at a single institution with
a relatively small sample size. Second, we did not explore the comprehensive mechanisms of Nox4 and
downstream pathways, nor investigate how Nox4 overexpression promotes tumor cell proliferation,
invasion and metastasis.
However, to the best of our knowledge, this study, at present, covers the largest series of patients
with OTSCC who received surgical resection and may thus be useful for understanding the role of
Nox4 in the prognosis of OTSCC.
5. Conclusions
The results of our study suggest that Nox4 plays an important role in disease progression of
OTSCC and Nox4 overexpression is a poor prognostic factor of patients with patients with OTSCC
who received surgical resection. Additional studies are warranted in order to clarify the complex
mechanism of Nox4 and downstream pathways in patients with OTSCC.
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Abstract: Oral squamous cell carcinoma (OSCC) is one of the most common cancer types worldwide
and can be divided into three major subsites: buccal mucosal SCC (BMSCC), tongue SCC
(TSCC), and lip SCC (LSCC). The autophagy marker microtubule-associated protein light chain
3B (MAP1LC3B) and adaptor sequestosome 1(SQSTM1) are widely used proteins to evaluate
autophagy in tumor tissues. However, the role of MAP1LC3B and SQSTM1 in OSCC is not fully
understood, particularly in certain subsites. With a tissue microarray comprised of 498 OSCC patients,
including 181 BMSCC, 244 TSCC, and 73 LSCC patients, we found that the expression levels of
MAP1LC3B and cytoplasmic SQSTM1 were elevated in the tumor tissues of three subsites compared
with those in adjacent normal tissues. MAP1LC3B was associated with a poor prognosis only in TSCC.
SQSTM1 was associated with poor differentiation in three subsites, while the association with lymph
node invasion was only observed in BMSCC. Interestingly, MAP1LC3B was positively correlated
with SQSTM1 in the tumor tissues of BMSCC, whereas it showed no correlation with SQSTM1
in adjacent normal tissue. The coexpression of higher MAP1LC3B and SQSTM1 demonstrated
a significantly worse disease-specific survival (DSS) and disease-free survival (DFS) in patients
with BMSCC and LSCC, but not TSCC. The knockdown of MAP1LC3B and SQSTM1 reduced
autophagy, cell proliferation, invasion and tumorspheres of BMSCC cells. Additionally, silencing both
J. Clin. Med. 2018, 7, 478; doi:10.3390/jcm7120478 www.mdpi.com/journal/jcm99
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MAP1LC3B and SQSTM1 enhanced the cytotoxic effects of paclitaxel in the tumorspheres of BMSCC
cells. Taken together, MAP1LC3B and SQSTM1 might modulate autophagy to facilitate tumorigenesis
and chemoresistance in OSCC, particularly in BMSCC.
Keywords: MAP1LC3B; SQSTM1; autophagy; subsites; tumorigenesis; prognosis; oral cancer
1. Introduction
Oral squamous cell carcinoma (OSCC), a type of head and neck cancer, is one of the most common
malignant tumors worldwide [1,2]. Oral cancer mainly originates from the epithelium of the oral cavity,
of which the tongue, buccal mucosa, and lip are the top three most common subsites [3]. Oral cancer is
a multistep process modulated by environmental and endogenous factors, such as alcohol and tobacco
and betel chewing. Other factors include poor oral hygiene and chronic infections caused by viruses
or bacteria. Although the standard treatment is effective for patients diagnosed at the early stage,
the morbidity rate for patients with advanced-stage disease has not decreased much in the past few
decades [4], requiring more precise biomarkers for either an early diagnosis or therapeutic targets for a
better outcome.
Autophagy is a clearance pathway that involves more than 38 autophagy-related (ATG)
proteins to recruit impaired proteins and organelles for bulk degradation for new synthesis [5].
Autophagy plays a crucial role in physiological homeostasis, and its dysfunction may cause various
diseases, such as cancer, neurodegeneration disease and infection. However, the role of autophagy
in tumor progression is a “double-edged sword”, with opposite functions in tumor imitation and
malignancy. Autophagy exhibits suppressive effects on chronic inflammation and ROS production,
thereby inhibiting carcinogenesis in the early phase [6,7] and facilitates cancer cell growth and
survival under microenvironmental stress conditions [8]. Autophagy can support tumor cell survival
through suppressing the p53 response and maintaining mitochondrial metabolism to prevent metabolic
stress and mitigate the accumulation of toxic substances [9–11]. Regarding the clinical association
of autophagy markers, microtubule-associated light chain 3B (MAP1LC3B), an essential protein
for autophagosome elongation, is associated with poor survival in various cancer types; however,
some studies have indicated that cancer patients with high MAP1LC3B expression have a better
outcome [12], particularly in K-Ras-mutated colorectal cancer cells. Additionally, SQSTM1 contains
an MAP1LC3B-interacting (LIR) domain and a ubiquitin-associated (UBA) domain, which serve
as an autophagy adaptor to recruit ubiquitinated proteins to the autophagosome for selective
autophagy [13,14]. High levels of cytoplasmic SQSTM1 have also been found to be associated with
poor survival in several cancer types [12]. However, little is known about the detailed clinical relevance
and functions of MAP1LC3B and SQSTM1 in certain subsites of OSCC. In this study, we compared
the MAP1LC3B and SQSTM1 protein levels in tumor tissues and adjacent normal tissues in three
major subsites of OSCC, including BMSCC, TSCC and LSCC. Our results show that both MAP1LC3B
and cytoplasmic SQSTM1 were elevated in tumor tissues in three subsites of OSCC compared with
that in adjacent normal tissues. Moreover, SQSTM1 was associated with poor survival in patients
with BMSCC, but not in those with TSCC and LSCC. The SQSTM1 protein level was also found to be
positively correlated with MAP1LC3B in the tumor tissues of BMSCC but not in adjacent normal tissues.
In contrast to the single expression of MAP1LC3B or SQSTM1, high coexpression of MAP1LC3B and
SQSTM1 showed a worse DSS and DFS in BMSCC. Silencing MAP1LC3B and SQSTM1 diminished
autophagy, cell proliferation, invasion, tumorsphere formation and paclitaxel resistance in BMSCC cell
lines, supporting our findings in clinical samples. Our results suggest that MAP1LC3B and SQSTM1
could serve as biomarkers or therapeutic targets for BMSCC.
100
J. Clin. Med. 2018, 7, 478
2. Experimental Procedure
2.1. Tissue Specimens and Tissue Microarray (TMA) Construction
In total, 498 margin-free (margin-size ≥ 0.2 cm) paraffin-embedded materials of primary BMSCC
(n = 181), TSCC (n = 244), and LSCC (n = 73) were established previously [3]. The data of sex, age,
cell differentiation, pathological stage, tumor TNM classification, tumor subsites, and tumor recurrence
time were also collected. Pathologic TNM classification was determined according to the guidelines
of the 2002 American Joint Committee on Cancer (AJCC) system. The Institutional Review Board at
Kaohsiung Veterans General Hospital (KVGH) approved this study to comply with the Declaration of
Helsinki (IRB number: VGHKS 11-CT12-13). All information was obtained from the archives of the
KVGH pathology department between 1993 and 2006.
The TMA block contained 144 cores, including 48 trios consisting of 2 cores from the tumor tissue
and 1 core from the adjacent normal tissue. After construction, TMA blocks were cut in 4-μm paraffin
sections using standard techniques [3].
2.2. Immunohistochemistry (IHC)
TMA blocks were cut into 4-μm paraffin sections for immunostaining processes as previously
reported [15]. Antigen retrieval was performed by a pressure boiler at 125 ◦C for 10 min in Tris-EDTA
(10 mM, pH 9.0) for MAP1LC3B and sodium citrate (10 mM, pH 6.0) for SQSTM1. After blocking
with 3% hydrogen peroxide in methanol, the slides were incubated with antibody against MAP1LC3B
(dilution 1:100; 5F10; NanoTools, Munich, Germany) and SQSTM1 (dilution 1:1000; BML-PW9860;
Enzo Life Sciences, Farmingdale, NY, USA) in a cold room overnight. The color was developed at
room temperature, and the sections were counterstained with hematoxylin.
2.3. Immunohistochemistry Analysis and Score
All the slides were independently reviewed by an oral cancer pathologist and a senior pathology
technician. Subsequently, 5%–20% of core samples were randomly selected for re-evaluation.
If disagreement occurred (intensity score discrepancy >1 or percentage level >20%), the slide was
re-evaluated to obtain a consensus diagnosis by a senior pathologist until all the discrepancies
was resolved. During the evaluation, none of them were aware of the clinical outcomes of the
patients. The scores for cytoplasmic staining were based on the staining intensity (0, no signal;
1, mild; 2, moderate; and 3, strong) and percentage of positive staining (0, <5%; 1, 5%–25%;
2, 26%–50%; 3, 51%–75%; and 4, >75%). In our preliminary test, the intensity score of staining for
LC3 and cytoplasmic SQSTM1 was measured and standardized (0, no expression; 1, weak expression;
2, moderate expression; and 3, strong expression; Figure 1) in OSCC. The final score, ranging from 0 to
7, was used to analyze the association of MAP1LC3B and SQSTM1 with clinicopathological features.
For survival analysis, the expression levels were dichotomized as low expression and high expression
with the cutoff based on the receiver operating characteristic (ROC) curve. The cutoff values were
determined for MAP1LC3B and SQSTM1 in BMSCC, TSCC, LSCC and OSCC.
2.4. Cell Culture and Transient Transfection
The buccal mucosal squamous cell lines TW2.6 and OC3 or OC3-I5 (gift of Dr. Lu-Hai Wang) [16]
were cultured in DMEM/F12 (Gibco, Life Technologies, CA, USA) with 10% FBS, 100 μg/mL of
streptomycin, 100 U/mL of penicillin, and 1% L-glutamine at 37 ◦C with 5% CO2:95% air. The cells
were cultured in Corning tissue culture-treated plastic dishes (Corning, Inc., Corning, NY, USA).
BMSCC cells were seeded with RNAiMAX (13778150; Life Technologies, CA, USA) in the presence
of 5 nM scrambled siRNA or siRNA against human MAP1LC3B (L-012846-00-0005; Dharmacon,
IL, USA) or SQSTM1 (L-010230-00-0005; Dharmacon, IL, USA) for 48 h. The knockdown efficiency
was determined with immunoblotting using anti-MAP1LC3B or SQSTM1 antibody as previously
reported [17].
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Figure 1. Protein levels of MAP1LC3B puncta and SQSTM1 in OSCC. The MAP1LC3B puncta and
cytoplasmic SQSTM1 were stained by immunohistochemistry and categorized into four different levels
as follows: 0 = negative staining; 1 = weak; 2 = moderate; 3 = strong.
2.5. Analysis of Cell Viability
The cell viability assay was performed using the CellTiter-Glo luminescent cell viability assay
kit (Promega, Madison, WI, USA). Briefly, 5–7 × 105 cells/mL were cultured in sterile 96-well
plates for 24–48 h, and then 100 μL of CellTiter-Glo reagent was added to lyse the cells for 10 min.
The luminescence signal was measured using a Fluoroskan Ascent FL reader (Thermo Fisher
Scientific, Waltham, CA, USA). For tumorsphere formation, the cells (OC3: 5 × 103 cells/well, TW2.6:
5 × 103 cells/well) were seeded into Nano Culture Plates (NCPs) (MBL Corporation, Nagoya, Japan)
in the presence of siRNA for 7 days to form spheroid cells that might induce stem cell-like properties.
The tumorspheres were then treated with or without the anticancer drug paclitaxel (Selleckchem,
Houston, TX, USA) for two days. The sphere viability was measured using the CellTiter Glo 3D system
(Promega, Madison, WI, USA).
2.6. Invasion Assay
For the wound-healing assay, Transwell invasion assays were performed using 8-μm pore inserts
(Greiner Bio-One, Stroud, UK). The cells were knocked down with siRNA for 48 h and then were
seeded into the top chamber of Transwell plates coated with 0.5% Matrigel in 300 μL of DMEM
containing 1% FBS. To the bottom wells were added with complete medium to stimulate invasion.
After seeding for 24 h, the cells were fixed and stained with 0.1% crystal violet. The cells that had
invaded through the Matrigel and had reached to the reverse side were pictured under a microscope
at a magnification of 200× and were quantified with ImageJ. Each assay was performed in triplicate.
2.7. Statistical Analysis
The Kruskal–Wallis one-way ANOVA test was used to evaluate the differential protein expression
in TAN tissues and tumor tissues in various OSCC types. The protein expression levels between
TAN tissues and tumor tissues were analyzed by the Wilcoxon signed-rank test. Student’s t test,
Mann–Whitney U test, Kruskal–Wallis one-way ANOVA test and one-way ANOVA test were used
to evaluate the correlation between each protein expression level and clinicopathologic parameters.
The Kaplan–Meier method was used to analyze cumulative survival curves, and survival curve
analysis was performed using the log-rank test. The Cox proportional hazards model was used to
evaluate the impact of the protein expression on survival using factors significant in univariate analysis
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as covariates. The association between cell differentiation and the relative protein expression levels in
tumor tissues compared with that in paired TAN tissues of individual OSCC patients with different
AJCC pathological stages was determined by Fisher’s exact test. A two-sided value of p < 0.05 was
considered statistically significant.
3. Results
3.1. Association of the MAP1LC3B and SQSTM1 Protein Levels with Tumorigenesis and
Clinicopathological Outcomes
MAP1LC3B can be divided into two major forms: cytosolic MAP1LC3B-I and autophagosome
membrane-bound MAP1LC3B-II (MAP1LC3B puncta), which indicates autophagy. We initially
checked for MAP1LC3B puncta with IHC staining in tissues. Representative photomicrographs
of MAP1LC3B and SQSTM1 for negative (0), weak (1+), moderate (2+), and strong (3+) expression in
tumor tissue are shown in Figure 1. However, we found that only a few slides contained MAP1LC3B
puncta in most of the OSCC TMA. Thus, we scored the total MAP1LC3B expression levels in all
tissues and found that the MAP1LC3B levels were increased in tumor tissues compared with those in
adjacent normal tissues in three major subsites of OSCC, including BMSCC (3.31 ± 1.44 vs. 2.30 ± 1.06,
p < 0.001), TSCC (1.48 ± 1.02 vs. 0.59 ± 0.94, p < 0.001) and LSCC (3.14 ± 1.43 vs. 2.32 ± 0.71,
p < 0.001) (Table 1). Although SQSTM1 was found in both the nucleus and cytoplasm of cells,
SQSTM1 interacts with MAP1LC3B to recruit damaged proteins to the autophagosome for degradation
in the lysosome via selective autophagy, suggesting SQSTM1 functions as an autophagy adaptor
in nonnuclear regions. Herein, we scored the cytoplasmic SQSTM1 level of tissues to analyze its
correlation with tumorigenesis and clinicopathological outcomes at three subsites of OSCC. Similar to
the results of MAP1LC3B, cytoplasmic SQSTM1 was elevated in three subsites of OSCC (BMSCC:
2.89 ± 1.11 vs. 1.89 ± 1.00, p < 0.001; TSCC: 2.78 ± 1.08 vs. 1.88 ± 0.77, p < 0.001; and LSCC: 3.22 ± 1.25
vs. 2.03 ± 0.64, p < 0.001) (Table 1). Regarding the expression levels of MAP1LC3B and cytoplasmic
SQSTM1 and clinicopathological outcomes, including cell differentiation, pathological stage, sex and
age, the MAP1LC3B expression levels in BMSCC and LSCC were significantly higher than those in
TSCC (p < 0.001, Table 2). A high MAP1LC3B protein level was associated with poor differentiation in
only TSCC (p = 0.042, Table 2) but not in BMSCC and LSCC. On the other hand, SQSTM1 protein levels
were associated with poor differentiation in BMSCC (p = 0.015), TSCC (p = 0.042) and LSCC (p = 0.003,
Table 3). High SQSTM1 expression was correlated with lymph node invasion in BMSCC (3.22 ± 1.29
vs. 2.74 ± 1.02, p = 0.033, Table 3) but not in TSCC and LSCC.
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Table 1. Comparisons of MAP1LC3B and SQSTM1 expression between tumor tissues and
corresponding tumor adjacent normal tissues at three subsites of oral SCC.
Variables No.
Tumor adjacent normal Tumor
Z p-value *
Mean ± SD Median Mean ± SD Median
BMSCC
MAP1LC3B 135 2.01 ± 1.08 2.00 3.31 ± 1.44 3.00 7.787 <0.001
SQSTM1 132 1.89 ± 1.00 2.00 2.89 ± 1.11 2.00 6.821 <0.001
TSCC
MAP1LC3B 174 0.59 ± 0.94 0.00 1.48 ± 1.02 2.00 7.710 <0.001
SQSTM1 192 1.88 ± 0.77 2.00 2.78 ± 1.08 2.00 7.939 <0.001
LSCC
MAP1LC3B 59 2.32 ± 0.71 2.00 3.14 ± 1.43 3.00 4.084 <0.001
SQSTM1 59 2.03 ± 0.64 2.00 3.22 ± 1.25 3.00 5.049 <0.001
OSCC
MAP1LC3B 368 1.39 ± 1.23 2.00 2.42 ± 1.54 2.00 11.717 <0.001
SQSTM1 383 1.91 ± 0.84 2.00 2.89 ± 1.13 2.00 11.620 <0.001
Abbreviations: SCC, squamous cell carcinoma; SD, standard deviation. * p-values were estimated by the Wilcoxon
signed-rank test. Bold values denote statistically significant.
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3.2. Expression Levels of MAP1LC3B and SQSTM1 and Disease-Specific Survival (DSS) of OSCC Patients
We further determined whether MAP1LC3B expression was correlated with SQSTM1 in tumor
tissues and adjacent normal tissues in three subsites of OSCC. Interestingly, Pearson’s correlation
analysis showed that MAP1LC3B was positively correlated with SQSTM1 in the tumor tissues of
BMSCC but showed no correlation in adjacent normal tissues (Table 4). Nevertheless, opposite effects
were observed in TSCC, whereas MAP1LC3B was correlated with SQSTM1 expression in both tumor
and adjacent normal tissues in LSCC (Table 4), suggesting these molecules might be differentially
regulated at diverse subsites of OSCC. Moreover, to determine whether MAP1LC3B and SQSTM1
could be used as prognostic factors in the different subsites of OSCC, we further investigated the
relationship of MAP1LC3B and SQSTM1 expression with DSS. Kaplan–Meier curve analysis showed
that higher MAP1LC3B (Figure 2) expression was associated with a poor DSS in LSCC (p = 0.008),
whereas high SQSTM1 (Figure 3) expression was associated with a poor DSS in BMSCC (p = 0.005).
After adjustment for cell differentiation (moderate + poor vs. well) and AJCC pathological stage
(stage III + IV vs. stage I + II) following Cox’s regression analysis, both MAP1LC3B (AHR: 1.59,
95% CI: 1.00–2.52, p = 0.05, Table 5) and SQSTM1 (AHR: 1.92, 95% CI: 1.19–3.09, p = 0.008, Table 4)
were correlated with unfavorable DSS in BMSCC. High MAP1LC3B expression showed a worse DSS
in LSCC (AHR: 19.93, 95% CI: 1.61–246.87, p = 0.02, Table 4). Additionally, BMSCC and LSCC with
high coexpression of MAP1LC3B and SQSTM1 had a shorter DSS than those with low coexpression
of MAP1LC3B and SQSTM1 (BMSCC: p = 0.019, LSCC: p = 0.012, Figure 3). After adjusting for cell
differentiation and AJCC pathological stage, the results also showed that BMSCC (AHR: 2.38, 95% CI:
1.27–4.46, p = 0.007, Table 5) and LSCC (AHR: 20.72, 95% CI: 1.72–250.12, p = 0.017, Table 5) patients
with high coexpression of MAP1LC3B and SQSTM1 had higher hazard of death.
Figure 2. DSS survival curves for MAP1LC3B and SQSTM1 expression in patients with different
subsites of OSCC. DSS survival curves of MAP1LC3 (A–D) and SQSTM1 (E–H) are shown for OSCC
(A,E) and three main subsites, BMSCC (B,F), TSCC (C,G) and LSCC (D,H). The cutoff values for high
or low expression of MAP1LC3B and SQSTM1 in tumor tissues were based on the receiver operating
characteristic (ROC) curve.
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Table 4. Correlation coefficients (r) between MAP1LC3B and SQSTM1 in OSCC.
Adjacent Normal Tumor
MAP1LC3B MAP1LC3B
BMSCC (n = 114) (n = 181)
SQSTM1 r = −0.053 r = 0.155
p = 0.578 p = 0.038
TSCC (n = 166) (n = 244)
SQSTM1 r = 0.162 r = 0.095
p = 0.037 p = 0.140
LSCC (n = 55) (n = 73)
SQSTM1 r = 0.266 r = 0.504
p = 0.049 p < 0.001
OSCC (n = 365) (n = 498)
SQSTM1 0.068 0.181
p = 0.218 p < 0.001
The correlation coefficient and p-value were estimated by the Spearman’s rank correlation coefficient.
Figure 3. DSS survival curves for the coexpression of MAP1LC3B and SQSTM1 in patients with
different subsites of OSCC. DSS survival curves for the coexpression of MAP1LC3 and SQSTM1 are
shown for OSCC (A) and three main subsites, BMSCC (B), TSCC (C) and LSCC (D). The cutoff values
for high or low coexpression of MAP1LC3B and SQSTM1 in tumor tissues were based on the receiver
operating characteristic (ROC) curve.
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Table 5. The expression levels of MAP1LC3B and SQSTM1 in disease-specific survival of oral
SCC patients.
Variable (ROC) No. (%) CHR (95% CI) p-value AHR (95% CI) p-value *
OSCC
MAP1LC3B expression Low (0–1) 116 (23.3) 1.00 1.00
High (2–7) 382 (76.7) 0.92 (0.67–1.27) 0.621 0.99 (0.71–1.36) 0.928
SQSTM1 expression Low (0–2) 264 (53.0) 1.00 1.00
High (3–7) 234 (47.0) 1.39 (1.05–1.84) 0.022 1.46 (1.10–1.94) 0.009
MAP1LC3B (L) SQSTM1 (L) 73 (14.7) 1.00 1.00
either 234 (47.0 0.71 (0.53–0.94) 0.017 0.78 (0.52–1.18) 0.235
MAP1LC3B (H) SQSTM1 (H) 191(38.4) 1.38 (1.04–1.84) 0.026 1.15 (0.76–1.73) 0.501
BMSCC
MAP1LC3B expression Low (0–3) 101 (55.8) 1.00 1.00
High (4–7) 80 (44.2) 1.42 (0.91–2.24) 0.127 1.59 (1.00–2.52) 0.050
SQSTM1 expression Low (0–3) 132 (72.9) 1.00 1.00
High (4–7) 49 (27.1) 1.96 (1.22–3.14) 0.005 1.92 (1.19–3.09) 0.008
MAP1LC3B (L) SQSTM1 (L) 79 (43.6) 1.00 1.00
either 75 (41.4) 1.23 (0.78–1.94) 0.367 1.59 (0.95–2.67) 0.077
MAP1LC3B (H) SQSTM1 (H) 27 (14.9) 1.87 (1.07–3.24) 0.027 2.38 (1.27–4.46) 0.007
TSCC
MAP1LC3B expression Low (0–2) 216 (88.5) 1.00 1.00
High (3–7) 28 (11.5) 1.25 (0.71–2.20) 0.432 1.09 (0.62–1.91) 0.777
SQSTM1 expression Low (0–2) 140 (57.4) 1.00 1.00
High (3–7) 104 (42.6) 1.27 (0.87–1.85) 0.223 1.36 (0.93–1.98) 0.117
MAP1LC3B (L) SQSTM1 (L) 126 (51.6) 1.00 1.00
either 104 (42.6) 1.33 (0.91–1.94) 0.141 1.36 (0.92–2.01) 0.120
MAP1LC3B (H) SQSTM1 (H) 14 (5.7) 1.11 (0.51–2.38) 0.795 1.27 (0.58–2.80) 0.553
LSCC
MAP1LC3B expression Low (0–5) 69 (94.5) 1.00 1.00
High (6–7) 4 (5.5) 11.40 (1.17–111.09) 0.036 19.93 (1.61–246.87) 0.020
SQSTM1 expression Low (0–2) 29 (39.7) 1.00 1.00
High (3–7) 44 (60.3) 2.79 (0.74–10.56) 0.132 2.61 (0.68–10.01) 0.161
MAP1LC3B (L) SQSTM1 (L) 28 (38.4) 1.00 1.00
either 42 (57.5) 1.90 (0.55–6.50) 0.309 2.53 (0.65–9.82) 0.180
MAP1LC3B (H) SQSTM1 (H) 3 (4.1) 11.40 (1.17–111.09) 0.036 20.72 (1.72–250.12) 0.017
Abbreviations: SCC, squamous cell carcinoma; CHR, crude hazard ratio; CI, confidence interval;
AHR, adjusted hazard ratio. * p-value were adjusted for cell differentiation (moderate + poor vs. well) and
AJCC pathological stage (stage III + IV vs. stage I + II) by multiple Cox’s regression. Bold values denote
statistically significant.
3.3. Association of the MAP1LC3B and SQSTM1 Expression Levels with Disease-Free Survival (DFS) in
OSCC Patients.
To determine whether MAP1LC3B and SQSTM1 are correlated with relapse in the main subsites
of OSCC, we further investigated the relationship of MAP1LC3B and SQSTM1 expression with DFS.
The Kaplan–Meier curve showed that a high expression level of MAP1LC3B was notably associated
with a poor DFS in BMSCC (p = 0.023, Figure 4) and LSCC (p = 0.009, Figure 4). High expression of
SQSTM1 was associated with shorter DFS in only LSCC (p = 0.007) but not at the other two subsites.
Likewise, the hazard factor was higher in patients with an elevated expression of MAP1LC3B after
adjustment for cell differentiation and AJCC pathological stage following Cox’s regression analysis in
BMSCC (AHR: 1.90, 95% CI: 0.94–3.85, p = 0.074, Table 6). High SQSTM1 expression had a poor DFS
in BMSCC (AHR: 3.77, 95% CI: 1.06–13.38, p = 0.040, Table 6). The combination of high MAP1LC3B
and SQSTM1 expression was highly associated with a shorter DFS in patients with BMSCC (p < 0.001,
Figure 5) and LSCC (p = 0.003, Figure 5). The adjusted hazard ratios of high coexpression of MAP1LC3B
and SQSTM1 in BMSCC and LSCC were also much higher than those with a high single expression of
MAP1LC3B or SQSTM1(BMSCC: AHR: 8.19, 95% CI: 2.52–26.64, p < 0.001; LSCC: AHR: 9.49, 95% CI:
2.19–41.08, p = 0.003, Table 6).
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Table 6. The expression levels of MAP1LC3B and SQSTM1 in disease-free survival of oral SCC patients.
Variable (ROC) No. (%) CHR (95% CI) p-value AHR (95% CI) p-value *
OSCC
MAP1LC3B expression Low (0–1) 116 (23.3) 1.00 1.00
High (2–7) 382 (76.7) 1.01 (0.73–1.40) 0.960 1.09 (0.78–1.52) 0.620
SQSTM1 expression Low (0–2) 264 (53.0) 1.00 1.00
High (3–7) 234 (47.0) 1.39 (1.05–1.84) 0.022 1.33 (1.00–1.76) 0.048
MAP1LC3B (L) SQSTM1 (L) 73 (14.7) 1 1
either 234 (47.0 0.77 (0.58–1.03) 0.075 0.93 (0.61–1.43) 0.737
MAP1LC3B(H) SQSTM1 (H) 191(38.4) 1.36 (1.03–1.81) 0.032 1.29 (0.84–1.98) 0.244
BMSCC
MAP1LC3B expression Low (0–5) 168 (92.8) 1.00 1.00
High (6–7) 13 (7.2) 2.20 (1.10–4.40) 0.027 1.90 (0.94–3.85) 0.074
SQSTM1 expression Low (0–4) 160 (88.4) 1.00 1.00
High (5–7) 21 (11.6) 1.62 (0.88–3.00) 0.123 1.47 (0.79–2.72) 0.227
MAP1LC3B (L) SQSTM1 (L) 150 (82.9) 1 1
either 28 (15.5) 1.39 (0.79–2.44) 0.251 1.45 (0.83–2.56) 0.195
MAP1LC3B(H) SQSTM1 (H) 3 (1.7) 7.66 (2.37–24.75) 0.001 8.19 (2.52–26.64) <0.001
TSCC
MAP1LC3B expression Low (0–1) 103 (42.2) 1.00 1.00
High (2–7) 141 (57.8) 1.07 (0.71–1.59) 0.751 1.00 (0.67–1.50) 1.000
SQSTM1 expression Low (0–2) 140 (57.4) 1.00 1.00
High (3–7) 104 (42.6) 1.38 (0.93–2.06) 0.109 1.35 (0.91–2.01) 0.137
MAP1LC3B (L) SQSTM1 (L) 65 (26.6) 1 1
either 113 (46.3) 0.76 (0.51–1.14) 0.179 0.90 (0.55–1.48) 0.680
MAP1LC3B(H) SQSTM1 (H) 66 (27.0) 1.50 (0.98–2.29) 0.061 1.41 (0.84–2.36) 0.199
LSCC
MAP1LC3B expression Low (0–4) 60 (82.2) 1.00 1.00
High (5–7) 13 (17.8) 3.82 (1.31–11.13) 0.014 2.44 (0.78–7.65) 0.127
SQSTM1 expression Low (0–2) 29 (39.7) 1.00 1.00
High (3–7) 44 (60.3) 4.75 (1.37–16.49) 0.014 3.77 (1.06–13.38) 0.040
MAP1LC3B (L) SQSTM1 (L) 28 (38.4) 1 1
either 33 (45.2) 1.66 (0.65–4.21) 0.287 3.80 (1.04–13.86) 0.043
MAP1LC3B(H) SQSTM1 (H) 12 (16.4) 4.01 (1.38–11.66) 0.011 9.49 (2.19–41.08) 0.003
Abbreviations: SCC, squamous cell carcinoma; CHR, crude hazard ratio; CI, confidence interval; AHR, adjusted
hazard ratio. * p-value were adjusted for cell differentiation (moderate + poor vs. well) and AJCC pathological stage
(stage III + IV vs stage I + II) by multiple Cox’s regression. Bold values denote statistically significant.
Figure 4. DFS survival curves for MAP1LC3B and SQSTM1 expression in patients with different
subsites of OSCC. DFS survival curves of MAP1LC3 (A–D) and SQSTM1 (E–H) are shown for OSCC
(A,E) and three main subsites, BMSCC (B,F), TSCC (C,G) and LSCC (D,H). The cutoff values for high
or low expression of MAP1LC3B and SQSTM1 on tumor tissues were based on the receiver operating
characteristic (ROC) curve.
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Figure 5. DFS survival curves for the coexpression of MAP1LC3B and SQSTM1 in patients with
different subsites of OSCC. DFS survival curves for the coexpression of MAP1LC3 and SQSTM1 are
shown for OSCC (A) and three main subsites, BMSCC (B), TSCC (C) and LSCC (D). The cutoff values
for high or low coexpression of MAP1LC3B and SQSTM1 in tumor tissues were based on the receiver
operating characteristic (ROC) curve
3.4. Involvement of MAP1LC3B and SQSTM1 in the Cell Proliferation and Migration of BMSCC Cells.
According to the clinical results described above, MAP1LC3B and SQSTM1 were more correlated
with cancer malignancy in BMSCC and LSCC. Because there was no LSCC cell line available,
we further verified the function of MAP1LC3B and SQSTM1 in BMSCC cell lines, including OC3
and TW2.6 (Figure 6A,B). Knockdown of MAP1LC3B resulted in accumulated SQSTM1 in BMSCC
cells, while silencing SQSTM1 decreased MAP1LC3B-II flux, implying that deprivation of either
MAP1LC3B and SQSTM1 diminished autophagic flux (Figure 6C,D). Similar to treatment with the
autophagy inducer ConA, knockdown of MAP1LC3B or SQSTM1 attenuated cell proliferation in
both OC3 and TW2.6 cells (Figure 7A). Autophagy is involved in cancer metastasis, and SQSTM1
is associated with lymph node invasion. To determine the effects of MAP1LC3B and SQSTM1 on
metastatic characteristics, invasion assays were used. Silencing SQSTM1 inhibited both the invasive
ability in highly invasive OC3 cells (OC3-I5, Figure 7B, Wang LH 2017, ROS1). We further mimicked
the in vivo status in a tumorsphere culture model for cancer cell stemness (REF) and drug resistance
(Figure 7C,D). Interestingly, ablation of MAP1LC3B or SQSTM1 or both decreased tumorsphere
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formation and enhanced the killing effects of paclitaxel (PTX, Figure 7C,D), implying that MAP1LC3B
and SQSTM1 might modulate autophagy for tumor growth and drug resistance in BMSCC cells.
Figure 6. Effects of silencing MAP1LC3B and SQSTM1 on autophagy and cell proliferation in
BMSCC cells. (A) The BMSCC cell lines OC3 and (B) TW2.6 were transfected with 5 nM scrambled
siRNA or siRNA against MAP1LC3B or SQSTM1 for 48 h and then were treated with ConA for 4 h.
The knockdown efficiency was determined by immunoblotting. (C) Silencing effects on MAP1LC3B
flux and (D) SQSTM1 levels were quantified and analyzed.
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Figure 7. Effects of silencing MAP1LC3B and SQSTM1 on metastatic characteristics, tumorsphere
formation and paclitaxel sensitivity in BMSCC cells. (A) The BMSCC cell lines OC3 and TW2.6 were
transfected with 5 nM scrambled siRNA or siRNA against MAP1LC3B or SQSTM1 for 72 h to measure
cell proliferation with Cell titer Glo. The cells treated with the autophagy inhibitor ConA for 24 h
were used as a control. (B) OC3-I5 cells, the highly invasive strain of OC3, were silenced for 48 h and
were seeded in Matrigel-coated Transwell filters to assess the cell invasion of BMSCC cells. (C) The
silenced OC3 and (D) TW2.6 cells were cultured in nanoplates to examine tumorsphere formation.
The tumorspheres were also treated with or without paclitaxel (PTX, 50 or 100 nM) to determine the
effects of genes on drug resistance. The results represented three independent experiments.
4. Discussion
MAP1LC3B and SQSTM1 are widely used autophagy markers and adaptors in mammalian cells.
Both proteins are essential for the autophagy machinery, and high expression levels of MAP1LC3B
and SQSTM1 are significantly associated with an unfavorable clinicopathological outcome in several
cancer types, including OSCC. However, the subsite-dependent impact of MAP1LC3B and SQSTM1
on OSCC, such as BMSCC, TSCC and LSCC, is not fully understood. Moreover, the function of
MAP1LC3B and SQSTM1 in OSCC remains unclear. In this study, we reported the following findings.
First, the expression levels of MAP1LC3B and SQSTM1 were higher in tumor tissues than in adjacent
normal tissues at three subsites—BMSCC, TSCC and LSCC. Second, SQSTM1 was correlated with
aggressive differentiation in three subsites and was associated with lymph node invasion in BMSCC.
Third, SQSTM1 was positively correlated with MAP1LC3B in the tumor tissues of BMSCC, but not
in adjacent normal tissues. High coexpression of MAP1LC3B and SQSTM1 was further associated
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with a poor survival, particularly in BMSCC and LSCC. Fourth, silencing of MAP1LC3B and SQSTM1
diminished autophagy, cell proliferation, and invasion and sensitized BMSCC cells to paclitaxel
treatment. Our results suggested that MAP1LC3B and SQSTM1 may modulate autophagy for cancer
development, malignancy and relapse in a subsite-dependent manner. To the best of our knowledge,
we are the first group to report that the correlation of MAP1LC3B and SQSTM1 with clinicopathological
outcomes at certain subsites using the largest cohort, comprising 498 paired tumor and adjacent normal
tissues of OSCC.
MAP1LC3B is cleaved and activated by ATG4 to mediate a ubiquitination-like reaction to initiate
autophagosome formation [18–20]. MAP1LC3B consists of a soluble form, MAP1LC3B-I, with a
molecular weight of 18 KD and a membrane-bound form, MAP1LC3B-II, with a molecular weight of
16 KD. MAP1LC3B-II accumulates on the autophagosome and interacts with SQSTM1 for recruitment
to damaged proteins to deliver them to lysosomes [21]. Thus, both MAP1LC3B-II and SQSTM1
can form puncta on autophagosomes during selective autophagy [21]. MAP1LC3B-II and SQSTM1
dot-like staining are shown in tissues and are associated with a poor prognosis in patients with colon
cancer [22]. Increased MAP1LC3B puncta is also associated with a poor prognosis in several other
cancer types, such as breast cancer and oral cancer [23,24]. However, the puncta of both MAP1LC3B-II
and SQSTM1 were very rare in all tissues of our TMA, likely due to the different cancer types or tissues
that we used. Moreover, increased MAP1LC3B expression typically shows unfavorable outcomes in
lung, melanoma, and pancreatic cancers [25,26], whereas the loss of MAP1LC3B has been reported in
several solid tumors, including brain cancer [27], prostate cancer [28], and breast cancer, indicating that
MAP1LC3B expression in cancer is still controversial. In our present study, MAP1LC3B expression
was higher in tumor tissues than in adjacent normal tissues at three subsites of OSCC. MAP1LC3B was
positively correlated with DSS in patients with BMSCC and LSCC, but not in those with TSCC and
OSCC. Deprivation of MAP1LC3B with siRNA suppressed cell viability and tumorsphere formation
in BMSCC cell lines, implying that MAP1LC3B may contribute to tumorigenesis and malignancy at
certain subsites of OSCC, particularly in BMSCC.
Autophagy induction causes SQSTM1 degradation, while defective autophagy leads to SQSTM1
accumulation. Higher SQSTM1 expression is associated with a poor prognosis in gastric cancer [29].
Previous studies have also reported that higher expression of SQSTM1 is correlated with a worse
survival in several solid tumors [30,31]. These results suggest that autophagy impairment accumulates
SQSTM1, ultimately leading to tumorigenesis by dysregulating the NF-κB signaling transduction
pathway and gene expression [14,32]. The interaction of SQSTM1 with tumor necrosis factor
receptor-associated factor (TRAF) 6, as well as the degradation of SQSTM1 by autophagy, is important
for the role of SQSTM1 in tumorigenesis and cell survival [32]. Nevertheless, the correlation of SQSTM1
with detailed subsites of cancers has never been reported. Our present data show that, at three subsites
of OSCC, cytoplasmic SQSTM1 protein expression in TAN tissue was significantly lower than that
in tumor tissue. Additionally, SQSTM1 was significantly associated with N classification following
Student’s t test in BMSCC. Silencing SQSTM1 inhibited cancer cell invasion in BMSCC cells. In the
Cox regression method, higher-level expression of cytoplasmic SQSTM1 was associated with a poor
prognosis in OSCC, mainly in BMSCC and LSCC, implying that SQSTM1 could be an independent
biomarker of the prognosis in BMSCC and LSCC.
The role of autophagy could be switched from a tumor suppressor to an oncogene during
tumor progression. Autophagy acts as a tumor suppressor to eliminate abnormal proteins or
organelles and reduce the production of reactive oxygen species and DNA damage in the early
stage of cancer development [33]. Prodigiosin, a red pigment isolated from gram-negative bacteria,
induces autophagic cell death in both lung and oral cancer cells [34,35]. By contrast, autophagy allows
cancer cells to survive during metastasis and chemotherapy, which, in turn, results in tumor
relapse [36,37]. Autophagic activity is higher in cancer stem cells (CSC) of ovarian cancer than
in non-CSC [37]. Pharmacologic inhibition with the autophagy inhibitor chloroquine or genetic
ablation with CRISPR/Cas9 knockout for the autophagy essential gene ATG5 significantly reduced the
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CSC property and chemoresistance of ovarian cancer cells. Pharmacologic inhibition of the essential
autophagy protease ATG4 with clinical drug tioconazole suppresses the tumor size and sensitizes
cancer cells to doxorubicin [5]. Moreover, autophagy inhibition decreases metastatic outbreak and
increases apoptosis in dormant BC cells [36]. Our study shows that higher cytoplasmic SQSTM1
expression is correlated with lymph node invasion in patients with BMSCC. The silencing of SQSTM1
reduces autophagic flux and invasion in BMSCC cells. SQSTM1 expression was positively correlated
with MAP1LC3B expression in tumor tissues of patients with BMSCC. Furthermore, high expression
of both MAP1LC3B and SQSTM1 was associated with a shorter DSS and DFS in patients with BMSCC
and LSCC, but not in those with TSCC patients. Similar to treatment with autophagy inhibitor,
knockdown of these genes repressed autophagy, cell proliferation and chemoresistance in BMSCC
cells. Our present results suggested that autophagy may act as a tumor promoter at certain subsites of
oral cancer, particularly in BMSCC.
On the other hand, autophagy diminishes the cytotoxic effects of T cells and natural killer (NK)
cells against tumor cells [38,39]. PD-L1 inhibits autophagy through activation of MTOR, while the
PD-L1 inhibitor attenuates autophagy for cancer cell survival [40]. The anti-malarial drug CQ or HCQ,
which blocks autophagosome-lysosome fusion and degradation, has been tested in at least 30 clinical
trials for cancer [41]. These results suggest that blocking autophagy might be helpful for cancer therapy
of OSCC, which requires further study to evaluate.
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Abstract: Objective: To investigate the risk of deep neck infection (DNI) in patients with type 1
diabetes mellitus (T1DM). Methods: The database of the Registry for Catastrophic Illness Patients,
affiliated to the Taiwan National Health Insurance Research Database, was used to conduct a
retrospective cohort study. In total, 5741 patients with T1DM and 22,964 matched patients without
diabetes mellitus (DM) were enrolled between 2000 and 2010. The patients were followed up until
death or the end of the study period (31 December 2013). The primary outcome was the occurrence
of DNI. Results: Patients with T1DM exhibited a significantly higher cumulative incidence of DNI
than did those without DM (p < 0.001). The Cox proportional hazards model showed that T1DM
was significantly associated with a higher incidence of DNI (adjusted hazard ratio, 10.71; 95%
confidence interval, 6.02–19.05; p < 0.001). The sensitivity test and subgroup analysis revealed a
stable effect of T1DM on DNI risk. The therapeutic methods (surgical or nonsurgical) did not differ
significantly between the T1DM and non-DM cohorts. Patients with T1DM required significantly
longer hospitalization for DNI than did those without DM (9.0 ± 6.2 vs. 4.1 ± 2.0 days, p < 0.001).
Furthermore, the patients with T1DM were predisposed to DNI at a younger age than were those
without DM. Conclusions: T1DM is an independent risk factor for DNI and is associated with a
10-fold increase in DNI risk. The patients with T1DM require longer hospitalizations for DNI and are
younger than those without DM.
Keywords: cervical; cellulitis; abscess; deep neck infection; diabetes mellitus
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1. Introduction
Deep neck infection (DNI) is a common infectious disease involving the deep neck space;
DNI usually requires intensive care and aggressive treatment [1]. The easy availability of antibiotics,
improvements in diagnostic technology, and the concept of early surgical debridement have
significantly reduced the morbidity and mortality of DNI [2,3]. However, DNI remains a potentially
life-threatening disease when lethal complications, such as descending necrotizing mediastinitis,
develop [4,5].
A study reported that patients with diabetes mellitus (DM) are at a 1.4-fold higher risk of DNI than
those without DM [6]. DNI can cause higher morbidity and mortality among patients with systemic
diseases such as DM, end-stage renal disease, liver cirrhosis, and autoimmune diseases [1,4,7–9].
However, the pathogenesis of type 1 DM (T1DM) is different from that of type 2 DM (T2DM). T1DM is
characterized by an immune-mediated depletion of beta cells, which causes a lifelong dependence on
exogenous insulin [10]. Patients with T1DM, considered to have an immunocompromised status, are
expected to be more vulnerable to complicated infection and have a higher infection-related mortality
risk than patients with T2DM [11]. Studies investigating the effect of T1DM on DNI are not currently




The government of Taiwan established the National Health Insurance Research Database (NHIRD),
which covered 99.6% of Taiwan’s population in 2017 [12,13]. The NHIRD provides all medical
claims data of all beneficiaries, including disease diagnoses during clinic visits and hospitalization,
prescription drugs and doses, examinations, procedures, surgery, payments, resident locations, and
income levels, generated during reimbursement for insurance in an electronic format. The diagnostic
codes in the NHIRD are based on the International Classification of Diseases, Ninth Revision, Clinical
Modification (ICD-9-CM). This study was exempted from obtaining informed consent from the
participants because the data were deidentified. All information of the insurants was unidentifiable,
and this study did not violate their rights or adversely affect their welfare. The study was approved by
the Institutional Review Board of Chang Gung Memorial Hospital (IRB Number: 201601249B1).
2.2. Study Cohort
In Taiwan, T1DM is categorized as a “catastrophic illness” in the NHIRD. Patients with T1DM
are certified by the government and included in the Registry for Catastrophic Illness Patients (RFCIP).
Therefore, they can avail considerable discounts on medical expenses. The certification process requires
critical evaluation of medical records, serological, and pathological reports by experts [14]. Therefore,
the T1DM diagnosis of the enrolled patients was highly accurate and reliable.
Data regarding patients who received new diagnoses of T1DM between January 2000 and
December 2010 in Taiwan were retrieved from the RFCIP (Figure 1). The patients who received
T1DM diagnoses in or after 2011 were not included to ensure a follow-up period of at least 3 years.
We used the following T1DM-associated ICD-9-CM codes, which were defined for the RFCIP: 250.01,
250.03, 250.11, 250.13, 250.21, 250.23, 250.31, 250.33, 250.41, 250.43, 250.51, 250.53, 250.61, 250.63, 250.71,
250.73, 250.81, 250.83, 250.91, and 250.93 [14]. In addition, patients who received DNI diagnoses before
T1DM were excluded. Finally, 6201 patients with T1DM were enrolled in the study cohort.
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Figure 1. Enrollment schema of the study and comparison cohorts. Abbreviations: RFCIP, Registry for
Catastrophic Illness Patients; LHID2000, Longitudinal Health Insurance Database 2000; DM, diabetes
mellitus; T1DM, type 1 diabetes mellitus; DNI, deep neck infection.
2.3. Comparison Cohort
The Longitudinal Health Insurance Database 2000 (LHID2000), a subset database of the NHIRD,
consists of 1,000,000 insurants who were randomly statistically selected from all insurants in Taiwan in
2000. Age distribution, sex distribution, or health care costs did not differ significantly between the
LHID2000 sample group and all enrollees in the NHIRD, according to a report by the National Health
Research Institutes [13]. The LHID2000 has been used in several population-based studies [15,16].
We used the LHID2000 to generate a comparison cohort, which consisted of patients without DM.
2.4. Matching Process
For each patient with T1DM, four patients without DM were randomly selected from the
LHID2000 database, matched for sex, age, urbanization level, and income level to form a comparison
cohort. The index date of the study cohort was the date of registry in the RFCIP for patients with
T1DM, and an index date matching that of patients with T1DM was created for the comparison cohort.
After the matching process, 5741 T1DM and 22,964 non-DM patients were enrolled in the study.
2.5. Main Outcome
The main outcome of this study was the occurrence of DNI, which is defined as hospitalization
with the following ICD-9 codes: 528.3 (cellulitis and abscess of oral soft tissues; Ludwig angina),
478.22 (parapharyngeal abscess), 478.24 (retropharyngeal abscess), and 682.1 (cellulitis and abscess of
neck) [1,17]. The follow-up period was from the index date to the diagnosis of DNI, death, or the end
of 2013.
2.6. Comorbidities
Comorbidities were defined using ICD-9-CM codes recorded in the claims data: hypertension
(HTN) (ICD-9-CM codes: 401–405), cerebrovascular accident (CVA) (ICD-9-CM codes: 430–438),
coronary artery disease (CAD) (ICD-9-CM codes: 410–414), chronic kidney disease (CKD) (ICD-9-CM
codes: 403, 404, 585, and 586), systemic autoimmune diseases (SADs) (ICD-9-CM codes: 443.1, 446.0,
446.2, 446.4–446.5, 446.7, 696.0–696.1, 710.0–710.4, and 714.0–714.4), and liver cirrhosis (LC) (ICD-9-CM
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codes: 571.2, 571.5–571.6) [1,17–19]. Medical comorbidities were included if they appeared at least
once in the diagnoses of inpatients or at least thrice in the diagnoses of outpatients.
2.7. Treatment Modalities
The treatment methods were divided into two subgroups: “surgical” and “nonsurgical.”
The patients who received surgical intervention were included in the “surgical” subgroup, whereas
those who received antibiotic or abscess aspiration without surgery were included in the “nonsurgical”
subgroup [1].
2.8. Prognosis Evaluation
For evaluating prognosis, we analyzed the duration of hospitalization, care in intensive care
units (ICUs), performance of tracheostomy, and mediastinal complications, which were defined
according to the receipt of mediastinal surgery during hospitalization or the diagnostic codes of
mediastinitis (ICD-9-CM codes: 510, 513, and 519.2) [1]. Mortality and mediastinitis-related mortality
were also investigated in both cohorts. Mortality was defined as death occurring during DNI treatment.
Mediastinitis-related mortality was defined as death during DNI treatment accompanied by the
diagnosis of mediastinitis [1]. In addition, we analyzed the age distribution of the patients with DNI
identified in the T1DM and non-DM cohorts.
2.9. Statistical Analysis
The demographic characteristic and comorbidities of the T1DM and non-DM cohorts were
compared using the Pearson’s chi-square test for categorical variables and the unpaired Student t-test
for continuous variables. Control variables, such as age, sex, urbanization level, income level, and
comorbidities (HTN, CVA, CAD, CKD, SADs, and LC) were included as covariates in the univariate
model. Variables in the univariate analysis that showed p < 0.1 were included in the multivariate
analysis. Kaplan–Meier analysis was used to estimate the cumulative incidence in the two cohorts,
and the differences were determined using a two-tailed log-rank test. Multivariable Cox proportional
hazard regression models were used to measure the hazard ratio (HR) and 95% confidence interval
(CI) of DNI incidence between the T1DM and non-DM cohorts. In addition, the stability of HR
was examined using sensitivity testing and subgroup analysis if the interaction effects between the
comorbidities and T1DM on DNI were significant. All analyses were performed using SAS software,
version 9.4 (SAS Institute, Cary, NC, USA), and the level of statistical significance was set at p < 0.05.
3. Results
Table 1 illustrates the distribution of sociodemographic characteristics, DNIs, and comorbidities
identified in the T1DM and non-DM cohorts. The T1DM cohort exhibited a significantly higher
prevalence of DNI, HTN, CVA, CAD, CKD, SADs, and LC. Among the 5741 patients with T1DM,
42 (0.7%) patients with DNI were identified, and the incidence rate was 92.4 per 100,000 person-years in
a mean follow-up period of 7.91 ± 2.41 years. By contrast, among the 22,964 controls, 16 (0.1%) patients
with DNI were identified in a mean observation period of 8.08 ± 2.29 years, and the incidence rate
was 8.6 per 100,000 person-years. The incidence rate ratio was 10.73 with a 95% CI of 6.03–19.08.
The incidence of DNI was significantly higher in the T1DM cohort than in the non-DM cohort
(p < 0.001).
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Table 1. Demographic characteristics of the T1DM and non-DM cohorts.
Characteristic
T1DM Non-DM p-Value *
N % N %
Total 5741 22,964
Gender 1
Male 2777 48.4 11,108 48.4
Female 2964 51.6 11,856 51.6
Age (years) 1
<20 2751 47.9 11,004 47.9
≥20 2990 52.1 11,960 52.1
Urbanized level 1
1 (City) 1616 28.2 6464 28.2
2 2662 46.4 10,648 46.4
3 867 15.1 3468 15.1
4 (Village) 596 10.4 2384 10.4
Income (NTD, per month) 1
0 4005 69.8 16,020 69.8
1–15,840 608 10.6 2432 10.6
15,841–25,000 731 12.7 2924 12.7
≥25,001 397 6.9 1588 6.9
Comorbidities
HTN 1073 18.7 1192 5.2 <0.001
CVA 227 4.0 350 1.5 <0.001
CAD 340 5.9 435 1.9 <0.001
CKD 332 5.8 111 0.5 <0.001
SADs 139 2.4 388 1.7 <0.001
LC 118 2.1 89 0.4 <0.001
DNI
Total 42 0.7 16 0.1 <0.001
Abbreviations: T1DM, type 1 diabetes mellitus; NTD, New Taiwan dollar; HTN, hypertension; CVA, cerebrovascular
accident; CAD, coronary artery disease; CKD, chronic kidney disease; SADs, systemic autoimmune diseases; LC,
liver cirrhosis; DNI, deep neck infection. * Pearson’s chi-square test.
Results of the Kaplan–Meier analysis revealed the cumulative incidence of DNI in both the cohorts
over a 10-year observation period. The T1DM cohort exhibited a significantly higher incidence of DNI
than the non-DM cohort did (log-rank test p < 0.001, Figure 2). The Cox proportional hazards model
revealed that T1DM was associated with a 10-fold higher risk of DNI (adjusted HR: 10.71, 95% CI:
6.02–19.05, p < 0.001, Table 2). In addition, the sensitivity test showed a stable effect of T1DM on DNI
risk in the study cohort in the main model with each additional covariate. The results of subgroup
analysis showed that T1DM is a risk factor for DNI in all the subgroups.
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Figure 2. Cumulative incidence of DNI in the T1DM versus non-DM cohorts. Kaplan–Meier analysis
demonstrated the cumulative DNI identified in the T1DM and non-DM cohorts during the 10-year
follow-up period. The log-rank test revealed a significantly higher cumulative incidence in the T1DM
cohort than in the non-DM cohort (p < 0.001).
Table 2. Multivariable Cox proportional hazards model for associations between DNI and T1DM.
Variables HR 95% CI p-Value
Main model * 10.71 (6.02–19.05) <0.001
Additional covariates †
Main model + HTN 10.20 (5.66–18.38) <0.001
Main model + CVA 10.54 (5.91–18.77) <0.001
Main model + CAD 10.67 (5.99–19.04) <0.001
Main model + CKD 10.36 (5.79–18.56) <0.001
Main model + SADs 10.66 (5.99–18.97) <0.001
Main model + LC 10.27 (5.75–18.33) <0.001
Subgroup effects
Gender
Male 4.69 (2.12–10.38) <0.001
Female 24.67 (8.51–71.52) <0.001
Age
<20 14.28 (5.74–35.56) <0.001
≥20 6.88 (3.07–15.39) <0.001
Without selected
comorbidity
HTN 10.03 (5.40–18.63) <0.001
CVA 9.41 (5.17–17.14) <0.001
CAD 9.34 (5.13–17.00) <0.001
CKD 9.47 (5.22–17.20) <0.001
SADs 9.27 (5.09–16.88) <0.001
LC 9.67 (5.32–17.56) <0.001
* Main model was adjusted for sex, age, urbanized level, and income. † The model was adjusted for sex, age,
urbanized level, income, and each additional comorbidity. Abbreviations: DNI, deep neck infection; T1DM, type 1
diabetes mellitus; NTD, New Taiwan dollar; HTN, hypertension; CVA, cerebrovascular accident; CAD, coronary
artery disease; CKD, chronic kidney disease; SADs, systemic autoimmune diseases; LC, liver cirrhosis.
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Table 3 presents the treatment modalities and prognosis of DNI in the patients in both cohorts
(Table 3). Although the percentage of patients requiring surgical treatment for DNI was higher in the
T1DM cohort than in the non-DM cohort, the difference in the percentages was not significant (T1DM vs.
non-DM cohorts = 33.3% vs. 18.8%, p = 0.276). DNI in the patients in the T1DM cohort required longer
hospitalization durations than did those in the non-DM cohort (T1DM vs. non-DM cohorts: 9.0 ± 6.2
vs. 4.1 ± 2.0 days, p < 0.001). Furthermore, care in ICU and mediastinal complications were only
identified in patients with T1DM and DNI (ICU: 6/42, 14.3%; mediastinitis: 1/42, 2.4%). DNI-related
mortality was observed in the T1DM cohort (mortality: 2/42, 4.8%) but not in the non-DM cohort.
Table 3. Treatment modalities, complications, and prognostic outcomes in patients with DNI.
Characteristic
T1DM-DNI Non-DM-DNI p-Value
N % N %
Total 42 16
Therapy 0.276 a
Non-surgery 28 66.7 13 81.3
Surgery 14 33.3 3 18.8
Tracheostomy 0 0.0 0 0.0
Hospitalization (day, mean ± SD) 9.0 ± 6.2 4.1 ± 2.0 <0.001 b
ICU care 6 14.3 0 0.0
Mediastinitis 1 2.4 0 0.0
Mediastinitis-Mortality 1 2.4 0 0.0
Mortality * 2 4.8 0 0.0
* Mortality occurrence after DNI. a Pearson’s chi-square tests. b Student t-tests. Abbreviations: DNI, deep neck
infection; SD, standard deviation; ICU, intensive care unit.
Figure 3 presents the age distribution of DNI identified in the T1DM and non-DM cohorts.
We divided the age into the following four groups: <10, 10–20, 21–40, and >40 years. Accordingly, the
proportions of DNI in the two cohorts (T1DM vs. non-DM) were 2.38% vs. 18.75% (<10 years), 40.47%
vs. 18.75% (10–20 years), 42.86% vs. 50% (21–40 years), and 14.28% vs. 12.5% (>40 years). In this
study, the peak age of DNI occurrence in the non-DM cohort was 21–40 years, while the T1DM cohort
exhibited two peak ages, namely 10–20 and 21–40 years.
Figure 3. Age distribution of DNI in the T1DM and non-DM cohorts. The peak age of DNI occurrence in
the non-DM cohort was 21–40 years, while those in the T1DM cohort were 10–20 years and 21–40 years.
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4. Discussion
Our nationwide study is the first to examine the influence of T1DM on DNI. Our study
demonstrated that T1DM is a definite risk factor for DNI. Our results revealed that patients with T1DM
are at a 10-fold higher risk of DNI than were those without DM. The higher frequency of infections in
patients with T1DM is attributable to hyperglycemia, which results in immune dysfunction, including
disrupted neutrophil function, depression of the antioxidant system and humoral immunity, micro-
and macroangiopathies, neuropathy, decrease in the antibacterial activity of urine, gastrointestinal and
urinary dysmotility, and the need for medical intervention in these patients [20].
Patients with T1DM are more likely to have complicated infections, such as pneumonia,
septicemia, and osteomyelitis, than are those without DM [21]. Simonsen et al. reported that the
incidence of bacterial infections was significantly higher in patients with T1DM than in those without
DM [22]. Muller et al. reported that patients with T1DM and T2DM have an increased risk of infections
of the lower respiratory tract, urinary tract, and skin and mucous membranes [23]. In addition, an
Australian diabetes register-based study revealed that patients with T1DM exhibited significantly
higher infection-related mortality (pneumonia, septicemia, and osteomyelitis) than did those with
T2DM [11]. Therefore, T1DM is a risk factor for complicated infections, and it might be associated with
higher incidence and severity of infection than T2DM.
Previous studies have reported that surgical treatment was used in 55–80% of patients with
DNI [4,9,24–28]. In our study, few patients received surgical treatment in both the cohorts (T1DM: 33.3%
and non-DM: 18.7%). This difference in percentage may result from previous studies being conducted
in medical centers or tertiary hospitals, which receive and treat patients with severe DNI [4,8,9,24–27].
Hence, patients with severe DNI were more likely accept surgical interventions. However, we enrolled
patients from all hospitals in our nationwide study. The distribution of patients with DNI was from
primary to tertiary hospitals, and patients with low DNI severity were also included; thus, our study
provided a complete spectrum of DNI treatment and prognosis [1]. In general, the use of surgical
interventions to treat a DNI indicates that the infection is more severe and life-threatening. In our
study, the percentage of surgical treatment for DNI was higher in the T1DM cohort than in the non-DM
cohort; however, the difference was not statistically significant.
DNIs in patients with DM have been reported to be associated with long hospitalization durations
and numerous complications [4,28–30]. In our study, the duration of hospitalization for DNI was
significantly higher in the T1DM than in the non-DM cohort, and this result was consistent with
previously reported findings. Patients with T1DM and DNI were reported to exhibit a higher frequency
of lethal complications, such as mediastinitis (2.7–10.0%), and higher mortality (1.6–7.5%) than those
without DM [4,28,29]. A higher rate of ICU care for DNI was noted in patients with T1DM than with
those without DM [1]. In our study, the occurrence of ICU care for DNI, mediastinitis, and DNI-related
mortality was higher in the T1DM cohort than in the non-DM cohort, and these results were consistent
with those of previous studies.
We analyzed the age distribution of DNI in the T1DM and non-DM cohorts in our study. In the
non-DM cohort, the peak age of DNI occurrence was 21–40 years, while in the T1DM cohort, the two
peak ages of DNI occurrence were 10–20 years and 21–40 years. In addition, in the T1DM cohort,
DNI developed at age 10–20 years. In general, the incidence of DNI was higher at age 20–40 years.
Patients with diabetes have been reported to have a late onset of DNI [24,25,28,31]. However, T1DM
was characterized by diagnosis at a young age; according to Magliano’s report, infection (pneumonia,
septicemia, and osteomyelitis) at a young age was more likely to occur in patients with T1DM than
in patients with T2DM (T1DM vs. T2DM = 26.9 vs. 60.4 years) [11]. In summary, we believe that
patients with T1DM tend to develop DNI at younger age (10–40 years) than do patients without DM
(21–40 years) and those with T2DM (>40 years).
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Our study has several strengths, including a large number of patients with T1DM representing
a nationwide population and a 10-year observation period. In addition, the diagnosis of T1DM
was based on data from the RFCIP, a highly accurate and reliable database affiliated to the NHIRD.
Nevertheless, the study has some limitations. The diagnoses were based on ICD-9-CM codes and not
on original medical records; therefore, it lacked blood sugar level, laboratory data, data from imaging
studies, surgical records, and pathologic reports, which are necessary for evaluating disease severity.
The bacterial spectrum and drug sensitivity of T1DM-DNI and the difference from non-DM-DNI are
important information for clinical management and prescription of antibiotics. However, our database
did not contain that information. The effects of the factors omitted in this study on T1DM and DNI
should be investigated in future studies. In addition, ICU care, mediastinitis, and mortality were
observed only in patients with T1DM; however, the number of patients was insufficient to develop a
statistical conclusion. Additional studies including detailed medical records and a large sample size of
patients with DNI are needed.
5. Conclusions
This nationwide population-based study was the first to investigate the epidemiological data of
DNI development and prognosis in patients with T1DM. We concluded that T1DM is a predisposing
factor for DNI. The duration of hospitalization for DNI is longer in patients with T1DM than in those
without DM. In addition, patients with T1DM are predisposed to developing DNI at a younger age
than are those without DM.
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Abstract: Synergistic effects between natural compounds and chemotherapy drugs are believed to
have fewer side effects with equivalent efficacy. However, the synergistic potential of prodigiosin
(PG) with doxorubicin (Dox) chemotherapy is still unknown. This study explores the synergistic
mechanism of PG and Dox against oral squamous cell carcinoma (OSCC) cells. Three OSCC cell lines
were treated with different PG/Dox combinatory schemes for cytotoxicity tests and were further
investigated for cell death characteristics by cell cycle flow cytometry and autophagy/apoptosis
marker labelling. When OSCC cells were pretreated with PG, the cytotoxicity of the subsequent
Dox-treatment was 30% higher than Dox alone. The cytotoxic efficacy of PG-pretreated was found
better than those of PG plus Dox co-treatment and Dox-pretreatment. Increase of Sub-G1 phase
and caspase-3/LC-3 levels without poly (ADP-ribose) polymeras (PARP) elevation indicated both
autophagy and necrosis occurred in OSCC cells. Dox flux after PG-priming was further evaluated
by rhodamine-123 accumulation and Dox transporters analysis to elucidate the PG-priming effect.
PG-priming autophagy enhanced Dox accumulation according to the increase of rhodamine-123
accumulation without the alterations of Dox transporters. Additionally, the cause of PG-triggered
autophagy was determined by co-treatment with endoplasmic reticulum (ER) stress or AMP-activated
protein kinase (AMPK) inhibitor. PG-induced autophagy was not related to nutrient deprivation and
ER stress was proved by co-treatment with specific inhibitor. Taken together, PG-priming autophagy
could sensitize OSCC cells by promoting Dox influx without regulation of Dox transporter. The
PG-priming might be a promising adjuvant approach for the chemotherapy of OSCC.
Keywords: prodigiosin; doxorubicin; priming; influx; autophagy
1. Introduction
Doxorubicin (Adriamycin, Dox), isolated from soil bacteria Streptomyces peucetius, is the first
member of anthracyclines (including daunorubicin, epirubicin, and idarubicin) [1,2]. The main
action of Dox is intercalating within DNA pairs, which leads to the inhibition of topoisomerase
IIβ and results in cell cycle blockage [3]. Rendering non-tissue specific characteristics, Dox gets
wide indications including leukemia, neuroblastoma, breast carcinoma, ovarian carcinoma, and most
recurrent or metastatic cancer [4]. Apart from these, the non-specific characteristics of Dox cause some
severe adverse effects in cancer patients including immunosuppression, bone marrow suppression,
hepatotoxicity, cardiotoxicity, and mucositis [5,6]. The cause of side effects is from the inhibition
of cell division as well as reactive oxygen species (ROS) by-products (doxorubicin-semiquinone,
doxorubicinol, dexrazoxane, and 7-deoxy-doxorubicinone) during metabolism of doxorubicin in
mitochondria [2,7–9]. As a result, these adverse effects might limit the applicable dosage and cancer
treating efficacy of Dox. Accordingly, the alternative approach or new formulation to attenuate Dox
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side effects and enhance Dox efficacy turns out to be a crucial issue for Dox use in the regimen of
chemotherapy. Recently, nanocarriers have exerted a favorable theme and some research has focused on
this topic to dissolve these obstacles, such as Dox encapsulated in pH-sensitive, ultrasonic-responsive,
or co-capsulated with MDR-1 inhibitor in PEGylated, liposome, or PLGA nano-carrier, which also
promote Dox uptake [10–14]. However, cytotoxicity of nanoparticle conjugated Dox was 10 times
lower than free-form Dox, which also restricted the use in cancer treatment [15].
A long treatment period with a low dose chemotherapeutic drug might induce chemoresistance
within cancer cells and subsequently toxicity could affect its use [16]. Notably, prevailing mechanisms
of chemoresistance could be classified into the following seven phases: drug flux, DNA damage
repair, cell death inhibition, epithelial-mesenchymal transition (EMT), drug target alteration, drug
inactivation, and epigenetics [17]. In Dox resistance, dug efflux would be the most concerning
phase [16]. Dox can import into cells through solute carrier family 22 member 16 (SLC22A16, also
known organic cation transporter 6, oct-6) and export by ATP-binding cassette transporter family
members, in which multidrug-related protein 1 (MDR-1 or p-glycoprotein) and breast cancer resistance
protein (BCRP or ABCG2) are involved [3]. These proteins will be regulated (upregulation of exporter
and downregulation of importer) during long-term exposure to a non-toxic dose of Dox [18]. Thereby,
numerous studies have put more attention to reducing MDR over-expression to reverse multidrug
resistance. CRISPER/Cas-9 gene editing, ursodeoxycholic acid, or Zingiber officinale Roscoe, have been
reported to down-regulate ABCB1 gene expressions in chemo-resistant cancer cells [19–21].
Prodigiosin (PG, PubChem CID: 5351169) is a red prodiginine pigment isolated from various
bacteria including Serratia marcescens, Pseudoalteromonas rubra, Hahella chejuensis, and actinomycete
bacteria [22–25]. Even though the original biological function in producer bacteria remains
unclear, PG has been identified with numerous biological activities including antimicrobial [26–29],
antimalarial [26,27,30], and antitumor [26,27,31–34] activities. Moreover, PG showed apoptotic
inducing property in many cancer types such as lung cancer [35–37], breast cancer [38,39],
colorectal cancer [40–42], leukemia [43,44], and hepatocellular carcinoma [45] without normal cell
cytotoxicity [41,46]. Recently, PG has also been identified as an autophagy inducer in OSCC cells [47,48].
However, the application of PG as an adjuvant in chemotherapy is still unknown.
2. Experimental Section
2.1. Research Aims
This study was conducted to explore the potential of PG combined with doxorubicin in anti-cancer
activity by using oral squamous cell carcinoma (OSCC) cells as a test platform. Next, experiments
tested the synergistic effects of PG and Dox against OSCC cells to evaluate the adjuvant potential of
PG for cancer therapy. Furthermore, the underlying molecular mechanisms of enhanced doxorubicin
cytotoxicity under PG-priming were also investigated.
2.2. Reagents
Cell-cultured medium and reagents were purchased from Thermo-Fisher (Waltham, MA, USA).
Prodigiosin was purified by Dr. Yu-Hsin Chen (Department of Life Science, National Dong-Hwa
University, Hualien, Taiwan). Liposome-coated doxorubicin (abbreviated as Dox) was obtained
from Dr. Ming-Fang Cheng (Division of Histology and Clinical Pathology, Hualian Army Forces
General Hospital, Hualien, Taiwan). Inhibitors used in this study were purchased from Santa Cruz
Biotechnology (Dallas, TX, USA). General chemicals were purchased from Sigma Aldrich (Merck
KGaA, Darmstadt, Germany). Polyvinylidene difluoride (PVDF) membrane used in Western blotting
was obtained from GE Healthcare (Chicago, IL, USA). The antibodies used in this study were obtained
from Santa Cruz Biotechnology, as shown in Table 1.
132
J. Clin. Med. 2018, 7, 375
Table 1. Antibodies used in this study.
Protein Host Source RRID MW (kDa) Dilution
MDR-1 Human Mouse AB_2565004 180 1:200
PARP1 Human Mouse AB_1127036 116 1:200
ABCG2 Human Mouse AB_629007 80 1:200
OCT-6 Human Mouse AB_10989254 46 1:200
GAPDH Human Mouse AB_1124759 37 1:1000
Caspase3 Human Mouse AB_1119997 32 1:200
LC3 I/II Human Mouse AB_2137722 15/18 1:200
HRP-conjugated 2nd Ab Mouse Goat AB_92635 1:5000
MW, molecular weight; RRID, Research Resource Identifiers.
2.3. Cell Culture
Cell lines used in this study were obtained from different sources: Human pharynx squamous
carcinoma FaDu from Dr. Chun-Shu Lin (Radiation Oncology Department, Tri-Service General
Hospital, Taipei, Taiwan), human oral squamous cell carcinoma cell line OECM1 and tongue carcinoma
cell line SAS from Professor Ta-Chun Yuan (Department of Life Science, National Dong Hwa University,
Hualien, Taiwan), and human bronchus epithelial cell BEAS-2b from American Type Culture Collection
(ATCC). OECM1 and SAS were cultured in Roswell Park Memorial Institute medium 1640 (RPMI 1640),
FaDu in minimum essential medium (MEM), and BEAS-2b in Dulbecco’s Modified Eagle Medium
(DMEM) and medium was changed every 2 days. All culture media were mixed with 10% fetal
bovine serum (FBS) and 1% antibiotic-antimycotic and cultured within 37 ◦C, 5% CO2 incubator
(Thermo-Fisher). Cells were detached by 0.25% trypsin/ethylenediaminetetraacetic acid (EDTA)
for further experiments. All experiments were obtained within 20 passages concerning uniformity
and reproducibility.
2.4. Cytotoxicity Assay
Cytotoxicity was determined using a colorimetric assay by MTT
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) previously described in the
literature [48]. The optical density (OD) alteration of mitochondrial enzymatic activity was converted
into the cell numbers according to the cell viability or cytotoxicity. Briefly, 1 × 104 cells per wells were
seeded in 96-well plate and incubated in culture conditions overnight. Then, cells were divided into
the six following treatment groups: (1) PG-Dox group: treated with PG followed by Dox, (2) Dox-PG
group treated with Dox and then PG, and (3) PG + Dox group: treated PG and Dox at the same time,
respectively. An additional three groups performed the same treatments with the above-described and
replaced Dox with cisplatin. All treatments were carried out in 12 h and 1 mg/mL of MTT solution
was added and further incubated for 4 h at 37 ◦C as treatment finished. Finally, liquid in wells was
replaced by dimethyl sulfoxide (DMSO), and the absorbance at 570 nm was measured by Multiskan™
FC microplate photometer (Thermo-Fisher). Cytotoxicity of each treatment was represented by cell
viability which calculated from the absorbance ratio at 570 nm between treated and untreated groups.
To understand the cause of PG- and Dox-induced cell death, inhibitor recovering assays were also
performed following the above protocol. Autophagy inhibitors (bafilomycin A1 and 3-methyladenine),
endoplasmic reticulum (ER) stress inhibitors (tauroursodeoxycholic acid, TUDC), and AMPK inhibitors
(dorsomorphin, CC) were cotreated with various concentrations of PG or Dox, respectively.
2.5. Cell Cycle Analysis
Cell cycle analysis was carried out by flow cytometry. Firstly, 1 × 106 cells/well of OSCC were
seeded into 6-well plates and incubated in culture condition overnight. To understand drug-pretreated
effect, cells were treated with PG for 12 h, Dox for 12 h, or PG for 12 h followed by Dox for additional
12 h, respectively. After treatment, cells including culture medium were collected using trypsin/EDTA
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and washed by phosphate buffer saline (PBS) twice before being fixed with pre-cooled 70% ethanol/PBS
overnight. After fixation, cells were washed twice by PBS and stained with staining buffer (20 μg/mL
of propidium iodide, 0.1% Triton X-100, 0.2 mg/mL RNase A) at 37 ◦C for 1 h. The fluorescent intensity
in the cells was measured by a flow cytometer (CytomicsTM FC500, Beckman, Fullerton, CA, USA).
Data from 104 cells were collected for each data file. Fluorescent intensities for each cell line were
acquiesced and plotted by flow cytometer software. The gating of each phase was based on the
acquisition histogram of untreated controls. Phases of each group were collected and the average of
each phase was calculated within the groups.
2.6. Doxorubicin Flux Analysis
Efflux and influx of Dox was determined by indirect method which used rhodamine 123, a
fluorescent Dox transporter substrate, detected as an indicator described previously [49,50]. Briefly,
1 × 104 cells/well of OSCC were seeded in 96-well plate and incubated in culture condition overnight.
After cell confluence, cells were divided into four groups and then treated with various regimens,
respectively. For Rhodamine-influx: short-term influx assay: 0.5 μM of PG in full-culture medium
was added and incubated for 1 h and replaced culture medium with 2 μM of rhodamine 123 in PBS
for additional 1 h; long-term influx assay: the same treatment as short-term influx assay instead the
incubation duration of PG from 1 h to 12 h. For Rhodamine-efflux: short-term efflux assay: 2 μM
of rhodamine 123 in PBS was firstly incubated for 1 h and followed by 0.5 μM of PG in full-culture
medium for additional 1 h; long-term efflux assay: the same as treatment as short-term influx assay
instead the incubation duration of PG from 1 h to 12 h. After incubation, cells were trebly washed by
PBS and lysed with 0.1% triton X-100 and the fluorescent intensity was determined at 485/538 nm by
α-screen multi-plate reader (Perkin Elmer, Waltham, MA, USA). These rhodamine flux studies were
used to estimate DOX flux.
2.7. Western Blotting
The detail protocol of Western blotting was described in our previous study [51]. In brief, 1 × 106
cells/well of OSCC cells were seeded into a 6-well plate and treated the same as with cell cycle
analysis. Cells were washed by PBS and lysed by radioimmunoprecipitation assay buffer (RIPA). Then,
30 μg of total proteins from cell lysates were electrophoretically separated by sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE) and transferred into polyvinylidene difluoride (PVDF)
membrane. Proteins of interest were identified via incubation with appropriate primary followed by
horseradish peroxidase (HRP)-conjugated secondary antibodies and exposed to the iBright imaging
system (Thermo-Fisher) for monitoring intensity of signals after soaking in enhance chemiluminescent
(ECL) reagents. Data acquisition was also performed by the iBright imaging system, and signal
intensity was normalized with GAPDH as an internal control.
2.8. Statistical Analysis
All quantified results were shown as mean ± standard deviation (SD) of three independent
experiments. Significant analysis used a one-way ANOVA, followed by Dunnett’s test. A data
histogram was built by GraphPad Prism 7.04 (La Jolla, CA, USA).
3. Results
3.1. Cytotoxicity Change of PG/Dox Treated Strategies
In this study, three combined manners (pretreatment, cotreatment, and posttreatment) of PG/Dox
were tested in OSCC. In pretreatment and post-treatment approaches, chemicals were previously
treated for 12 h and subsequently washed out, followed by new chemical treatment for additional
12 h. Therefore, the term “PG-pretreatment” would be defined as a “PG-priming” procedure in the
subsequent section. The cell viability of all tested OSCC cells were declined in all combined strategies
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except cotreatment in SAS (p < 0.05). In three combined strategies, PG-pretreatment got the highest
reducing levels (as compared with Dox alone) than those of the other two strategies, as shown in
Figure 1A. This result posed the potential of PG-pretreatment as PG-priming in OSCC. When doubling
the concentrations of PG, cell viability was the same as that of single concentration, revealed 0.5 μM
of PG, which was the maximum concentration for PG-priming. Also, extending the PG-priming
period up to 24 h, the cytotoxicity of Dox failed to exhibit an additive potentiation. These results
indicated that 12 h of PG-priming might reach the maximum effect (data not shown). Moreover, with
PG-priming in normal cell lines BEAS-2b, the cell viability of Dox treatment did not show the decrease
as much as OSCC, even though the concentrations of PG and Dox were twice higher than that of
OSCC, as shown in Figure 1B. This result indicated that PG-priming was more effective and less toxic
than that of Dox alone. An additional experiment was to investigate whether the PG-priming effect
could also be observed in golden chemotherapy drug cisplatin, however, the cytotoxic enhancement in
PG/Dox combination could not be found in PG/cisplatin combination, as shown in Figure 1C. Taking
all results together, PG-priming could enhance Dox cytotoxicity in OSCC cells through a Dox-related
mechanism. In subsequent experiments, the type of cell death triggered by PG-priming and the
underlying mechanism were further investigated.
Figure 1. Alteration of cytotoxicity in sequential PG (prodigiosin)/Dox (doxorubicin) and PG/cisplatin
combination in oral squamous cell carcinoma (OSCC) and BEAS-2b cells. (A) OSCC and (B) normal
bronchus cells-BEAS-2b were treated with various schemes of PG and Dox, and (C) Cisplatin substituted
Dox for 12 h and analyzed cell viability by 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium
bromide (MTT) assay. The results were represented as mean ± SD from three individual experiments.
* p < 0.05 as compared with Dox alone.
3.2. Identification of Cell Death Characteristics
Numerous types of cell death were found in cells, but the most common types were apoptosis and
autophagy, respectively. These two cell-death types could be distinguished by analyzing apoptosis and
autophagy-related protein and cell markers, and the most obvious marker would be cell cycle analysis.
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In cell cycle analysis of SAS, Sub-G1 was significantly increased, but non-cleaved PARP1 and caspase-3
protein levels were not decreased after PG-priming, as shown in Figures 2B and 3B,C. These results
revealed that PG-priming prior to Dox treatment would lead to SAS undergoing necrosis. Moreover,
while PG combined with autophagic inhibitor (bafilomycin A1 (BA1) and 3-methyladenine (3MA), cell
viability of PG-priming could be recovered, as shown in Figure 4. This phenomenon might indicate
that both necrosis and autophagy were activated after PG-priming and the autophagy would be a
major clue, which was further confirmed by increases in LC3 protein levels, as shown in Figure 3A.
In FaDu cells, Sub-G1 phase was not significantly increased after PG/Dox treatment, as shown in
Figure 2C. Also, non-cleaved PARP1 and caspase-3 protein levels while PG-priming followed by Dox
treatment were decreased when compared with Dox alone, as shown in Figure 3B,C. The results
also showed the necrosis activation within FaDu cells similar to SAS cells. Unlike SAS cells, this cell
viability could not be recovered by autophagy inhibitor, as shown in Figure 4. In FaDu cells, LC3
protein levels were also significantly increased in the PG/Dox group, as shown in Figure 3A. These
results revealed that both necrosis and autophagy were activated in FaDu cells and necrosis would
be the main cause of cytotoxicity, whereas OECM1 cells showed different patterns from the above
two cells lines. The sub-G1 phase did not significantly increase either in the non-cleaved PARP1 or
caspase-3 protein levels, as shown in Figures 2A and 3B,C. Taken together, PG-priming cell death of
OECM1 was not related to apoptosis or necrosis. On the other hand, the cell viability of OECM1 after
PG-priming could be recovered by autophagy inhibitors, as shown in Figure 4. Also, LC3 protein
levels were increased 10-fold, as shown in Figure 3A. These two results gave a clear clue for autophagy
in OECM1 by PG-priming. Considering all above results, induced cell death characteristics in three
different cell lines by PG-priming illustrated in different configurations. OECM1 showed autophagy,
and SAS and FaDu posed both cell death and autophagy. In the subsequent experiments, the potential
pathways of PG-enhanced Dox cytotoxicity were under investigation.
Figure 2. Alteration of cell cycle in (A) OECM1, (B) SAS, and (C) FaDu cells. OSCC cells were treated
with PG/Dox for 12/12 h prior to staining with propidium iodide (PI) and fluorescent intensity
was analyzed by flow cytometry. The results were represented as mean ± SD from three individual
experiments. * p < 0.05 as compared with DOX alone.
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Figure 3. Expression of (A) LC3, (B) PARP1, and (C) Caspase3 in OSCCs after PG-priming. OSCC
cells were treated with PG/Dox for 12/12 h and then desired protein levels were analyzed by Western
blotting. The results were normalized with GAPDH and represented as mean ± SD from three
individual experiments. Molecular weight: PARP1, 116 KDa; GAPDH, 37 KDa; Caspase3, 34 KDa; LC3,
18 KDa. # p < 0.05 compared with untreated control; * p < 0.05 as compared with Dox alone.
Figure 4. Alteration of cell viability combined with autophagy inhibitor. OSCC cells were treated
with PG + inhibitor/DOX or PG/Dox + inhibitor and cell viability was analyzed. Table under figure
was the scheme of treatment. “X” meant incubated with complete medium without PG or Dox.
The results were represented as mean ± SD from three individual experiments. * p < 0.05 as compared
with PG/Dox.
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3.3. Doxorubicin Flux Affected by PG-Induced Autophagy
To measure the possible action of PG-induced autophagy, we examined the Dox flux in PG-priming
OSCC cells. This Dox flux was determined by rhodamine-123 (R123) accumulation. R123 is a green
fluorescent dye which acts as a Dox-transporter substrate over decades [52]. Accordingly, PG and Dox
are all red fluorescence and PG is stronger fluorescence than that of Dox. After PG/Dox combination
treatment, PG will interfere with the measurement of Dox fluorescent-intensity. Also, the less cytotoxic
nature of R123 could eliminate the interference of cell death caused by Dox. Therefore, R123 was
employed as an indicator to indirectly determine the Dox-flux in this study. In short-term priming (1 h),
PG-priming did not enhance R123 accumulation, which revealed PG did not allosterically regulate
Dox transporter, as shown in Figure 5A. Subsequently, PG-priming showed additional 50–70% of R123
accumulation for long-term priming (12 h). Moreover, the enhancing R123 could be attenuated by
autophagy inhibitor, as shown in Figure 5B. This result indicated that PG-priming either enhanced
Dox importer expressions or reduced exporter expressions. When checking Dox transporter levels,
however, the importer (Oct-6) was not significantly decreased, and exporters (MDR-1 and ABCG2)
slightly increased in OECM1 and decreased in SAS and FaDu, as shown in Figure 6. This result was not
associated with previous results. It might be postulated as an indication of an unknown but important
mechanism of Dox transport.
Figure 5. Rhodamine 123 accumulation after PG pretreatment. OSCC cells were treated with
PG/R123 for (A) short term (1/1 h) and (B) long term (12/1 h) followed by analyzed fluorescent
intensity within cells. The results were represented as mean ± SD from three individual experiments.
# p < 0.05 as compared with R123 alone; * p < 0.05 compared with PG/R123 combination.
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Figure 6. Protein levels of Doxorubicin-related importer and exporter after PG-priming. OSCC cells
were treated with PG/Dox for 12/12 h and then were analyzed for Importer OCT-6 (A) and exporter
MDR-1 (B) and ABCG2 (C) protein levels by Western blotting. The results were normalized with
GAPDH and represented as mean ± SD from three individual experiments. Molecular weight: MDR-1,
170 KDa; ABCG2, 72 KDa; OCT-6, 58 KDa; GAPDH, 37 KDa. * p < 0.05 compared with Dox alone.
3.4. ER Stress and Energy Deprivation Analysis in PG-Priming OSCC Cells
PG could activate autophagy of OSCC cells as proven by the previous section and literature [48].
In this final part, the aim was to find the trigger of PG-induced autophagy in OSCC cells. As we
noted, the two known triggers of autophagy are ER stress (unfolded protein response) and energy
deprivation, which may be involved in the PG-priming reaction. ER stress was determined by adding
ER stress inhibitor TUDC while energy deprivation was blocked by addition of AMPK specific inhibitor
CC. When we combined TUDC or CC with PG and Dox treatment, cell viability of three OSCC cells
lines were not significantly changed, as shown in Figure 7, (data of FaDu not shown). This result
further postulated that PG-induced autophagy and Dox flux increase were not caused by ER stress
and energy deprivation.
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Figure 7. Cell viability change when PG/Dox combined with ER stress and energy deprivation
inhibitors. OSCC cells were treated with PG + inhibitor/Dox or PG/Dox + inhibitor and were analyzed
for cell viability. The inhibitors contained tauroursodeoxycholic acid (TUDC) and dorsomorphin
(compound C, CC). The results were represented as mean ± SD from three individual experiments.
* p < 0.05 compared with PG/Dox.
4. Discussion
The present study is the first demonstration of PG-enhanced Dox influx by activating autophagy
in OSCC cells. Based on the Dox flux experiments, the enhancing mechanism of Dox influx was
neither related to known importers nor exporters. PG could be a potential adjuvant for Dox treatment.
Also, this study excluded the characteristics of known autophagy-triggers in PG-induced autophagy,
which posed a new site for autophagy triggering mechanisms. In this work, we first report about
the autophagy-activating property of Dox, as this activity was known to be inhibited by the intrinsic
activation of autophagy.
Due to the non-tissue specific nature and high-cardiotoxicity, several studies have tried to discover
natural compounds that could synergistically potentiate the efficacy of Dox without elevating normal
cell toxicity. In a previous report, gambogic acid, a xanthonoid from Garcinia hanburyi, sensitized
ovarian cancer cells toward Dox through accumulation of ROS [53]. Nitidine chloride, an alkaloid,
synergized Dox cytotoxicity in breast cancer cell through PI3K/Akt signaling pathway [54]. Gingerol
synergized Dox against liver cancer cells, leading to G2/M arrest [55]. Not only pure compounds;
phenolic extract of flaxseed oil also promoted Dox efficacy against breast cancer cells [56]. Evodiamine,
a major element of Evodiae fructus, reversed chemoresistance in multi-drug resistant breast cancer
cells through the Ras/MEK/ERK signaling pathway [57]. Additionally, neferine could combat Dox
resistance through ROS accumulation and Fas signaling pathway in lung cancer [58]. In gastric
cancer, curcumin and formononetin posed different mechanisms to enhance Dox cytotoxicity [59,60].
These natural compounds exhibit potentiation for main applications in cancer treatment, and also play
a supporting role in Dox regimen to overcome the limitation of Dox usage [61–66].
The first aim of this study was to explore the synergistic effect within PG/Dox regimen.
PG combined with current chemotherapy agents was studied in breast cancer and found that PG could
facilitate paclitaxel sensitivity in triple-negative human breast carcinoma cells via down-regulating
survivin expression, an anti-apoptotic protein that acts as a caspase inhibitor [67,68]. Our results
demonstrated new evidence that PG acts as an adjuvant with conventional chemotherapeutic drugs,
such as paclitaxel and Dox as well.
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The synergism of natural compounds with Dox could be found in priming fashion, nevertheless
the co-treatment is addressed in main efforts [53–60]. While priming with CDK inhibitor in
triple-negative breast cancer cell MDA-MB-231, Dox-induced DNA double-strand break would
be activated and resulted in cytotoxic enhancement [69]. Cyclophosphamide, a conventional
chemotherapeutic drug that acts as an intercalator of DNA, could increase HER2-targeted liposomal
Dox accumulation in breast cancer cells [70]. An in vivo study focused on Dox efficacy after mitomycin
C and carboplatin (two conventional chemotherapeutic drugs) pretreatment in human metastatic
breast cancer-bearing mice. The results showed inhibition growth of xenografted tumors and reducing
expressions of p-glycoprotein [71]. In our study, we showed that PG potentiated Dox cytotoxicity only
in a pretreatment fashion (as a PG-priming effect), which was the first report of natural compound that
primed cancer cells to be sensitized with Dox, and posed the potential of PG as an adjuvant using Dox
as a chemotherapeutic agent. The clinical application of PG-priming might provide a great clue for
reducing the dosage of Dox and dampening the side effects of Dox.
Due to red fluorescent nature [72], we preliminarily examined PG influx into OSCC cells. The data
showed that PG could enter OSCC cells within 1 h and reached saturation after 1.5 h exposure (data
not shown). When OSCC cells were primed with PG for 1 h, R123 fluorescent intensity did not
significantly accumulate. This gave clear insight into PG action that did not allosterically modulate
Dox importer or exporter activity. A previous study has also indicated that PG was not the substrate of
multidrug resistance-related protein including MDR-1, BCRP (ABCG2), and MRP2 [73]. Again, our
study confirmed that Dox efflux protein was not allosterically activated by PG-priming and further
exposed that PG did not allosterically mediate Oct-6 activity.
By R123 accumulation assay, PG did not allosterically control Dox transporter activity but affected
transporter expression in long-term priming, as shown in Figure 5. To our best knowledge, the Dox
uptake of cells via Oct-6 and excretion of Dox by MDR-1 and ABCG2 have been reported [3,74]. In
our study, Dox influx significantly increased in PG-priming for 12 h, which hypothesized that Oct-6
might be up-regulated or MDR-1/ABCG2 down-regulated. However, Oct-6 was down-regulated after
PG/Dox treatments in Western blotting. Furthermore, expression levels of MDR-1 and ABCG2 did
not show significant reductions. These results proposed a new Dox flux mechanism that needs to be
further investigated.
PG was known as apoptotic and autophagic inducer in previous studies [47,75]. According to
a recent study, PG induced apoptosis via inhibiting Bcl-2, activating Bak/Bax, intercalating DNA
leading to suppress the cell cycle [75]. However, the action of PG-induced autophagy has not been fully
explored yet. Remarkably, autophagy was triggered by stresses, such as ER stress (unfolded protein
response), nutrient deprivation, and oxidative stress [76–79]. Hence, these cellular stresses would be
the trigger clue of PG-induced autophagy. However, our test exposed that using ER stress inhibitor
(TUDC) and nutrient deprivation inhibitor (CC) could not restore the cell viability of PG/Dox. Also,
our data showed that PG did not elevate ROS level within OSCC cells (data not shown). All-known
causes of autophagy, including ER stress, nutrient deprivation, and oxidative stress, were excluded
from the trigger clue of PG-induced autophagy in this study, which the new potential mechanism of
autophagy activation necessitates to be further elucidated.
During the screening of an autophagic marker, we also found that Dox-induced autophagy in both
OECM1 and FaDu cells. It is well known that Dox was an apoptotic inducer via inhibiting cell cycle and
producing ROS [80]. The potentiated role of autophagy in Dox treatment is focused on the activation
of autophagy to ameliorate cardiotoxicity, and consequently inhibiting autophagy could promote Dox
sensitivity in cancer cells [81–84]. The autophagy-activating features of Dox suggested the unclear
field of Dox action. In the result of autophagy inhibitor recovery assay, autophagic inhibitors could
not recover Dox-induced cell death, which implies that Dox-induced autophagy might not be solely
involved in Dox-induced cell death, as shown in Figure 3.
Collectively, a model for the mechanical action of PG-priming autophagy potentiated Dox influx
is proposed, as shown in Figure 8. When PG entered OSCC cells, autophagy which was irrelevant to
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nutrient deprivation, ER stress, and ROS, was activated. Subsequently, PG-induced autophagy could
up-regulate Dox importer expression and in terms translocated to cell membrane, and consequently
led to the enhancement of Dox influx resulting in cell death.
Figure 8. Potential mechanism of PG-priming doxorubicin cytotoxicity enhancement. “X” indicates not
according to this mechanism. “?” illustrates still unknown. ER, endoplasmic reticulum; ROS, reactive
oxygen species.
5. Conclusions
The present study firstly demonstrated the potential of PG as an adjuvant for Dox treatment
in OSCC cells. PG-induced autophagy was not associated with ER stress, nutrient deprivation,
and oxidative stress. Also, the enhancement of Dox influx triggered by PG-primed autophagy did
not induce via Dox transporter, such as MDR-1, ABCG2, and OCT-6. The potential mechanism of
PG-priming remains unclear and would be a further challenge for PG and Dox investigation.
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Abstract: This study assessed the significance of the neutrophil-to-lymphocyte ratio (NLR) in head
and neck squamous cell carcinoma (HNSCC), and the relationships of the NLR with the aldehyde
dehydrogenase 1 (ALDH1) level in tumors and the proportion of myeloid-derived suppressor cells
(MDSCs) in the peripheral circulation. In total, 227 HNSCC patients who had received curative
treatment at our hospital were enrolled into the present study. The NLR of each HNSCC patient before
treatment was calculated. The associations of NLR with various clinicopathological parameters and
prognoses were then examined. In addition, correlations between the proportion of MDSCs and level
of ALDH1 with the NLR were assessed. Our data revealed that an elevated NLR was significantly
correlated with the risk of developing locoregional recurrence and with a reduced overall survival in
HNSCC patients. Multivariate analyses revealed that the NLR pretreatment and surgical resection
were significantly correlated with the rate of treatment failure and the overall survival rate in HNSCC
patients. Furthermore, the levels of ALDH1 in tumors and MDSCs in the peripheral circulation were
significantly correlated with the prognosis of HNSCC, and the NLR was positively correlated with
MDSC levels in the circulation and ALDH1 staining intensity in tumor specimens. In conclusion,
the NLR has power in predicting the expression of ALDH1 in tumors, the circulating level of MDSCs,
and the prognosis in HNSCC. We suggest that the NLR is an important biomarker that can assist the
clinician and patient in making informed decisions regarding treatment options for HNSCC patients.
Keywords: head and neck squamous cell carcinoma (HNSCC); neutrophil-to-lymphocyte ratio (NLR);
myeloid-derived suppressor cells (MDSC); aldehyde dehydrogenase 1 (ALDH1); prognosis
1. Introduction
Head and neck squamous cell carcinoma (HNSCC) is a heterogeneous disease occurring in various
sites, including the oral cavity, oropharynx, and hypopharynx [1]. Treatment failure and locoregional
recurrence are common and account for the majority of deaths [2]. Identification of potential molecular
markers predicting aggressive tumor growth and treatment response is important for the effective
management and prognosis of HNSCC.
Abundant epidemiological data have revealed a strong correlation between inflammation and
cancer incidence. Systemic inflammation is a recognized characteristic of malignancy, and numerous
inflammatory markers have been investigated as prognostic indicators for cancer patients [3,4]. Host
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inflammatory responses were reported to play an important role in tumor development and progression [5].
The neutrophil-to-lymphocyte ratio (NLR) is an inflammatory- and immunologically-based index [6,7].
The NLR may reflect host inflammatory responses and changes in the tumor microenvironment [8].
An elevated NLR in many solid tumors, including HNSCC, has been associated with reduced
survival [8–10]. However, the predictive value of the NLR in the immune and treatment responses of
HNSCC is still unclear. Myeloid-derived suppressor cells (MDSCs) have been reported to attenuate
immune surveillance and induce an immunosuppressive tumor microenvironment to promote cancer
metastasis [11,12]. We previously reported that the recruitment of MDSCs is significantly associated
with a poor prognosis in patients with HNSCC [13]. Furthermore, one of the main causes of treatment
failure is the emergence of resistant cancer cells after therapy, which can be partly explained by cancer
stem cells (CSCs) [14,15]. CSCs produce immunosuppressive molecules that attenuate the immune
system and recruit or activate cells that suppress the immune system, such as MDSCs [16–18]. Aldehyde
dehydrogenase 1 (ALDH1), a novel CSC-like cell marker, was reported to play important roles in the
treatment response and tumor-promoting microenvironment in squamous cell carcinomas (SCCs) of
the aerodigestive tract [19–21]. Accordingly, in the present study, we examined the predictive role
of an elevated NLR in the prognosis and relationships of the NLR with the ALDH1 level in tumors,
and the proportion of MDSCs in the peripheral circulation of patients with HNSCC.
2. Materials and Methods
2.1. Study Population and Study Design
The study protocol was approved by the institutional review board of Chang Gung Memorial
hospital (No. 1035434B). Written informed consent was obtained from all patients. A total of
227 patients with a histologically confirmed diagnosis of HNSCC who received curative treatment were
enrolled in our study. The planned treatments included definitive radiotherapy and chemotherapy
(CCRT) or surgery +/− adjuvant treatment for patients with HNSCC, according to the guidelines
proposed by the oncology team at our hospital. We included patient demographics (age and sex),
diagnosis, clinical stage, and treatment characteristics (Table 1). In addition, the patients enrolled in the
study had available data regarding ALDH1 levels in tumor specimens and/or the percentage of MDSCs
in the peripheral circulation. The NLR was calculated by dividing the absolute neutrophil count by the
absolute lymphocyte count. The mean absolute neutrophil count was 5.77 ± 3.29 × 103/μL, and the
mean absolute lymphocyte count was 1.55 ± 0.85 × 103/μL. To assess the predictive value of the NLR,
NLR was redefined as a binary variable by finding the value from a receiver operating characteristic
(ROC) curve that maximized the percentage correctly classified for predicting tumor recurrence after
treatment. The optimal cut-offs for NLR was 3. Accordingly, all HNSCC patients were divided into
two groups according to the pretreatment NLR: high (NLR ≥ 3) and low (NLR < 3) groups.
Table 1. Characteristics of head and neck squamous cell carcinoma (HNSCC) patients with
curative-intent treatment.
Number of Patients
NLR < 3 NLR ≥ 3 p-Value
Patient 108 119
Age
<55 (median) 52 53 0.58
≥55 56 66
Differentiation 0.38
Well differentiated 39 39
150
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Table 1. Cont.
Number of Patients
NLR < 3 NLR ≥ 3 p-Value
Moderately differentiated 38 41









Definite CCRT 31 34
Surgery +/− neoadjuvant/adjuvant Tx 77 85
Location 0.23
Oral cavity 72 88
Pharynx (Oro-Hypo) 36 31









NLR: neutrophil-to-lymphocyte ratio; CCRT: radiotherapy and chemotherapy; LN: lymph node; Tx: treatment; *:
Statistically significant covariate; T: tumor.
2.2. Immunohistochemical (IHC) Staining
Formalin-fixed and paraffin-embedded tissues, collected at diagnosis from 227 patients with
HNSCC who had completed curative treatment, were subjected to IHC analysis (Table 2). The IHC
data were assessed using the semiquantitative immunoreactive score, and positive staining was defined
as an immunoreactive score ≥ 2 [21]. The clinical end points were overall survival (OS), disease-free
survival, and failure pattern. Disease failure was defined as documented locoregional recurrence
and/or distant metastases.
Table 2. Characteristics of head and neck squamous cell carcinoma (HNSCC) patients with
curative-intent treatment.
Number of Patients
ALDH1 (−) ALDH1 (+) p-Value
Patients 118 109
Age
<55 (median) 56 49 0.71
≥55 62 60
Differentiation 0.38
Well differentiated 44 34
Moderately differentiated 39 40
Poorly differentiated 27 28
Unknown 8 7
151
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Table 2. Cont.
Number of Patients








Definite CCRT 35 34
Surgery +/− neoadjuvant/adjuvant Tx 83 75
Location 0.96
Oral cavity 72 77




Loco-regional recurrence <0.001 *
Control 104 49
Failure 14 60






ALDH1. aldehyde dehydrogenase 1; *: Statistically significant covariate.
2.3. MDSC Isolation and Flow Cytometry Analysis
Peripheral blood samples were obtained from 118 patients with pathologically and clinically
confirmed HNSCC (Table 3). To assess the proportion of MDSCs among peripheral blood mononuclear
cells (PBMCs), multicolor fluorescence-activated cell sorting (FACS) was performed using the FACS
Caliber flow cytometer (BD Biosciences, San Jose, CA, USA). Human low-density neutrophils and
granulocytic MDSCs are closely related, and presently there is no generally accepted consensus
on mutually exclusive definitions for these cell types [22]. In the majority of oncological studies,
human granulocytic MDSCs are characterized as CD14−CD15+CD11b+HLA-DR− cells [7]. Accordingly,
the human MDSC subset characterized as CD11b+CD14−HLA-DR− cells was sorted from the peripheral
blood. The leukocytes were separated from the peripheral blood using a Ficoll gradient before analysis or
sorting. Multicolor cell analysis was performed using the following antibodies: PerCP-Cy5.5-conjugated
CD14, polyethylene (PE)-conjugated CD11b, and fluorescein isothiocyanate-conjugated HLA-DR.
The percentage of MDSCs was measured using multicolor flow cytometry, and isotype-specific antibodies
were used as negative controls.
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Table 3. Characteristics of head and neck squamous cell carcinoma (HNSCC) patients with
curative-intent treatment.
Number of Patients
MDSC (Low) MDSC (High) p-Value
Patients 59 59
Age
<55 (median) 28 26 0.72
≥55 31 33
Differentiation 0.15
Well differentiated 12 9
Moderately differentiated 24 18
Poorly differentiated 17 23
Unknown 6 9
Tumor stage 0.005 *
≤T2 35 20
T3–T4 24 39




Definite CCRT 26 39
Surgery +/− neoadjuvant/adjuvant Tx 33 20
Location 0.19
Oral cavity 29 22




ALDH1 staining <0.001 *
Negative 55 9
Positive 4 50






MDSC: myeloid-derived suppressor cell; *: Statistically significant covariate.
2.4. Statistical Analysis
The Kaplan–Meier method was used to plot survival curves, and the log-rank test was used to
determine differences in the survival curves between the two groups. The Cox proportional hazard
model was used to compute hazard ratios with 95% confidence intervals (CI) after adjustment for
esophageal cancer treatment and clinical characteristics. All analyses were conducted using SAS
statistical software, version 9.2 (SAS Institute, Cary, NC, USA).
3. Results
3.1. Correlations Between the Pretreatment NLR and Clinicopathological Characteristics of HNSCC Patients
A total of 227 patients with HNSCC were enrolled in this study (Table 1). The median follow-up
time was 25.6 months (range 1.37–148 months). There were 114 (50%) patients with clinical tumor stage
T1/T2 disease and 140 (62%) with clinical lymph node involvement. Of these patients, 162 (71%)
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received surgery with or without adjuvant treatment, and the others received definitive RT and
chemotherapy. The pretreatment NLR was calculated as the ratio of the absolute neutrophil count to
the lymphocyte count. The median pretreatment NLR of the overall cohort was 3.12 (range 0.5 to 31.8).
At baseline, 119 (52%) patients had a high NLR of three or higher and 108 (48%) a low NLR less than
three. The relationships between the clinicopathological variables and the pretreatment NLR values are
shown in Table 1 and Figure 1a. A high NLR at baseline was significantly associated with locoregional
recurrence (p < 0.001) and a higher risk of death during follow-up (p < 0.001). To further examine
whether the pretreatment NLR was associated with the outcomes of HNSCC patients after curative
treatment, Kaplan–Meier survival analysis was used to compare the low and high NLR subgroups.
Patients with a high pretreatment NLR had a shorter overall survival (OS) time (p < 0.001; Figure 1b).
As shown in Figure 1c,d, a high NLR was significantly associated with a reduced OS rate in both
oro/hypopharyngeal cancer (p < 0.001) and oral cancer patients (p = 0.047). The results of multivariate
analyses (Tables 4 and 5) revealed that the pretreatment NLR and surgical resection were significantly
correlated with the risk of developing disease failure after treatment and with the OS rate. We further
analyzed the predictive value of the NLR according to treatment modality. The data revealed that high
NLR was associated with shorter disease-specific survival (DSS) time in patients treated with CCRT
and those treated with surgery (Figure 1e,f). Moreover, in the subgroup of surgery, a high NLR was
the significant predictor independent of clinical T-stage. In the subgroup of CCRT, a high NLR was
associated with shorter disease-specific survival time in patients with advanced tumor stage (p = 0.021),
but not in those with early tumor stage (p = 0.053).
 
Figure 1. Correlations between the baseline neutrophil-to-lymphocyte ratio (NLR) and the prognosis for
patients with head and neck squamous cell carcinoma (HNSCC). (a) The pretreatment NLR in HNSCC
patients. Box-plot showing NLR at baseline was elevated in patients with locoregional recurrence and
having higher risk of death during follow-up. The data showed the third quartile (Q3) and first quartile
(Q1) range of the data and data outliers. Lines indicate the median values. The survival differences
are according to the pre-treatment NLR (NLR ≥ 3 vs. NLR < 3) in (b) all, (c) subgroup of oral cancer
patients, and (d) the subgroup of patients with oro-hypopharyngeal cancer. In addition, the differences
of disease-specific survival (DSS) are according to the pre-treatment NLR in (e) the subgroup of definite
CCRT, and (f) the subgroup of surgery.
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Table 4. Adjusted hazard ratio (HR) of determining factors associated with overall survival (OS) of
patients with head and neck squamous cell carcinoma (HNSCC).
Variable HR 95% CI p-Value
Age
<50 Ref
≥50 1.51 0.92–2.47 0.1
Differentiation
Well–Moderately differentiated Ref
Poorly differentiated. 0.77 0.43–1.36 0.36
Clinical T stage
≥T2 Ref
T3–T4 0.85 0.54–1.36 0.5
Clinical N stage
N 0 Ref
N (+) 1.49 0.9–2.47 0.12
NLR
<3 Ref
≥3 2.69 1.62–4.46 <0.001 *
Treatment
Definite CCRT Ref
Surgery +/− neoadjuvant/adjuvant Tx 0.44 0.24–0.79 0.006 *
CI: Confidence Interval; Ref: Reference Group; N: Lymph node staging; *: Statistically significant covariate.
Table 5. Adjusted hazard ratio (HR) of determining factors associated with disease failure of patients
with head and neck squamous cell carcinoma (HNSCC).
Variable HR 95% CI p-Value
Age
<50 Ref
≥50 1.26 0.8–1.99 0.314
Differentiation
Well–Moderately differentiated Ref
Poorly differentiated 0.87 0.52–0.47 0.61
Clinical T stage
≤T2 Ref
T3–T4 0.94 0.61–1.45 0.77
Clinical N stage
N 0 Ref
N (+) 1.6 0.99–2.58 0.057
NLR
< 3 Ref
≥ 3 2.71 1.69–4.38 <0.001 *
Treatment
Definite CCRT Ref
Surgery +/− neoadjuvant/adjuvant Tx 0.37 0.22–0.63 <0.001 *
*: Statistically significant covariate.
3.2. Relationships of ALDH1 Expression with the Pretreatment NLR and Clinical Outcome
We previously reported that positive ALDH1 staining was significantly related to a poor treatment
response and higher disease failure rate in oral squamous cell carcinoma (SCC) [21]. Accordingly,
we analyzed the predictive role of ALDH1 levels in the clinical outcome and its correlation with the
pretreatment NLR in the 227 HNSCC patients. Figure 2a shows representative slides of positive and
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negative ALDH1 staining in HNSCC specimens at diagnosis. IHC revealed ALDH1 overexpression
in 109 (48%) in these patients. As shown in Table 2, positive ALDH1 staining was significantly
associated with the risk of lymph node involvement (p = 0.016), a higher rate of locoregional failure
(p < 0.001), and distant metastasis (p = 0.019). As shown in Figure 2b,c, positive staining of ALDH1 was
significantly associated with a higher locoregional failure rate and lower OS rate. In the multivariate
analysis, positive staining of ALDH1 was significantly associated with a higher risk of developing
disease failure and a shorter OS time in HNSCC (Tables 6 and 7). Furthermore, the distribution of
the pretreatment NLR was significantly associated with ALDH1 staining in tumor specimens (Table 2
and Figure 2d). Based on the results, we suggest that positive staining of ALDH1 is an independent
predictor of shorter survival and a higher rate of disease failure, and a high pretreatment NLR plays a
role in predicting ALDH1 expression levels and subsequently a poor prognosis in HNSCC.
Figure 2. Relationships between NLR, aldehyde dehydrogenase 1 (ALDH1) expression level,
and clinical outcome. (a) Representative images of immunohistochemical (IHC) staining with
anti-ALDH1 antibodies of oral cancer and hypopharyngeal cancer specimens. Survival differences
demonstrated according to the staining of ALDH1 in (b) overall survival rate and (c) disease failure-free
rate. (d) NLR levels in the groups of HNSCC patients with and without ALDH1 positive staining in
tumor specimens. The data show the third quartile (Q3) and first quartile (Q1) range of the data and
data outlier. Lines indicate the median values.
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Table 6. Adjusted hazard ratio (HR) of determining factors associated with overall survival (OS) of
patients with head and neck squamous cell carcinoma (HNSCC).
Variable HR 95% CI p-Value
Age
<50 Ref
≥50 1.36 0.84–2.12 0.21
Differentiation
Well–Moderately differentiated Ref
Poorly differentiated 0.79 0.45–1.39 0.42
Clinical T stage
≤T2 Ref
T3–T4 1.01 0.62–1.60 0.98
Clinical N stage
N 0 Ref
N (+) 1.17 0.71–1.93 0.53
ALDH1
Negative Ref
Positive 4.1 2.43–6.92 <0.001 *
Treatment
Definite CCRT Ref
Surgery +/− neoadjuvant/adjuvant Tx 0.48 0.27–0.87 0.015 *
*: Statistically significant covariate.
Table 7. Adjusted hazard ratio (HR) of determining factors associated with disease failure of patients
with head and neck squamous cell carcinoma (HNSCC).
Variable HR 95% CI p-Value
Age
<50 Ref
≥50 1.12 0.71–1.77 0.62
Differentiation
Well–Moderately differentiated Ref
Poorly differentiated 0.88 0.53–1.47 0.63
Clinical T stage
≤T2 Ref
T3–T4 1.1 0.70–1.71 0.68
Clinical N stage
N 0 Ref
N (+) 1.26 0.78–2.03 0.35
ALDH1
Negative Ref
Positive 5.92 3.46–10.11 <0.001 *
Treatment
Definite CCRT Ref
Surgery +/− neoadjuvant/adjuvant Tx 0.42 0.25–0.71 0.001 *
*: Statistically significant covariate.
3.3. Predictive Role of Pretreatment NLR on Levels of CD11b+CD14−HLA-DR− Cells in
Peripheral Circulation
Accumulating evidence indicates that MDSCs, a population of cells with suppressive activity,
contribute to the negative regulation of immune responses and subsequently to tumor promotion [11].
We previously reported that circulating MDSC levels were significantly increased in patients with HNSCC,
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and this was associated with the clinical tumor burden [13]. In the present study, the percentage of
CD11b+CD14−HLA-DR− cells, a subset of MDSCs, in the peripheral circulation of 118 patients with
HNSCC was evaluated by flow cytometry. Representative flow cytometry data from two HNSCC patients
are shown in Figure 3a. The mean percentage of CD11b+CD14−HLA-DR− cells in the peripheral blood
mononuclear cells of the 118 HSCC patients was 11.6 ± 7.4%. As shown Figure 3b,c, the percentage of
CD11b+CD14−HLA-DR− cells was significantly correlated with the risk of developing disease failure
and death after treatment (p < 0.001). An increased MDSC level was reported to be associated with
attenuating immune surveillance noted in CSC tumors [16,17,21]. Figure 3d shows that the level of MDSCs
was significantly higher in the ALDH1-positive group than in the ALDH1-negative group (p < 0.001).
The 118 patients were further divided into two groups according to the mean CD11b+CD14−HLA-DR−
cell percentage at diagnosis (11.6%): high (≥11.6%) and low (<11.6%) groups. As shown in Table 3,
a high percentage of CD11b+CD14−HLA-DR− cells was associated with a more advanced clinical tumor
stage (T3/T4, p = 0.005), lymph node involvement (p = 0.018), a higher pretreatment NLR, and shorter
survival compared with a low CD11b+CD14−HLA-DR− cell percentage. In the multivariate analysis,
a higher percentage of circulating MDSCs was significantly associated with a higher risk of developing
disease failure and a shorter survival in patients with HNSCC (Tables 8 and 9). We further assessed the
usefulness of the NLR in predicting the CD11b+CD14−HLA-DR− cell percentage. A strong correlation
was found between the pretreatment NLR and the percentage of CD11b+CD14−HLA-DR− cells in
peripheral circulation of HNSCC patients (Figure 3e).
 
Figure 3. Correlation between pre-treatment NLR in the levels of circulating CD11b+CD14-HLA-DR−
cells and ALDH1. (a) Flow cytometric analysis of circulating CD11b+CD14-HLA-DR− cells in isolated
peripheral blood mononuclear cells (PBMCs). HLA-DR−CD11b+ cells were gated, and the CD14
negative population was then selected. Representative data from two cancer patients are shown (upper
row, the patient with pretreatment NLR < 3; lower row, the patient with pretreatment NLR ≥ 3).
Elevated circulating levels of CD11b+CD14-HLA-DR− cells associated with the higher risk of death (b),
disease recurrence after treatment (c), and ALDH1 positive staining (d). (e) Positive correlation between
the levels of CD11b+CD14−HLA-DR− cells and pre-treatment NLR in the peripheral circulation.
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Table 8. Adjusted hazard ratio (HR) of determining factors associated with overall survival (OS) of
patients with neck squamous cell carcinoma (HNSCC).
Variable HR 95% CI p-Value
Age
<50 Ref
≥50 0.71 0.32–1.55 0.39
Differentiation
Well–Moderately differentiated Ref
Poorly differentiated 0.44 0.18–1.06 0.07
Clinical T stage
≤T2 Ref
T3–T4 1.04 0.44–2.48 0.93
Clinical N stage
N 0 Ref
N (+) 1.19 0.49–2.90 0.70
MDSC
Low Ref
High 6.19 2.34–18.0 <0.001 *
Treatment
Definite CCRT Ref
Surgery +/− neoadjuvant/adjuvant Tx 0.43 0.19–0.98 0.044 *
*: Statistically significant covariate.
Table 9. Adjusted hazard ratio (HR) of determining factors associated with disease failure of patients
with neck squamous cell carcinoma (HNSCC).
Variable HR 95% CI p-Value
Age
<50 Ref
≥50 0.70 0.34–1.40 0.31
Differentiation
Well–Moderately differentiated Ref
Poorly differentiated 0.61 0.29–1.25 0.18
Clinical T stage
≤T2 Ref
T3–T4 1.28 0.60–2.76 0.52
Clinical N stage
N 0 Ref
N (+) 1.59 0.68–3.75 0.29
ALDH1
Negative Ref
Positive 5.31 2.23–12.62 <0.001 *
Treatment
Definite CCRT Ref
Surgery +/− neoadjuvant/adjuvant Tx 0.39 0.19–0.82 0.012 *
*: Statistically significant covariate.
4. Discussion
The tumor microenvironment plays an important role in cancer development and progression and
may be associated with systemic inflammation [23]. Neutrophils form the first line of host immune
defense against bacterial and fungal infections [24]. Compared with their role in host defenses, which is
relatively well established, we are just beginning to learn about the precise role of neutrophils in
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cancer [25,26]. Many recent studies suggested that an elevated NLR is associated with poor survival of
subjects with cancer [8,27], including head and neck cancer [10,28]. In the present study, an advantage
of our analyses was that the results were based on a relatively large population of HNSCC patients from
a single institute, with available information regarding staging and primary treatment details. Based on
the analyses of 227 HNSCC patients who received curative treatment, an elevated pretreatment NLR
was significantly associated with higher loco-regional recurrence rate and reduced OS rate. According
to univariate and multivariate analyses, a pretreatment NLR of three or higher was associated with a
shorter OS compared with a NLR below three. Treatment policy included surgery with or without
adjuvant treatment for oral cancers and definitive radiation and chemotherapy for oropharyngeal and
hypopharyngeal cancers. We further analyzed the predictive value of the NLR according to treatment
modality. The data revealed that an increased NLR was a significant predictor for poor prognosis in
patients treated with CCRT and those treated with surgery. Based on these results, the NLR is a useful
baseline variable for assessing prognosis in HNSCC patients considered for curative treatment.
Circulating blood contains several types of immune cells that participate in the immune response.
The interactions among the various populations of immune cells have been recognized as critical
in forming the immune microenvironment, which provides the milieu for the anti-cancer immune
response to occur [29–32]. MDSCs constitute an immature population of myeloid cells thought to be an
important subset of cells that contribute to an immunosuppressive tumor microenvironment, and MDSC
numbers are significantly increased in cancer patients [33,34]. Increasing evidence has demonstrated an
association between suppressive neutrophils and granulocytic MDSCs related to immune suppression
and their relevance to disease [35]. Many of the pro-tumor features of suppressive neutrophils are
shared with granulocytic MDSCs, and the distinction between these two cell populations is a matter of
intensive debate. We previously found that MDSC recruitment provided a microenvironment conducive
to tumor growth and the development of treatment resistance in HNSCC [13]. To date, granulocytic
MDSCs have been defined mainly as CD11b+CD14−HLA-DR− cell lineages in human cancers [7,22,35].
Accordingly, we characterized the proportions of CD11b+CD14−HLA-DR− myeloid cells in a cohort
of HNSCC patients. FACS analyses revealed that the percentage of these MDSCs was correlated with
the clinical tumor burden, disease status, and survival. We further demonstrated a positive correlation
between the NLR and circulating CD11b+CD14−HLA-DR− cell level in HNSCC patients. In the present
study, we showed that the pretreatment NLR was related to the circulating CD11b+CD14−HLA-DR−
cell level and disease progression.
Much of the relationship between immune cells, either circulating or within tumors, and disease
outcome in cancer can probably be explained by the inflammatory response that is secondary to the
cancer. CSCs are becoming recognized as being responsible for metastasis and treatment resistance [36,37].
ALDH1, a detoxifying enzyme, has been identified as a novel CSC-like cell marker and is relevant
to the prognosis of cancers [19,20,38,39]. Immune evasion was reported to play a role in the
contribution of CSCs in tumor promotion [16,40]. CSCs can recruit cells that suppress the immune
system, such as the activation of myeloid-derived suppressor cells (MDSCs), to attenuate immune
surveillance [16–18,41–43]. Our previous data revealed correlations between ALDH1 expression levels
and treatment resistance, CSC-like properties, higher circulating MDSC levels, and poor prognosis in
oral SCC. Accordingly, we further examined the predictive value of ALDH1 for HNSCC prognosis
and the correlations of the ALDH1 level with the MDSC level and NLR. By analyzing the clinical
outcomes of 227 patients with HNSCC, the elevated expression of ALDH1 was correlated with a higher
incidence of lymph node involvement, higher disease failure rate, and lower survival rate. Moreover,
there were significant correlations among ALDH1 IHC staining, the levels of circulating MDSCs,
and NLR. Patients with a higher NLR had a higher ALDH1 level in their tumors and more MDSCs in
the peripheral circulation, which are associated with poor prognosis of HNSCC. The current study
is limited by the inherent nature of investigating a hospital-based registry and the nonrandomized
approach to treatment selection. Furthermore, we could not account for potential unmeasured selection
biases regarding performance status, comorbidity, access to health care, or other patient-related factors.
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5. Conclusions
With the increasing use of personalized therapy, patient selection has become an important issue
in assessing efficacy. The targeted therapy of CSCs may enhance the treatment response, thereby
resulting in improved clinical outcomes in patients with HNSCC. In addition, MDSCs have been
suggested to be a novel target for multiple cancers, and numerous clinically available agents have
been developed [34]. Thus, it is imperative to identify clinically feasible parameters highly relevant
to the characteristics of CSC and the level of MDSCs. The NLR is a cheaper and faster laboratory
measure compared with other biomarkers, and it does not involve any additional cost. In the present
study, we showed that the NLR was relevant to ALDH1 and MDSC levels and a strong prognostic
indicator for HNSCC patients. Discussions based on pretreatment NLR results may help the patient
decide whether the side effects of curative treatments are worth the risk. We suggest the NLR to be an
important biomarker for patients that can assist the clinician and patient to make informed decisions
regarding treatment options.
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Abstract: The purpose of this study was to evaluate the value of diffusion-weighted MRI (DW-MRI)
in differentiating benign and malignant head and neck masses by comparing their apparent diffusion
coefficient (ADC) values. The study included 32 patients with a neck mass >1 cm in diameter who
were examined with echo planar DW-MRI. Two different diffusion gradients (b values of b = 0 and
b = 1000 s/mm2) were applied. DWI and ADC maps of 32 neck masses in 32 patients were obtained.
Mean ADC values of benign and malignant neck lesions were measured and compared statistically.
A total of 15 (46.9%) malignant masses and 17 (53.1%) benign masses were determined. Of all
the neck masses, the ADC value of cystic masses was the highest and that of lymphomas was the
lowest. The mean ADC values of benign and malignant neck masses were 1.57 × 10−3 mm2/s and
0.90 × 10−3 mm2/s, respectively. The difference between mean ADC values of benign and malignant
neck masses was significant (p < 0.01). Diffusion-weighted MRI with ADC measurements can be
useful in the differential diagnosis of neck masses.
Keywords: neck mass; diffusion-weighted MRI; apparent diffusion coefficient
1. Introduction
Quick and accurate diagnosis directly affects treatment success for patients with a neck mass,
which is a common finding in ENT clinics. Inadequate or late diagnosis of a malignant mass increases
the morbidity and mortality of a disease.
The rapid development of diagnostic imaging technology has provided clinical practice with
new facilities for the evaluation of neck masses. These new methods are gaining importance with the
advantageous factors of cost and ease of use. At present, ultrasonography (USG) and/or computed
tomography (CT) are used as conventional methods for the evaluation of neck lesions.
If necessary, magnetic resonance imaging (MRI) is used for the characterization of neck masses.
MRI evaluates the morphology, signal intensity and enhancement pattern of lesions. However, none of
these methods can accurately differentiate benign from malignant lesions. This has led to the necessity
of researching new diagnostic methods. Diffusion-weighted magnetic resonance imaging (DW-MRI) is
a non-contrast enhanced technique that can be obtained during a single breath-hold. In the literature,
DW-MRI was first used in the early diagnosis of stroke in neuroradiology [1,2]. In the early period,
the use of this technique was limited in the central nervous system due to its sensitivity to cardiac,
respiratory, and peristaltic movements. However, following improvements in the echo planar imaging
technique as a fast MRI sequence, it became possible to successfully apply diffusion-weighted echo
planar MRI even in other areas with high-susceptibility artifacts. DW-MRI was first applied to head
and neck lesions in 2001 and promising results have been achieved [3]. Subsequent studies showed that
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DW-MRI appeared to be helpful in differentiating epidermoid carcinoma and malignant lymphoma,
staging neck nodal disease, and distinguishing radiotherapy-induced tissue changes from persistent
or recurrent cancer. In these studies, apparent diffusion coefficient (ADC) values of tissues and lesions
are calculated using diffusion-weighted images and different values in the differential diagnosis.
Moreover, with the use of this imaging technique, the creation of an ADC map is an excellent method
for differentiation between the viable and necrotic parts of head and neck tumors. Thus, the ADC map
can be used to select the best biopsy site and to detect tumor viability in the post-treatment follow-up
of patients after radiation therapy. The technique may also be useful in characterizing thyroid nodules
and salivary gland neoplasms.
The purpose of this study was to evaluate the value of DW-MRI in differentiating benign and
malignant head and neck masses by comparing their ADC values.
2. Materials and Methods
This prospective study was performed on 43 consecutive patients who underwent MRI for a
diagnosis of head and neck lesions in our center. All patients were examined with contrast-enhanced
MRI and DW-MRI. The study was conducted in the Department of Otorhinolaryngology, Bakırköy Dr.
Sadi Konuk Training and Research Hospital, in the period of June 2009 to June 2010.
Institutional Ethics Committee approval was obtained for the study.
2.1. Subjects
A total of 11 patients were excluded from the study; four patients with neck masses <1 cm in the
greatest minimal transverse diameter, two who had undergone biopsy, three due to distortion artifacts,
and two with a final diagnosis of neck metastasis of a thyroid carcinoma.
Thus the final study population of 32 consecutive patients with neck masses >1 cm in diameter
consisted of 12 females (37.5%) and 20 males (62.5%) with a mean age of 45.13 ± 17.08 years (range,
9–78 years). All patients were questioned in detail about age, location, and duration of the mass,
associated symptoms, and then routine blood tests such as serological tests were applied. Within the
head and neck examination, diagnostic pan-endoscopy of the nasal cavity, nasopharynx, oropharynx,
hypopharynx, and larynx was also performed. All clinical evaluations were documented.
When patients had multiple neck masses with the same histological diagnosis, only the largest
one was used for calculation of ADC values. Thus, the diffusion-weighted images and ADC maps of
32 neck masses in 32 patients were studied.
Localization of the lesions was classified according to the lymph node regions and neck
facial spaces. The final diagnosis of the patients was made by histopathological examination of
surgical specimens. A diagnosis of tuberculosis lymphadenitis was made by histology and culture,
two undifferentiated nasopharyngeal carcinoma metastases by primary tumor biopsy and FNAB,
neck metastasis in five patients with NHL diagnosed by excisional lymph node biopsy, and one
adenocarcinoma metastasis by FNAB. A diagnosis of SCC metastasis was confirmed with neck
dissection. Diagnosis of carotid body paraganglioma in one patient was established with MR
angiography and DSA (digital subtraction angiography) before excision.
2.2. MR Imaging Techniques
All the MR examinations were performed with a 1.5 Tesla MR unit (Siemens Avanto, Erlangen,
Germany). Routine examination consisted of T2-weighted fast spin-echo images (with a section
thickness of 4 mm, an interslice gap of 1–2 mm, a field of view (FOV) of 25–30 cm and an acquisition
matrix of 256 × 224) and DW-MRIs. Before DW-MRI, T2-weighted images were obtained in the axial
plane. A total of 14 transverse images covering the lesions were obtained. DW-MRIs were obtained at
the section level where the largest transverse section of the lesion was detected on the MRIs which
were obtained before administration of contrast material. DW-MRI was obtained using multi-slice
spin-echo single-shot echo planar imaging in the axial plane. For each patient, diffusion-weighted
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images and ADC maps were obtained by applying diffusion-sensitive gradients in three orthogonal
directions (x, y, and z) and two different b-values (0 and 1000 s/mm2). ADC maps of the images were
automatically reconstructed on the main console. Then, the region of interest (ROI) was defined by a
radiologist measuring the signal intensity of the lesion. ROIs were determined on the solid appearing
parts for the solid masses and on the cystic areas for the cystic lesions. The ADC values of the lesions
were calculated with an ROI >1 cm2.
2.3. Statistical Analysis
Statistical analyses of the study data were performed using NCSS (Number Cruncher Statistical
System) 2007 and PASS (Power Analysis and Sample Size) 2008 Statistical Software (HyLown
Consulting LLC., Atlanta, GA, USA). The Student’s t-test was used to compare data between two
groups. Results were stated as the mean and standard deviation. Qualitative data were compared
using the chi-square test. The receiver operating characteristic (ROC) curve was applied to determine
the cut-off point with the highest accuracy and sensitivity. The value of p < 0.05 was considered
statistically significant at a 95% confidence level.
3. Results
This study was performed on 32 consecutive patients with head and neck masses who underwent
echo planar DW-MRI from June 2009 to June 2010. The patients consisted of 12 females (37.5%) and
20 males (62.5%) with a mean age of 45.13 ± 17.08 years (range, 9–78 years).
Malignant masses were determined in 15 (46.9%) cases and benign masses in 17 (53.1%).
The benign masses consisted of five pleomorphic adenoma originating from major salivary glands,
three reactive lymphadenopathies, two branchial cleft cysts, two cervical sympathetic chain
schwannomas, two Whartin’s tumors, one glomus tumor, one tbc lymphadenitis, and one thyroglossal
duct cyst. The malignant masses were five Non-Hodgkin’s lymphoma, three larynx SCC met., two
undifferentiated carcinoma met., two oropharynx SCC met., one GIS adeno ca met., one primary
unknown carcinoma met., and one tonsil SCC met. The diagnoses of the patients are listed in Table 1.
Of the total neck masses, the ADC value of cystic masses was the highest (1.98 × 10−3 mm2/s)
and that of lymphomas (0.80 × 10−3 mm2/s) was the lowest. The mean ADC values of benign and
malignant neck masses were 1.57 × 10−3 mm2/s and 0.90 × 10−3 mm2/s, respectively. The difference
between the mean ADC value of benign and malignant neck masses was statistically significant
(p < 0.01). The localizations of the masses are listed in Table 1. The numbers of malignant and benign
masses were 15 (46.9%) and 17 (53.1%), respectively. The mean ADC value of benign masses with
high signal intensity was statistically significantly higher than that of malignant masses with low
signal intensity (p < 0.01) (Table 2). Malignant masses were classified in two categories as malignant
lymphomas (33.3%) and carcinomas (66.7%, squamous cell carcinoma or adenocarcinoma). There was
no statistically significant difference between the two categories in the malignant group (p > 0.05)
(Table 2). When an ADC value of 1.13 × 10−3 mm2/s or less was used to predict malignancy, the best
results were achieved with high accuracy, with sensitivity of 93.33%, specificity of 82.35%, positive
predictive value of 82.35%, and a negative predictive value of 93.33% (Table 3).
The ROC curve was used to evaluate the diagnostic capability of the ADC value to differentiate
benign from malignant masses. When 1.13 × 10−3 mm2/s was used as a threshold value in
differentiating benign from malignant masses, the area under the curve was 0.918 (Table 4, Figure 1).
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Table 1. Diagnosis and localization of 32 head and neck masses.
Diagnosis n %
Pleomorphic adenoma 5 15.6
Reactive lymphadenitis 3 9.4
Branchial cleft cyst 2 6.3
Schwannoma 2 6.3
Whartin tumor 2 6.3
Glomus tumor 1 3.1
Tbc lymphadenitis 1 3.1
Thyroglossal duct cyst 1 3.1
Non-hodgkin’s lymphoma 5 15.6
Larynx SCC metastasis 3 9.4
Undifferentiated carcinoma metastasis 2 6.3
Oropharynx SCC metastasis 2 6.3
GIS adenocarcinoma metastasis 1 3.1
Primary unknown carcinoma met. 1 3.1
Tonsil SCC metastasis 1 3.1
Localizations n %
Anterior cervical 1 3.1
Superior lateral cervical 9 28.1
Middle lateral cervical 3 9.4
Posterior cervical 1 3.1
Sup-mid lateral cervical 2 6.3
Parapharyngeal area 3 9.4
Parotid area 7 21.9
Submandibular area 5 15.6
Supraclavicular area 1 3.1
Table 2. Pathological diagnosis and distribution of mean ADC values in the examined groups.
Pathology n % ADC (×10−3 mm2/s) Ave. ± SD. +p
Malignant 15 46.9 0.90 ± 0.17
0.001 **Benign 17 53.1 1.57 ± 0.42
Lymphoma 5 33.3 0.80 ± 0.14
0.100Carcinoma 10 66.7 0.96 ± 0.17
+ Student t test; ** p ≤ 0.001.
Table 3. Calculating the threshold value.
Value Sensitivity Specificity Positive Predictive Value Negative Predictive Value Accuracy Relative Risk
0.95 66.67 88.24 83.33 75.00 78.13 3.33
0.98 66.67 82.35 76.92 73.68 75.00 2.92
1.05 80.00 82.35 80.00 82.35 81.25 4.53
1.12 86.67 82.35 81.25 87.50 84.38 6.50
1.13 93.33 82.35 82.35 93.33 87.50 12.35
1.20 100.00 82.35 83.33 100.00 90.63 -
1.21 100.00 76.47 78.95 100.00 87.50 -
1.34 100.00 70.59 75.00 100.00 84.38 -
Table 4. Area under the curve (AUC).
Area under the Curve
Area Std. Error (a) p
95% Confidence Interval
Upper Lower
0.918 0.05 0.001 0.819 1.016
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Figure 1. Receiver operating characteristic (ROC) curve of the ADC value.
4. Discussion
Diffusion is defined as the randomized microscopic movement of water molecules and is used
as a sensitive parameter for the characterization of tissue at a microscopic level. Today, in vivo
measurement of diffusion is possible with DW-MRI and ADC measurements. As a result of new
technological developments, MRI has become sensitive to the diffusion of water protons in biological
tissues and diffusion-weighted imaging can be obtained. Intracellular and extracellular water balance
is also shown in a way that is important for diagnosis and follow-up of stroke. Initially, the use of
this technique was limited to brain studies because of technical problems regarding motion artifact
due to cardiac, respiratory, and peristaltic movements. However, following improvements in echo
planar imaging techniques, an echo planar DW-MRI can now be successfully performed even in areas
with high susceptibility artifacts [4]. This technique was first used in neuroradiological imaging for
diagnosis of early cerebral ischemia and has become a diagnostic tool in this area [1,5].
In 1994, Muller et al. measured the ADC of water in liver, spleen, kidney, and muscle and showed
that in vivo diffusion measurements of abdominal organs obtained with MRI could prove helpful
in the identification and classification of abdominal disease [6]. Subsequently, in several studies,
DW-MRI has been shown to be able to be used in the differential diagnosis of lesions in the liver,
kidney, and other abdominal organs with the measurement of ADCs [7,8].
In the literature, DW-MRI has also been seen to have an application area in the different regions
of the head and neck. The characterization of head and neck lesions with echo planar DW-MRI by
Wang et al. [3] was the first study in this area. They found that the mean ADC value of the benign
lesions was statistically significantly different than that of malignant lesions. In 2003, Sumi et al. [9]
studied the differential diagnosis of metastatic lymph nodes with diffusion-weighted MR imaging.
Over several years, further studies have been made in this area. In another study on neck lymph nodes,
ADC maps, as a new technique, have been used to determine the necrotic and non-necrotic solid
areas of malignant lesions [10]. Eida et al. [11] reported that preoperative tissue characterization of
salivary gland tumors could be made with ADC map construction. In another study, Abdel Razek et al.
reported that the mean ADC value of malignant thyroid nodules was statistically significantly lower
than that of benign ones [12]. The diffusion technique involves the diffusion motion of water protons in
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the tissues. According to the diffusion of tissue, the diffusion of water molecules varies in the different
regions of tissue. Therefore, the diffusion coefficient of the tissue varies depending on any change in
the proportion of extracellular to intracellular water molecules. Thus, diffusion-weighted MR imaging
produces different contrast and ADC values according to the microstructure of the tissues [3].
In the current study, the mean ADC value of benign masses with high signal intensity was
significantly (Figure 2) higher than that of malignant (Figure 3) masses with low signal intensity. These
differences in ADC values may be explained by the differences in the histopathological characteristics of
benign and malignant tumors. Generally, malignant tumors show hypercellularity and have enlarged
nuclei, and hyperchromatism. These histopathological characteristics reduce the diffusion space of
water protons in the extracellular and intracellular regions [13,14].
 
Figure 2. Pleomorphic adenoma of the parotid gland. (a) Axial T2-weighted image (T2WI) shows a
mass in the left parotid gland; (b) the lesion shows low signal intensity on DWI; and (c) the mass is
hyperintense on the ADC map (ADC value of 1.55 × 10−3 mm2/s).
 
Figure 3. Undifferentiated nasopharyngeal carcinoma. (a) Axial T2WI shows bilateral metastatic
cervical lymph nodes; (b) lymph node, on the left side of the neck, shows high signal intensity on DWI;
and (c) the mass is hypointense on the ADC map (ADC value of 0.91 × 10−3 mm2/s).
Apparently higher ADC values for benign cystic masses may be expected because of the relatively
freer mobility of water protons in the fluid. In the current study, cystic masses were not grouped
separately due to low numbers. However, consistent with previous studies, the mean ADC value of
three cystic masses (Figure 4) (1.98 × 10−3 mm2/s) was higher than that of other benign solid masses
(ADC = 1.48 × 10−3 mm2/s). In addition, the differences in ADC values among cystic masses could be
explained by the different protein concentrations. A high protein level restricts the movement of water
molecules by increasing the viscosity [15].
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Figure 4. Second branchial cleft cyst. (a) Axial T2WI shows a unilocular cystic mass in the left carotid
space; (b) the lesion shows low signal intensity on DWI; and (c) the lesion is hyperintense on the ADC
map (ADC value of 2.02 × 10−3 mm2/s).
Sumi et al. [16] reported that the mean ADC value of lymphomas is lower than that of metastatic
lymph nodes of carcinomas due to the difference in cellular density. Maeda et al. [17] also reported
that carcinomas could contain small foci of necrosis on histopathological examination that was not
identifiable on conventional MRI. This investigation has also been used to explain the higher ADC
values of SCCs than those of lymphomas. In the current study, although there was no statistically
significant difference, the mean ADC value of lymphomas (Figure 5) (0.80 × 10−3 mm2/s) was lower
than that of the other malignant tumors (0.96 × 10−3 mm2/s). In the malignant group, larynx SCC
metastasis with the value of 1.15 × 10−3 mm2/s showed the highest values.
 
Figure 5. Non-Hodgkin lymphoma. (a) Axial T2WI shows metastatic cervical lymph node nearby SCM;
(b) the lymph node, on the right side of the neck at level of lateral cervical region, shows high signal
intensity on DWI; and (c) the mass is hypointense on the ADC map (ADC value of 0.62 × 10−3 mm2/s).
One of the considerations that must be taken into account when using diffusion-weighted MRI
for the differential diagnosis of masses is the recognition of the fact that some malignant masses
behave like a benign tumor independently of the ‘cut-off’ ADC value obtained at the end of the study.
These masses are some primary or metastatic SCC and thyroid carcinoma metastases [3]. In the current
study, a case with diagnosis of larynx SCC metastasis in the ADC value of 1.20 × 10−3 mm2/s showed
the feature of a benign tumor. The reason that the high ADC values are non-standardized might be
the presence of small foci of micronecrosis and the hypervascular tumor portions that escalate the
perfusion effect in some malignant tumors and of dense extracellular fluid in follicular components in
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thyroid carcinomas [3]. Considering this situation, the macroscopic solid portions were determined
using MRI observations and the ADC measurements were made, and the cases with neck masses
of thyroid origin were excluded from the study. Although DW-MRI is more reliable than that of
other MR imaging techniques to identify micronecrosis of primary or metastatic tumors, [18–20] the
differentiation between the viable and necrotic parts of head and neck tumors with DW-MRI by
reconstructing ADC maps is possible for accurate biopsy results [21]. In addition, DW-MRI with
ADC measurement may be used for differentiating residual or recurrent head and neck tumors from
postoperative or postradiation changes [22].
With concern for inaccurate ADC measurements in small lesions according to the susceptibility
artifacts and image distortions as a limitation of this imaging technique, neck masses <1 cm in the
greatest minimal transverse diameter on MRI were excluded from the study. In a study by Chen et al.,
performed to compare periodically rotated overlapping parallel lines with enhanced reconstruction
(PROPELLER) DW-MRI and echo planar DW-MRI techniques, it was suggested that it was possible
to reduce the distortion of head and neck masses through PROPELLER diffusion-weighted MRI to a
large extent [23].
One of the limitations of the current study was the area of necrosis that showed falsely higher
ADC values, especially in the center of metastatic neck masses [10]. Therefore, ADC values were
measured by selecting the solid portions of tumors.
In the study, three masses in the benign group indicated lower ADC values than the cut-off
value in accordance with the malignant mass. In one of these masses, which was tuberculous
lymphadenopathy (ADC = 0.92 × 10−3 mm2/s); restriction of diffusion could be explained by the
presence of inflammatory cells in the pus that reduced the diffusion space of water protons [24].
In another study, this situation was explained by the thickness of the caseous material of granulomatous
lesions [25]. Whartin tumor (ADC = 0.88 × 10−3 mm2/s) was the other case that was falsely diagnosed
as a malignant tumor (Figure 6). Intense lymphoid accumulation in the stroma and proliferation
of the epithelial component could be the reason for the limited motion of the water protons in the
extracellular space [3]. Reactive lymphadenitis was the third case. A varying amount of fibrosis in the
stroma of inflammatory cells could have resulted in the low ADC value by restriction of the diffusion
of water molecules [3].
 
Figure 6. Warthin tumor. (a) Axial T2WI showing the mass localised in the superficial lobe and
spreading into the deep lobe of the left parotid gland; (b) the lesion shows high signal intensity on
DWI; and (c) the lesion is hypointense on the ADC map (ADC value of 0.88 × 10−3 mm2/s) and the
tumor was falsely diagnosed as a malignant lesion.
In the current study, in cases with malignant diseases, the mass appeared hyperintense on
diffusion images (obtained at b = 1000 s/mm2) and with low signal intensity on ADC maps and,
conversely, benign masses appeared hypointense and hyperintense, respectively. There was a
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statistically significant difference in ADC values between the malignant masses and benign lesions
(p < 0.01). When an ADC value of 1.13 × 10−3 mm2/s or less was used to predict malignancy, the best
results were achieved with high accuracy, with 93.33% sensitivity, 82.35% specificity, 82.35% positive
predictive value, and 93.33% negative predictive value.
In this study, the patient groups were heterogeneous with different histopathological entities and
there was a limited number of cases in each benign or malignant group. Further investigations of a
larger series with a specific group of the same pathological diagnosis are necessary.
5. Conclusions
In summary, DW-MRI seems to be a promising non-invasive imaging technique for
characterization of head and neck masses or for any other subjects as discussed above. It can be
concluded that further studies on larger series and advances of diffusion MR techniques to improve
the image quality would help DW-MRI to become a routine imaging technique.
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Abstract: Purpose: to present the mid-term results of canaloplasty in a small cohort of
corticosteroid glaucoma patients. Material and Methods: Nine eyes from seven patients with
various types of corticosteroid glaucoma in maximum medical therapy underwent canaloplasty.
Patients underwent complete ophthalmic examination every six months. Success was defined as:
post-operative intraocular pressure (IOP) ≤ 21 mmHg and ≤ 16 mmHg without (“complete success”),
and with/without medical treatment (“qualified success”). The IOP reduction had to be ≥ 20.
The number of medications before and after surgery was considered. The follow-up mean
period was 32.7 ± 20.8 months (range 14–72 months). Results: The pre-operative mean IOP was
30.7 ± 7.2 mmHg (range: 24–45). The mean IOP at 6 and 12-month follow-up was 13.1 ± 2.6 mmHg,
and 13.7 ± 1.9 mmHg, respectively. Qualified and complete success at 6 and 12 months was 100% for
both of the two definitions. The number of medications used preoperatively and at the 12-month
follow-up was 4.3 ± 0.7, and 0.2 ± 1.0, respectively. No serious complication was observed.
Conclusions: The mid-term results of canaloplasty in patients with corticosteroid-induced glaucoma
appear to be very promising. Canaloplasty should be considered as a possible alternative to filtering
surgery in this form of glaucoma, when medical therapy is not sufficient to maintain the IOP within
reasonable limits.
Keywords: canaloplasty; non-perforating surgical procedures; corticosteroid-induced glaucoma;
Schlemm’s canal
1. Introduction
Corticosteroid-induced glaucoma is a quite common form of secondary glaucoma due to
either systemic or, more frequently, topical, peri- or intraocular administration of glucocorticoids
in predisposed subjects [1–5]. It is known that corticosteroids raise intraocular pressure (IOP) by
lowering the facility of aqueous outflow. Quite a high percentage of normal subjects (ranging
from 5% to over 40% depending on the definition of corticosteroid-responders [6,7] may undergo
a significant increase of IOP after using topical corticosteroids for several days. The increasing use
of intravitreal injections of triamcinolone acetonide and intravitreal implants of dexamethasone for
exudative maculopathies will probably exacerbate this problem. A secondary glaucoma can develop
in some cases, even though for most patients the IOP returns to baseline after ceasing steroid use.
If traditional medical therapy is not able to lower IOP within the safe range, structural and functional
damage can quickly develop. In these cases, a laser trabeculoplasty can be attended [8–10], but more
often a surgical treatment must be performed before serious visual impairment occurs. Trabeculectomy
with intra-operative antimetabolites is still considered to be the gold standard surgical procedure for
different types of glaucoma, including corticosteroid-induced glaucoma [11,12]. This technique is
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simple to perform and effective, however, several early and late potentially serious complications can
occur. In particular, problems related to the subconjunctival bleb, and the frequent development of
a cataract can be particularly disturbing in young patients, who are often the subjects that develop
corticosteroid-induced glaucoma.
Canaloplasty is a non-perforating bleb-less technique, introduced some years ago, in which
a 10-0 prolene suture is positioned and tensioned within Schlemm’s canal, previously dilated with
a viscoelastic agent, thus facilitating aqueous outflow through natural pathways [13,14].
The purpose of this study is to present the mid-term results of canaloplasty in a small cohort of
patients with corticosteroid-induced glaucoma resistant to medical management.
2. Experimental Section
In this non-randomized prospective study, 9 eyes from 7 patients with uncontrolled
corticosteroid-induced glaucoma under maximum tolerated medical therapy underwent canaloplasty
under peribulbar anesthesia. Surgery was performed either at the Department of Ophthalmology at
the Azienda Ospedaliero-Universitaria “Santa Maria della Misericordia” Hospital in Udine (Italy),
or at the “Città di Udine” Health Center in Udine (Italy) by one surgeon (PB), with a 10-year experience
with this type of surgery, from February 2008 to July 2016.
All patients provided written informed consent. The protocol was approved by the institutional
review board or ethics committee.
Inclusion criteria included: (1) patients with ocular hypertension due to corticosteroid use;
(2) IOP ≥ 24 mmHg with maximum tolerated medical therapy after stopping corticosteroid use (in the
case of topical administration); (3) open irido-corneal angle; (4) age over 18 years. Patients with
or without typical optic nerve alterations, and with or without glaucomatous visual field defects
were considered.
Exclusion criteria included: (1) elapsed time after steroids stopping shorter than 3 months;
(2) age under 18 years; (3) other possible causes of glaucoma (i.e., pseudoesfoliation, previous trauma,
etc.); (4) previous ocular surgery, apart from cataract and intravitreal injections; (5) refusal to
undergo surgery.
The patients’ demographic data, causes of secondary glaucoma, preoperative IOP, number of
drugs used, visual functions and length of the follow-up at the last visit and other clinical data are
reported in Table 1.
Table 1. Patient data before surgery.










1 M 49 Dex IV CRVO 38 4 6/10 NA 31
2 M 45 Triam IV EM 30 6 3/10 NA 16
3 M 48 Dex drops AC 26 4 8/10 1 72
4 M 48 Dex drops AC 24 4 9/10 1 60
5 F 18 Dex drops AC 28 4 10/10 1 18
6 F 18 Dex drops AC 30 4 10/10 1 23
7 M 69 Dex IV CRVO 28 4 5/10 5 14
8 F 69 Dex IV EM 45 5 2/0 0 19
9 M 34 Dex drops PK 25 4 CF NA 41
Mean (±SD) 44.2 ± 10.6 30.4 ± 6.8 4.3 ± 0.7 32.7 ± 20.9
OHT = ocular hypertension; Pre-op IOP = preoperative intraocular pressure; Dex IV CRVO = Intravitreal
dexametason for central retinal vein occlusion; Triam IV EM = Triamcinolone acetonide for exudative maculopathy;
Dex drops AC = dexametason drops for allergic conjunctivitis; Dex drops PK = dexametason drops after perforating
keratoplasty; VA = visual acuity; VF = visual field; GSS 2 = Glaucoma Staging System 2; NA = not applicable;
CF = counting fingers; SD = standard deviation.
The canaloplasty surgical technique is well known and has been extensively reported in the
literature [15–19]. Briefly, surgery starts with a fornix-based conjunctival flap, and a 3 × 4 mm
superficial scleral flap, which is dissected forward into the clear cornea for 1.5 mm. A deep scleral
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flap is then created, in order to open the Schlemm’s canal. The deep scleral flap is removed and
the two openings of the canal are dilated with hyaluronic acid in order to cannulate the Schlemm’s
canal, by means of a special microcatheter (iTrack by iScience Interventional, Menlo Park, CA, USA),
connected to a flickering red laser light source for easy identification of the distal tip through the sclera.
The microcatheter is inserted and pushed forward within Schlemm’s canal for the entire 360◦ until it
comes out of the other end of the canal opening. A 10-0, prolene suture is then tied to the distal tip and
the microcatheter is withdrawn back through the canal in the opposite direction. During this maneuver,
a small amount of high-molecular weight viscoelastic agent (Healon GV, Abbot Medical Optics,
Santa Ana, CA, USA) is delivered within the canal every two hours of circumference, using a special
screw-driven syringe. The suture is then knotted under tension in order to inwardly distend the
trabecular meshwork. The superficial scleral flap is sutured with seven 10-0 Polyglactin 910 stitches
to ensure a watertight closure in order to prevent any bleb formation. The conjunctival flap is then
sutured with two 10-0 sutures to complete the surgery.
All patients underwent a visit once a week for the first month in order to measure IOP and
detect any possible postoperative complication, then went on to have a complete ophthalmic
examination every six months, including slit-lamp examination, best corrected visual acuity (BCVA),
IOP measurement with Goldmann applanation tonometer, fundus examination with a 78 D Volk
lens, visual field testing (Humphrey Field Analyzer (Carl Zeiss Meditec Inc. Dublin, CA, USA) 30-2
SITA standard test), retinal nerve fiber layer assessment with spectral-domain OCT and gonioscopy.
Moreover, the corneal astigmatism was measured after one week and one month by means of
a keratometer of Javal and corneal topography. Visual field damage severity was assessed using
the Glaucoma Staging System 2 (P. Brusini, Italy) [20]. The definition of success was based on two
different criteria: post-operative IOP ≤ 21 mmHg and ≤ 16 mmHg. When this goal was obtained
without any medical treatment, the success was defined as “complete”. When the same IOP levels were
obtained with or without medical treatment, the success was defined as “qualified”. Moreover, the IOP
reduction had to be ≥20% for defining a case as successful. The number of medications before and
after canaloplasty was also taken into consideration.
Differences between test results were calculated using the paired t-test for variables that showed
a normal distribution. The statistical analysis was performed using SPSS 11.0 (IBM Analytics, Chicago,
IL, USA). Statistical significance was defined as p < 0.05.
3. Results
The entire standard procedure could be performed as planned in all of the nine eyes. Follow-up
ranged from 14 to 72 months (mean: 32.7 ± 20.8). The mean pre-operative IOP was 30.4 ± 6.8 mmHg,
ranging from 24 to 45 mmHg. The mean IOP after 6 and 12 months was 13.1 ± 2.6 mmHg,
and 13.7 ± 1.9 mmHg, respectively, ranging 11 to 18 mmHg (paired t-test, p = 0.0001). The mean
IOP reduction from baseline after 6 and 12 months was of 56.9% and 54.9%, respectively. The IOP
values at various follow-up sessions within a period of 36 months are shown in Table 2. The scatter
plot in Figure 1 shows the pre- and one-year post-operative IOP values. After the 6 and 12-month
follow-up, a complete and qualified success, was obtained in all 9 eyes, using both the definitions
of success (IOP ≤ 21 mmHg and ≤ 16 mmHg), with an IOP within normal limits during the entire
follow-up period, except for one eye that showed an increase of IOP after two years, successfully
controlled with medical therapy. The number of medications used pre- and at the 12-month follow-up
was 4.3 ± 0.7, and 0.2 ± 1.0, respectively (difference statistically significant, p < 0.001). Only one
patient (11%) was under IOP-lowering drops after one year, but medical treatment was needed in
both the two patients which reached a five-year follow-up. No patient required adjunctive surgical
procedures. Gonioscopy showed that the prolene suture remained correctly positioned within the
Schlemm’s canal for the entire follow-up period in all cases. At the last visit, visual acuity worsened of
two lines in two eyes (case #1 and case #2), depending on retina conditions, and improved of three
lines in one eye (case #7) due to the effects of corticosteroid treatment. A reliable visual field testing
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was not possible in three eyes due either to a poor visual acuity (case #9) or to artifacts related to retinal
disease (case #1 and #2). Before surgery, visual field was normal in one case (#5), showed only slight
defects in four cases, whereas only small islands of vision were present in another case (#9). All of
these defects remained stable over time. Optic nerve appearance (normal in all eyes but one) and
retinal nerve fiber layer did not show any significant change during the follow-up period.
Table 2. Mean post-operative intraocular pressure (IOP).
Time Point IOP, Mean ± SD (mmHg) No. of Eyes
Preoperative 30.4 ± 6.8 9
1 month 12.6 ± 1.9 * 9
6 month 13.2 ± 2.6 * 9
12 month 13.7 ± 1.9 * 9
24 month 16.8 ± 6.3 * 5
30 month 15.7 ± 2.5 * 4
36 month 15.7 ± 2.3 * 3
42 month 15.5 ± 2.1 * 2
48 month 17.0 ± 4.2 * 2
54 month 16.0 ± 1.4 * 2
60 month 14.5 ± 0.7 * 2
* p < 0.0001 vs. preoperative values.
 
Figure 1. Pre- and one-year post-operative IOP values.
The early post-operative complications (within four weeks from surgery) included: microhyphema
in two eyes (22.2%); hypotonus (IOP < 5 mm/Hg) in one eye (11.1%); and, IOP spikes > 10 mmHg in
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one case (11.1%). A transient decrease in visual acuity in the first weeks after canaloplasty was a rather
common finding, which was due to an induced according to-the-rule astigmatism which can reach five
diopters, but usually disappear within one month. No surgery-related complications were observed
after two months.
4. Discussion
Surgery is sometimes needed to control ocular hypertension and delay damage progression
in patients with corticosteroid-induced glaucoma, especially considering that visual field defect
progression can be fast and severe if IOP is very high. However, unlike from patients with primary
open-angle glaucoma or pseudoesfoliation glaucoma, which often show advanced visual field loss,
patients with corticosteroid-induced glaucoma usually have normal optic nerves and visual fields
at the beginning. For this reason, an IOP in the mid-teens is usually adequate in order to avoid any
structural and/or functional damage. In this type of patient, even with very high pre-operative IOP
levels, non-filtering surgical procedures, such as goniotomy [21], trabeculotomy [22–25], trabecular
stents [26], viscocanalostomy [27] or deep sclerectomy [28] may be an interesting option, even if they
are less effective than trabeculectomy in lowering IOP, considering the lower risk of complications.
Nowadays, canaloplasty should be considered as a step ahead of these procedures with very interesting
long-term outcomes in various forms of open-angle glaucoma [15–19].
Our mid-term results in a small cohort of patients with corticosteroid-induced glaucoma
unresponsive to medical therapy appear to be particularly good in comparison with other types
of glaucoma, where the mean IOP usually ranges between 15 and 17 mmHg, with a percentage
of success after one year ranging between 60% and 95%, depending on the definition of success
used [14–19]. In particular, if a cut-off of ≤ 16 mmHg is taken in order to define successful cases,
the percentage of qualified success reported in literature is about 50% in comparison with the 100%
obtained in our nine cases.
The reasons for this favorable behavior are probably various and include: (1) histopatologic
studies in corticosteroid-induced glaucoma demonstrated an increased density of the cribriform
meshwork and thinning of the endothelial lining of Schlemm’s canal [29,30]; in cases of elevated IOP,
a collapse of aqueous plexus and collector channel ostia obstructed by herniation was observed in
bovine eyes [31], resulting in a decrease in the effective filtration area. Canaloplasty is able to overcome
this obstacle, allowing the restoration of the aqueous humor outflow; (2) patients with this type of
glaucoma are usually relatively young with well-functioning aqueous humor pathways, which is
a fundamental requirement to obtain satisfactory results after canaloplasty; (3) all of our patients were
under medical therapy for a short period before the operation; it is well known that topical therapy for
glaucoma has negative effects in all glaucoma surgeries.
It should be noted, however, that the percentage of patients which require a pharmacological
therapy, even at a lower dosage, to maintain adequate IOP control seems to increase with time.
Even if the results we obtained are very promising, it should be remembered that this was
a non-randomized study with a small sample of patients without a control group. Another limitation
of our study is that both eyes of two patients have been considered. Even if this could be incorrect from
a statistical point of view, considering the small number of patients treated, we decided to describe all
cases we treated with this surgical procedure. The study is currently still underway. New patients
with corticosteroid-induced glaucoma that fit the inclusion criteria are being added and follow-up data
of existing patients are being constantly updated to provide long term results and a larger cohort for
our future study. Regarding these patients, multicentric randomized studies with a larger population,
where canaloplasty is compared to gold standard surgery (trabeculectomy), are needed to draw more
definite and robust conclusions.
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5. Conclusions
Canaloplasty is a very promising surgical technique in eyes with high IOP, which is usually the
case in patients with corticosteroid-induced glaucoma. In our small cohort of patients, postoperative
IOP was able to be maintained within physiological values, even if some medical therapy is occasionally
still required. Considering that ocular hypertension is the main risk factor for structural and functional
damage in corticosteroid-induced glaucoma, target IOP may not need to be very low to avoid the onset
or the progression of the damage. Even if the sample taken into consideration in our study was limited,
the good outcomes and the low rate of complications observed with this non-perforating procedure
are very encouraging and could entice glaucoma specialists to consider early surgical treatment in the
management of this kind of patient.
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Abstract: The influence of genes and the environment on the development of Post-Traumatic Stress
Disorder (PTSD) continues to motivate neuropsychological research, with one consistent focus
being the Brain-Derived Neurotrophic Factor (BDNF) gene, given its impact on the integrity of the
hippocampal memory system. Research into human navigation also considers the BDNF gene in
relation to hippocampal dependent spatial processing. This speculative paper brings together trauma
and spatial processing for the first time and presents exploratory research into their interactions
with BDNF. We propose that quantifying the impact of BDNF on trauma and spatial processing is
critical and may well explain individual differences in clinical trauma treatment outcomes and in
navigation performance. Research has already shown that the BDNF gene influences PTSD severity
and prevalence as well as navigation behaviour. However, more data are required to demonstrate
the precise hippocampal dependent processing mechanisms behind these influences in different
populations and environmental conditions. This paper provides insight from recent studies and
calls for further research into the relationship between allocentric processing, trauma processing
and BDNF. We argue that research into these neural mechanisms could transform PTSD clinical
practice and professional support for individuals in trauma-exposing occupations such as emergency
response, law enforcement and the military.
Keywords: BDNF; Brain-Derived Neurotrophic Factor; navigation; spatial processing; trauma;
trauma processing; Post-Traumatic Stress Disorder; PSTD; allocentric; hippocampus
1. Introduction
Post-Traumatic Stress Disorder (PTSD) is an increasingly visible mental health issue that
represents a considerable public health burden [1] across many civilian and professional populations.
With mounting pressure on health, military and emergency response sectors (https://www.pdtrust.
org/help/research/post-traumatic-stress/) to look after the psychological wellbeing of their staff
in the face of unprecedented demand from major incidents and resource deficits, understanding
PTSD has perhaps never been so critical. Fortuitously, neuropsychological research over recent
years has also moved at a commensurate pace and in this paper, we seize the opportunity to
reflect on the progress (and pitfalls) of that research. We review recent literature, present findings
from exploratory research (provided in more detail in the Appendix A) and highlight design
issues which may be key to understanding how genetic and environmental conditions interact to
influence PTSD vulnerability, etiology and recovery. To do this, we look at another area of cognitive
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function—navigation—which may provide us with vital information about the resilience of a specific
part of our brain (the hippocampus) on which we rely to process trauma exposure [2–6].
2. The Neural Basis of Post-Traumatic Stress Disorder (PTSD)
Contemporary theories of PTSD which have been developed from cognitive theories and clinical
research [2–9] describe PTSD in the context of information processing. A predominant theory is
that of dual representation [2,4,6–8]. Dual Representation Theory describes how trauma processing
operates with two types of memory representations in the limbic system: those which are associative
and those which are contextual [8]. Associative representations of trauma are typically involuntary,
fear-based, and originate in the amygdala. Contextual representations, in contrast, are retrieved
voluntarily and mediated by the hippocampus [10,11]. According to Dual Representation Theory,
effective trauma processing involves applying context to the sensory and evocative experiences
of trauma to consolidate them into long term memory and file them as “past”. Trauma literature
often refers to egocentric, associatively conditioned responses to stimuli as being typical in cases of
post-traumatic stress, and these responses can be described by a signature symptom of PTSD, the
“flashback” [9–13]. Hippocampal representations, on the other hand, provide episodic and spatial
context for extreme experiences, which enables individuals to make sense of when and where traumatic
incidents occurred [14–18]. However, when the hippocampus is down-regulated (e.g., by trauma or
stress) it is less able to contextualise or anchor traumatic experiences in space and time, allowing them
to intrude in the present, thus prolonging the stress response [4,19–24].
3. Brain-Derived Neurotrophic Factor (BDNF)
Stressful or traumatic incidents in the environment are not the only causes of down-regulation
in the hippocampus; genetics also has a substantial impact [1,5,24–30]. Identifying genes which are
relevant to the development of PTSD has been a relentless motivator for numerous genome-wide
association studies, twin studies and candidate gene studies [1,5]. A recent review [31] identified
25 such studies, many of which highlighted the specific role of a gene called Brain-Derived
Neurotrophic Factor (BDNF). BDNF is expressed in the limbic system, moderating fear responses and
broadly regulating the stress response [5,20,22,23,30–32]. It is also expressed outside the limbic system,
such as in the retina, kidneys and prostate [33], and has been considered integral to critical periods
of human development [34]. The BDNF gene codes for the BDNF protein which is then expressed
to promote the growth and survival of neurons, particularly those in the hippocampus [26,31,35].
BDNF-related neuroplasticity is considered an important component in maintaining the integrity of
the hippocampus [5,25,34,35].
However, this operation is complicated by the fact that the BDNF gene has two variants, derived
from carrying “met” and “val” alleles, which differ in their functionality [5,15,18,20,24,25,29,31,32,35].
At a genetic level, allelic variation occurs at codon 66 on chromosome 11, resulting in an amino acid
switch from valine (val) to methionine (met) and producing a val66met polymorphism which is unique
to humans [18,31,35,36]. In the Caucasian population, 30% carry the met allele, either as the metmet
homozygotes or valmet heterozygotes [35]. Typically, met carriers show less activity-dependent release
of the BDNF protein in the hippocampus than val homozygotes [5,24,25,29,35]. This means that
in met carriers (rather than val homozygotes) sufficient BDNF protein may not be released into the
hippocampus for it to respond appropriately to the demands that the environment may place on it, such
as the demand for consolidating traumatic experiences into long term memory [20,22,26,30–32,37,38].
Given the compounding effect of the BDNF polymorphism on hippocampal function, we would
anticipate that post-traumatic stress would be more prevalent and severe in met carriers, if other
environmental conditions have been controlled for. This appears to be borne out by Zhang et al.’s
(2014) finding that PTSD was more prevalent and severe in met allele carriers [32]. Specifically, the
study revealed that the allelic frequency of BDNF met was twofold higher in those with probable PTSD.
In support of this finding, it has recently been proposed that sufficient BDNF release may be involved
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in helping to prevent PTSD because its operation induces fear extinction and ensures successful trauma
processing [5,20,22,30–32,37,38].
It is worth noting from BDNF and PTSD studies [32] the importance of controlling for
environmental conditions. Indeed, a failure to consider the demand on the hippocampus that different
environmental conditions can present may account for mixed findings to date in studies relating BDNF
to PTSD [1,31,32,36]. Nonetheless, in 2014, Zhang and colleagues [32] successfully controlled for these
conditions and reported a direct relationship between the BNDF gene and PTSD in a population of
U.S. military Special Operations personnel.
4. Hippocampal Function, Navigation and BDNF
Next, we consider how navigation can be used to assay hippocampal function [10,11,39–41].
Our situational awareness and our ability to orient ourselves and navigate our way through the world
rely on two forms of mental representations, those that are hippocampal independent (egocentric
representations) and those that are hippocampal dependent (allocentric, see Figure 1).
(i) Egocentric processing is viewpoint dependent and associative, relying on local landmarks in
line of sight. This form of processing is not dependent on hippocampal processing: egocentric
spatial memory representations are independent of the hippocampus, relying on the striatal
circuit, whereas allocentric representations are thought to rely heavily on the hippocampal
circuit [2,6,8,10,11,39].
(ii) Allocentric processing enables individuals to construct a viewer-independent representation of
the relationship between objects /landmarks/ places in an environment. A spatial “map” [11] is
created in which key landmarks are represented in relation to one another rather than in relation
to the viewer. This form of representation is particularly important in route planning and is
vital for contextualising information during navigation [10,11,28,29]. Allocentric processing, in
contrast to egocentric processing, relies heavily on the hippocampal circuit [10,11,39].
(a) (b) 
Figure 1. (a) Egocentric processing and (b) allocentric processing of spatial relationships.
So, given that the hippocampus facilitates (allocentric) spatial processing, individuals’ navigation
skills depend on effective hippocampal function and can therefore act as an index of hippocampal
integrity [5,6,8,10,23,41]. There have been very few studies examining the effects of BDNF on
navigation. However, there is evidence in recent neuropsychological literature for a relationship
between the BDNF gene and hippocampal dependent (allocentric) spatial processing. A study from
2011 by Banner et al. [29] provides supportive evidence that met-carrying BDNF genotypes rely more
on hippocampal independent (egocentric) spatial processing to complete a navigation task than valval
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homozygotes (see also Lövdén et al., 2011, for a similar proposal based on a study with a much smaller
sample) [28]. To demonstrate this, Banner et al. assessed participants’ spontaneous strategy use in
a virtual maze. A higher proportion of BDNF metmet homozygotes spontaneously used egocentric
strategies in comparison to valval homozygotes, whereas a higher proportion of valval homozygotes
spontaneously used allocentric strategies. Both studies [28,29] made an explicit connection between
less BDNF release in met carriers, lack of hippocampal engagement in spatial tasks and a bias toward
implicit, associative spatial processing. In short, BDNF met carriers are generally considered to be more
likely to engage in egocentric processing (which does not rely on the hippocampus) in comparison to
valval homozygotes (see also [5,15,28,29,40]), who have greater access to effective allocentric processing
via the hippocampus.
5. Bringing Together Allocentric Spatial Processing, the BDNF Gene and PTSD
This focused literature review shows that the relationship between BDNF and hippocampal
dependent processing and trauma is complicated, as illustrated in Figure 2.
Figure 2. The relationship between Brain-Derived Neurotrophic Factor (BDNF) genotype,
Post-Traumatic Stress Disorder (PTSD), hippocampal processing, and navigation skills (represented
by the anchor). BDNF genotype influences activity-dependent release of the BDNF protein used in
hippocampal processing of traumatic and spatial information, potentially placing some genotypes at a
disadvantage for trauma resilience and navigation competence.
With regard to trauma processing, severity and prevalence of PTSD is positively related to carrying
the BDNF met allele [5,20,30–32,36–38]. With regard to spatial processing, there is evidence of an
egocentric bias in BDNF met carriers but no clear differences in allocentric performance between BDNF
genotypes were reported in either study [28,29]. Interestingly, egocentric bias in navigation strategy use
and allocentric performance deficits have also been recently demonstrated in cases of PTSD (and trauma
exposure) [2,3,6,8,40]. Neuropsychology has yet to bring these findings about BDNF, hippocampal
dependent processing and trauma (or PTSD) together into one human experiment. A rodent model
in 2007 [41] went so far as to demonstrate impaired spatial learning in the Morris Water Maze and
significantly reduced extinction of conditioned fear in BDNF “knockout” rats. Although based on
deleting rodent genes rather than genotyping human populations, this cross-discipline study stresses
the possibility that cognitive spatial processing deficits and impairment in managing trauma exposure
may be directly related to BDNF gene expression in the hippocampus.
In 2012, we sought to investigate how spatial processing impairment and trauma exposure
processing may be related to BDNF genotypes in an exploratory extension of a human study (n = 150)
which assessed the impact of PTSD on navigation [6,40]. Full details of and data from the exploratory study
are provided in the Appendix A. Our intention was to determine if any bias in BDNF met carriers toward
hippocampal independent spatial processing:
(a) was evident in the virtual environment navigation task being used in the main study [6,28,29,40],
(b) remained, when controlling for hippocampal down-regulation from PTSD [2–4,6,8,40–42], and/or
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(c) correlated with subjective measures of self-reported navigation competence [43–45].
In summary, in the diverse sample (n = 150) of civilian, police and military populations, PTSD
severity and prevalence were similar across BDNF groups. In the sample population, 57 participants
had probable levels of PTSD and of those without probable PTSD, 60 were trauma exposed and 33 were
not. Participants’ navigation performance was assessed using the Alternative Route paradigm [6,10,46].
When graphed (see Figure A1 in the Appendix A), the data showed a distinctly divergent pattern of
egocentric performance between BDNF valval homozygotes and met carriers, resulting in significantly
higher egocentric performance in met carriers at the end of the navigation task, echoing interpretations
of egocentric bias in met carriers in the previous studies [28,29]. Using self-report navigation
questionnaires (specific questions from which had been shown to “predict” allocentric spatial
processing in earlier studies [43–45]), we were also able to show for the first time that only BDNF
valval homozygotes (not met carriers) were accurate in judging their own competence at allocentric
spatial processing (see Table A1 in the Appendix A). Overall, our exploratory data were indicative
of BDNF-related differences in hippocampal dependent and independent navigation behaviour,
irrespective of PTSD. While interesting, it is important to note that these findings were limited by
several design features. These limitations provide valuable insights for further research, and it is to
those insights that we now turn.
6. The Future of BDNF Research
For candidate gene (BDNF) research to shape the future of clinical trauma interventions or to
influence professional practices in occupations requiring situational awareness, studies need to be
able to deliver accurate and ecologically relevant data [1,3,47,48]. Our exploratory research [40]
into the relationship between BDNF, PTSD and spatial processing was limited by several factors.
If these factors could be addressed in replication studies, significant progress in our understanding of
gene × environment interactions in trauma and navigation could be imminent. Here, we briefly critique
the design limitations of recent studies (including our own) and offer suggestions for improving
data quality in key areas: experimental groups, performance measurement, subjective measures of
navigation, and collection of further neurological data.
Sample populations for BDNF studies can be a contentious issue, with some traditional academic
disciplines [30] typically favouring large cohorts (of thousands) and genome-wide association studies
over the much smaller designs and sample sizes seen in candidate gene studies [1,36,42,47,48].
While some candidate gene study sample sizes have simply been too small (n < 20) to adequately
represent the three BDNF genotypes (see [1,28,46]), other moderate samples (n > 100) (see [24,26,29,32])
have been able to demonstrate the influence of the gene on PTSD when other environmental conditions
within and between experimental groups have been adequately controlled. This was a lesson learnt by
Zhang et al. in 2014 [32], in their replication of an earlier study from 2006 [42] which did not control for
trauma exposure type or severity, time since exposure or treatment status. Another important factor
to control for in studies of hippocampal function is age [2,5,6,10,25,46]. A primary recommendation
is for future BDNF and PTSD research to control for: age, time since exposure, treatment status and
trauma exposure type or severity (at least distinguishing between civilian exposure and occupational
exposure, such as the military or blue light services).
Navigation performance as a measure or index of hippocampal integrity is also key to BDNF
research design. Identifying navigation tasks which produce data that can discriminate between
hippocampal dependent and independent performance is challenging [6,8,10,11,40,41,46], yet vital.
In our own study, the purity of the egocentric performance measure [6,40,46] was somewhat
compromised by the fact that egocentric trials in the route learning task could feasibly be solved
allocentrically. Some theorists may challenge this concern on the basis that egocentric processing is
generally considered more parsimonious and therefore more likely a universal default means of solving
simple tasks [49,50]. Nonetheless, implementing spatial processing measures which can accurately
distinguish between allocentric and egocentric processing should remain a priority for any future
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studies which intend to compare functionality of the two memory systems. Similarly, disparity between
studies which assess performance in allocentric and egocentric strategy use as opposed to allocentric
or egocentric spontaneous strategy choice, is also something to be mindful of when comparing
participants’ navigation behaviours [6,28,46,51]. Spontaneous navigation behaviour and navigation
behaviour over the course of a learning paradigm likely measure different components of spatial
processing and need to be clarified as such in research design. Asking participants directly how they
think their behaviour may have changed over the course of a navigation task is a common approach
and is it our recommendation that developing post-test self-report (i.e., think aloud) [28,29,43,46]
measures may provide useful insights into how individuals think they navigate, even if this contradicts
with their performance data.
Understanding individuals’ self-awareness of their ability to apply hippocampal dependent
processing when required is not only valuable to research into the declarative hippocampal dependent
memory system [26,28,29] but could be highly valuable for clinical trauma processing and professional
navigation training interventions that rely on that form of information processing [2,3,6,7,9,13,23,39,40].
Developing more ecologically relevant subjective measures of spatial processing would benefit
future BDNF studies greatly. The navigation questionnaire literature shows that the Santa Barbara
Sense of Direction questionnaire [43] and selected questions from the Questionnaire of Spatial
Representation [44] and the Fragebogen Räumliche Strategien [45] can predict navigation performance,
yet the validity of the questions could be enhanced by introducing terminology and frames of reference
more aligned with the types of spatial processing that sample populations may be familiar with
on a day-to-day basis. For example, a subjective navigation measure for a military population
could refer to topographical (landscape) changes from conflict as a frame of reference for certain
questions. Whereas for policing populations, references to using satellite navigation while driving
a response vehicle may be a more meaningful context. Using terms participants can relate to, they
may increase task engagement, and their more focused self-reflection could enhance the validity of the
self-report measures.
Finally, we consider the use of supplementary neurological data to support future research into
the influence of BDNF on hippocampal processing. While research to date has clearly suggested a
relationship between BDNF, hippocampal dependent processing, PTSD and navigation, the precise
neural mechanisms underlying this relationship are as yet undefined. BDNF research has looked at
volumetric measurement in the hippocampus using magnetic resonance imaging (MRI) and fluorescent
microscopy [51–53], but whether volume differences are the result of BDNF-related protein release,
neurogenesis, neuronal survival or synaptic plasticity is not clear [50–54]. Investigating these neural
mechanisms is further complicated by the possibility that BDNF is released in response to different
environmental conditions over the life span, meaning that age (or critical periods of development)
and time since trauma exposure may need to be controlled for when investigating levels of BDNF in
plasma, blood or saliva (as opposed to BDNF genotypes) [5,25,33,34,36,54–58].
Implementing a solid framework for future research into the relationship between hippocampal
integrity, PSTD and spatial processing is likely a daunting, but we argue, necessary task. Such a
framework could comprise combining:
(a) ecologically valid behavioural and subjective tests of navigation, supported by
(b) functional MRI (fMRI) and MRI-assessing activity or volume, possibly pre- and post-trauma
exposure, with
(c) adequate neurochemical assessment of activity-dependent hippocampal BDNF release (for
example, using blood serum) between genotypes, and
(d) closely matching participants to control for numerous differentiating variables, which may
influence hippocampal and broader neuro degradation syndromes, ranging from age and
environmental conditions of trauma exposure to epigenetic history and even nutrition [59].
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7. Conclusions
Understanding the gene × environment interaction in relation to both trauma exposure and
spatial processing has far-reaching practical, clinical and academic implications. In practical terms, if
research could accurately quantify the contribution that carrying the BDNF met allele makes to an
individual being able to successfully adopt hippocampal dependent information processing techniques,
this could transform how trauma management and navigation training interventions are delivered
in clinical and occupational settings. If 30% of the Caucasian (and up to 50% of non-Caucasian)
populations [31,35,36,60] (i.e., BDNF met carriers) could access interventions that either deliberately
encouraged hippocampal dependent processing or provided workable alternatives to hippocampal
dependent processing, this could equate to a substantial improvement in those intervention outcomes.
The contribution that research on the hippocampus has made to 21st century neuropsychology
(epitomized by the awarding of the Nobel Prize for Physiology or Medicine to Professor John O’Keefe
in 2014 https://www.nobelprize.org/nobel_prizes/medicine/laureates/2014/okeefe-facts.html) is
well recognised. Further research into the BDNF gene would reinforce the value of understanding
how the human hippocampus shapes our emotional and professional lives. Perhaps above all, we
believe that developing this research will enable science and society to take an important step toward
protecting the wellbeing and mental integrity of the hundreds of thousands of men and women who
put themselves in the face of trauma as part of their everyday public service, in defence, emergency
response and law enforcement. To do this, we need to embrace lessons from earlier (sometimes
exploratory) research across the disciplines of genetics, trauma and navigation to ensure that as we
move forward, we can offer neuroscience the caliber of data it needs to meet some pressing public
issues head on.
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Appendix A. Exploratory Research Data
The appendix contains details and data from the exploratory research into the Brain-Derived
Neurotrophic Factor (BDNF) gene, undertaken as part of a study into the impact of trauma and
Post-Traumatic Stress Disorder (PTSD) on navigation behaviour [5,6,40,46].
Appendix A.1. Participants
The study sample population (n = 150) was diverse and was recruited from a university
volunteer scheme (n = 83), two psychotherapy treatment centres (Traumatic Stress Clinic, Camden and
Islington NHS) and the Intensive Psychotherapy Treatment Centre (Dorset Healthcare University NHS
Foundation Trust) (n = 10), two police forces (n = 26) (Dorset and Cambridgeshire constabularies), and
a military veteran treatment centre for PTSD (Combat Stress, Tyrwhitt House, Leatherhead, Surrey:
registered charity #2060002) (n = 25 plus n = 6 staff). PTSD symptom severity and prevalence rates
were measured using the PTSD Diagnostic Scale (PDS) [61]. Saliva samples for BDNF genotyping
were collected using DNA Genotek Orangene™ self-test kits (DNA Genotek, Ottawa, ON, Canada).
Participants were grouped according to whether they had been exposed to trauma or not, and if they
had, whether or not they had clinical or probable levels of PTSD, using the PDS [46,61]. Sample sizes
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for PTSD were modest for the purpose of analysis by BDNF genotype. Of the 150 participants,
57 had probable levels of PTSD and of those who did not, 60 were trauma exposed and 33 were not
trauma exposed. The frequency of the genotypes did not differ between experimental groups (Trauma
Unexposed, Trauma Exposed No PTSD, and PTSD) for either the valval group, χ2 = 0.24, p = 0.88 or the
“met carrying” group, χ2 = 0.04, p = 0.98. An independent samples t-test revealed no differences in
PDS scores between BDNF groups, t (54) = −1.23, p = 0.23. This enabled the analysis of the influence
of the BDNF gene to control for PTSD. The findings supported Zhang et al.’s conclusion in 2014 [32]
that in order to demonstrate BDNF-related group differences in PTSD prevalence or severity, other
environmental conditions may need to be controlled for (such as time since and severity of exposure,
previous trauma and treatment access). It is important to note that this study could not assess the
relationship between BDNF, spatial processing and PTSD, rather the relationship between BDNF and
spatial processing.
Appendix A.2. Methods
DNA saliva samples were genotyped for one single nucleotide polymorphisms (SNP): rs6265
(Val66Met), using a Taqman® allele discrimination assay. The genotyping information acquired described
which BDNF alleles were carried by the (anonymous) participant, i.e., whether they carried only the
val allele (and were therefore valval homozygotes), both the val allele and the met allele (and were
therefore valmet heterozygotes) or if they carried only the met allele (and were metmet homozygotes).
Allocentric and egocentric performance were assessed using a navigation paradigm, the
Alternative Route (AR, [46]) which required participants to learn a route through a virtual environment.
The task involved testing participants on their ability to re-join a route from the same direction and
different directions from which they learned it. There were six blocks to the task. Mean performance
on trials which involved joining the route from the same direction (same direction trials) provided
a measure of egocentric performance. Mean performance on trials which involved joining the route
from a different direction to the route as it was learned (different direction trials) provided a measure
of allocentric performance. An ANOVA was used to assess BDNF group differences (met carriers vs.
valval homozygotes) in egocentric and allocentric performance on a navigation task. Planned contrasts
were then made at individual block level (1–11) using t-tests (see [6,40,46]).
Participants’ self-reported navigation competence was assessed using validated questionnaires;
the Santa Barbara Sense of Direction (SBSOD) [43] and two items from the Questionnaire of Spatial
Representation (QSR) [44] that target allocentric processing. Correlation analysis was used to analyse
the relationship between self-reported competence and navigation performance within the BDNF
groups (met carriers and valval homozygotes).
Appendix A.3. Results
Appendix A.3.1. BDNF and Hippocampal Independent Performance
A repeated measures 2 × 6 ANOVA with the dependent variable egocentric performance, the
between factor BDNF group (met carriers vs. valval homozygotes) and the within factor block (1 to 6)
revealed no significant main effect of block, F (4.49, 138) = 0.90, p = 0.48, ηp2 < 0.01, nor BDNF group,
F (1, 138) = 0.99, p = 0.32, ηp2 < 0.01, but a significant group × block interaction, F (4.49, 138) = 2.48,
p = 0.03, ηp2 = 0.02, visible in the divergent pattern in performance in Figure A1.
190
J. Clin. Med. 2017, 6, 108
 
Figure A1. Mean egocentric performance on the Alternative Route (AR) paradigm between BDNF
genotypes (n = 140, with n = 96 valval homozygotes and n = 44 met carriers) with standard error bars,
showing significant performance differences in block 6, * p < 0.05.
Planned contrasts using independent samples t-tests revealed met carriers performed better than
valval homozygotes in the final block 6 (89% SD ± 17% vs. 78% SD ± 28%), t (138) = 5.65, p = 0.006
(equal variances not assumed). Applying Bonferroni’s correction (0.05/6 blocks) would require a
p value of 0.008.
Despite the lack of significance in the overall BDNF group and egocentric performance interaction,
closer examination of the data was undertaken to understand these final performance differences
in block 6 and to look for any plausible explanation (other than chance) for the inverted curves in
egocentric performance between the BDNF genotypes. The data showed there to be a statistically
significant quadratic (rather than linear) effect of BDNF group, F (1, 138) = 5.59, p = 0.02 which
supports earlier hypotheses for met carrier status explaining differences in egocentric navigation
strategy preference over the course of the task [28,29,62].
Allocentric performance was comparable between BDNF genotypes, as found by both Banner et al.
and Lövdén et al. in 2011 [28,29] and as illustrated in Figure A2. A repeated measures 2 × 6 ANOVA
with the dependent variable (DV) of allocentric performance, the between factor BDNF group and
within factor block (1 to 6) revealed a significant main effect of block (with performance increasing
by block), F (4.07, 138) = 27.2, p < 0.01, ηp2 = 0.17, but no significant main effect of BDNF group,
F (1, 138) = 2.20, p = 0.14, ηp2 = 0.02, and no significant interaction F (4.07, 138) = 1.71, p = 0.14,
ηp2 = 0.01.
Figure A2. Mean allocentric performance on the AR paradigm between BDNF genotypes (n = 140,
with n = 96 valval homozygotes and n = 44 met carriers) with standard error bars.
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Appendix A.3.2. BDNF and Self-Reported Navigation Competence
The final part of the analysis was to assess the navigation questionnaire data in relation to
BDNF genotype. Participants’ scores for general self-reported competence in navigation (SBSOD
total score) and the allocentric targeted QSR questionnaire items were positively correlated with
their performance in allocentric navigation in the AR task. As illustrated in Table A1, only valval
homozygotes’ self-reported competence positively correlated with their performance in allocentric
navigation, suggesting that met carriers were less able than valval homozygotes to accurately describe
their capacity for hippocampal dependent (allocentric) spatial processing.
Table A1. Pearson’s correlations (r) between Questionnaire of Spatial Representation (QSR) allocentric
items, the Santa Barbara Sense of Direction (SBSOD) and allocentric performance in the AR paradigm







BDNF Met Carriers (n = 45)
General competence (SBSOD) 0.26 * 0.05
Allocentric competence (QSR) 0.28 ** 0.03
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Abstract: Head and neck squamous cell carcinomas (HNSCCs) arise in the mucosal lining of the
upper aerodigestive tract. Tobacco and alcohol use have been reported to be associated with
HNSCC. Infection with high-risk human papillomaviruses (HPVs) has recently been implicated
in the pathogenesis of HNSCCs. It is now widely accepted that high-risk HPV is a cause of almost all
cervical cancers as well as some forms of HNSCCs. HPV-related HNSCCs are increasing. HPV-related
HNSCCs and HPV-unrelated HNSCCs differ with respect to the molecular mechanisms underlying
their oncogenic processes. HPV-related HNSCCs are known to have a better prognosis response
to treatment as compared with HPV-unrelated HNSCCs. Therefore, in recent years, it has been
required to accurately discriminate between HPV-related and HPV-unrelated HNSCCs. To diagnose
the HPV-related HNSCCs, various methods including P16 immunohistochemistry, FISH, and genetic
analyses of the HPV gene from histopathological and liquid biopsy specimens have been employed.
Based on the results of the differential diagnosis, various treatments employing EGFR TKI and
low-dose radiation have been employed. Here, we review the involvement of the HPV virus in
HNSCCs as well as the molecular mechanism of carcinogenesis, classification, prognosis, diagnostic
procedures, and therapy of the disease.
Keywords: human papillomavirus; human cancer; head and neck; reduction therapy
1. Introduction
The role of human papillomavirus (HPV) in carcinogenicity was confirmed in 1983 following
the cloning of HPV 16 type from cervical carcinoma tissue by Durst and colleagues [1]. It has since
become widely accepted that high-risk HPV is a cause of almost all cervical cancers. Many cases of
HPV infection are asymptomatic and resolve spontaneously, but cervical cancer may arise in cases of
persistent HPV infection of the cervical basal cells [1,2]. As reviewed by Kreimer et al. [3], HPV DNA
has been detected by polymerase chain reaction (PCR) in head and neck squamous cell carcinoma
arising from various anatomic sites. HPV16 is the predominant HPV type, accounting for 90% of
HPV DNA-positive HNSCCs. Various studies involving mainly HPV 16 have shown that viral DNA
is diffusely present in tumor cells of whole tumor, and exhibits clonality when detected by in situ
hybridization (ISH) [4–6]. As shown in several oral and oropharyngeal carcinoma cell lines [7–9],
the retention of viral DNA during the growth of tumor cells in culture provides further evidence
suggestive of viral clonality.
Various studies have reported that oral and tonsillar epithelial cells can be immortalized by
full-length HPV 16 or its E6/E7 oncogenes [10–14]. Additionally, transgenic mouse models have
revealed that HPV 16 E6/E7 strongly increases susceptibility to oral and oropharyngeal carcinomas [15].
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Although E7 was much more competent in inducing these tumors [15], a clear synergy between E6 and
E7 in causing HNSCC was discovered [16]. In an analysis of paraffin-embedded biopsies of 116 cases
of laryngeal squamous cell carcinomas by in situ DNA hybridization using 35S-labelled HPV (types 6,
11, 16 and 30) DNA probes, 15/116 (12.9%) tumors were shown to contain the DNA of at least 1
HPV type. HPV 11 was the most frequent DNA type, found in 9/116 (7.8%) of the lesions; HPV 16
was found in 5.2%, and HPV 6, in 4.3% [17]. HPV was recognized as a risk factor for oropharyngeal
carcinogenesis by the International Agency for Research on Cancer (IARC) in 2007 [18].
A higher frequency of oral sex and a greater number of sex partners are thought to increase the
risk of HPV-related cancer in the oropharynx [19,20].
The development of a vaccine for the primary prevention of HPV infection subsequently became
an urgent worldwide priority. In 2017, Muranaka was awarded the John Maddox Prize for raising
public awareness of the efficacy of the HPV vaccine for the prevention of cervical and other cancers
(http://senseaboutscience.org/activities/2017-john-maddox-prize/). This review summarizes the
involvement of HPV virus, molecular pathological implications, classification and prognosis, and
prospects for future treatment in head and neck cancers.
2. Involvement of HPV Virus in Head and Neck Cancers
HPV is a DNA virus that infects the skin and mucous membranes. More than 100 types of HPV
have been classified to date. Previous studies have examined the role of HPV-related carcinogenesis in
uterine cervical cancer. HPV infecting the uterine cervix is divided into high- and low-risk groups.
HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 68, 69, and 73 are classified as high-risk HPV [21],
which is estimated to account for almost 100% of cases of cervical cancer, about 90% of cases of anal
cancer, and 40% of vulva, vagina, and penile cancer. Additionally, at least 12% of pharyngeal cancer,
3% of oral cancer, and 30–60% of oropharyngeal carcinoma cases are caused by HPV infection [22].
An increase in squamous cell carcinoma of the head and neck has been reported and attracted global
attention recently in the world [23]. It is now recognized that there are two types of squamous cell
carcinoma of the head and neck. Classically, most oropharynx cancers are hyperdifferentiated and
often show keratinization. Squamous cell carcinoma of the head and neck can be of the keratinized or
nonkeratinized type. The former occurs most often in elderly males and is associated with smoking and
alcohol consumption, but HPV is not involved. Conversely, nonkeratinizing squamous cell carcinoma
occurs most commonly at age 40–55 years in men with little exposure to tobacco and alcohol, and HPV
DNA is detected as the most characteristic feature [24–27]. Since the smoking rate in the USA is
declining [28], the incidence of HPV-negative tobacco-related oropharyngeal cancer has decreased;
however, that of HPV-positive oropharyngeal cancer is increasing [29]. According to repository data
from the Surveillance, Epidemiology, and End Results (SEER) program, the prevalence of HPV-negative
cancers decreased by 50% from 1988 to 2004, while HPV-positive oropharyngeal carcinoma increased
by 225% [30]. In a study by Junor and associates involving patients at the Edinburgh Cancer Center,
41% of head and neck cancers were HPV-positive between 1999 and 2001 and 63% were HPV-positive
between 2003 and 2005 [31]. HPV-positive oropharyngeal cancer is considered to be a separate disease
with a causal relationship to HPV infection and a good prognosis. Several studies have shown that
patients with HPV-positive oropharyngeal cancer, identified through PCR, in situ hybridization or
P16 immunohistochemistry on tumour tissues, have a significantly improved overall and disease-free
survival compared with patients with HPV-negative oropharyngeal cancer patients [32–40]. In a
prospective study involving 253 newly diagnosed or recurrent HNSCC patients, HPV was detected
in 25% of patients. A low tumor grade and the oropharyngeal site increased the likelihood of the
presence of HPV, respectively [5]. Oropharyngeal tumors are more likely to be positive for HPV (57%)
compared with sites other than the tumor site and the oropharynx (14%) and the oral cavity (12%).
HPV-positive oropharyngeal carcinoma occurs primarily in the tonsillar of the palatine or tonsils of
the tongue. In the tonsils or tongue base, 62% of the tumors were HPV-positive, whereas in other parts
of the oropharynx 25% were HPV-positive.
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3. Pathological Molecular Mechanism in Carcinogenesis
HPV-unrelated HNSCC cigarette smoking and alcohol has p53 mutations [41]. Deletion of
9p21–22 is also observed early in the oncogenic process, and as a result, the function of the tumor
suppressor gene P16 is lost [42]. P16INK4a produced by the P16 gene forms a complex with cyclin
1-cyclin-dependent kinase 4/cyclin-dependent kinase 6 (CDK4/CDK6), inhibits phosphorylation of Rb,
and inhibits transcription factor E2F-related cell rotation (pRB pathway) [43]. In HPV-associated head
and neck cancer, wild-type p53 is present and mutations occur at a rate of only 10% or less. However,
HPVE6 inactivates p53 resulting in a decrease in function. Furthermore, there is no deletion of P16 in
these tumors. Since HPVE7 inactivates phosphorylated Rb, which controls cell cycling of host cells,
control of E2F is inhibited [44] and P16 is overexpressed. P16 is a tumor suppressor gene encoding
a CDK repressor, which inhibits the complex formation of cyclin D1 and cyclin-dependent kinase
(CDK) 4/6. Cyclin D1 and CDK 4/6 complex promotes cell cycling through the release of E2F via
phosphorylation of the Rb protein, whereas the Rb protein/E2F complex also suppress the transcription
of P16, so that when HPV-E7 inactivates the Rb protein, P16 is overexpressed (Figure 1) [45].
Figure 1. Signaling pathways of high-risk HPV oncogenes. High-risk HPVs encodes two known
viral oncogenes. E6 protein inactivates tumor suppressor p53 mediated DNA damage and apoptosis
pathway. E7 protein inactivates tumor suppressor pRb mediated cell cycle regulation pathway.
Thus, the phenotype at the molecular level is completely different between HPV-positive and
HPV-negative cancer of the head and neck. Various methods have therefore been employed for the
detection of HPV in head and neck cancer such as consensus primer or type-specific PCR, real-time
PCR, in situ hybridization, and serum antibody assays. For cervical cancer screening, accepted
international guidelines recommend using hybrid capture II (QIAGEN) and PCR (GP 5/GP 6).
P16 immunohistochemistry is also useful as a surrogate maker for HPV infection detection,
especially in head and neck cancers. P16 immunohistochemistry has 100% sensitivity and 79%
specificity; it is the gold standard for HPV detection, based on HPV 16 E6 and E7 mRNA, in head
and neck cancer specimens and is useful as a surrogate maker for clinical HPV detection. P16 is
also a useful molecular marker for judging prognosis and is a component of the WHO classification
scheme, described below. P16-positive and P16-negative HNSCCs could clearly be distinguished in
our specimens (Figure 2).
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Figure 2. (A–D) A case of P16 positive squamous cell carcinoma of Oropharynx. (A) HE, (B) P16,
(C) p53, (D) MIB-1. (E–H) A case of P16 positive squamous cell carcinoma of Oropharynx. (E) HE,
(F) P16, (G) p53, (H) MIB-1.
A general consensus has been achieved for the definition of HPV associated tumors that require
expression of the virus oncogenic proteins E6 and E7 that are involved in neoplastic transformation
of infected cells. However, the integration of HPV-DNA into the host cell genome confirms the
belief that it is an essential step for viral oncogene expression in oropharyngeal cancer, as in the case
of cervical cancer. Regardless of the process leading to oncogene expression, HPV E6/E7 mRNA
identification based on DNA or protein expression, for patient stratification and epidemiologic
purposes, is considered a gold standard for HPV-related classification [46,47]. More accessible
strategies are generally accepted. In the examination of the pathological specimen, the detection
of HPV-DNA using PCR and ISH examination are typically used together with immunohistochemistry
of P16. Various new methods have been examined for HPV testing in head and neck cancers [48].
When infected cells become malignant, HPV DNA remains in the nucleus, and viral oncoproteins,
in particular against E6, are detected in virtually all cases of HPV-driven OPC cases [49,50]. There are
reports that HPV-DNA and HPV16 E6 antibodies in oral and in body fluids can be used for detection
of HPV-infected head and neck cancers and prediction of the risk of recurrence [51].
Studies using next-generation sequencing of HNSCCs have also been reported in recent years.
Matthias Lechner did 20 HPV+ and 20 HPV-laser capture microdissection pharyngeal carcinoma
studies. HPV-positive and HPV-negative oropharyngeal cancers are divided into two different
subgroups. A TP53 mutation was detected in 100% of HPV-negative cases and invalidation of G1/S
checkpoint by CDKN2A/B deficiency and/or CCND1 amplification was shown to occur in the majority
of HPV tumors [52]. In a study that examined the somatic mutations of 279 HNSCCs performed in
2015, In HPV-positive oropharyngeal carcinoma, deletion of TRAF3, activation mutation of PIK3CA,
and amplification of E2F1 were observed. In HPV-negative HNSCC, subsets recognizing simultaneous
mutations of CASP8 with amplicons on 11q with CCND1, FADD, BIRC2, and YAP1, or with HRAS,
were observed. Either type of tumor was abnormal with respect to target cell cycle, death, NF-κB and
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other oncogenic pathways [53]. In a study of 92 cases of HNSCC using the next generation sequencer,
TPK 53was the most common mutation, occurring in 47 (51%) patients followed by CDKN 2A (n = 23,
25%), CCND 1 (n = 22, 24%), and PIK 3 CA (n = 19, 21%). Changes in TPV, CDKN2A, and CCND1
genes occurred more frequently in HPV-negative tumors, but the total amount of mutations was
similar between HPV-negative and HPV-positive tumors. HPV-positive tumors were significantly
associated with immune-related genes compared to HPV-negative tumors. Mutations in NOTCH1
(p = 0.027), CDKN2A (p < 0.001), and TP53 (p = 0.038) were significantly associated with decreased
overall survival. FAT1 mutation was highly enriched in cisplatin responders and targetable alterations
such as PIK3CA E545K and CDKN2A R58X were found in 14 patients (15%) [54].
As an emerging technology, liquid biopsies, involving the use of a small amount of DNA and
mRNA collected from blood samples, have been used in recent cancer studies. Allen et al. [55] reported
a novel in vitro diagnostic approach in which miRNA is examined from exposed cancer cells using sera
from HNSCC patients. Of 377 miRNAs detected, 16 different miRNAs were found to be differentially
expressed when comparing cells exposed to serum from HNSCC versus healthy individuals. Real-time
PCR analysis revealed that serum from HNSCC patients downregulated the expression of 5 genes
involved in carcinogenesis and 2 of these—P53 and SLC2A1—are direct targets for the detected
miRNAs. This technique has potential for a new therapeutic approach using tumor-specific cell lines
or single cell in vitro assays, and the possibility of more specific diagnosis could facilitate individual
treatment and early detection of primary tumors or metastasis.
4. Classification and Prognosis of Head and Neck Cancers
In general, HPV-positive oropharyngeal carcinoma is highly susceptible to radiation and
anticancer drugs and has a better prognosis compared with HPV-negative cancer. HPV-negative
oropharyngeal carcinoma is caused by the disappearance of function due to p53 gene mutation [56–59].
In a prospective phase II clinical trial of pharyngeal and laryngeal cancer patients by the Eastern
Cooperative Oncology Group, 63% of 60 cases were HPV 16 positive, and all of the HPV16-positive
cases were also positive for P16. For HPV-positive and HPV-negative cancers the respective response
rates were 84% versus 57%, the 2-year progression-free survival rates were 86% vs. 53%, the overall
2-year survival rates were 95% vs. 62%, and the prognosis for HPV-positive cancer was significantly
better [37]. Previous reports have examined the prognosis of HPV in relation to P16, and the
outcomes of oropharyngeal cancer in relation to tobacco exposure. In a phase III study involving
400 oropharyngeal carcinomas, the 2-year progression-free survival rates for HPV-positive and
HPV-negative cancer were 72% vs. 51% and the 2-year overall survival rates were 88% vs. 67%.
Due to differences in prognosis, squamous cell carcinoma of the head and neck was classified in the
new WHO scheme as HPV-negative or HPV-positive. Classification by P16 immunostaining or HPV
testing is recommended. In addition, some recently proposed classification schemes are based on
the EGFR status according to 2 categories: HPV-positive/P16 positive squamous cell carcinoma and
HPV-negative/P16 negative squamous cell carcinoma [60]. Cetuximab, a monoclonal antibody that
inhibits the function of EGFR, is known to have efficacy in colorectal cancer [61,62] and head and neck
cancer [63,64], and it was also shown to be more specific and cost-effective for these types of cancers.
5. Prospects for Treatment
For the reasons outlined herein, HPV virus is expected to be a therapeutic target in the treatment
of human cancer [65] We believe that the prognosis for cervical cancer can be greatly improved through
the implementation of methods for early detection such as cytodiagnosis, HPV screening, and P16
immunostaining, Furthermore, HPV vaccination may also be useful for preventing HPV-related
cancers other than cervical cancer. For example, most cases of oropharyngeal carcinoma are caused
by HPV 16 (about 90%) and HPV 18, and HPV vaccination for this condition can be expected to
have a greater disease-suppressing effect than in cervical cancer. Randomized trials have provided
strong evidence for high efficacy of the 2 FDA-approved VLP vaccines: the bivalent HPV16/18 vaccine
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(CervarixÒ, GlaxoSmithKline Biologicals, GlaxoSmithKline plc, Brentford, UK) and the quadrivalent
HPV 6/11/16/18 vaccine (Gardasil™, Merck Sharp and Dohme, Merck & Co., Kenilworth, NJ, USA)
against cervical, vaginal, and vulvar HPV16/18 infections and related diseases, and against anal
HPV16/18 infections in women [66–70]. One of the methods proposed for prevention of HPV-related
oropharyngeal cancer is vaccination. The US Centers for Disease Control Advisory Committee on
Immunization Practices (ACIP) has recommended HPV vaccination for females and males between
the ages of 11 and 12 years, starting as early as 9 years, with booster doses at up to 26 and 21 years for
females and males, respectively. In order for the vaccination to be effective in preventing oropharyngeal
cancer, the protective effect must last for at least 2 decades, and ongoing studies have shown no waning
of systemic antibodies at 8 years after vaccination. However, in June 2013, the Ministry of Health,
Labour and Welfare of Japan suspended proactive recommendation of the vaccine after unconfirmed
reports of adverse events. To investigate any potential association between the vaccine and reported
symptoms, the Nagoya City Council conducted a questionnaire-based survey. The anonymous
postal questionnaire investigated the onset of 24 symptoms, associated hospital visits, frequency, and
influence on school attendance. A total of 29,846 residents responded. No significant increase in
occurrence of any of the 24 reported post-HPV vaccination symptoms was found. The results suggest
no causal association between the HPV vaccines and reported symptoms [71].
Also, Reduction surgery or minimally invasive treatment should be considered in cases of HPV
virus-related oropharyngeal carcinoma. Although limited to the T1 and T2 stages of oropharynx cancer,
transoral robotic surgery approved by the FDA since 2009. In addition, many reduction surgeries and
post-operative adjuvant therapies based on pathologic staging are being studied [72–74].
As mentioned above, it is known that EGFR is expressed in HNSCCs, and combination use
of cetuximab and radiation is, therefore, being studied for treatment instead of standard cisplatin
therapy [38,61,64,75–78]. Several researchers have hypothesized that radiation dose reduction is
feasible and safe for some HPV-positive patients when induction chemotherapy (IC) is used for patient
selection. Three points have been raised to support this assertion. First, HPV-positive HNSCCs are
considered to be more radiosensitive than HPV-negative HNSCCs [79]. Second, doses comparable
to the supplemental radiation dosage is sufficient for the treatment of patients with asymptomatic
disease [80]. Finally, the response to chemotherapy can predict the future response to subsequent
radiation therapy. Chen et al. [79] conducted an arm Phase II trial (NCT 01716195) in 44 patients with
stage III/IV P16-positive OPCs treated 2 cycles of IC (paclitaxel and carboplatin was for 21 days),
followed by radiation and paclitaxel. The radiation dose was also reduced in complete or partial
responders (54 Gy, n = 24), and even in patients with partial or no response (n = 20, 60 Gy instead of
standard 70 Gy). Except for 1patient, all patients completed the IC. Two years PFS and local region
control were 92% (95% CI 77–97) and 95% (95% CI 80–99), respectively. The two-year degree of freedom
for grade 3 or adverse events of worsening mucosa and esophagus was 85% (95% CI 80–90) in patients
treated with 54 Gy. These results were achieved with doses reduced by 15–20% compared with these
in the ECOG 2399 trial using the same protocol, except that a dose of 70 Gy, dose was used as a
standard chemoradiotherapy regimen. Besides that, Removal of chemotherapy and Alternative to the
“conventional” photon beam therapy are considered as new treatment methods [80].
Differences in the prognosis and etiologic mechanisms of HPV-related head and neck cancer from
conventional head and neck cancers (mostly HPV-negative) suggest that the detection of HPV may
significantly change the future diagnosis, treatment, and management [31]. HPV not only plays a
role in the development of pharyngeal cancer but is also involved in 23.5% of oral cancer and 24% of
laryngeal cancer cases, suggesting that indications for HPV vaccination could be expanded to also
include oral and laryngeal cancer [37].
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Abstract: Objective: To review the current published literature on the use of procalcitonin as a
diagnostic and prognostic marker in adult patients with meningitis. Methods: We conducted a
PubMed search to identify all relevant publications regarding the diagnostic and prognostic value of
serum procalcitonin in patients with a known or suspected central nervous system infection. We also
reviewed the bibliographies of all identified manuscripts in an attempt to identify additional relevant
references. Results: A significant body of evidence suggests that serum procalcitonin has a promising
role and can be a useful biomarker in the assessment of patients with meningitis. Conclusions:
Our literature review suggests that data on the role of Cerebrospinal Fluid (CSF) procalcitonin are
limited, whereas serum procalcitonin (S–PCT) is probably a useful tool in the evaluation of patients
with a known or suspected central nervous system infection and can help distinguish between
bacterial and viral meningitis.
Keywords: procalcitonin; bacterial meningitis; viral meningitis; antibiotic therapy; biomarker;
differential diagnosis
1. Introduction
Meningitis is a serious medical condition and can be a major cause of morbidity and mortality.
Early diagnosis and timely initiation of appropriate antibiotic therapy is crucial for reducing mortality
from bacterial meningitis.
The term “biomarker”, as used in daily clinical practice, refers to molecules and biological products
used as markers for the assessment of disease progression or as indicators for the presence of an
abnormal clinical state. Biomarkers can be specific cells or genes, gene products, enzymes or hormones,
have characteristic defined biological properties, and can be detected and measured in biological
fluids (plasma, serum, cerebrospinal fluid, bronchoalveolar lavage) or body tissues. More than
178 biomarkers have been identified in the field of sepsis, but none seem to have sufficient specificity
or sensitivity for routine use in daily clinical practice [1] and some require considerable time, effort,
and costs to measure. In addition, the reliability and validity of certain proposed biomarkers have
not been thoroughly tested [2]. Procalcitonin (PCT) and C-reactive Protein (CRP) are the biomarkers
most commonly used, but have a limited ability to distinguish sepsis from other inflammatory and
non-inflammatory states or to predict outcomes.
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Serum procalcitonin (S–PCT) has been used as biomarker in sepsis because S–PCT levels are
elevated in bacterial, parasitic, or fungal infections, while they remain normal or only slightly elevated
in viral infections. Because early recognition of viral versus bacterial meningitis is critical for the prompt
initiation of treatment to improve prognosis, a reliable method distinguishing bacterial from viral
meningitis could help clinicians limit inappropriate antibiotic treatment. This review was conducted
to evaluate the current knowledge on the use of S–PCT as a tool for the diagnosis of meningitis and for
distinguishing bacterial meningitis (BM) from viral meningitis (VM).
2. Methods
To identify relevant publications of interest, we conducted a PubMed search on 24 May 2018
using the terms ‘procalcitonin and meningitis’ as “Title/Abstract” or as “MeSH Terms”. Because
“Procalcitonin” is not a “Mesh Term” in PubMed, we also used the term “Calcitonin” in “Mesh Terms”
during the search. The structure of the search in the “Search details” window of the PubMed website
was (procalcitonin [Title/Abstract] OR “calcitonin” [MeSH Terms]) AND (meningitis [Title/Abstract]
OR “meningitis” [MeSH Terms]). For the purposes of this review, we then limited the search to
“Humans” and only considered manuscripts presenting data on adults. We also reviewed the
bibliographies of all identified manuscripts to identify additional relevant publications. For the
purposes of this review, we included all types of publications, including case reports, case series,
and review articles, regardless of publication date. Publications in languages other than English were
included only if they had a meaningful detailed abstract in English.
3. Results
The PubMed literature search generated 157 references, but the number of references was reduced
to 125 after limiting the search to “Humans”. After further evaluation, 38 publications were included
in this review.
In a prospective study published in 1999, Viallon et al. evaluated 105 emergency department
patients admitted with suspected meningitis. Based on clinical findings, gram staining, cultures,
and Cerebrospinal Fluid (CSF) chemical analysis, 23 patients had bacterial meningitis, 57 had viral
meningitis, and meningitis was ruled out in 25 patients. Although two patients with previous antibiotic
therapy had S–PCT levels of <0.5, S–PCT was the best marker for differentiating between bacterial
and viral meningitis: Using S–PCT of >0.2 ng/mL as the threshold, S–PCT sensitivity and specificity
approaches 100% for the diagnosis of acute bacterial meningitis [3].
A prospective study published by Schwarz in 2000 included 30 patients with meningitis (16 with
acute bacterial and 14 with abacterial meningitis) and assessed whether S–PCT levels were elevated
in patients with bacterial meningitis. Results of the study showed that, although false negative
results can occur, S–PCT is a useful variable for distinguishing bacterial from non-bacterial meningitis:
Because S–PCT levels do not increase in cases of viral meningitis, even with viral sepsis, increased
S–PCT levels indicated bacterial origins of an infection with high specificity [4].
In 2000, Viallon et al. published the results of a prospective study on 179 patients admitted to
the emergency department on suspicion of meningitis. Of those, 32 patients had bacterial meningitis
and 90 had viral meningitis, whereas 57 patients did not have meningitis. The authors assessed the
role of CSF parameters (cytology, protein, glucose, lactate) and serum parameters (CRP, S–PCT) for
differentiating between bacterial and viral meningitis, and demonstrated that S–PCT was the most
discriminant variable, using a threshold value of 0.93 ng/mL in their population [5].
Shimetani et al. reported extremely high CSF CRP levels in patients with bacterial meningitis,
but only in 10% of patients with viral meningitis. Among patients with bacterial meningitis, S–PCT
levels were more elevated in those with a more serious infection. PCT levels in CSF did not differ
significantly between patients with bacterial, viral, or mycotic meningitis. However, S–PCT levels
were very high in all bacterial meningitis patients, especially in the most serious cases [6].
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A report by Hoffmann et al., published in 2001, assessed S–PCT levels in 12 adult patients with
meningitis and suggested that S–PCT has limited diagnostic value in adults with bacterial meningitis,
especially in cases with unusual agents or nosocomial origin. Increased S–PCT levels in bacterial
meningitis may indicate the presence of bacterial inflammation outside the Central Nervous System
(CNS) [7].
A review by O’Connor published in 2001 included manuscripts published from 1990–2001
to assess the diagnostic usefulness of S–PCT in critical illness. This publication concluded that,
although there is debate regarding the superiority of S–PCT as a sepsis biomarker compared to other
biomarkers, a number of studies support the usefulness of S–PCT in differentiating between bacterial
and viral meningitis [8].
A prospective study on 45 adult patients with CNS infection (20 with bacterial meningitis and 25
with tick-borne encephalitis), published in 2001, evaluated the role of S–PCT and CSF procalcitonin
in differentiating acute bacterial vs. viral meningitis. Median S–PCT level was 6.45 ng/mL
(0.25–43.76 ng/mL) in patients with bacterial meningitis vs. 0.27 ng/mL (0.05–0.44 ng/mL) in patients
with viral meningitis, and the authors concluded that S–PCT and CSF PCT concentrations >0.5 ng/mL
seem to be reliable indicator of bacterial CNS infection [9].
A study by Martinez et al. in 2002 attempted to evaluate the role of S–PCT monitoring in the
differential diagnosis of ventriculitis in adult Intensive Care Unit (ICU) patients. The study included
15 consecutive ICU patients with ventriculitis and a ventricular catheter in place, and compared these
data with 10 patients with community-acquired bacterial meningitis. The authors concluded that,
in contrast to bacterial meningitis, monitoring of S–PCT alone is not helpful for the diagnosis of
ventriculitis [10].
A case report published in 2004 presented the case of a 73-year-old woman with progressively
worsening headaches, nausea, vomiting, and neck stiffness. As her clinical condition deteriorated,
she developed diffuse brain edema and hydrocephalus, requiring external ventricular drainage (EVD)
and admission to a neurologic ICU, with a subsequent diagnosis of severe post-myelographic chemical
meningitis. The authors compared CSF and serum inflammatory markers of this patient versus seven
patients with proven bacterial meningitis and concluded that S–PCT may be useful in differentiating
between bacterial and chemical causes of CNS inflammation [11].
A study by Kepa et al. assessed the role of CSF PCT and S–PCT levels in the differential diagnosis
of adults with CNS infections. The study included 17 patients with bacterial meningoencephalitis and
16 patients with lymphocytic meningitis and showed that CSF and plasma PCT levels were significantly
different between these two patient groups. These results supported the usefulness of measuring
plasma PCT levels in the differential diagnosis of CNS infections in adults. With regards to the role
of CSF PCT, the authors concluded that CSF PCT levels are less important for differential diagnosis,
but correlate with the severity of bacterial meningoencephalitis and can be taken into consideration
when predicting prognosis and outcomes [12].
In 2005, a study by Viallon et al. described the change in S–PCT levels during the treatment of
48 patients with community-acquired acute bacterial meningitis. Bacterial infection was documented in
45 patients and initial antibiotic treatment was effective in all patients. Serum PCT levels were measured
on admission and on day two, and showed that S–PCT levels decline rapidly with appropriate antibiotic
therapy. The authors concluded that the rapid decline of S–PCT levels reduces the value of performing
lumbar puncture 48 to 72 h after admission to assess the effectiveness of antibiotic therapy [13].
Ernst and colleagues evaluated serum and CSF procalcitonin levels in patients with dementia
disorders and neuro-inflammation. The study included 40 patients with probable Alzheimer’s
disease, 12 patients with frontotemporal dementia (FTD), 8 patients with dementia with Lewy
bodies (DLB), 12 patients with vascular dementia (VD), 16 patients with acute neuroinflammation,
and 50 non-dementia control patients (18 surgery patients and 32 patients with other neurologic
diseases)and showed that, compared to non-dementia controls, CSF procalcitonin levels were increased
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in patients with dementia diseases and acute neuro-inflammation. In addition, in matched serum
samples, S–PCT levels were elevated in meningitis patients, but not in dementia patients [14].
An observational cohort study by Knudsen et al. included 55 patients with suspected meningitis
and compared the diagnostic value of serum sCD163 levels, CRP, and procalcitonin in bacterial
infection and meningitis and showed that, although elevated serum sCD163 levels seem to be the
most specific biomarker for differentiating between bacterial and non-bacterial disease (specificity 0.91;
sensitivity 0.47), the overall diagnostic accuracy of CRP (Area Under the Curve (AUC) = 0.91) and
PCT (AUC = 0.87) were superior compared to sCD163. The authors concluded that, although PCT and
CRP had very high accuracy for distinguishing between bacterial and viral infection, none of them
were useful as an independent tool for diagnosis in patients presenting with purulent meningitis [15].
A prospective multicenter study, published in 2007, included 151 patients with bacterial or
nonbacterial meningitis and negative initial Gram stains from three teaching hospitals in France and
reported laboratory data, including results of CSF analysis (CSF leukocyte count, percentage of CSF
leukocyte, CSF/blood glucose ratio, CSF protein), serum CRP, and serum PCT, together with clinical
findings and outcomes. The study evaluated the accuracy of laboratory results in differentiating
between bacterial and non-bacterial meningitis in patients with meningitis and a negative gram
stain, and concluded that CSF laboratory results have some role in distinguishing bacterial from
non-bacterial meningitis, whereas serum CRP (AUC 0.81 (95% CI 0.58–0.92) and S–PCT levels (AUC
0.98, 95% CI, 0.83–1.00) are excellent predictors of bacterial meningitis, with S CPT being clearly
superior (p < 0.05) [16].
A prospective study from the Saint-Etienne University Hospital in France collected data from all
patients admitted to the emergency unit with suspected meningitis between 1997 and 2009. Data were
collected on 97 patients with bacterial meningitis and 218 patients with viral meningitis, but, after
62 patients with Bacterial Meningitis (BM) were excluded for various reasons, the study only included
data from 35 patients with BM and negative direct CSF examination. The aim of the study was to
determine the ability of several parameters used for the diagnosis of acute meningitis in differentiating
between bacterial and viral meningitis in adult patients with a negative CSF examination. In this study,
S–PCT had a 95% sensitivity, 100% specificity, and 100% negative predictive value, as well as a 97%
positive predictive value for distinguishing BM versus Viral Meningitis (VM) when using a diagnostic
cut-off level of 0.28 ng/mL (AUC, 0.99; 95% CI, 0.99 to 1) [17].
A prospective study on 36 adult patients with acute meningitis was published in 2012. The aim of
the study was to evaluate the role of serum procalcitonin levels over time during treatment for central
nervous system infections. Serum procalcitonin levels were measured before the initiation of treatment
and 24 and 72 h after treatment started. Results showed that mean PCT levels were higher in patients
who did not improve and that the reduction of serum PCT levels were more significant after 72 h in
patients who improved. The authors emphasized the role of serum PCT levels as a marker for follow
up in treating patients with bacterial meningitis [18].
A study by Choi assessed the value of serum procalcitonin in differentiating post-operative
bacterial meningitis (PBM) versus postoperative aseptic meningitis (PAM) after neurological surgery
and included patients who had cerebrospinal fluid pleocytosis within 14 days of surgery. The study
compared PCT in 14 patients with PBM against 64 patients with PAM and showed that serum PCT
had limited value for diagnosing PBM and serum PCT levels of ≥0.15 ng/mL had 80% specificity.
However, CPT combined with other biomarkers can be a useful adjunct for increasing diagnostic
sensitivity [19].
An observational study by Tian et al., from Guadong, China and published in 2014, investigated
the value of procalcitonin in the discrimination between sepsis and systemic inflammatory response
syndrome (SIRS). The study included patients treated in a neurological intensive care unit and serum
levels of C-reactive protein and S–PCT were evaluated on admission day, on the day of diagnosis
of SIRS or sepsis, and on days three and seven after the diagnosis. Results of the study showed
significant differences in S–PCT levels between groups at all stages of sepsis. The authors concluded
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that S–PCT has significant value as an index for discriminating sepsis from SIRS and in determining
sepsis severity [20].
A study by Abdelkader et al. published in 2014 evaluated 40 patients with suspected acute
meningitis and negative gram stains compared to 10 healthy controls. The goal of the study was to
evaluate the role of S–PCT in differentiating bacterial from aseptic meningitis in patients with negative
cerebrospinal fluid (CSF) examination on admission and after three days of treatment, and to assess the
role of PCT and other inflammatory markers in relation to treatment efficacy. In this study, patients in
the bacterial group had significantly higher serum PCT on admission compared to the aseptic group
(2.49 ± 2.54 vs. 0.89 ± 0.69, p < 0. 001), and there was a significant difference in bacterial versus. aseptic
meningitis, even after three days of treatment (1.70 ± 1.58 vs. 0.64 ± 0.51, p < 0.001) [21].
A prospective observational study, published by Shen et al. in 2015, assessed the diagnostic
value of serum and CSF PCT levels in 120 patients with meningitis-like symptoms and showed that
both S–PCT and CSF PCT levels were increased in patients with bacterial meningitis (BM). The area
under the Receiver Operator Characteristic (ROC) curve was 0.96 (CI 0.93–1.00) for S–PCT versus
0.9 (CI 0.83–0.96) for CSF PCT in the diagnosis of BM. When using 0.88 ng/mL as a threshold, S–PCT
had an 87% sensitivity and 100% specificity for the diagnosis of BM. The study concluded that
both S–PCT and CSF PCT have value for the diagnosis of BM, but the diagnostic value of S–PCT is
superior [22].
In another prospective observational study, Omar et al. collected data on CRP, S–PCT, and
CSF cultures every other day in 36 adult patients with severe head trauma and ventriculostomy,
and observed elevated S–PCT concentration in all five patients who developed ventriculostomy-related
infections. Mean serum PCT was <2.0 ng/mL in patients with negative CSF cultures versus 4.18 ng/mL
in patients with positive cultures. The study concluded that an early increase of S–PCT levels is a valid
indicator of bacterial CNS infection in patients with head trauma and External Ventricular Drainage
(EVD) [23].
A retrospective clinical study by Li et al. assessed the diagnostic value of CSF procalcitonin
combined with CSF lactate levels in distinguishing post-neurosurgical bacterial meningitis (PNBM)
from aseptic meningitis in 178 hospitalized patients with suspected PNMB (50 patients with PNBM vs.
128 patients without PNBM). Median (min, max) CSF procalcitonin levels were 0.2 (0–3.1) in patients
with PNBM versus 0 (0–0.5) in patients with non-PNBM (p < 0.001), and ROC analysis revealed a
cut-off value of 0.075 ng/mL (AUC = 0.746, sensitivity 68.0%; specificity 72.7%, p < 0.001) for CSF
procalcitonin. Similarly, median (min, max) CSF lactate levels were 5.3 (2.2–10.6) in patients with
PNBM versus 2.3 (1.2–5.4) in patients with non-PNBM (p < 0.001), and ROC analysis revealed a
cut-off value of 3.45 mmol/L (AUC = 0.943, sensitivity 90.0%; specificity 84.4%, p < 0.001) for CSF
lactate. The study showed that PNBM patients have significantly higher CSF procalcitonin and CSF
lactate levels compared with non-PNBM patients and concluded that CSF lactate and PCT levels
have significant diagnostic value for PNBM, and could be useful in differentiating PNBM from
non-PNBM [24].
A publication by Konstantinidis et al. in 2015 evaluated CSF procalcitonin levels and compared
CSF procalcitonin levels with CSF levels of other established markers of infection, such as CRP,
high-sensitivity CRP, and White Blood Cells (WBC) in 30 ICU, Medicine, Neurology, Hematology,
and Pediatric patients with bacterial (n = 19) or viral (n = 11) meningitis, and in 28 patients with
non-infectious diseases. In this study, CSF PCT levels were 4.714 ± 1.59 ng/mL in bacterial meningitis
versus 0.1327 ± 0.03 ng/mL in patients with viral meningitis versus <0.1 ng/mL in patients with
non-infectious diseases, with the authors concluding that S–PCT can be helpful in distinguishing
bacterial meningitis from viral meningitis and other noninfectious CNS diseases [25].
A meta-analysis published in 2015 by Vikse et al. included nine studies with a total of
725 patients and concluded that serum procalcitonin had a pooled sensitivity of 0.90 (95% CI 0.84–0.94),
a specificity of 0.98 (0.97–0.99), a positive likelihood ratio of 27.3 (8.2–91.1), a negative likelihood ratio
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of 0.13 (0.07–0.26), a diagnostic odds ratio of 287.0 (58.5–1409.0), and, thus, is far superior to CRP for
rapid differentiation between bacterial and viral meningitis [26].
Kim et al. compared S–PCT levels in 26 patients with tuberculosis meningitis versus 70 patients
with BM and 49 patients with VM in a retrospective study and showed that low S–PCT levels
(≤1.27 ng/mL) independently distinguished tuberculosis meningitis from bacterial meningitis, with a
96.2% sensitivity and a 62.9% specificity. However, S–PCT levels were not significantly different in
patients with tuberculosis versus viral meningitis. Logistic regression showed that an S–PCT level
of >0.4 ng/mL was an independent predictor of a poor prognosis in patients with tuberculosis
meningitis and had a negative correlation with Glasgow Coma Scale (GCS) scores at discharge
(r = 0.437, p = 0.026) [27].
A prospective observational study published by Morales-Casado et al. in 2016 assessed the role of
32 clinical and epidemiological variables as predictors of bacterial meningitis in 154 patients aged over
15 years who presented in the Emergency Department with symptoms of acute meningitis. Multivariate
logistic regression showed that four variables (S–PCT, CSF lactate ≥33 mg/dL, CSF glucose <60% of
blood value, and CSF polymorphonuclears ≥50%) were excellent tools for the prediction of bacterial
meningitis; the model using S–PCT ≥0.8 ng/mL and CSF lactate ≥33 mg/dL had an AUC of 0.992,
with a 99% sensitivity and a 98% specificity for predicting bacterial meningitis (95% CI: 0.979–1;
p < 001) [28].
Another prospective observational study by Morales-Casado et al. evaluated the usefulness of
inflammatory markers for the diagnosis of bacterial meningitis in 220 patients and showed that S–PCT
had the highest AUC (0.972; 95% CI, 0.946–0.998; p < 001) for the diagnosis of BM. Using 0.52 ng/mL as
a cutoff, S–PCT had 93% sensitivity and 86% specificity for the diagnosis of BM overall, but sensitivity
was 96% and specificity was 75% in patients >75 years old [29].
In 2016, Wei and colleagues published a systematic review and meta-analysis on the role of
procalcitonin in the diagnosis of bacterial versus non-bacterial meningitis. The review included
twenty-two studies with a total of 2058 patients; diagnostic accuracy of S–PCT and CSF PCT was
assessed using the bivariate model and analysis showed that PCT is a useful biomarker for the
diagnosis of bacterial meningitis: CSF PCT had 0.86 specificity and 0.8 sensitivity, whereas S–PCT had
0.97 specificity and 0.95 sensitivity [30].
A prospective, observational study published in 2016 by Morales Casado et al. evaluated
serum PCT and C-reactive protein as markers for detection of bacterial meningitis in 98 patients
diagnosed with acute meningitis in the emergency department (38 pts with BM, 33 with VM, 15 with
probable VM, and 12 with presumptively diagnosed, partially treated acute meningitis). Data analysis
showed that S–PCT levels were significantly higher in patients with BM (11.47 ± 7.76 ng/mL vs.
0.10 ± 0.15 ng/mL in viral meningitis, p < 0.001). Using 1.1 ng/mL as cutoff, S–PCT as diagnostic tool
achieved 94.6% sensitivity, 72.4% specificity, 95.4% NPV, and 69.2% PPV, and AUC was 0.965 (95% CI,
0.921–1; p < 0.001). Based on these results, the authors concluded that S–PCT performs better than
CRP in the detection of bacterial meningitis [31].
In a prospective observational study published in 2017, Zhang et al. measured S–PCT and CSF
PCT, high-sensitivity C-reactive proteins (Hs-CRP), proteins, chloride, and glucose in three patient
groups: 24 patients with suppurative meningitis, 20 with VM, and 22 with tuberculous meningitis
(TBM). S–PCT values were significantly higher in the suppurative meningitis group, but declined
significantly in suppurative meningitis patients after 72 h and seven days of treatment. In addition,
admission CSF PCT levels were significantly lower in VM compared to TBM and suppurative
meningitis patients, but CSF PCT values did not change significantly with treatment. The authors
concluded that S–PCT changes over time can be useful in evaluating disease progression and response
to treatment in patients with suppurative meningitis [32].
A retrospective clinical study on 80 patients with BM and 58 with VM, published by Park in 2017,
showed that S–PCT >0.12 ng/mL is a significant marker for differentiating BM from VM, and also that
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S–PCT levels >7.26 ng/mL are associated with higher risk of death (OR = 9.09, 95% CI: 1.74–47.12,
p = 0.016) [33].
Last, a prospective observational study published by Li et al. in 2017 included 143 ICU patients
(49 with BM, 25 with TBM, 34 with viral meningitis/encephalitis (VM/E), 15 with autoimmune
encephalitis (AIE), and 20 with non-inflammatory nervous system diseases (NINSD) to assess the
value of CSF PCT, S–PCT and other biomarkers in the diagnosis of BM. In this study, CSF PCT levels
(median, range) were significantly (P < 0.01) higher in BM patients (0.22, 0.13–0.54 ng/mL) compared to
TBM (0.12, 0.07–0.16 ng/mL), VM/E (0.09, 0.07–0.11 ng/mL), AIE (0.06, 0.05–0.10 ng/mL), or NINSD
(0.07, 0.06–0.08 ng/mL) patients. Furthermore, CSF PCT had the highest area under the receiver
operating characteristic curve (AUROC) (0.881; 95% CI 0.810–0.932; cutoff 0.15 ng/mL; sensitivity
69.39%; specificity 91.49%), whereas S–PCT was less useful (AUROC 0.759, 95% CI 0.669–0.849, cutoff
0.19 ng/mL, with sensitivity 67.35% and specificity 75.53% for the diagnosis of BM [34]. Findings
of clinical studies evaluating the role of PCT in patients with known or suspected meningitis are
summarized in Table 1. Quantitative measures, including AUC, sensitivity, specificity, and cut-off
points, reported in clinical studies included in this review are summarized in Table 2.
Table 1. Clinical studies evaluating the role of procalcitonin (PCT) in patients with known or
suspected meningitis.
Reference Origin Study Design Patient Population Findings
[3] St. Etienne,France Prospective study
105 pts (23 with BM, 57 with VM,
25 controls), 54 women, 51 men, mean
age 42 years (range 16–82 years)
S–PCT was the best marker for differentiating
BM vs. VM. with S–PCT > 0.2 ng/mL as the
cutoff, S–PCT sensitivity and specificity
approaches 100% for diagnosing acute BM
[4] Heidelberg,Germany Prospective case series
30 pts (13 men, 17 women), mean age
52 (range, 16–87 years)
S–PCT is useful for distinguishing BM from
VM. Increased S–PCT levels have a high
specificity for bacterial infection
[5] St. Etienne,France Prospective study
179 patients with suspected
meningitis: 32 patients with BM, 90
patients with VM, 57 patients did not
have meningitis
S–PCT is the most discriminant variable for
differentiating BM vs. VM, with a threshold
value 0.93 ng/mL
[6] Saitama, Japan Prospective study
42 patients requiring CSF
examination, 12 patients with
non-inflammatory CNS disease as
controls, 22 men, mean age 37.8 years;
20 women, mean age 38.1 years
CSF PCT levels not significantly different in
BM, VM, or mycotic meningitis. S–PCT >
0.1 mcg/L in all BM patients. AUC and cut-off
values were not reported
[7] Berlin,Germany
Case series, 12 adults
with meningitis
12 pts: 7 men, 5 women, mean age
48.6 years






20 BM patients: 11 men, 9 women,
mean age 55 years; 25 TBE patients:
13 men, 12 women, mean age 49 years
Median S–PCT 6.45 ng/mL (0.25–43.76) in
patients with BM vs. 0.27 ng/mL (0.05–0.44) in
patients with TBE. S–PCT and CSF PCT >
0.5 ng/mL is a reliable indicator of BM
[10] Dresden,Germany Prospective ICU study
11 ventriculitis patients with negative
CSF (6 men, 5 women, mean age
44.3 years), 4 ventriculitis patients
with positive CSF (2 men, 2 women,
mean age 56.2 years), 10 community
BM (7 men, 3 women, mean age
49.4 years)
S–PCT alone is not helpful for diagnosis
of ventriculitis
[11] Munich,Germany




7 ICU BM patients (4 men, 3 women,
mean age 55 years), and one woman
with aseptic, chemical meningitis
S–PCT is useful in differentiating bacterial vs.
chemical CNS inflammation
[12] Poland Observational study,33 adult patients
17 bacterial meningoencephalitis
patients vs. 16 lymphocytic
meningitis patients
CSF PCT and S–PCT significantly higher in BM
vs. lymphocytic meningitis (CSF PCT
0.63 ng/mL vs. 0.23 ng/mL, p < 0.05, S–PCT
9.97 ng/mL vs. 0.27 ng/mL, p < 0.01
[13] St. Etienne,France
Prospective study,
48 BM patients with
S–PCT > 0.5 ng/mL
on admission
48 BM patients: 21 men, 27 women,
mean age 55 years
S–PCT levels declined rapidly with
antibiotic therapy
[14] Borgsdorf,Germany Prospective Study
40 patients with AD, 12 with FTD, 8
with DLB, 12 with VD, 16 with acute
neuroinflammation, 50 controls
Measured S–PCT, CSF PCT. S–PCT elevated in
meningitis. CSF PCT helpful in
diagnosing dementia
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Table 1. Cont.




52 patients (25 men, 27 women) with
suspected meningitis, median age
36 (range, 13–92 years)
S–PCT has a moderate overall accuracy for





133 NBM patients: 66 men, 67 women,
mean age 33 years vs. 18 BM patients:
9 men, 9 women, mean age 52 years






35 patients (17 men, 18 women, mean
age 55 years) with BM, 218 patients
(116 men, 102 women, mean age
35 years) with VM
S–PCT had very high diagnostic value for
distinguishing BM vs. VM
[18] Ahvaz, Iran
Prospective study,
36 patients with acute
meningitis
36 acute meningitis patients: 26 men,
10 women, mean age 38.4 years
S–PCT levels were reduced after 72 h in
patients who improved, but remained higher in





14 patients with BM: 4 men,
10 women, median age 52 (range
44–63) vs. 64 aseptic meningitis
patients: 35 men, 29 women, median
age 47.5 (range 35–61 years)
S–PCT has limited value for diagnosing BM





22 sepsis patients (16 men, 6 women,
mean age 58 years), 22 severe sepsis
patients (17 men, 5 women, mean age
55.4 years), 12 septic shock patients
(5 men, 6 women, mean age
51.9 years), and 48 SIRS patients
(28 men, 20 women, mean age 51.8
years)
Assessed S–PCT for discrimination between
sepsis and SIRS. S–PCT levels were
significantly different between groups at all
stages of sepsis. S–PCT has value for







16 ABM patients (9 men, 7 women,
mean age 39 years) and 24 patients
with acute ASM (21 men, 3 women,
mean age 29 years), 10 controls
(7 men, 3 women, mean age 40 years)
S–PCT significantly higher in BM compared to
ASM patients (2.49 ± 2.54 vs. 0.89 ± 0.69,
p < 0.001). Difference in BM vs. ASM persisted





45 BM patients (30 men, 15 women,
mean age 50) vs. 75 non-BM patients
(55 men, 20 women, mean age
47 years)





36 head trauma patients with EVD
(30 men, 6 women, mean age
32.8 years)
High S–PCT in patients with
ventriculostomy-related infections. Early






50 with PNBM (23 men, 27 women,
median age 42 years) vs. 128 without
PNBM 49 men, 79 women, median
age 42 years)
CSF lactate and PCT have significant
diagnostic value for PNBM and could be useful





19 BM patients (12 men, 7 women,
mean age 41 years) vs. 11 VM patients
(8 men, 3 women, mean age 24 years)
vs. 28 controls (20 men, 8 women,
mean age 30 years)
CSF–PCT is helpful in distinguishing BM from






26 TBM patients (13 men, 13 women,
mean age 57 years) vs. 70 BM patients
(42 men, 28 women, mean age
64 years) vs. 49 VM patients (24 men,
25 women, mean age 40 years)
S–PCT levels not significantly different in TBM
vs. VM, but S–PCT > 0.4 ng/mL was a
predictor of poor prognosis in TBM
[29] Toledo, Spain Prospective,observational study
220 meningitis patients (136 men,
84 women, mean age 30 years)
PCT has high diagnostic powers and
outperforms CRP and leukocytes for the
detection of bacterial meningitis
[28] Toledo, Spain Prospectiveobservational study 154 ED patients over age 15
Logistic regression shows that
S–PCT ≥ 0.8 ng/mL + CSF lactate ≥ 33 mg/dL
are strong predictors of BM (p < 0.001)
[31] Toledo, Spain Prospective,observational study
98 ED patients (66 men, 32 women,
mean age 44 years), 38 BM patients
(mean age 61.5 years), 33 VM patients
(mean age 36 years) 15 with probable
VM, but negative cultures, 12 with
antibiotic treatment and
negative cultures
S–PCT higher in BM vs. VM (11.47 ± 7.76 vs.
0.10 ± 0.15 ng/mL, p < 0.001). S–PCT is
superior to S-CRP for BM detection
[32] Jilin, China Prospectiveobservational study
66 meningitis patients: 37 men,
29 women, mean age 40.21 years
(24 suppurative meningitis, 20 VM,
22 TBM), 20 controls: 11 men,
9 women, mean age 43.05 years
S–PCT is significantly higher in suppurative
meningitis, declined significantly after 72 h and
7 days of treatment. CSF PCT is significantly
lower in VM compared to TBM and
suppurative meningitis.
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Table 1. Cont.





80 patients with BM (49 patients,
31 women, median age 66 years) vs.
58 VM patients (30 men, 28 women,
median age 37 years)
S–PCT levels >0.12 ng/mL are significant




143 ICU patients with
CNS disease
49 BM patients (36 men, 13 women,
median age 43 years) vs. 25 TBM
patients (15 men, 10 women, median
age 42 years) vs. 34 VM patients
(25 men, 9 women, median age
39.5 years) vs. 15 AIE patients (6 men,
9 women, median age 27 years) vs.
20 NINSD (11 men, 9 women, median
age 43 years)
CSF PCT levels were significantly higher in BM
compared to TBM, VM, AIE, or NINSD
ABM = Acute Bacterial Meningitis, AD = Alzheimer’s disease, AIE = Autoimmune Encephalitis, ASM = Aseptic
Meningitis, AUC = Area Under the Curve, AUROC = Area Under The Receiver Operating Characteristic
Curve, BM = Bacterial Meningitis, CI = Confidence Interval, CRP = C-reactive protein, CSF = cerebrospinal
fluid, DLB = Dementia with Lewy bodies, ED = Emergency Department, EVD = External Ventricular Drainage,
FTD = Frontotemporal dementia, LP = Lumbar Puncture, NBM = Nonbacterial Meningitis, NICU = Neurological
Intensive Care Unit, NINSD = Non-Inflammatory Nervous System Disease, NPV = Negative Predictive Value,
PMN = Polymorphonuclear, PNBM = Post-Neurosurgical Bacterial Meningitis, PPV = Positive Predictive Value,
Pts = patients, S–PCT = Serum Procalcitonin, SIRS = Systemic Inflammatory Response Syndrome, Tb = Tuberculosis,
TBE = Tick-Borne Encephalitis, TBM = Tuberculous Meningitis, VD = Vascular Dementia, VM/E = Viral
Meningitis/Encephalitis, VM = Viral Meningitis.
Table 2. Area under the Curve (AUC), sensitivity, specificity, and cut-off points reported in clinical
studies evaluating Serum Procalcitonin (S–PCT) or Cerebrospinal Fluid Procalcitonin (CSF PCT) in
patients with known or suspected meningitis.
Reference Biomarker AUC (95% CI) p Value Cut-off Point Sensitivity Specificity Comments
[3] S–PCT Not reported 0.2 ng/mL 100% 100%
CSF PCT found only in two patients with
hemorrhage. S–PCT sensitivity and specificity
approach 100% for diagnosing acute BM
[4] S–PCT Not reported 0.5 ng/mL 69%(41–89%)
100%
(79–100%)
S–PCT is a useful variable for distinguishing
BM from VM. Increased S–PCT levels have a
high specificity for bacterial infection
[5] S–PCT Not reported 0.93 ng/mL Notreported 100%
S–PCT is the most discriminant variable for
differentiating BM vs. VM
[7] S–PCT Not reported 1 ng/mL 58.3% Notreported











Median S–PCT is significantly higher in BM
(6.45 ng/mL range 0.25–43.76) vs. TBE
(0.27 ng/mL, 0.05–0.44). S–PCT, CSF
PCT > 0.5 ng/mL is a reliable indicator of BM
[10] S–PCT Not reported 1.0 ng/mL 100% 83% S–PCT is not helpful for diagnosis ofventriculitis, but is highly diagnostic for BM
[11] S–PCT Not reported 1.0 ng/mL Notreported
Not
reported
S–PCT is useful in differentiating bacterial vs.
chemical causes of CNS inflammation





CSF PCT and S–PCT are significantly higher
in bacterial meningoencephalitis vs.
lymphocytic meningitis
[13] S–PCT Not reported Not reported Notreported
Not
reported
Rapid S–PCT decline with antibiotic therapy
reduces the value of repeating LP to assess
antibiotic therapy effectiveness







S–PCT levels are elevated in meningitis, but
not in dementia
[15] S–PCT 0.93 (0.64–0.99) 0.25 ng/mL 0.90(0.55–1.0)
0.92
(0.62–1.0)
S–PCT is helpful for differentiating BM vs.











S-CRP and S–PCT are excellent predictors of
BM
[17] S–PCT 0.99 (0.99–1.00) 0.28 ng/mL 97% 100% S–PCT: High diagnostic value fordistinguishing BM vs. VM
[18] S–PCT Not reported Not reported Notreported
Not
reported
S–PCT can be a useful marker for the follow
up of BM patients
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Reference Biomarker AUC (95% CI) p Value Cut-off Point Sensitivity Specificity Comments
[19] S–PCT 0.617 0.15 ng/mL 50% 80% S–PCT is of limited value for diagnosing BM
[20] S–PCT 0.799 (0.711–0.887) 2 ng/mL 75% 83.3% S–PCT has value for discriminating sepsis vs.SIRS and determining sepsis severity
[21] S–PCT AUC shown, but valuenot reported 1.2 ng/mL 68.8% 83.3%
Admission S–PCT is higher in BM patients
compared to ASM patients (2.49 ± 2.54 vs.
0.89 ± 0.69, p < 0. 001). The difference in BM
vs. ASM persisted after 3 days of therapy
(1.70 ± 1.58 vs. 0.64 ± 0.51, p < 0.001)
[22] S–PCT 0.96 (0.93–1.00) 0.88 ng/mL 87% 100% S–PCT and CSF PCT increased in BM patients.
[23] S–PCT Not reported Not reported Notreported
Not
reported
Mean S–PCT < 2.0 ng/mL in patients with

















CSF lactate and CSF PCT have significant
diagnostic value for PNBM
[25] CSFPCT Not reported Not reported 100% 96.4%
CSF PCT 4.71 ± 1.59 ng/mL in BM,
0.13 ± 0.03 ng/mL in VM, <0.1 in patients
with non-infectious disease
[27] S–PCT 0.876 (0.688–0.972) 1.27 ng/mL 96.2%(80.4–99.9)
62.9%
(50.5–74.1)
S–PCT useful for distinguishing TBM from
BM. S–PCT > 0.4 ng/mL is predictor of poor
outcome in TBM












The combination of S–PCT ≥ 0.8 ng/mL +
CSF lactate ≥ 33 mg/dL has excellent
diagnostic value for predicting BM
[31] S–PCT 0.965 (0.921–1),p < 0.001 1.1 ng/mL 94.6% 72.4%
S–PCT significantly higher in BM vs. VM
(11.47 ± 7.76 vs. 0.10 ± 0.15 ng/mL, p < 0.001).
Concluded that S–PCT is superior to serum
CRP for detecting BM
[32] S–PCT Not reported Not reported Notreported
Not
reported
S–PCT is significantly higher in suppurative
meningitis and declined 72 h and 7 days after
treatment
[33] S–PCT Not reported 0.12 ng/mL 88.75% 74.14%
S–PCT > 0.12 ng/mL is useful for
differentiating BM vs. VM. S–PCT >
7.26 ng/mL associated with higher mortality
(OR = 9.09, 95% CI: 1.74–47.12, p = 0.016)
[34] CSFPCT 0.881 (0.810–0.932) 0.15 ng/mL 69.39 91.49%
CSF PCT levels are the most useful biomarker
for the diagnosis of BM
[34] S–PCT 0.759 (0.669–0.849) 0.19 ng/mL 67.35% 75.53% S–PCT is less useful than CSF PCT for thediagnosis of BM
4. Discussion
Procalcitonin, a precursor of calcitonin, is a 116 amino acid peptide and a member of the calcitonin
superfamily of peptides, with a molecular weight of 14.5 kDa. PCT is synthesized by the parafollicular
C cells of the thyroid gland and is involved in calcium homeostasis. In addition, PCT is also produced
by the neuroendocrine cells of the lung and the intestine. In the CNS, cells likely to be sources of
CSF PCT include the neurons, astrocytes, and microglia in the parenchyma and meningeal cells.
Normal S–PCT concentration is <0.05 ng/mL, with a reported half-life of 25–30 h [35]. Procalcitonin
is considered a sensitive and specific marker of certain bacterial infections, such as pneumonia,
meningitis, and pyelonephritis, and has been used as tool for the assessment of disease severity.
In addition to bacterial infections, increased PCT levels have been identified in other clinical conditions,
including severe fungal infections, trauma, burns, major surgery, and medical therapy that stimulates
cytokine production. In these cases, S–PCT levels are less elevated and rarely exceed 0.5 ng/mL [36].
There are several hypotheses regarding the pathophysiology of PCT; most suggesting that procalcitonin
may be involved in calcium metabolism, cytokine network, and the modulation of nitric oxide (NO)
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synthesis [37]. In sepsis, PCT hypersecretion emanates from multiple tissues throughout the body,
which are not traditionally viewed as endocrine tissues. It is likely that PCT in sepsis potentiates the
inflammation cascade by increasing leukocyte-derived cytokines and augmenting reactive oxygen
species [38]. PCT secretion is stimulated in bacterial infections by various cytokines, such as IL–1, IL–6,
and tumor necrosis factor-alpha. In contrast, PCT production is down-regulated in viral infections,
probably due to increased interferon gamma production. Consequently, PCT is considered a useful
tool for diagnosing sepsis and repeat S–PCT measurements over time can be used to monitor response
to therapy. Most currently used inflammatory markers do not reliably differentiate between a systemic
inflammatory response and sepsis. However, because PCT is, generally, not induced by severe viral
infections or non-infectious inflammatory reactions, PCT can help distinguish bacterial from viral
infections and differentiate between infectious and non-infectious origins of systemic inflammatory
response syndrome (SIRS), acute respiratory distress syndrome (ARDS), pancreatitis, cardiogenic
shock, and acute rejection of transplanted organs [39].
In CNS infections, disruption of the blood brain barrier (BBB) has been documented in patients
with bacterial infections and in experimental models [40,41]. Elevated CSF PCT levels in bacterial
meningitis patients seem to be the result of this mechanism and some studies have shown higher
CSF PCT levels in patients with Gram-negative bacteria compared to patients with Gram-positive
bacteria [42]. In CNS infection cases, microglia and meningeal cells express the responding
receptors (Toll-like receptors [TLRs]) to the invading bacteria [43]. Several questions regarding PCT
synthesis and secretion by brain cells during bacterial meningitis have not been resolved and need
further investigation.
Prompt diagnosis and appropriate antimicrobial treatment are of paramount importance and can
contribute to a reduced morbidity and mortality in sepsis. Procalcitonin is an acute-phase protein
with faster kinetics than C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR), and is
detectable in serum within 4–6 h after the onset of a bacterial infection. PCT serum levels peak within
24 h and start to decline by approximately 50% daily with effective treatment [44–46]. Although there
is no “gold standard” for the diagnosis of most infections, several biomarkers have been used as tools
to monitor disease progression. An ideal marker should help with early diagnosis and therapeutic
decision-making in bacterial infections and should also help clinicians assess the course and prognosis
and, in that regard, PCT seems to be superior compared to other commonly used biomarkers.
Despite advances in diagnosis and treatment, bacterial meningitis is a neurological emergency,
requires treatment in a high acuity care unit, and remains an important cause of mortality. The diagnosis
and management of bacterial meningitis requires various biological tests and a multidisciplinary
approach. Empiric antimicrobial and adjunctive therapy should start as soon as there is clinical
suspicion of meningitis. Regarding laboratory findings, a left shift in peripheral white blood cell count,
elevated serum PCT and C-reactive protein, CSF pleocytosis with predominance of polymorphonuclear
leukocytes, and decreased glucose concentration are predictive of bacterial meningitis. CSF analysis
is a gold standard for the diagnosis of meningitis: CSF gram staining reveals bacteria in 50% to
80% of cases and cultures are positive in 80% of cases, at best. However, the sensitivity of both
tests is <50% in patients already receiving antibiotics. CSF leukocyte count, protein, glucose and
lactate concentration, and a latex agglutination test adapted for the rapid direct detection of soluble
bacterial antigens in CSF lack the specificity and sensitivity for the diagnosis of meningitis and can
only define a clinical probability. In fact, the relatively imprecise nature of the cutoff values for these
markers can make their interpretation difficult. Furthermore, in the early phases of acute bacterial and
viral meningitis, differential diagnosis is difficult because signs and symptoms are often non-specific
and, therefore, differentiation between bacterial and viral meningitis remains a difficult problem for
clinicians. Biomarkers, like CRP, procalcitonin, or sTREM–1, may be useful for diagnosis and can help
differentiate between viral and bacterial meningitis [47,48]. Serum and CSF PCT levels can be more
useful in the diagnosis of bacterial meningitis and in distinguishing bacterial from viral meningitis.
A systematic review published by Markanday in 2015 compared serum PCT versus CRP as markers for
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bacterial infection and showed that, compared to CRP, S–PCT had a higher sensitivity and specificity
for differentiating bacterial from noninfectious causes of inflammation [49].
Diagnosis of meningitis requires a detailed history and physical examination combined with
high clinical suspicion and appropriate cultures. Prognosis of meningitis depends on rapid
diagnosis, identification of the cause, and prompt implementation of appropriate antibiotic treatment.
Because clinical and laboratory data available within a few hours after hospital admission are not
reliable (except for when bacteria are found in CSF under the microscope), use of biological markers
has been proposed as a tool to improve the accuracy of initial diagnosis and, in this setting, serum and
CSF procalcitonin measurements seem to be of great value. Because of its high specificity and positive
predictive value, elevated S–PCT concentrations (>0.5 ng/mL) indicates ongoing and, potentially,
severe systemic infection. Because C-reactive protein is the inflammatory marker most widely used
in emergency departments to discriminate bacterial from viral infections, Gerdes et al. published a
meta-analysis in 1998 from 35 studies aiming to assess the usefulness of CRP in discriminating bacterial
from viral meningitis. The meta-analysis showed that, although the majority of authors propose using
CRP as an additional tool for discriminating bacterial from viral meningitis, only negative CRP tests
are highly informative in most clinical settings [50]. However, procalcitonin seems to be a valuable
tool for discriminating the causative factor of meningitis as, since 1997 and 1998, two French studies
showed that, using a cut-off range of 0.5–2 ng/mL, S–PCT had 100% sensitivity and specificity in
discriminating bacterial from viral meningitis [51]. Similarly, a more recent meta-analysis published
by Vikse et al. in 2015 showed that procalcitonin has a 90% sensitivity and a 98% specificity in the
discrimination between bacterial and viral meningitis [26].
This review aims to provide clinicians with an overview of the role of S–PCT and CSF-PCT as
diagnostic markers in CNS infections. Several publications assessing the role of PCT as a guide for
antibiotic therapy in adult meningitis patients suggest that S–PCT is a sensitive, specific, and prognostic
marker of bacterial infections, therefore, S–PCT and CSF PCT measurement can help differentiate
bacterial from viral meningitis. Interpretation of PCT levels must take into consideration the clinical
presentation of the CNS infection. In addition, knowledge of assay characteristics is important for
setting specific cut-off values and functional assay sensitivities. Most clinical studies presented in
this review have limitations, including small sample sizes and inconsistent reporting of laboratory
findings: In some, AUC values and cut-off values were not reported, while a few were published
in languages other than English and, therefore, we only included in the review data reported in the
Abstract. Therefore, even though S–PCT seems to be a useful biomarker for the diagnosis and possible
prognosis in patients with BM, additional data from larger, well-designed studies are needed to better
evaluate the role of procalcitonin in the differentiation between viral and bacterial meningitis and as
tool to improve the overall management of patients with meningitis.
5. Conclusions
Serum PCT is a biomarker with high sensitivity and specificity in identifying patients with
sepsis and can be useful for the diagnosis of bacterial infections. This literature review identified
several studies evaluating the role of S–PCT in the assessment of patients with central nervous system
infections. Published data suggests that, compared to other acute phase biomarkers, S–PCT is superior
as a sepsis biomarker in acute meningitis and can help differentiate bacterial from viral meningitis.
Combined with good clinical judgment and appropriate use of antimicrobial agents, S–PCT could be a
valuable adjunct in the timely diagnosis and management of sepsis in patients with CNS infection.
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Abstract: Malignancies of the nasal cavity and paranasal sinuses account for 1% of all malignancies
and 3% of malignancies of the upper aerodigestive tract. In the sinonasal tract, nearly half of all
malignancies arise in the nasal cavity, whereas most of the remaining malignancies arise in the
maxillary or ethmoid sinus. Squamous cell carcinoma is the most common histological subtype
of malignant tumors occurring in this area, followed by other epithelial carcinomas, lymphomas,
and malignant soft tissue tumors. Although many of these tumors present with nonspecific symptoms,
each tumor exhibits characteristic imaging features. Although complex anatomy and various normal
variants of the sinonasal tract cause difficulty in identifying the origin and extension of large sinonasal
tumors, the invasion of vital structures such as the brain, optic nerves, and internal carotid artery
affects patients’ prognosis. Thus, diagnostic imaging plays a key role in predicting the histological
subtype and in evaluating a tumor extension into adjacent structures. This article describes the
computed tomography and magnetic resonance imaging findings for malignant sinonasal tumors.
Keywords: sinonasal tract; malignant tumor; CT; MRI
1. Introduction
Sinonasal neoplasms are relatively rare and malignant sinonasal neoplasms are more common
than their benign counterparts. Sinonasal malignancies comprise only 3% of all head and neck cancers
and 1% of all malignancies [1–3]. The complex anatomy of the region and the rare occurrence of
these tumors pose diagnostic and therapeutic challenges. Of the various histological subtypes of
malignant sinonasal tumors, squamous cell carcinoma (SCC) is the most common subtype, whereas
the other subtypes, such as adenocarcinoma, minor salivary gland carcinoma, undifferentiated
carcinoma, neuroendocrine carcinoma, and nonepithelial malignancies (such as sarcoma, lymphoma,
plasmacytoma, olfactory neuroblastoma, and melanoma) are considerably less common. The treatment
modalities vary depending on the tumor histological subtype, location, and extent of the disease
and include surgery, radiation, chemotherapy, or a combination of two or more of these modalities.
The prognosis of the patients largely depends on tumor histology, location, and stage.
2. Anatomy
The sinonasal tract comprises the nasal cavity, maxillary sinus, ethmoid sinus, frontal sinus,
and sphenoid sinus. It includes various tissue types such as epithelium, mucosal epithelium, vessel,
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nerve, cartilage, bone, and lymphatic tissue. The maxillary, ethmoid, nasal, frontal, palatine, sphenoid,
and lacrimal bones are also included. This area comprises bone and cartilage lined with ciliated
respiratory epithelium and is located between the orbit and the oral cavity. This area is also close to the
frontal cortex through the cribriform plate of the ethmoid bone and is connected with the cerebrum by
vessels, lymph channels, and nerves.
The nasal cavity is divided by the nasal septum in the midline. Bilateral nasal cavities include
the superior, middle, and inferior turbinates; in addition, the nasal meatus is located under each of
them. The common nasal meatus lies between the nasal turbinate and the nasal septum, and the
olfactory cleft is located superior to the lower border of the middle turbinate. The paranasal sinuses
are connected to the nasal cavity and categorized according to the location of the ostium. The middle
meatus drains the maxillary, frontal, and anterior ethmoid sinuses, whereas the superior meatus drains
the posterior ethmoid and sphenoidal sinuses. These are located close to important structures, such as
the cavernous sinus, the internal carotid artery, the pituitary gland, and the optic nerve.
The upper third of the nasal cavity, the frontal sinus, and parts of the ethmoid and sphenoid
sinuses are supplied by the ophthalmic artery, whereas most of the remaining sinonasal tracts are
supplied by facial and maxillary arteries. The olfactory mucosa in the upper part of the nasal cavity
is innervated by the olfactory nerve. The ophthalmic nerve (V1) provides sensory innervation to the
ethmoid sinus, sphenoid sinus, lateral wall of the nasal cavity, and the anterior part of the nasal septum.
The maxillary nerve (V2) provides sensory innervation to the maxillary sinus. Submandibular lymph
nodes drain the anterior components of the sinonasal tract (anterior drainage pathway), whereas the
retropharyngeal lymph nodes drain the posterior components of the sinonasal tract (posterior drainage
pathway). These routes of lymphatic drainage finally reach the superior deep cervical lymph nodes.
3. Clinical Presentation
The clinical presentations of sinonasal malignancies are nonspecific and identical to those of
inflammatory sinus disease, such as nasal obstruction, rhinorrhea, epistaxis, headache, and facial
pain. In addition, these malignancies are often asymptomatic until they erode and invade the adjacent
structures. Therefore, sinonasal malignancies are usually diagnosed in advanced stages, and the
survival rate and prognosis of these patients remain poor. Sinonasal malignancies should be considered
in patients with unilateral nasal obstruction or recurrent epistaxis. Progressive sinonasal malignancies
that often invade the adjacent structures produce characteristic symptoms, such as cranial neuropathies
due to intracranial extension, facial subcutaneous soft tissue swelling, exophthalmos, diplopia,
visual disturbances, eye movement disorders, olfactory dysfunction, and respiratory symptoms.
Early detection and adequate treatment are required to improve the survival and mortality rates.
4. Imaging
Computed tomography (CT) and magnetic resonance imaging (MRI) are very useful tools
for the assessment of tumor size, nature, extent, and invasion. The evaluation of the potential
extension into adjacent regions impacts the surgical or therapeutic planning, particularly in cases
with the involvement of the anterior and middle cranial fossa, orbit, pterygopalatine fossa, palate,
or infratemporal fossa (masticator and parapharyngeal space). CT is the most commonly used imaging
modality because of its wider availability, easy access, lower cost, and potential to offer greater anatomic
detail. In comparison to MRI, CT is particularly effective in delineating calcification and evaluating
the pattern of bone invasion. Intralesional calcifications are observed in some sinonasal disorders,
such as adenocarcinoma, olfactory neuroblastoma, inverted papilloma, fibrous dysplasia, osteoma,
osteosarcoma, cartilaginous tumor, fungal sinusitis, and dentigerous tumor. Characteristic patterns
of bone invasion help predict the tumor histology. High grade malignancies show extensive bony
destruction, whereas small round cell tumors show permeative invasion and lack of bony destruction.
Benign lesions and low grade malignancies may cause bony expansion due to their slow and expansile
growth. Contrast-enhanced CT is invaluable for the identification of the feeding artery (because of its
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high spatial resolution) and for the diagnosis of hypervascular tumors. In contrast, MRI provides higher
contrast resolution and affords an excellent characterization of the soft tissue components of the tumor.
The signal intensity within a tumor varies according to the tissue components. Malignant tumors
usually exhibit nonspecific hyperintensity on T2-weighted images (T2WI) and hypo- to isointensity on
T1-weighted images (T1WI). On T2WI, mucinous or cartilaginous tumors show marked hyperintensity,
hypercellular tumors show slight hyperintensity, and tumors with fibrosis, calcification, or flow
void show hypointensity. On T1WI, hyperintensity within a tumor is indicative of the presence of
methemoglobin, melanin, lipid, protein, and mineral elements. Diffusion-weighted image (DWI) with
measurement of apparent diffusion coefficient (ADC) captures the degree of Brownian movement
of the water molecules in tissues, which serves as a useful imaging biomarker. Low-ADC lesions
with strong diffusion restriction indicate hypercellularity, abscess, or hemorrhage, whereas high-ADC
lesions indicate hypocellularity, mucus, cartilage, or fluid. Therefore, DWI with ADC measurement is
usually useful to differentiate between benign and malignant tumors. The ADC values of malignant
sinonasal tumors (0.87–1.10 × 10−3 mm2/s) have been shown to be significantly lower than those of
benign sinonasal lesions (1.35–1.78 × 10−3 mm2/s) [4–6]. Contrast-enhanced MRI is a useful method
in detecting perineural spread and dural invasion. Perineural spread can be diagnosed as nerve
thickening, widening of the neural foramen, loss of perineural fat, and enhancement of the nerve.
Linear enhancement alone is not a conclusive sign of dural invasion; however, dural thickening > 5 mm,
pial enhancement, or the presence of focal dural nodules are indicative of dural invasion.
5. Sinonasal Malignancies
5.1. Squamous Cell Carcinoma
Squamous cell carcinoma (SCC) is the most common histological subtype and accounts for more
than half of all sinonasal malignant tumors. It most commonly affects patients in the sixth and seventh
decade of life with male predominance. The maxillary sinus is the most frequently affected site,
followed by the nasal cavity and the ethmoid sinus. Primary SCCs of the sphenoid sinus and frontal
sinus are rare. In the past, sinonasal SCC has been linked to cigarette smoking and occupational
exposures [7]. However, in recent years, the generational changes in sexual behavior may have
led to an increased positivity rate for human papillomavirus (HPV) among patients with sinonasal
SCC; consequently, HPV has been identified in 32–62% of all sinonasal SCCs [8,9]. HPV positivity is
more common in SCCs of the nasal cavity than in paranasal SCCs [9]. As with oropharyngeal SCCs,
patients with a HPV-positive sinonasal SCC have a better prognosis than patients with a HPV-negative
sinonasal SCC [8,9].
Sinonasal SCCs are characterized by aggressive bony destruction of the adjacent sinus walls
(Figure 1). Because sinonasal SCCs are often detected at an advanced stage, the invasion of the
contralateral sinonasal area, orbital wall, infratemporal fossa, and skull base is sometimes observed.
Hypoxia is a common feature in most cases of SCC, and prolonged oxygen deprivation often leads
to chronic hypoxic stress and consequent tumor necrosis [10]. Thus, intratumoral necrosis is also
one of the characteristic findings in SCCs. On MRI, isointensity on T1WI, slight hyperintensity on
T2WI, and moderate enhancement on contrast-enhanced T1WI are typical and nonspecific imaging
findings for SCCs. Smaller lesions are typically homogeneous, whereas larger tumors are usually more
heterogeneous and exhibit areas of necrosis and hemorrhage [11]. In the maxillary sinus, the ADC
values of SCC (0.95 × 10−3 mm2/s) were higher than those of non-Hodgkin’s lymphoma (NHL)
(0.61 × 10−3 mm2/s) [12].
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Figure 1. Squamous cell carcinoma of the left maxillary sinus. Contrast-enhanced CT image showing
an ill-demarcated, heterogeneously enhanced bulky mass with extensive bony destruction (arrows).
5.2. Adenocarcinoma
Adenocarcinomas account for 10–20% of all sinonasal malignancies. Sinonasal adenocarcinomas
are categorized into salivary type adenocarcinomas and non-salivary type adenocarcinomas [13].
The latter are further classified into intestinal-type adenocarcinomas (ITAC) and nonintestinal-type
adenocarcinomas (non-ITAC) [13]. Sinonasal ITACs, which histopathologically resemble colorectal
adenocarcinoma, can occur sporadically or are associated with occupational exposure to hardwood
and leather dust. Sinonasal non-ITACs do not exhibit the histopathological features of sinonasal
ITACs or of salivary type adenocarcinomas; they are categorized into high-grade type and low-grade
type. Most sinonasal non-ITACs are of the low-grade type, whereas high-grade non-ITACs are rare.
Although the age of the patients with sinonasal ITAC and non-ITAC may vary widely, patients in the
sixth decade of life are most commonly affected. The nasal cavity is the most common site for ITAC
and non-ITAC, whereas the paranasal sinuses are less commonly affected [14].
On CT, sinonasal adenocarcinomas appear as a soft-tissue mass and occasionally exhibit areas of
calcification, which reflect the mucin content. In unilateral olfactory cleft adenocarcinomas, the bulging
of the nasal septum across the midline and widening of the olfactory cleft are observed [15]. High-grade
adenocarcinomas often show bone destruction. Adenocarcinomas arising from the ethmoid sinus may
potentially extend to the skull base and intracranially to the frontal lobes [16]. On MRI, the signal
intensity of the adenocarcinomas varies according to their mucin content, cellularity and the presence
of hemorrhage. Mucin-producing adenocarcinomas usually show hyperintensity on T2WI and
exhibit gradual enhancement on contrast-enhanced T1WI, whereas adenocarcinomas without mucin
production show iso- to hypointensity on T2WI. The imaging characteristics of adenocarcinomas are
often indistinguishable from those of SCCs (Figure 2).
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Figure 2. Non-intestinal type adenocarcinomas of the right maxillary sinus. T2-weighted image
showing a heterogeneously hyperintense lesion (arrow).
5.3. Adenoid Cystic Carcinoma
Adenoid cystic carcinomaa (ACC) are slow-growing and relentless salivary gland tumors
comprising epithelial and myoepithelial neoplastic cells. ACCs are the most common malignant
salivary gland tumors of the sinonasal tract; sinonasal ACCs account for 10–25% of all head and neck
ACCs. The average age at presentation is the fifth to sixth decade of life. The maxillary sinus is the most
commonly affected primary site, followed by the nasal cavity, ethmoid sinus, and sphenoid sinus [17].
There are three distinct histopathological subtypes of ACC: tubular, cribriform, and solid subtype.
ACCs are characterized by wide local infiltration, perineural spread, a propensity for local recurrence,
and late distant metastasis. Bone invasion (41%), perineural invasion (40%), and angioinvasion (3.8%)
are observed in the surgical specimens of sinonasal ACCs [17]. Lymph node and distant metastases are
uncommon at presentation, but the reported overall recurrence rate is 56.2% [17]. The most common
sites of distant metastases are the lungs, followed by the liver and bone.
Low-grade sinonasal ACCs may present as polypoid lesions that remodel the bone and mimic
a simple polyp, whereas high-grade sinonasal ACCs may present as large irregular masses with bone
destruction and heterogeneous density or signal intensity [18]. The growth pattern of maxillary sinus
ACCs can be classified into expansile type with minimal bony defects and destructive type with
extensive bony defects, and these tumors usually extend to the nasal cavity and, occasionally, to the
retroantral fat pad, pterygopalatine fossa, or orbit [19]. ACCs show isointensity on T1WI and iso- to
hyperintensity on T2WI, depending on the amount of cellularity (Figure 3). ACCs exhibit the greatest
propensity for perineural spread, and the maxillary division of the trigeminal nerve is most commonly
affected by sinonasal ACCs. These tumors sometimes easily extend into intracranial components
including the cavernous sinus and the Gasserian ganglion, which are far away from the original
site [20,21]. Furthermore, for the surgeons, it is often important to first evaluate on images whether
the tumor is resectable or not and far away from vital structures. In cases with an advanced tumor,
fluid collection and thickened mucosa caused by the isolated sinuses sometimes make it difficult to
diagnose and stage the disease.
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Figure 3. Adenoid cystic carcinoma of the left maxillary sinus and nasal cavity. T2-weighted image
showing a well-demarcated, lobulated, heterogeneously and strongly hyperintense lesion (arrow).
5.4. Sinonasal Undifferentiated Carcinoma
Sinonasal undifferentiated carcinoma (SNUC) is a rare and highly aggressive malignancy, which
accounts for approximately 3–5% of all sinonasal cancers. SNUC is a clinicopathologically distinct
carcinoma of uncertain histogenesis with no glandular or squamous features. The median age at
presentation is the sixth decade of life; the reported male-to-female ratio is 2–3:1. SNUC most commonly
arises from the superior nasal cavity and the ethmoid sinus. SNUC usually presents as a rapidly
enlarging tumor, and the majority of these patients presents with Stage IV disease. Orbital and
intracranial invasion, nodal involvement, and distant metastasis are frequent findings. The recurrence
rate is 42.3%. The time to recurrence ranges from 3 to 33 months; 32.1% of patients die of local disease,
whereas 14.3% of patients die of metastatic disease [22].
Most SNUCs are larger than 4 cm in maximal diameter at presentation and have ill-defined
margins [23]. The aggressive nature of the tumor is reflected in the bone destruction and invasion of adjacent
structures, including the paranasal sinuses, anterior fossa, orbit, pterygopalatine fossa, parapharyngeal
space, and cavernous sinus [23]. On CT, SNUCs usually appear as a noncalcified mass and show variable
contrast enhancement and areas of central necrosis. On MRI, SNUCs show isointensity on T1WI, iso- to
hyperintensity on T2WI, and exhibit heterogeneous enhancement on contrast-enhanced T1WI. Owing
to the nonspecific imaging findings, it is typically difficult to distinguish between SNUCs and SCCs
(Figure 4).
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Figure 4. Sinonasal undifferentiated carcinoma of the right nasal cavity. Contrast-enhanced CT image
showing an ill-demarcated, heterogeneously enhanced lesion (arrow).
5.5. Malignant Lymphoma
The head and neck region is the second most common site for extranodal lymphomas after the
gastrointestinal tract. NHL is the second most common malignancy in the sinonasal tract after SCC.
Patients classically present in the sixth to eighth decades of life; the reported male-to-female ratio
is 2:1. Diffuse large B-cell lymphoma (DLBCL) most commonly arises from the paranasal sinuses;
the maxillary sinus is the most common site of involvement, although DLBCL may arise from the nasal
cavity. NK/T-cell lymphoma most commonly involves the nasal cavity and shows a predilection for
occurrence in Asian and South American populations. B-cell lymphoma has a better prognosis than
T-cell lymphoma.
On CT, sinonasal lymphomas frequently show both infiltrative or permeative bony invasion
and exhibit varying degrees of regional bony destruction [12]. NHLs with permeative-type tumor
invasion typically cross the sinus wall and exhibit remnants of sinus wall as a linear structure within
the tumor (Figure 5) [24]. In contrast, bony resorption or remodeling caused by the lymphoma
may also be accompanied by bone sclerosis [25]. NHLs usually show isointensity on T1WI and
slightly hyperintensity on T2WI [11]. Although the signal intensity of NHLs is nonspecific, the ADC
measurement helps differentiate these tumors from other malignancies. In the maxillary sinus,
the ADC values of NHL (0.61 × 10−3 mm2/s) were shown to be lower than those of SCCs
(0.95 × 10−3 mm2/s), which reflects the greater cellularity of NHLs [12]. Although NHLs usually
appear as a homogeneously enhanced mass, necrotic areas within the tumor are occasionally observed
in NK/T-cell lymphoma [26,27].
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Figure 5. Diffuse large B-cell lymphoma of the left maxillary sinus. Contrast-enhanced CT image
showing a homogeneously enhanced lesion accompanied by remaining sinus walls as a linear structure
within the tumor (arrows).
5.6. Extramedullary Plasmacytoma
Extramedullary plasmacytomas (EPMs) (also referred to as extraosseous plasmacytomas) are
characterized by soft-tissue monochronal plasma cell proliferation with no evidence of underlying
multiple myeloma; these tumors account for 4% of all plasma cell tumors. EPMs usually occur in the
sixth decade of life; the reported male-to-female ratio is 3–4:1. Approximately 80% of EPMs involve the
head and neck region; the nasal cavity and paranasal sinuses are most commonly affected, followed
by the nasopharynx, oropharynx, and larynx [28]. Regional recurrence or spread to other osseous
sites may occur. Approximately 15% of the patients develop multiple myeloma [28]. The prognosis
depends on the tumor size (>5 cm) and nodal involvement [29].
On CT, EMPs typically appear as well-defined, polypoid soft-tissue masses, which exhibit
homogenous enhancement. Large tumors may show areas of necrosis, destruction of the adjacent
bone, infiltration of the adjacent structures, and vascular encasement [30,31]. On MRI, EMPs show
isointensity on T1WI, iso- to slight hyperintensity on T2WI, and exhibit variable enhancement on
contrast-enhanced T1WI [30,31] (Figure 6). Because they are highly vascularized tumors, vascular flow
void may be observed within the tumor.
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Figure 6. Extramedullary plasmacytoma of the bilateral nasal cavity. T2-weighted image showing
a homogeneously isointense lesion (arrows).
5.7. Olfactory Neuroblastoma
Olfactory neuroblastomas (ONB) arise from the specialized sensory neuroepithelial
(neuroectodermal) olfactory cells that are normally found in the cribriform plate, the superior turbinate,
and the upper third of the nasal septum. ONBs account for 3% of all sinonasal tumors [32]. ONB may
occur at any age, with a peak incidence in the fifth and sixth decades of life; the reported male-to-female
ratio is 1.2:1. Direct tumor extension into the adjacent paranasal sinuses, cribriform plate, skull base,
orbit, and intracranial cavity is frequently observed. Cervical lymph node metastasis (20–25%) and
distant metastases (10–40%) develop over the course of the disease. The most frequent sites of distant
metastasis are the lungs, liver, and bone. The most commonly used staging systems are the modified
Kadish and Dulguerov classifications.
On CT, ONBs appear as a homogeneous, well-defined soft-tissue mass. Scattered speckled
calcifications may be observed within the tumor. The tumor commonly extends into the ethmoid
and maxillary sinuses, but rarely involves the sphenoid sinus. CT is essential for the evaluation of
osseous involvement of the cribriform plate, fovea ethmoidalis, and lamina papyracea. On MRI, ONBs
usually show hypointensity relative to the gray matter on T1WI and hyperintensity relative to the
gray matter on T2WI [33]. These tumors demonstrate an avid and homogeneous enhancement except
for occasional areas of necrosis or hemorrhage (Figure 7). When an intracranial extension is present,
the peripheral or marginal cysts are a characteristic and specific feature of ONBs [34].
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Figure 7. Olfactory neuroblastoma of the right nasal cavity. Contrast-enhanced CT image showing
a homogeneously enhanced lesion in the right olfactory cleft (arrow).
5.8. Malignant Melanoma
Malignant melanoma (MM) originates from the pigment-producing cells (melanocytes)
predominantly located in the skin. Sinonasal mucosal MMs account for 0.5–2% of all MMs and
approximately 4% of all head and neck MMs. The age at occurrence may vary widely; the peak
incidence is in the seventh decade of life. The tumor exhibits no gender predilection. The nasal cavity
(including nasal septum, inferior and middle turbinates, and lateral nasal wall) is the second most
common site for mucosal melanoma followed by the oral cavity. The paranasal sinuses are rarely
affected; of these, the maxillary sinus is the most commonly affected. The occurrence of regional and
distant metastases is relatively common (≥25% in most series) [35].
CT findings are nonspecific; however, CT is useful for the evaluation of the remodeling of
the the surrounding bone or bony erosion [36]. On T1WI, sinonasal MMs that contain melanin or
hemorrhage usually show iso- to hyperintensity relative to the gray matter; however, amelanotic
melanoma may also show hypointensity (Figure 8). T1 shortening more often appears as a reflection
of the paramagnetic effects associated with the products of hemorrhage rather than the presence of
melanin [37]. On T2WI, sinonasal MMs typically show hyperintensity relative to the gray matter;
however, melanotic melanomas may show iso- to hypointensity. MMs typically show a heterogeneous
strong contrast enhancement owing to the rich vascular network.
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Figure 8. Malignant melanoma of the right nasal cavity. T1-weighted image showing heterogeneously
hyperintense areas within tumor (arrow).
5.9. Rhabdomyosarcoma
Rhabdomyosarcoma (RMS) is a malignant mesenchymal tumor with skeletal muscle
differentiation and is one of the most common pediatric soft tissue sarcomas, accounting for 3–5% of all
malignancies in childhood. RMS is classified into embryonal, alveolar, pleomorphic, and spindle-cell
subtypes. The mean age at diagnosis is 5–6 years, and 72–81% of patients are younger than 10 years;
the reported male-to-female ratio is 1.3:1 [38]. Approximately 40% of all RMSs occur in the head and
neck region; the most common sites are the orbit, nasopharynx, middle ear and mastoid, and sinonasal
tracts. Embryonal RMS is the most common histopathological subtype occurring in the head and neck
region and in the genitourinary system and is typically associated with a favorable prognosis.
The average diameter of head and neck RMSs (HNRMS) is 4.5 cm. Most of the HNRMSs have
ill-defined margins with adjacent bony destruction and extension into the surrounding spaces [39,40].
On CT, HNRMSs appear as an isodense or slightly hypodense mass and show homogeneous
enhancement on contrast-enhanced CT (Figure 9). Intratumoral calcification and hemorrhage rarely
occur in HNRMS. On MRI, HNRMSs show isointensity relative to muscle on T1WI, and moderate
hyperintensity relative to muscle on T2WI [39,40]. On contrast-enhanced T1WI, HNRMSs show various
enhancement patterns; however, the majority of HNRMS shows moderate homogenous enhancement.
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Figure 9. Rhabdomyosarcoma of the right nasal cavity. Contrast-enhanced CT image showing a
homogeneously, slightly enhanced lesion (arrow).
5.10. Malignant Peripheral Nerve Sheath Tumor
Malignant peripheral nerve sheath tumors (MPNST) are highly aggressive malignant
mesenchymal tumors that usually arise from peripheral nerves or cells of the peripheral nerve sheath
and show variable differentiation toward one of the cellular components of the nerve sheath. MPNSTs
account for approximately 5–10% of all soft tissue sarcomas, of which only approximately 8–16%
occur in the head and neck region [41]. They occur mainly in adults; the age at presentation may vary
widely, although the peak incidence is in the fifth decade of life. They are commonly associated with
neurofibromatosis type 1 (NF1) but can also arise through sporadic mutation [41]. The cases associated
with NF1 occur in younger patients (mean patient age in the third to fourth decades). MPNSTs may
occur in the sinonasal tract, nasopharynx, oral cavity, and orbit. Approximately two thirds of the cases
metastasize, usually hematogenously, to the lung and bone.
On CT, MPNSTs appear as a large, hypodense soft-tissue mass with infiltration of the adjacent
structures. On MRI, 51% of MPNST on T1WI and 78% of MPNST on T2WI exhibit heterogeneous
signal intensity [42] (Figure 10). Compared to neurofibromas, the peripheral enhancement pattern,
perilesional edema, and intratumoral cystic change are characteristic MRI findings of MPNSTs [42].
Compared to non-neurogenic malignant soft tissue tumors, the intermuscular distribution, nodular
morphology with a fusiform shape, location on the course of a large nerve, and homogeneity of the
signal intensity and enhancement are characteristic MRI findings of MPNSTs [43].
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Figure 10. Malignant peripheral nerve sheath tumor of the right maxillary sinus. T2-weighted image
showing a heterogeneously hypo- to hyperintense lesion (arrow).
6. Conclusions
Although the radiological differentiation of sinonasal malignancies is very difficult because
of the similarity of imaging findings, the tumor location, growth pattern into adjacent bone, tumor
homogeneity, internal signal intensity, contrast enhancement pattern, and DWI with ADC measurement
may facilitate an adequate diagnosis. CT and MRI are useful tools for pretreatment evaluation of the
characterization, localization, and distribution of malignant sinonasal tumors.
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Abstract: Both infectious and non-infectious etiologies of acute encephalitis have been described,
as well as their specific presentations, diagnostic tests, and therapies. Classic findings of
acute encephalitis include altered mental status, fever, and new lesions on neuroimaging or
electroencephalogram (EEG). We report an interesting case of a 61-year-old male with a history
of diffuse large B-cell lymphoma with secondary involvement of the central nervous system
(SCNS-DLBCL). He presented with acute encephalitis: altered mental status, fever, leukocytosis,
neuropsychiatric symptoms, multiple unchanged brain lesions on computed tomography scan of the
head, and EEG showed mild to moderate diffuse slowing with low-moderate polymorphic delta and
theta activity. With such a wide range of symptoms, the differential diagnosis included paraneoplastic
and autoimmune encephalitis. Infectious and autoimmune/paraneoplastic encephalitis in patients
with SCNS-DLBCL are not well documented in the literature, hence diagnosis and therapy becomes
challenging. This case report describes the patient’s unique presentation of acute encephalitis.
Keywords: neuropsychiatric presentation of encephalitis; paraneoplastic encephalitis; autoimmune
encephalitis; infectious encephalitis; diffuse large B-cell lymphoma
1. Introduction
The substantial morbidity and mortality that is associated with encephalitis is well documented
in the literature, although the specific etiology is not often well characterized. Among the identified
etiologies, the most commonly described is of infectious nature, either through direct effects on the
brain parenchyma or by post-infectious processes, including acute disseminated encephalomyelitis
(ADEM) and acute hemorrhagic leukoencephalitis [1,2]. Viruses are the most common cause of
encephalitis, with herpes simplex virus (HSV) being the most common [3]. Non-infectious etiologies
are typically immune-mediated, divided between autoimmune pathogenic autoantibodies against
surface neuronal antigens and paraneoplastic onconeural antibodies (most common Hu and Ma2)
against intracellular neuronal antigens [4,5].
Boucher et al. revealed an estimated annual incidence of infectious encephalitis to be
1.5–7/100,000 [3]. A United Kingdom-based prospective surveillance study found the annual incidence
of non-infectious autoimmune encephalitis to be 0.85/1,000,000 in children [6].
Per the International Encephalitis Consortium held in March 2012, the major criterion for the
diagnosis of encephalitis includes altered mental status lasting ≥24 h without an otherwise identifiable
cause [7]. Minor criteria for diagnosis include: temperature ≥ 100.4 ◦F (38 ◦C), new-onset seizure, new
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focal neurological abnormalities, cerebral spinal fluid (CSF) white blood cell (WBC) ≥ 5/mm3, acute
lesion on neuroimaging, or abnormality on electroencephalogram (EEG) indicative of encephalitis [7].
In an EEG study of 52 patients with diagnosed encephalitis, 96.2% demonstrated generalized or focal
slowing, 50% showed abnormal delta activity, and 46% of patients showed abnormal theta activity [8].
Overall, EEG rhythm disorder recordings were mild, moderate, and severe for 40.4%, 44.2%, and 13.5%
of patients, respectively [8].
Not surprisingly, the neurologic manifestations of encephalitis are most commonly
described in the literature; however, on rare occasions, psychiatric pathology can be the only
clinical symptom marking the initial presentation of encephalitis, specifically in non-infectious,
autoimmune encephalitis [9]. Psychiatric manifestations in non-infectious, autoimmune encephalitis
have a well-documented association with autoantibodies against anti-N-methyl-D-aspartate
receptor (NMDAR), α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR),
and γ-aminobutyric acid receptor (GABAR) [10]. Symptoms of psychosis may include paranoid
delusions and visual/auditory hallucinations; additionally, patients may also present with insomnia,
confusion, and short-term memory loss, similar to delirium [10,11]. The CSF in these non-infectious
cases may show lymphocytic pleocytosis and increased protein; further analysis of the CSF can show
antibodies to the aforementioned autoantibodies [12]. An increased T2 signal of the medial temporal
lobe on magnetic resonance imaging (MRI) or the complete absence of cerebral pathology can be seen
on neuroimaging of patients with these autoantibodies [10].
We report an interesting case of acute encephalitis in a 61-year-old male with history of
diffuse large B-cell lymphoma (DLBCL) with secondary involvement of the central nervous system
(SCNS-DLBCL). Very few cases of encephalitis that are associated with DLBCL have been reported in
the literature, and considerations of infectious versus non-infectious etiologies in this particular
clinical scenario are not well addressed. Furthermore, previously documented cases of acute
encephalitis in patients with DLBCL have not specified secondary lymphomatous central nervous
system (CNS) involvement. Was the patient’s presentation of altered mental status, fever, leukocytosis
and neuropsychiatric symptoms secondary to infectious causes, or were non-infectious, paraneoplastic,
or autoimmune processes responsible?
2. Case Report
A 61-year-old male presented to the Emergency Department (ED) with altered mental status and
fever after a follow-up lumbar puncture (LP) one day prior. 18 h after the procedure, the patient’s
wife noted that he was “shaking in his wheelchair, mumbling to himself, unresponsive and staring
into space”. She recorded a home temperature of 99 ◦F. The patient has a past medical history of
SCNS-DLBCL (diagnosed two years ago with right axillary lymph node biopsy and LP with CNS
cytology, unknown location of primary tumor), associated with warm autoimmune hemolytic anemia,
that has received multiple trials of chemotherapy and improved, but has not entered remission.
Of note, this patient was previously hospitalized two months ago for similar symptoms, including
aphasia, lethargy, and right hemiparesis; he was found to have worsening SCNS-DLBCL involvement
on computed tomography (CT) scan of the head. Imaging revealed significant left temporal lobe,
left parietal lobe, and right occipital lobe lesions, with leptomeningeal involvement in the medial
right parietal region. The patient clinically stabilized following whole brain radiation. A follow-up
MRI (one month prior to this hospitalization) showed a marked improvement of CNS infiltration and
disease. The patient saw his neuro-oncologist five days prior to hospitalization, who stated that the
patient’s neurologic symptoms, including his memory, had greatly improved. The patient’s other
medical problems include a urinary tract infection (UTI) that was diagnosed two weeks prior to
admission (treated with cefadroxil) and likely steroid-induced hyperglycemia. The patient has never
been diagnosed with any psychiatric disorder, has never taken any psychiatric medication, and has
never been admitted to a psychiatric hospital. However, the patient’s wife mentioned that he had been
242
J. Clin. Med. 2017, 6, 117
more isolative in the past few weeks, less talkative, and easily angered. She denies noting paranoia or
any complaints of auditory/visual hallucinations from the patient.
On admission, the patient was febrile (102.1 ◦F, 38.94 ◦C) with sinus tachycardia (125 beats/min).
His physical exam was notable for altered mental status (oriented to self only), generalized weakness,
and unspecified aphasia. Pertinent negatives included: no neck stiffness, photophobia, vomiting,
respiratory distress, recent trauma, or headache. Medications on admission included: dexamethasone
1 mg daily, long-acting insulin 11 units at bedtime, levetiracetam 500 mg twice/day, metformin 1000 mg
daily, pantoprazole 40 mg daily, and ibrutinib 560 mg daily. The patient had no known drug allergies.
Admission laboratory results included: leukocytosis, WBC count = 16.6 K/μL (neutrophils
77%, stabs 3%, lymphocytes 17%, monocytes 9%), venous blood gas lactate of 3.3 mmol/L
(n = 0.5–2.2 mmol/L), and normal chemistry with the exception of elevated blood urine nitrogen (BUN
25 mg/dL, creatinine 0.8 mg/dL). Other laboratory results include: normal aspartate aminotransferase
(AST) of 13 IU/L (n = 4–36), normal alanine aminotransferase (ALT) of 13 IU/L (n = 13–39),
elevated C-reactive protein (CRP) of 76.98 mg/L (n < 3), normal sedimentation rate (9 millimeters/h
(MM/HR), n < 20 MM/1HR), elevated ferritin (1593 ng/mL, n = 14–235 ng/mL), normal thyroid
stimulating hormone (TSH) (4.136 μIU/mL, n = 0.36–5.80 μIU/mL), and thyroxine (T4) (1.27 ng/dL,
n = 0.89–1.76 ng/dL). Patient’s urinalysis was positive for WBC > 182 (n < 3/high power field (HPF)),
2+ urine protein, 1+ occult blood, 3+ leukocyte esterase, and positive nitrite. Patient’s CSF analysis
from LP two days prior was within normal limits.
The patient’s concerning symptoms on evaluation necessitated repeat LP, which was performed
one day after admission. CSF analysis was significant only for elevated protein (51 mg/dL,
n = 8–32 mg/dL) and appearance was non-xanthochromic and clear. The remaining CSF analysis
showed 0/μL WBCs, 13/μL red blood cell (RBC), and 2.2 mmol/L lactic acid. CSF was negative
for Cytomegalovirus polymerase chain reaction (PCR), Epstein Barr Virus PCR, HSV-1 PCR, HSV-2
PCR, Herpes 6 Virus IgG antibody and West Nile IgG/IgM. CSF cytology was non-diagnostic and
flow cytometry was negative for the involvement of lymphoma. The patient was discharged before
consideration arose to test his CSF for paraneoplastic or autoimmune antibodies. CSF culture with
Gram stain showed no growth for three days.
CT scan of the head was reassuring, showing no significant changes from the patient’s previous
MRI, performed one month prior to this hospitalization. Unchanged lesions include: small inferolateral
left temporal density, associated white matter low density, small medial right and left parietal occipital
low densities, and a posterior cerebral white matter hypodensity (Figure 1). Patient’s EEG result
read: abnormal EEG due to mild to moderate diffuse slowing, with excess low-moderate voltage
polymorphic delta and theta activity (Figure 2).
The patient’s clinical presentation of acute altered mental status, fever, and generalized weakness,
in combination with temporally related recent LP, abnormal EEG, and history of SCNS-DLBCL,
suggests multiple different diagnoses, including acute encephalitis. This was added to the list of
differential diagnoses, which included sepsis, meningitis, and delirium secondary to UTI. Therefore,
the patient was treated with 1 dose of IV vancomycin 1 g and 2 doses at 1.5 g; 1 dose of IV meropenem
1 g and 4 doses at 2 g; and, 2 doses of oral (tablet) dexamethasone 1 mg. The patient also received 1 L
of IV normal saline on admission.
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Figure 1. Computed tomography (CT) head of a 61-year-old male with SCNS-DLBCL presenting
with acute encephalitis. (a) CT Head shows a small area of inferolateral left temporal density, which
correlates with the blood products that were seen in patient’s previous magnetic resonance imaging
(MRI) associated with the temporal lobe lesion. There is associated white matter low density, which is
similar to the non-enhancing signal on previous MRI; (b) CT Head shows a small area of medial left
parietal occipital low density corresponds to the lesion and old blood seen on the MRI. It also shows a
very small area of medial right parietal occipital low density corresponds to signal seen on the MRI.
 
Figure 2. Electroencephalogram (EEG) of a 61-year-old male with SCNS-DLBCL presenting with
acute encephalitis. Consistent with an abnormal EEG reading due to mild-moderate diffuse slowing.
This specific frame shows excess low to moderate voltage (15 to 40 uV) polymorphic delta and
theta activity. Interpretation of this EEG suggests mild to moderate diffuse cerebral dysfunction.
Technical information: Electrodes were placed according to the 10–20 International Electrode System.
Digital EEG was recorded using the Natus Digital EEG System and EEG was reformatted into multiple
montages as needed.
Treatment resulted in resolution of fever and leukocytosis (98.3 ◦F and 4.7 K/μL WBC upon
discharge). The patient was discharged appearing clinically stable; however, his neuropsychiatric
impairments revealed on admission were unresolved. The patient remained disoriented to place
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and time, aphasic, and emotionally distressed by word recall disturbances. Initially, the patient’s
presentation was suggestive of memory impairment given his reluctance and anger toward questions
that tested memory. Further examination with Montreal Cognitive Assessment (MoCA) score of 7/30
suggested profound memory loss and cognitive disturbances (Table 1) [13]. Additionally, the patient
had several bizarre mannerisms in speech and behavior, sometimes speaking in paradoxes, e.g., “I am
afraid, but I have no fear, is that not strange?” Mental status exam before discharge revealed: guarding
throughout the interview, soft speech with regular rhythm and prosody, and blunted affect with anxious
qualities. The patient appeared somewhat internally preoccupied and paranoid at times, although
he specifically denied persecutory delusions and auditory/visual hallucinations. Motor behavior
was significant for prominent psychomotor agitation. Overall, he demonstrated poor insight into his
condition and poor judgment about the need for hospitalization, stating multiple times “there is no
reason for me to be here, I am being held against my will.”
Table 1. Patient Montreal Cognitive Assessment (MoCA) test assessment result of 7/30 with good effort.
MoCA
Visuospatial/executive function 0/5, patient attempted a digital clock at first, could not put numbers on circle clock
Naming 3/3
Memory Unscored, able to repeat 5/5 words in both 1st and 2nd trials
Attention 2/2 for repeating digits forward and backward0/1 attending to the letter A in a list (9 errors), and 0/3 serial 7’s
Language 2/2 repeating phrase0/1 naming > 11 words that begin with the letter “F” in 1 min (named 3 words)
Abstraction 0/2
Delayed recall
0/5 with no cue
0/5 with category cue
3/5 with multiple choice cue
Orientation 0/6 (date, month, year, day, place, city)
Final score 7/30
Score = n; n ≥ 26/30 (normal), n ≤ 23/30 (mild cognitive impairment), n ≤ 17/30 (mild dementia), n ≤ 9/30
(moderate dementia).
3. Discussion
Our patient with SCNS-DLBCL presented with symptoms of altered mental status, aphasia,
fever, leukocytosis, and multiple neuropsychiatric symptoms. This clinical presentation yielded a
wide differential diagnosis, including encephalitis, sepsis, meningitis, increased CNS tumor burden,
and delirium. Appropriate procedural, imaging, and laboratory testing was performed. An MRI brain
should have been considered to check for cerebral ischemia; however, this diagnosis was not on the
differential at the time of admission. Though the patient presented after an LP, the absence of a stiff
neck and negative CSF findings eliminated acute bacterial meningitis in the differential. Although the
patient’s presentation of dehydration and elevated CRP support the diagnosis of sepsis secondary to a
UTI, the resolution of symptoms was not achieved with rehydration and the appropriate antibiotic
therapy [14]. Regarding delirium, the patient had multiple risk factors, including underlying brain
injury from his cancer and an active source of infection (UTI) [15]. Additionally, the disturbances in
consciousness and diffuse slowing on EEG were consistent with delirium [16]. However, the clinical
picture of ‘waxing-waning’ cognition and hypoactive/agitated states that classically characterizes
delirium was not present in our patient [17].
Acute encephalitis was our diagnosis, given that our patient met the criteria of the International
Encephalitis Consortium: major criteria of altered mental status and minor criteria of fever (102.5 ◦F),
new abnormal EEG findings that were consistent with encephalitis and new focal neurological deficits,
presenting as aphasia and psychiatric abnormalities on mental status examination [6]. We suggest
that the patient’s acute psychiatric presentation should be considered a focal neurological deficit,
as it can be directly linked to the perturbations in the temporal lobe resulting in symptoms of fear,
profound memory loss, and internal preoccupation [18–20]. Per the patient’s neuro-oncologist, these
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symptoms were not present five days prior to our evaluation. Furthermore, the EEG findings of diffuse
background slowing and abnormal delta/theta activity are indicative of encephalitis [7,8].
Extensive CSF analysis lowered infectious encephalitis on the differential. Additional CSF testing
for Zika, chikungunya and dengue viruses was not performed. Acevedo et al. recommend multiplex
real-time reverse transcription PCR (rRT-PCR) testing for patients in endemic areas presenting
new neurological symptoms [21]. We believe that the acute change in fear, profound memory
impairments, and mild internal preoccupation are suggestive of limbic encephalitis. However, we are
not confident in labeling the patient with limbic encephalitis, given that temporal lobe inflammation is
confounded by the patient’s preexisting mass from SCNS-DLBCL in that region. The cost of ordering
paraneoplastic/autoimmune autoantibodies tests is high, and testing all patients with SCNS-DLBCL
with possible encephalitis may be impractical [22]. Therefore, we suggest a thorough examination of
the neuropsychiatric symptoms of patients with SCNS-DLBCL presenting with acute encephalitis to
prompt investigation of non-infectious etiologies.
4. Conclusions
In an adult with diffuse large B-cell lymphoma with secondary involvement of the central nervous
system presenting with altered mental status, fever, and neuropsychiatric symptoms, it is imperative
that clinicians consider encephalitis, both infectious and non-infectious etiologies.
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